<html lang="en"><head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no">
    <link rel="shortcut icon" href="./favicon.png">
    <link rel="preload" href="./static/media/SourceSansPro-Regular.DZLUzqI4.woff2" as="font" type="font/woff2" crossorigin="">
    <link rel="preload" href="./static/media/SourceSansPro-SemiBold.sKQIyTMz.woff2" as="font" type="font/woff2" crossorigin="">
    <link rel="preload" href="./static/media/SourceSansPro-Bold.-6c9oR8J.woff2" as="font" type="font/woff2" crossorigin="">

    <title>app</title>

    <!-- initialize window.prerenderReady to false and then set to true in React app when app is ready for indexing -->
    <script>
      window.prerenderReady = false
    </script>
    <script type="module" crossorigin="" src="./static/js/index.BlylrL8P.js"></script>
    <link rel="stylesheet" crossorigin="" href="./static/css/index.DpJG_94W.css">
  <style media=""></style><style data-emotion="st-emotion-cache-global" data-s=""></style><style data-emotion="st-emotion-cache" data-s=""></style><link rel="modulepreload" as="script" crossorigin="" href="https://pieree369-olmocr.hf.space/static/js/index.BqlD3NTA.js"><link rel="modulepreload" as="script" crossorigin="" href="https://pieree369-olmocr.hf.space/static/js/index.DW_MHI2K.js"><link rel="modulepreload" as="script" crossorigin="" href="https://pieree369-olmocr.hf.space/static/js/FormClearHelper.UtDFKbpT.js"><link rel="modulepreload" as="script" crossorigin="" href="https://pieree369-olmocr.hf.space/static/js/FileHelper.DV2KuUj6.js"><link rel="modulepreload" as="script" crossorigin="" href="https://pieree369-olmocr.hf.space/static/js/ProgressBar.BtMHwdZZ.js"><link rel="modulepreload" as="script" crossorigin="" href="https://pieree369-olmocr.hf.space/static/js/Hooks.YZgOFmbn.js"><link rel="modulepreload" as="script" crossorigin="" href="https://pieree369-olmocr.hf.space/static/js/UploadFileInfo.C-jY39rj.js"></head>
  <body>
    <noscript>You need to enable JavaScript to run this app.</noscript>
    <div id="root"><div class=""><div class="withScreencast" data-testid="stScreencast"><div class="stApp stAppEmbeddingId-t79e8qt70h9f st-emotion-cache-1r4qj8v ee4bbma0" data-testid="stApp" data-test-script-state="notRunning" data-test-connection-state="CONNECTED"><header tabindex="-1" class="stAppHeader st-emotion-cache-12fmjuu e4hpqof0" data-testid="stHeader"><div class="stDecoration st-emotion-cache-1dp5vir e4hpqof1" data-testid="stDecoration" id="stDecoration"></div><div class="stAppToolbar st-emotion-cache-15ecox0 e4hpqof2" data-testid="stToolbar"><div class="stToolbarActions st-emotion-cache-1p1m4ay e1i26tt72" data-testid="stToolbarActions"></div><span id="MainMenu" class="stMainMenu st-emotion-cache-czk5ss ev04twb8" data-testid="stMainMenu" aria-haspopup="true" aria-expanded="false"><button kind="headerNoPadding" data-testid="stBaseButton-headerNoPadding" aria-label="" class="st-emotion-cache-l1ktzw em9zgd018"><svg viewBox="0 0 24 24" aria-hidden="true" focusable="false" fill="currentColor" xmlns="http://www.w3.org/2000/svg" class="e144pc0f1 st-emotion-cache-1pbsqtx ex0cdmw0"><path fill="none" d="M0 0h24v24H0V0z"></path><path d="M12 8c1.1 0 2-.9 2-2s-.9-2-2-2-2 .9-2 2 .9 2 2 2zm0 2c-1.1 0-2 .9-2 2s.9 2 2 2 2-.9 2-2-.9-2-2-2zm0 6c-1.1 0-2 .9-2 2s.9 2 2 2 2-.9 2-2-.9-2-2-2z"></path></svg></button></span></div></header><div class="stAppViewContainer appview-container st-emotion-cache-1yiq2ps eht7o1d0" data-testid="stAppViewContainer" data-layout="narrow"><section tabindex="0" class="stMain st-emotion-cache-bm2z3a eht7o1d1" data-testid="stMain"><div class="stMainBlockContainer block-container st-emotion-cache-mtjnbi eht7o1d4" data-testid="stMainBlockContainer"><div data-testid="stVerticalBlockBorderWrapper" data-test-scroll-behavior="normal" class="st-emotion-cache-0 eu6p4el5"><div class="st-emotion-cache-b95f0i eu6p4el4"><div class="stVerticalBlock st-emotion-cache-1n76uvr eu6p4el3" data-testid="stVerticalBlock" width="704"><div class="stElementContainer element-container st-emotion-cache-kj6hex eu6p4el1" data-testid="stElementContainer" data-stale="false" width="auto"><div class="stHeading" data-testid="stHeading"><div data-testid="stMarkdownContainer" class="st-emotion-cache-1104ytp e1icttdg0"><div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 id="olmocr">OLMOCR<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#olmocr" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div></div></div></div><div class="stElementContainer element-container st-emotion-cache-kj6hex eu6p4el1" data-testid="stElementContainer" data-stale="false" width="auto"><div class="st-emotion-cache-8atqhb e1mlolmg0"><div class="stFileUploader st-emotion-cache-0 e17y52ym15" data-testid="stFileUploader" width="704"><label data-testid="stWidgetLabel" aria-hidden="true" class="st-emotion-cache-1s2v671 e1dx5vew0"><div data-testid="stMarkdownContainer" class="st-emotion-cache-wq5ihp e1icttdg0"><p>Upload a PDF or Image</p></div></label><section role="presentation" data-testid="stFileUploaderDropzone" aria-label="Upload a PDF or Image" class="st-emotion-cache-1gulkj5 e17y52ym0" tabindex="0"><input data-testid="stFileUploaderDropzoneInput" accept="application/streamlit,.pdf,.png,.jpg,.jpeg" type="file" style="border: 0px; clip: rect(0px, 0px, 0px, 0px); clip-path: inset(50%); height: 1px; margin: 0px -1px -1px 0px; overflow: hidden; padding: 0px; position: absolute; width: 1px; white-space: nowrap;" tabindex="-1"><div data-testid="stFileUploaderDropzoneInstructions" class="st-emotion-cache-u8hs99 e17y52ym1"><span class="st-emotion-cache-nwtri e17y52ym2"><svg viewBox="0 0 24 24" aria-hidden="true" focusable="false" fill="currentColor" xmlns="http://www.w3.org/2000/svg" class="e144pc0f1 st-emotion-cache-6rlrad ex0cdmw0"><path fill="none" d="M0 0h24v24H0V0z"></path><path d="M19.35 10.04A7.49 7.49 0 0012 4C9.11 4 6.6 5.64 5.35 8.04A5.994 5.994 0 000 14c0 3.31 2.69 6 6 6h13c2.76 0 5-2.24 5-5 0-2.64-2.05-4.78-4.65-4.96zM19 18H6c-2.21 0-4-1.79-4-4 0-2.05 1.53-3.76 3.56-3.97l1.07-.11.5-.95A5.469 5.469 0 0112 6c2.62 0 4.88 1.86 5.39 4.43l.3 1.5 1.53.11A2.98 2.98 0 0122 15c0 1.65-1.35 3-3 3zM8 13h2.55v3h2.9v-3H16l-4-4z"></path></svg></span><div class="st-emotion-cache-j7qwjs e17y52ym4"><span class="st-emotion-cache-9ycgxx e17y52ym3">Drag and drop file here</span><small class="st-emotion-cache-1rpn56r ejh2rmr0">Limit 200MB per file • PDF, PNG, JPG, JPEG</small></div></div><button kind="secondary" data-testid="stBaseButton-secondary" aria-label="" class="st-emotion-cache-ocsh0s em9zgd02">Browse files</button></section><div class="st-emotion-cache-fis6aj e17y52ym5"><ul class="st-emotion-cache-14m29r0 e17y52ym6"><li class="st-emotion-cache-1l95nvm e17y52ym7"><div class="stFileUploaderFile st-emotion-cache-12xsiil e17y52ym10" data-testid="stFileUploaderFile"><div class="st-emotion-cache-10ix4kq e17y52ym12"><svg viewBox="0 0 24 24" aria-hidden="true" focusable="false" fill="currentColor" xmlns="http://www.w3.org/2000/svg" class="e144pc0f1 st-emotion-cache-4mjat2 ex0cdmw0"><path fill="none" d="M0 0h24v24H0V0z"></path><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zM6 20V4h7v5h5v11H6z"></path></svg></div><div class="stFileUploaderFileData st-emotion-cache-1l4firl e17y52ym8"><div class="stFileUploaderFileName st-emotion-cache-1uixxvy e17y52ym9" data-testid="stFileUploaderFileName" title="8_PDFsam_Essentials_of_Medical_Pharmacology_8th_Edition_DIGITAL_VERSION_K.pdf">8_PDFsam_Essentials_of_Medical_Pharmacology_8th_Edition_DIGITAL_VERSION_K.pdf</div><small class="st-emotion-cache-1rpn56r ejh2rmr0">31.2MB</small></div><div data-testid="stFileUploaderDeleteBtn"><button kind="minimal" data-testid="stBaseButton-minimal" aria-label="" class="st-emotion-cache-8ccstr em9zgd06"><svg viewBox="0 0 24 24" aria-hidden="true" focusable="false" fill="currentColor" xmlns="http://www.w3.org/2000/svg" class="e144pc0f1 st-emotion-cache-1pbsqtx ex0cdmw0"><path fill="none" d="M0 0h24v24H0V0z"></path><path d="M19 6.41L17.59 5 12 10.59 6.41 5 5 6.41 10.59 12 5 17.59 6.41 19 12 13.41 17.59 19 19 17.59 13.41 12 19 6.41z"></path></svg></button></div></div></li></ul></div></div></div></div><div class="stElementContainer element-container st-emotion-cache-kj6hex eu6p4el1" data-testid="stElementContainer" data-stale="false" width="auto"><div class="stButton st-emotion-cache-8atqhb e1mlolmg0" data-testid="stButton"><button kind="secondary" data-testid="stBaseButton-secondary" aria-label="" class="st-emotion-cache-ocsh0s em9zgd02"><div data-testid="stMarkdownContainer" class="st-emotion-cache-1hyd1ho e1icttdg0"><p>Submit</p></div></button></div></div><div class="stElementContainer element-container st-emotion-cache-kj6hex eu6p4el1" data-testid="stElementContainer" data-stale="false" width="auto"><div class="stMarkdown" data-testid="stMarkdown"><div data-testid="stMarkdownContainer" class="st-emotion-cache-1104ytp e1icttdg0"><p><strong>Processing file:</strong> 8_PDFsam_Essentials_of_Medical_Pharmacology_8th_Edition_DIGITAL_VERSION_K.pdf</p></div></div></div><div class="stElementContainer element-container st-emotion-cache-kj6hex eu6p4el1" data-testid="stElementContainer" data-stale="false" width="auto"><div class="stMarkdown" data-testid="stMarkdown"><div data-testid="stMarkdownContainer" class="st-emotion-cache-1104ytp e1icttdg0"><div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="contents">Contents<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#contents" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="section-1-br-general-pharmacological-principles">SECTION 1 &lt;br&gt; General Pharmacological Principles<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#section-1-br-general-pharmacological-principles" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ol>
<li>Introduction, Routes of Drug Administration ..... 1</li>
<li>Pharmacokinetics: Membrane Transport, Absorption and Distribution of Drugs ..... 15</li>
<li>Pharmacokinetics: Metabolism and Excretion of Drugs, Kinetics of Elimination ..... 28</li>
<li>Pharmacodynamics: Mechanism of Drug Action; Receptor Pharmacology ..... 45</li>
<li>Aspects of Pharmacotherapy, Clinical Pharmacology and Drug Development ..... 71</li>
<li>Adverse Drug Effects ..... 92
SECTION 2
Drugs Acting on Autonomic Nervous System
Autonomic Nervous System: General Considerations ..... 103</li>
<li>Cholinergic Transmission and Cholinergic Drugs ..... 110</li>
<li>Anticholinergic Drugs and Drugs Acting on Autonomic Ganglia ..... 124</li>
<li>Adrenergic Transmission and Adrenergic Drugs ..... 136</li>
<li>Antiadrenergic Drugs (Adrenergic Receptor Antagonists) and Drugs for Glaucoma ..... 153
SECTION 3
Autacoids and Related Drugs</li>
<li>Histamine and Antihistaminics ..... 174</li>
<li>5-Hydroxytryptamine, its Antagonists and Drug Therapy of Migraine ..... 185</li>
<li>Prostaglandins, Leukotrienes (Eicosanoids) and Platelet Activating Factor ..... 197</li>
<li>Nonsteroidal Antiinflammatory Drugs and Antipyretic-Analgesics ..... 209</li>
<li>Antirheumatoid and Antigout Drugs ..... 227
SECTION 4
Respiratory System Drugs</li>
<li>Drugs for Cough and Bronchial Asthma ..... 237</li>
</ol>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="section-5">SECTION 5<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#section-5" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="hormones-and-related-drugs">Hormones and Related Drugs<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#hormones-and-related-drugs" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Introduction ..... 255
17. Anterior Pituitary Hormones ..... 257
18. Thyroid Hormones and Thyroid Inhibitors ..... 267
19. Insulin, Oral Antidiabetic Drugs and Glucagon ..... 280
20. Corticosteroids ..... 306
21. Androgens and Related Drugs, Drugs for Erectile Dysfunction ..... 320
22. Estrogens, Progestins and Contraceptives ..... 330
23. Oxytocin and Other Drugs Acting on Uterus ..... 354
24. Hormones and Drugs Affecting Calcium Balance ..... 360
SECTION 6
Drugs Acting on Peripheral (Somatic) Nervous System
25. Skeletal Muscle Relaxants ..... 373
26. Local Anaesthetics ..... 386
SECTION 7
Drugs Acting on Central Nervous System
27. General Anaesthetics ..... 399
28. Ethyl and Methyl Alcohols ..... 415
29. Sedative-Hypnotics ..... 424
30. Antiepileptic Drugs ..... 438
31. Antiparkinsonian Drugs ..... 452
32. Drugs Used in Mental Illness: Antipsychotic and Antimanic Drugs ..... 462
33. Drugs Used in Mental Illness: Antidepressant and Antianxiety Drugs ..... 481
34. Opioid Analgesics and Antagonists ..... 497
35. CNS Stimulants and Cognition Enhancers ..... 515
SECTION 8
Cardiovascular Drugs
Cardiac Electrophysiological Considerations ..... 521
36. Drugs Affecting Renin-Angiotensin System ..... 524
37. Nitric Oxide and Vasoactive Peptide Signal Molecules ..... 540</p>
<ol start="38">
<li>
<p>Cardiac Glycosides and Drugs for Heart Failure ..... 556</p>
</li>
<li>
<p>Antiarrhythmic Drugs ..... 570</p>
</li>
<li>
<p>Antianginal and Other Anti-ischaemic Drugs ..... 584</p>
</li>
<li>
<p>Antihypertensive Drugs ..... 604
SECTION 9
Drugs Acting on Kidney
Relevant Physiology of Urine Formation ..... 621</p>
</li>
<li>
<p>Diuretics ..... 625</p>
</li>
<li>
<p>Antidiuretics ..... 639
SECTION 10
Drugs Affecting Blood and Blood Formation</p>
</li>
<li>
<p>Haematinics and Erythropoietin ..... 645</p>
</li>
<li>
<p>Drugs Affecting Coagulation, Bleeding and Thrombosis ..... 659</p>
</li>
<li>
<p>Hypolipidaemic Drugs ..... 682
SECTION 11
Gastrointestinal Drugs</p>
</li>
<li>
<p>Drugs for Peptic Ulcer and Gastroesophageal Reflux Disease ..... 695</p>
</li>
<li>
<p>Antiemetic, Prokinetic and Digestant Drugs ..... 709</p>
</li>
<li>
<p>Drugs for Constipation and Diarrhoea ..... 721
SECTION 12
Antimicrobial Drugs</p>
</li>
<li>
<p>Antimicrobial Drugs: General Considerations ..... 739</p>
</li>
<li>
<p>Sulfonamides, Cotrimoxazole and Quinolones ..... 755</p>
</li>
<li>
<p>Beta-Lactam Antibiotics ..... 766</p>
</li>
<li>
<p>Tetracyclines and Chloramphenicol (Broad-Spectrum Antibiotics) ..... 784</p>
</li>
<li>
<p>Aminoglycoside Antibiotics ..... 793</p>
</li>
<li>
<p>Macrolide, Lincosamide, Glycopeptide and Other Antibacterial Antibiotics; Urinary Antiseptics ..... 801</p>
</li>
<li>
<p>Antitubercular Drugs ..... 815</p>
</li>
<li>
<p>Antileprotic Drugs ..... 831</p>
</li>
<li>
<p>Antifungal Drugs ..... 838</p>
</li>
<li>
<p>Antiviral Drugs (Non-retroviral) ..... 849</p>
</li>
<li>
<p>Antiviral Drugs (Anti-retrovirus) ..... 860</p>
</li>
<li>
<p>Antimalarial Drugs ..... 873</p>
</li>
<li>
<p>Antiamoebic and Other Antiprotozoal Drugs ..... 893</p>
</li>
<li>
<p>Anthelmintic Drugs ..... 906
SECTION 13
Chemotherapy of Neoplastic Diseases</p>
</li>
<li>
<p>Anticancer Drugs ..... 915
SECTION 14
Miscellaneous Drugs</p>
</li>
<li>
<p>Immunosuppressant Drugs ..... 937</p>
</li>
<li>
<p>Drugs Acting on Skin and Mucous Membranes ..... 946</p>
</li>
<li>
<p>Antiseptics, Disinfectants and Ectoparasiticides ..... 957</p>
</li>
<li>
<p>Chelating Agents ..... 964</p>
</li>
<li>
<p>Vitamins ..... 968</p>
</li>
<li>
<p>Vaccines, Antisera and Immuneglobulins ..... 978</p>
</li>
<li>
<p>Drug Interactions ..... 987
Appendices
Appendix 1: Solution to Problem Directed Study ..... 995
Appendix 2: Prescribing in Pregnancy ..... 1017
Appendix 3: Drugs in Breastfeeding ..... 1020
Appendix 4: Drugs and Fixed Dose Combinations Banned in India ..... 1024
Selected References for Further Reading ..... 1033
Index ..... 1037</p>
</li>
</ol>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="list-of-abbreviations">List of Abbreviations<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#list-of-abbreviations" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>AA Amino acid
Ab Antibody
ABC ATP-binding cassette (transporter)
ABLC Amphotericin B lipid complex
AC Adenylyl cyclase
ACE Angiotensin II converting enzyme
ACh Acetylcholine
AChE Acetylcholinesterase
ACS Acute coronary syndromes
ACT Artemisinin-based combination therapy
ACTH Adrenocorticotropic hormone
AD Alzheimer's disease
ADCC Antibody-dependent cellular cytotoxicity
ADE Adverse drug event
ADH Antidiuretic hormone
ADHD Attention deficit hyperactivity disorder
ADP Adenosine diphosphate
Adr Adrenaline
ADR Adverse drug reaction
ADS Anti diphtheritic serum
AES Atrial extrasystole
AF Atrial fibrillation
AF1 Atrial flutter
AG Antigen
AGS Antigasgangrene serum
AHG Antihaemophilic globulin
AI Aromatase inhibitor
AIDS Acquired immunodeficiency syndrome
AIP Aldosterone induced protein
ALA Alanine
ALS Amyotrophic lateral sclerosis
Am Amikacin
AMA Antimicrobial agent
AMB Amphotericin B
amp Ampoule
AMP Adenosine mono phosphate
AMPA <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>α</mi></mrow><annotation encoding="application/x-tex">\alpha</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.4306em;"></span><span class="mord mathnormal" style="margin-right: 0.0037em;">α</span></span></span></span></span>-Aminohydroxy methylisoxazole propionic acid
ANC Acid neutralizing capacity
Ang-I/II/III Angiotensin I/II/III
ANP Atrial natriuretic peptide
ANS Autonomic nervous system
ANUG Acute necrotizing ulcerative gingivitis
AP Action potential
AP-1 Activator protein-1
APC Antigen presenting cell
APD Action potential duration
aPTT Activated partial thromboplastin time
AQ Amodiaquine
AR Androgen receptor</p>
<p>ARB Angiotensin receptor blocker
ARC AIDS related complex
ARS Anti rabies serum
ART Antiretrovirus therapy
ARV Antiretrovirus (drug)
AS Artesunate
5-ASA 5-Amino salicyclic acid
ASCVD Atherosclerotic cardiovascular disease
AT-III Antithrombin III
ATG Antithymocyte globulin
ATP Adenosine triphosphate
ATPase Adenosine triphosphatase
ATPIII Adult treatment panel III
ATS Antitetanic serum
AUC Area under the plasma concentration-time curve
A-V Atrioventricular
AVP Arginine vasopressin
AZT Zidovudine</p>
<p>BAL British anti lewisite
BAN British approved name
BB Borderline leprosy
BBB Blood-brain barrier
BCG Bacillus Calmette Guérin
BCNU Bischloroethyl nitrosourea (Carmustine)
BCRP Breast cancer resistance protein
BD Twice daily
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>β</mi></mrow><annotation encoding="application/x-tex">\beta</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mord mathnormal" style="margin-right: 0.05278em;">β</span></span></span></span></span>-ARK <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>β</mi></mrow><annotation encoding="application/x-tex">\beta</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mord mathnormal" style="margin-right: 0.05278em;">β</span></span></span></span></span> adrenergic receptor kinase
BHC Benzene hexachloride
BHP Benign hypertrophy of prostate
BI Bacillary index
BL Borderline lepromatous leprosy
BMD Bone mineral density
BMR Basal metabolic rate
BNP Brain nartriuretic peptide
BOL 2-Bromolysergic acid diethylamide
BP Blood pressure
BPN Bisphosphonate
BSA Body surface area
BT Borderline tuberculoid leprosy
BuChE Butyryl cholinesterase
BW Body weight
BZD Benzodiazepine
C-10 Decamethonium
CA Catecholamine
CAB Combined androgen blockade
CaBP Calcium binding protein
CAD Coronary artery disease</p>
<p>CAM Calmodulin
cAMP 3', 5' Cyclic adenosine monophosphate
CAP Community acquired pneumonia
cap Capsule
CAse Carbonic anhydrase
CAT Computerized axial tomography
CBF Cerebral blood flow
CBG Cortisol binding globulin
CBS Colloidal bismuth subcitrate
CCB Calcium channel blocker
CCNU Chloroethyl cyclohexyl nitrosourea (lomustine)
CCR5 Chemokine coreceptor 5
CD Collecting duct/Cluster of differentiation
CDC Complement dependent cytotoxicity
CFTR Cystic fibrosis transport regulator
cGMP 3', 5' Cyclic guanosine monophosphate
CGRP Calcitonin gene related peptide
CH Cholesterol
ChE Cholinesterase
CHE Cholesterol ester
CHF Congestive heart failure
Chy Chylomicron
Chy. rem. Chylomicron remnants
CI Cardiac index
CINV Chemotherapy induced nausea and vomiting
CKD Chronic kidney disease
CL Clearance
CLcr Creatinine clearance
Cm Capreomycin
CMI Cell mediated immunity
CMV Cytomegalovirus
CNS Central nervous system
c.o. Cardiac output</p>
<p>CoEn-A Coenzyme-A
COMT Catechol-O-methyl transferase
COX Cyclooxygenase
c.p.s. Cycles per second</p>
<p>CPS Complex partial seizures
CPZ Chlorpromazine
CQ Chloroquine
CRABP Cellular retinoic acid binding protein
CRBP Cellular retinol binding protein
CrD Crohn's disease
CREB Cyclic AMP response element binding protein
CRF Corticotropin releasing factor
CS Cycloserine
CSF Cerebrospinal fluid
CTL Cytotoxic T-lymphocytes
CTZ Chemoreceptor trigger zone
CV Cardiovascular
CVP Central venous pressure
CVS Cardiovascular system
CWD Cell wall deficient
CYP450 Cytochrome P450</p>
<p>DA Dopamine
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mrow><mi mathvariant="normal">D</mi><mi mathvariant="normal">A</mi></mrow><mo>−</mo><msub><mi mathvariant="normal">B</mi><mn>12</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{DA}-\mathrm{B}_{12}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7667em; vertical-align: -0.0833em;"></span><span class="mord"><span class="mord mathrm">DA</span></span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">B</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">12</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> Deoxyadenosyl cobalamin
DAD Delayed after-depolarization
DAG Diacyl glycerol
DAM Diacetyl monoxime
DAMP Diphenyl acetoxy-N-methyl piperidine methiodide
DAT Dopamine transporter
dDAVP Desmopressin
DDS Diamino diphenyl sulfone (Dapsone)
DDT Dichloro diphenyl trichloroethane
DEC Diethyl carbamazine citrate
DHA Dihydroartemisinin
DHE Dihydroergotamine
DHFA Dihydro folic acid
DHFRase Dihydrofolate reductase
DHP Dihydropyridine
DHT Dihydrotestosterone
DI Diabetes insipidus
DIT Diiodotyrosine
dl Decilitre
DLE Disseminated lupus erythematosus
DMA Dimethoxy amphetamine
DMARD Disease modifying antirheumatic drug
DMCM Dimethoxyethyl-carbomethoxy- <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>β</mi></mrow><annotation encoding="application/x-tex">\beta</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mord mathnormal" style="margin-right: 0.05278em;">β</span></span></span></span></span>-carboline
DMPA Depot medroxyprogesterone acetate
DMPP Dimethyl phenyl piperazinium
DMT Dimethyltryptamine/Divalent metal transporter
DNA Deoxyribose nucleic acid
DOC Deoxycholate
DOCA Desoxy corticosterone acetate
DOM Dimethoxymethyl amphetamine
dopa Dihydroxyphenyl alanine
DOPAC 3, 4, Dihydroxyphenyl acetic acid
DOSS Dioctyl sulfosuccinate
DOTS Directly observed treatment short course
DPD Dihydropyrimidine dehydrogenase
DPP-4 Dipeptidyl peptidase-4
DPT Diphtheria-pertussis-tetanus triple antigen
DRC Dose-response curve
DRI Direct renin inhibitor
DST Drug sensitivity testing (for TB)
DT Distal tubule
DT-DA Diphtheria-tetanus double antigen
d-TC d-Tubocurarine
DTIC Dacarbazine
DTPA Diethylene triamine pentaacetic acid
DVT Deep vein thrombosis
DYN Dynorphin
E Ethambutol
EACA Epsilon amino caproic acid
EAD Early after-depolarization
ECE Endothelin converting enzyme
e.c.f. Extracellular fluid</p>
<p>ECG Electrocardiogram
ECT Electroconvulsive therapy
ED Erectile dysfunction</p>
<table><thead><tr><th style="text-align: center;">EDRF</th><th style="text-align: center;">Endothelium dependent relaxing factor</th></tr></thead><tbody><tr><td style="text-align: center;">EDTA</td><td style="text-align: center;">Ethylene diamine tetraacetic acid</td></tr><tr><td style="text-align: center;">EEG</td><td style="text-align: center;">Electroencephalogram</td></tr><tr><td style="text-align: center;">EF</td><td style="text-align: center;">Ejection fraction</td></tr><tr><td style="text-align: center;">EGF</td><td style="text-align: center;">Epidermal growth factor</td></tr><tr><td style="text-align: center;">ELAM-1</td><td style="text-align: center;">Endothelial leukocyte adhesion molecule-1</td></tr><tr><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>β</mi></mrow><annotation encoding="application/x-tex">\beta</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mord mathnormal" style="margin-right: 0.05278em;">β</span></span></span></span></span>-END</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>β</mi></mrow><annotation encoding="application/x-tex">\beta</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mord mathnormal" style="margin-right: 0.05278em;">β</span></span></span></span></span>-Endorphin</td></tr><tr><td style="text-align: center;">eNOS</td><td style="text-align: center;">Endothelial nitric oxide synthase</td></tr><tr><td style="text-align: center;">ENS</td><td style="text-align: center;">Enteric nervous system</td></tr><tr><td style="text-align: center;">ENT</td><td style="text-align: center;">Extraneuronal amine transporter</td></tr><tr><td style="text-align: center;">EPAC</td><td style="text-align: center;">cAMP regulated guanine nucleotide exchange factors</td></tr><tr><td style="text-align: center;">EPEC</td><td style="text-align: center;">Enteropathogenic E. coli</td></tr><tr><td style="text-align: center;">EPO</td><td style="text-align: center;">Erythropoietin</td></tr><tr><td style="text-align: center;">EPP</td><td style="text-align: center;">End plate potential</td></tr><tr><td style="text-align: center;">EPSP</td><td style="text-align: center;">Excitatory postsynaptic potential</td></tr><tr><td style="text-align: center;">ER</td><td style="text-align: center;">Estrogen receptor</td></tr><tr><td style="text-align: center;">ERA</td><td style="text-align: center;">Endothelin receptor antagonist</td></tr><tr><td style="text-align: center;">ERP</td><td style="text-align: center;">Effective refractory period</td></tr><tr><td style="text-align: center;">ES</td><td style="text-align: center;">Extrasystole</td></tr><tr><td style="text-align: center;">ESR</td><td style="text-align: center;">Erythrocyte sedimentation rate</td></tr><tr><td style="text-align: center;">ET</td><td style="text-align: center;">Endothelin</td></tr><tr><td style="text-align: center;">ETEC</td><td style="text-align: center;">Enterotoxigenic E. coli</td></tr><tr><td style="text-align: center;">Eto</td><td style="text-align: center;">Ethionamide</td></tr><tr><td style="text-align: center;">FA</td><td style="text-align: center;">Folic acid</td></tr><tr><td style="text-align: center;">FAD</td><td style="text-align: center;">Flavin adenine dinucleotide</td></tr><tr><td style="text-align: center;">5-FC</td><td style="text-align: center;">5-Flucytosine</td></tr><tr><td style="text-align: center;">FDC</td><td style="text-align: center;">Fixed dose combination</td></tr><tr><td style="text-align: center;">FDT</td><td style="text-align: center;">Fixed duration therapy (of leprosy)</td></tr><tr><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">F</mi><mi mathvariant="normal">E</mi><mi mathvariant="normal">V</mi></mrow><mn>1</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{FEV}_{1}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">FEV</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span></td><td style="text-align: center;">Forced expiratory volume in 1 second</td></tr><tr><td style="text-align: center;">FFA</td><td style="text-align: center;">Free fatty acid</td></tr><tr><td style="text-align: center;">FKBP</td><td style="text-align: center;">FK 506 (tacrolimus) binding protein</td></tr><tr><td style="text-align: center;">FLAP</td><td style="text-align: center;">Five-lipoxygenase activating protein</td></tr><tr><td style="text-align: center;">FMN</td><td style="text-align: center;">Favin mononucleotide</td></tr><tr><td style="text-align: center;">FP</td><td style="text-align: center;">Ferroportin</td></tr><tr><td style="text-align: center;">FQ</td><td style="text-align: center;">Fluoroquinolone</td></tr><tr><td style="text-align: center;">FRase</td><td style="text-align: center;">Folate reductase</td></tr><tr><td style="text-align: center;">FSH</td><td style="text-align: center;">Follicle stimulating hormone</td></tr><tr><td style="text-align: center;">5-FU</td><td style="text-align: center;">5-Fluorouracil</td></tr><tr><td style="text-align: center;">G</td><td style="text-align: center;">Genetic</td></tr><tr><td style="text-align: center;">GABA</td><td style="text-align: center;">Gamma amino butyric acid</td></tr><tr><td style="text-align: center;">GAT</td><td style="text-align: center;">GABA-transporter</td></tr><tr><td style="text-align: center;">GC</td><td style="text-align: center;">Guanylyl cyclase</td></tr><tr><td style="text-align: center;">GCP</td><td style="text-align: center;">Good clinical practice</td></tr><tr><td style="text-align: center;">G-CSF</td><td style="text-align: center;">Granulocyte colony stimulating factor</td></tr><tr><td style="text-align: center;">GDP</td><td style="text-align: center;">Guanosine diphosphate</td></tr><tr><td style="text-align: center;">GERD</td><td style="text-align: center;">Gastroesophageal reflux disease</td></tr><tr><td style="text-align: center;">g.f.</td><td style="text-align: center;">Glomerular filtration</td></tr><tr><td style="text-align: center;">g.f.r.</td><td style="text-align: center;">Glomerular filtration rate</td></tr><tr><td style="text-align: center;">GH</td><td style="text-align: center;">Growth hormone</td></tr><tr><td style="text-align: center;">GHRH</td><td style="text-align: center;">Growth hormone releasing hormone</td></tr><tr><td style="text-align: center;">GHRIH</td><td style="text-align: center;">Growth hormone release inhibitory hormone</td></tr><tr><td style="text-align: center;">GIP</td><td style="text-align: center;">Gastric inhibitory peptide/Glucosedependent insulinotropic polypeptide</td></tr><tr><td style="text-align: center;">g.i.t.</td><td style="text-align: center;">Gastrointestinal tract</td></tr><tr><td style="text-align: center;">GITS</td><td style="text-align: center;">Gastrointestinal therapeutic system</td></tr></tbody></table>
<p>GLP Glucagon-like peptide
GLUT Glucose transporter
GM-CSF Granulocyte macrophage colony stimulating factor
GnRH Gonadotropin releasing hormone
GPCR G-protein coupled receptor
G-6-PD Glucose-6-phosphate dehydrogenase
GPI Globus pallidus interna
GST Glutathione-S-transferase
GTCS Generalised tonic-clonic seizures
GTN Glyceryl trinitrate
GTP Guanosine triphosphate
H Isoniazid (Isonicotinic acid hydrazide)
HAP Hospital acquired pneumonia
Hb Haemoglobin
HBV Hepatitis B virus
HCG Human chorionic gonadotropin
HCV Hepatitis C virus
HDCV Human diploid cell vaccine
HDL High density lipoprotein
HETE Hydroxyeicosa tetraenoic acid
5-HIAA 5-Hydroxyindole acetic acid
HIV Human immunodeficiency virus
HLA Human leucocyte antigen
HMG-CoA Hydroxymethyl glutaryl coenzyme A
HMW High molecular weight
HPA axis Hypothalamo-pituitary-adrenal axis
HPETE Hydroperoxy eicosatetraenoic acid
hr Hour
HR Heart rate
HRIG Human rabies immuneglobulin
HRT Hormone replacement therapy
5-HT 5-Hydroxytryptamine
5-HTP 5-Hydroxytryptophan
HVA Homovanillic acid
I Indeterminate leprosy
IAP Islet amyloid polypeptide
IBD Inflammatory bowel disease
IBS Irritable bowel syndrome
ICAM-1 Intracellular adhesion molecule-1
ICSH Interstitial cell stimulating hormone
i.d. Intradermal (injection)</p>
<p>IDL Intermediate density lipoprotein
IFN Interferon
IG Immuneglobulin
IGF Insulin-like growth factor
IL Interleukin
ILEU Isoleucine
i.m. Intramuscular</p>
<p>INH Isonicotinic acid hydrazide
INR International normalized ratio
i.o.t. Intraocular tension</p>
<div class="math math-display"><span class="katex-display"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML" display="block"><semantics><mtable rowspacing="0.25em" columnalign="right left" columnspacing="0em"><mtr><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow></mrow></mstyle></mtd><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow><mrow></mrow><msub><mtext>&nbsp;IP&nbsp;</mtext><mn>3</mn></msub><mtext>&nbsp;Inositol&nbsp;trisphosphate&nbsp;</mtext></mrow></mstyle></mtd></mtr><mtr><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow></mrow></mstyle></mtd><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow><mrow></mrow><msub><mtext>&nbsp;IP&nbsp;</mtext><mn>4</mn></msub><mtext>&nbsp;Inositol&nbsp;tetrakisphosphate&nbsp;</mtext></mrow></mstyle></mtd></mtr></mtable><annotation encoding="application/x-tex">\begin{aligned}
&amp; \text { IP }_{3} \text { Inositol trisphosphate } \\
&amp; \text { IP }_{4} \text { Inositol tetrakisphosphate }
\end{aligned}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 3em; vertical-align: -1.25em;"></span><span class="mord"><span class="mtable"><span class="col-align-r"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 1.75em;"><span style="top: -3.75em;"><span class="pstrut" style="height: 2.84em;"></span><span class="mord"></span></span><span style="top: -2.25em;"><span class="pstrut" style="height: 2.84em;"></span><span class="mord"></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 1.25em;"><span></span></span></span></span></span><span class="col-align-l"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 1.75em;"><span style="top: -3.91em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="mord"></span><span class="mord"><span class="mord text"><span class="mord">&nbsp;IP&nbsp;</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">3</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mord text"><span class="mord">&nbsp;Inositol&nbsp;trisphosphate&nbsp;</span></span></span></span><span style="top: -2.41em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="mord"></span><span class="mord"><span class="mord text"><span class="mord">&nbsp;IP&nbsp;</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">4</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mord text"><span class="mord">&nbsp;Inositol&nbsp;tetrakisphosphate&nbsp;</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 1.25em;"><span></span></span></span></span></span></span></span></span></span></span></span></div>
<p>IPSP Inhibitory postsynaptic potential</p>
<p>IPV Inactivated poliomyelitis vaccine
IRS Insulin response substrate
ISA Intrinsic sympathomimetic activity
ISH Isolated systolic hypertension
IU International unit
IUCD Intrauterine contraceptive device
i.v. Intravenous</p>
<p>JAK Janus-kinase
Km Kanamycin
KTZ Ketoconazole
LA Local anaesthetic
LCAT Lecithin cholesterol acyl transferase
LC3-KAT Long chain 3-ketoacyl-CoA-thiolase
LDL Low density lipoprotein
LES Lower esophageal sphincter
leu-ENK Leucine enkephalin
LH Luteinizing hormone
liq Liquid
LL Lepromatous leprosy
LMW Low molecular weight
LOX Lipoxygenase
LSD Lysergic acid diethylamide
LT Leukotriene
LVF Left ventricular failure
MAbs Monoclonal antibodies
MAC Minimal alveolar concentration
MAC Mycobacterium avium complex
MAO Monoamine oxidase
MAP Muscle action potential
MAPKinase Mitogen activated protein kinase
max Maximum
MBC Minimum bactericidal concentration
MBL Multibacillary leprosy
MCI Mild cognitive impairment
MDI Manic depressive illness
MDMA Methylene dioxy methamphetamine
MDR Multidrug resistant
MDT Multidrug therapy (of leprosy)
met-ENK Methionine enkephalin
mEq milliequivalent
methyl <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">B</mi><mn>12</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{B}_{12}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">B</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">12</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> Methyl cobalamin
Mf Microfilariae
MF Multifactorial
MHC Major histocompatibility complex
MHT Methylene dioxy methamphetamine
MI Myocardial infarction
MIC Minimal inhibitory concentration
MIF Migration inhibitory factor
min Minimum
MIT Monoiodo tyrosine
MLCK Myosin light chain kinase
MMF Mycophenolate mofetil
6-MP 6-Mercaptopurine
MPPT Methylprednisolone pulse therapy
MPTP 4-methyl-4-phenyltetrahydro pyridine
MQ Mefloquine</p>
<p>MRP2 Multidrug resistance associated protein-2
MRSA Methicillin resistant Staphylococcus aureus
MSH Melanocyte stimulating hormone
mTOR Mammalian target of rapamycin
Mtx Methotrexate
mV millivolt
MW Molecular weight
NA Noradrenaline
NABQI N-acetyl-p-benzoquinoneimine
NADP Nicotinamide adenine dinucleotide phosphate
NADPH Reduced nicotinamide adenine dinucleotide phosphate
NAG N -acetyl glucosamine
NAM N -acetyl muramic acid
NANC Nonadrenergic noncholinergic
NAPA N -acetyl procainamide
NaSSA Noradrenergic and specific serotonergic antidepressant
NAT N -acetyl transferase
NCEP National cholesterol education programme
NEE Norethindrone enanthate
NEP Neutral endopeptidase (Neprolysin)
NET Norepinephrine transporter
NFAT Nuclear factor of activated T-cell
NFкB Nuclear factor кB
NICE National Institute for Health and Care Excellence (UK)
NIS <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">N</mi><mi mathvariant="normal">a</mi></mrow><mo lspace="0em" rspace="0em">+</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{Na}^{+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8446em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Na</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8446em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span>(sodium)-iodide symporter
NLEP National leprosy eradication programme
NMDA N-methyl-D-aspartate
nNOS Neural nitric oxide synthase
NNRTI Nonnucleoside reverse transcriptase inhibitor
NPY Neuropeptide-Y
NR Nicotinic receptor
N-REM Non rapid eye movement (sleep)
NRTI Nucleoside reverse transcriptase inhibitor
NSAID Nonsteroidal antiinflammatory drug
NSTEMI Non ST-segment elevation myocardial infarction
NTS Nucleus tractus solitarius
NVBDCP National vector borne diseases control programme
NYHA New York Heart Association
OAT Organic anion transporter
OATP Organic anion transporting polypeptide
OC Oral contraceptive
OCD Obsessive-compulsive disorder
OCT Organic cation transporter
OD Once daily
OPG Osteoprotegerin
OPV Oral poliomyelitis vaccine
ORS Oral rehydration salt (solution)
ORT Oral rehydration therapy
PABA Paraamino benzoic acid
PAE Post antibiotic effect
PAF Platelet activating factor</p>
<table><thead><tr><th style="text-align: center;">PAH</th><th style="text-align: center;">Pulmonary arterial hypertension</th></tr></thead><tbody><tr><td style="text-align: center;">PAI-1</td><td style="text-align: center;">Plasminogen activator inhibitor-1</td></tr><tr><td style="text-align: center;">2-PAM</td><td style="text-align: center;">Pralidoxime</td></tr><tr><td style="text-align: center;">PAN</td><td style="text-align: center;">Primary afferent neurone</td></tr><tr><td style="text-align: center;">PAS</td><td style="text-align: center;">Paraamino salicylic acid</td></tr><tr><td style="text-align: center;">PBI</td><td style="text-align: center;">Protein bound iodine</td></tr><tr><td style="text-align: center;">PBL</td><td style="text-align: center;">Paucibacillary leprosy</td></tr><tr><td style="text-align: center;">PBPs</td><td style="text-align: center;">Penicillin binding proteins</td></tr><tr><td style="text-align: center;">PCA</td><td style="text-align: center;">Patient controlled anaesthesia</td></tr><tr><td style="text-align: center;">PCEV</td><td style="text-align: center;">Purified chick embryo cell vaccine (rabies)</td></tr><tr><td style="text-align: center;">PCI</td><td style="text-align: center;">Percutaneous coronary intervention</td></tr><tr><td style="text-align: center;">PCPA</td><td style="text-align: center;">Parachloro phenylalanine</td></tr><tr><td style="text-align: center;">PD</td><td style="text-align: center;">Parkinsons's disease</td></tr><tr><td style="text-align: center;">PDE</td><td style="text-align: center;">Phosphodiesterase</td></tr><tr><td style="text-align: center;">PE</td><td style="text-align: center;">Pulmonary embolism</td></tr><tr><td style="text-align: center;">PEMA</td><td style="text-align: center;">Phenylethyl malonamide</td></tr><tr><td style="text-align: center;">PEP</td><td style="text-align: center;">Postexposure prophylaxis</td></tr><tr><td style="text-align: center;">PF</td><td style="text-align: center;">Purkinje fibre</td></tr><tr><td style="text-align: center;">PFOR</td><td style="text-align: center;">Pyruvate: ferredoxin oxidoreductase</td></tr><tr><td style="text-align: center;">PG</td><td style="text-align: center;">Prostaglandin</td></tr><tr><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">P</mi><mi mathvariant="normal">G</mi><mi mathvariant="normal">I</mi></mrow><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{PGI}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">PGI</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span></td><td style="text-align: center;">Prostacyclin</td></tr><tr><td style="text-align: center;">Pgp</td><td style="text-align: center;">P-glycoprotein</td></tr><tr><td style="text-align: center;">PI</td><td style="text-align: center;">Protease inhibitor</td></tr><tr><td style="text-align: center;">PIG</td><td style="text-align: center;">Phosphatidyl inositol glycan</td></tr><tr><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">P</mi><mi mathvariant="normal">I</mi><mi mathvariant="normal">P</mi></mrow><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{PIP}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">PIP</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span></td><td style="text-align: center;">Phosphatidyl inositol-4,5-bisphosphate</td></tr><tr><td style="text-align: center;">PKA</td><td style="text-align: center;">Protein kinase: cAMP dependent</td></tr><tr><td style="text-align: center;">PKC</td><td style="text-align: center;">Protein kinase C</td></tr><tr><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">P</mi><mi mathvariant="normal">L</mi></mrow><mi>A</mi></msub></mrow><annotation encoding="application/x-tex">\mathrm{PL}_{A}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">PL</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3283em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mathnormal mtight">A</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span></td><td style="text-align: center;">Phospholipase A</td></tr><tr><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">P</mi><mi mathvariant="normal">L</mi></mrow><mi mathvariant="normal">C</mi></msub></mrow><annotation encoding="application/x-tex">\mathrm{PL}_{\mathrm{C}}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">PL</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3283em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mathrm mtight">C</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span></td><td style="text-align: center;">Phospholipase C</td></tr><tr><td style="text-align: center;">Pl. ph.</td><td style="text-align: center;">Platelet phospholipid</td></tr><tr><td style="text-align: center;">pMDI</td><td style="text-align: center;">pressurized multidose inhaler</td></tr><tr><td style="text-align: center;">PnG</td><td style="text-align: center;">Penicillin G</td></tr><tr><td style="text-align: center;">POMC</td><td style="text-align: center;">Pro-opio melanocortin</td></tr><tr><td style="text-align: center;">PONV</td><td style="text-align: center;">Postoperative nausea and vomiting</td></tr><tr><td style="text-align: center;">PP</td><td style="text-align: center;">Partial pressure</td></tr><tr><td style="text-align: center;">PPAR <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>γ</mi></mrow><annotation encoding="application/x-tex">\gamma</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.625em; vertical-align: -0.1944em;"></span><span class="mord mathnormal" style="margin-right: 0.05556em;">γ</span></span></span></span></span></td><td style="text-align: center;">Paroxysome proliferator-activated receptor <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>γ</mi></mrow><annotation encoding="application/x-tex">\gamma</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.625em; vertical-align: -0.1944em;"></span><span class="mord mathnormal" style="margin-right: 0.05556em;">γ</span></span></span></span></span></td></tr><tr><td style="text-align: center;">PPH</td><td style="text-align: center;">Post partum haemorrhage</td></tr><tr><td style="text-align: center;">PPI</td><td style="text-align: center;">Proton pump inhibitor</td></tr><tr><td style="text-align: center;">ppm</td><td style="text-align: center;">Part per million</td></tr><tr><td style="text-align: center;">PPNG</td><td style="text-align: center;">Penicillinase producing N. gonorrhoeae</td></tr><tr><td style="text-align: center;">PRA</td><td style="text-align: center;">Plasma renin activity</td></tr><tr><td style="text-align: center;">PrEP</td><td style="text-align: center;">Pre-exposure prophylaxis (of HIV)</td></tr><tr><td style="text-align: center;">PRF</td><td style="text-align: center;">Prolactin releasing factor</td></tr><tr><td style="text-align: center;">PRIH</td><td style="text-align: center;">Prolactin release inhibitory hormone</td></tr><tr><td style="text-align: center;">PSVT</td><td style="text-align: center;">Paroxysmal supra-ventricular tachycardia</td></tr><tr><td style="text-align: center;">PT</td><td style="text-align: center;">Proximal tubule</td></tr><tr><td style="text-align: center;">PTCA</td><td style="text-align: center;">Percutaneous transluminal coronary angioplasty</td></tr><tr><td style="text-align: center;">PTH</td><td style="text-align: center;">Parathyroid hormone</td></tr><tr><td style="text-align: center;">PTMA</td><td style="text-align: center;">Phenyl trimethyl ammonium</td></tr><tr><td style="text-align: center;">PTP</td><td style="text-align: center;">Post-tetanic potentiation</td></tr><tr><td style="text-align: center;">PTSD</td><td style="text-align: center;">Post-traumatic stress disorder</td></tr><tr><td style="text-align: center;">PTZ</td><td style="text-align: center;">Pentylenetetrazol</td></tr><tr><td style="text-align: center;">PUV A</td><td style="text-align: center;">Psoralen-Ultraviolet A</td></tr><tr><td style="text-align: center;">PVRV</td><td style="text-align: center;">Purified verocell rabies vaccine</td></tr></tbody></table>
<p>QID Four times a day
R Rifampin (Rifampicin)
RANK Receptor for activation of nuclear factor <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>κ</mi><mi>B</mi></mrow><annotation encoding="application/x-tex">\kappa B</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal">κ</span><span class="mord mathnormal" style="margin-right: 0.05017em;">B</span></span></span></span></span>
RANKL RANK ligand
RAS Renin-angiotensin system
RBC Red blood cells
RBP Retinol binding protein
RC Respiratory centre
RCT Randomized clinical trial
RE Reticuloendothelial
REM Rapid eye movement (sleep)
RGS Regulator of G-protein synthesis
RIG Rabies immuneglobulin
RIMA Reversible inhibitor of MAO-A
rINN Recommended international nonproprietary name
RMP Resting membrane potential
RNA Ribonucleic acid
RNTCP Revised National Tuberculosis Control Programme
RP Refractory period
RTF Resistance transfer factor
RTKs Receptor tyrosine kinases
RXR Retinoid X receptor
RyR Ryanodine receptor
S Streptomycin
SA Sinoauricular (node)
SABE Subacute bacterial endocarditis
s.c. Subcutaneous</p>
<p>SCC Short course chemotherapy (of tuberculosis)
SCh Succinylcholine
SCID Severe combined immunodeficiency disease
SERCA Sarcoplasmic-endoplasmic reticular calcium ATPase
SERDs Selective estrogen receptor down regulators
SERM Selective estrogen receptor modulator
SERT Serotonin transporter
SGA Second generation antihistaminic
SGLT Sodium-glucose transporter
SHBG Sex hormone binding globulin
SIADH Syndrome of inappropriate ADH secretion
s.l. Sublingual</p>
<p>SLC Solute carrier
SLE Systemic lupus erythematosus
SMON Subacute myelo-optic neuropathy
SNP Single nucleotide polymorphism
SN-PC Substantia nigra-pars compacta
SN-PR Substantia nigra-pars reticularis
SNRI Serotonin and noradrenaline reuptake inhibitor
s.o.s. as required</p>
<p>S/P Sulfonamide + pyrimethamine
SP Substance <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>P</mi></mrow><annotation encoding="application/x-tex">P</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.13889em;">P</span></span></span></span></span>
SPF Sun protection factor
SPRM Selective progesterone receptor modulator
SPS Simple partial seizures</p>
<table><thead><tr><th style="text-align: center;">SR</th><th style="text-align: center;">Sustained release</th><th style="text-align: center;">TRE</th><th style="text-align: center;">Thyroid hormone response element</th></tr></thead><tbody><tr><td style="text-align: center;">SRS-A</td><td style="text-align: center;">Slow reacting substance of anaphylaxis</td><td style="text-align: center;">TRH</td><td style="text-align: center;">Thyrotropin releasing hormone</td></tr><tr><td style="text-align: center;">SSG</td><td style="text-align: center;">Sodium stibogluconate</td><td style="text-align: center;">TSH</td><td style="text-align: center;">Thyroid stimulating hormone</td></tr><tr><td style="text-align: center;">SSI</td><td style="text-align: center;">Surgical site infection</td><td style="text-align: center;">TT</td><td style="text-align: center;">Tuberculoid leprosy</td></tr><tr><td style="text-align: center;">SSRIs</td><td style="text-align: center;">Selective serotonin reuptake inhibitors</td><td style="text-align: center;">TTS</td><td style="text-align: center;">Transdermal therapeutic system</td></tr><tr><td style="text-align: center;">STAT</td><td style="text-align: center;">Signal transducer and activator of transcription</td><td style="text-align: center;">TX</td><td style="text-align: center;">Thromboxane</td></tr><tr><td style="text-align: center;">STEMI</td><td style="text-align: center;">ST-segment elevation myocardial infarction</td><td style="text-align: center;">U</td><td style="text-align: center;">Unit</td></tr><tr><td style="text-align: center;">StK</td><td style="text-align: center;">Streptokinase</td><td style="text-align: center;">UA</td><td style="text-align: center;">Unstable angina</td></tr><tr><td style="text-align: center;">SU</td><td style="text-align: center;">Sulfonylurea</td><td style="text-align: center;">UDP</td><td style="text-align: center;">Uridine diphosphate</td></tr><tr><td style="text-align: center;">SULT</td><td style="text-align: center;">Sulfotransferase</td><td style="text-align: center;">UFH</td><td style="text-align: center;">Unfractionated heparin</td></tr><tr><td style="text-align: center;">SUR</td><td style="text-align: center;">Sulfonyl urea receptor</td><td style="text-align: center;">UGDP</td><td style="text-align: center;">University group diabetic programme</td></tr><tr><td style="text-align: center;">susp</td><td style="text-align: center;">Suspension</td><td style="text-align: center;">UGT</td><td style="text-align: center;">UDP-glucuronosyl transferase</td></tr><tr><td style="text-align: center;">SVR</td><td style="text-align: center;">Sustained viral response</td><td style="text-align: center;">USAN</td><td style="text-align: center;">United States adopted name</td></tr><tr><td style="text-align: center;">SWD</td><td style="text-align: center;">Shift work disorder</td><td style="text-align: center;">UT</td><td style="text-align: center;">Urea transporter</td></tr><tr><td style="text-align: center;">SWS</td><td style="text-align: center;">Slow wave sleep</td><td style="text-align: center;">UTI</td><td style="text-align: center;">Urinary tract infection</td></tr><tr><td style="text-align: center;">syr</td><td style="text-align: center;">Syrup</td><td style="text-align: center;">v</td><td style="text-align: center;">Volt</td></tr><tr><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">t</mi><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">\mathrm{t} \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord mathrm">t</span><span class="mord">%</span></span></span></span></span></td><td style="text-align: center;">Half life</td><td style="text-align: center;">V</td><td style="text-align: center;">Volume of distribution</td></tr><tr><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">T</mi><mn>3</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{T}_{3}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">T</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">3</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span></td><td style="text-align: center;">Triiodothyronine</td><td style="text-align: center;">VAL</td><td style="text-align: center;">Valine</td></tr><tr><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">T</mi><mn>4</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{T}_{4}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">T</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">4</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span></td><td style="text-align: center;">Thyroxine</td><td style="text-align: center;">VAP</td><td style="text-align: center;">Ventilator associated pneumonia</td></tr><tr><td style="text-align: center;">tab</td><td style="text-align: center;">Tablet</td><td style="text-align: center;">VDR</td><td style="text-align: center;">Vit D receptor</td></tr><tr><td style="text-align: center;">TAB</td><td style="text-align: center;">Typhoid, paratyphoid A and B vaccine</td><td style="text-align: center;">VES</td><td style="text-align: center;">Ventricular extrasystole</td></tr><tr><td style="text-align: center;">TAL</td><td style="text-align: center;">Thick ascending limb (loop of Henle)</td><td style="text-align: center;">VF</td><td style="text-align: center;">Ventricular fibrillation</td></tr><tr><td style="text-align: center;">TB</td><td style="text-align: center;">Tubercle bacilli</td><td style="text-align: center;">VIP</td><td style="text-align: center;">Vasoactive intestinal peptide</td></tr><tr><td style="text-align: center;">TBG</td><td style="text-align: center;">Thyroxine binding globulin</td><td style="text-align: center;">Vit</td><td style="text-align: center;">Vitamin</td></tr><tr><td style="text-align: center;">TCII</td><td style="text-align: center;">Transcobalamin II</td><td style="text-align: center;">VKOR</td><td style="text-align: center;">Vitamin K epoxide reductase</td></tr><tr><td style="text-align: center;">TCAs</td><td style="text-align: center;">Tricyclic antidepressants</td><td style="text-align: center;">VL</td><td style="text-align: center;">Visceral leishmaniasis</td></tr><tr><td style="text-align: center;">TCID <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow></mrow><mn>50</mn></msub></mrow><annotation encoding="application/x-tex">_{50}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.4511em; vertical-align: -0.15em;"></span><span class="mord"><span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">50</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span></td><td style="text-align: center;">Tissue culture infectious dose 50%</td><td style="text-align: center;">VLDL</td><td style="text-align: center;">Very low density lipoprotein</td></tr><tr><td style="text-align: center;">TDM</td><td style="text-align: center;">Therapeutic drug monitoring</td><td style="text-align: center;">VMA</td><td style="text-align: center;">Vanillyl mandelic acid</td></tr><tr><td style="text-align: center;">TDS</td><td style="text-align: center;">Three times a day</td><td style="text-align: center;">VMAT</td><td style="text-align: center;">Vesicular monoamine transporter</td></tr><tr><td style="text-align: center;">Tf</td><td style="text-align: center;">Transferrin</td><td style="text-align: center;">VRE</td><td style="text-align: center;">Vancomycin resistant enterococci</td></tr><tr><td style="text-align: center;">TG</td><td style="text-align: center;">Triglyceride</td><td style="text-align: center;">VRSA</td><td style="text-align: center;">Vancomycin resistant Staphylococcus aureus</td></tr><tr><td style="text-align: center;">6-TG</td><td style="text-align: center;">6-Thioguanine</td><td style="text-align: center;">VRUT</td><td style="text-align: center;">Vasopressin regulated urea transporter</td></tr><tr><td style="text-align: center;">TGF- <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>β</mi></mrow><annotation encoding="application/x-tex">\beta</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mord mathnormal" style="margin-right: 0.05278em;">β</span></span></span></span></span></td><td style="text-align: center;">Transforming growth factor <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>β</mi></mrow><annotation encoding="application/x-tex">\beta</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mord mathnormal" style="margin-right: 0.05278em;">β</span></span></span></span></span></td><td style="text-align: center;">VT</td><td style="text-align: center;">Ventricular tachycardia</td></tr><tr><td style="text-align: center;">THC</td><td style="text-align: center;">Tetrahydrocannabinol</td><td style="text-align: center;">VTE</td><td style="text-align: center;">Venous thromboembolism</td></tr><tr><td style="text-align: center;">THFA</td><td style="text-align: center;">Tetrahydro folic acid</td><td style="text-align: center;">vWF</td><td style="text-align: center;">von Willebrand factor</td></tr><tr><td style="text-align: center;">Thio TEPA</td><td style="text-align: center;">Triethylene thiophosphoramide</td><td style="text-align: center;">WBC</td><td style="text-align: center;">White blood cells</td></tr><tr><td style="text-align: center;">THR</td><td style="text-align: center;">Threonine</td><td style="text-align: center;">WCVs</td><td style="text-align: center;">Water channel containing vesicles</td></tr><tr><td style="text-align: center;">TIAs</td><td style="text-align: center;">Transient ischaemic attacks</td><td style="text-align: center;">WHO</td><td style="text-align: center;">World Health Organization</td></tr><tr><td style="text-align: center;">TNF- <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>α</mi></mrow><annotation encoding="application/x-tex">\alpha</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.4306em;"></span><span class="mord mathnormal" style="margin-right: 0.0037em;">α</span></span></span></span></span></td><td style="text-align: center;">Tumour necrosis factor <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>α</mi></mrow><annotation encoding="application/x-tex">\alpha</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.4306em;"></span><span class="mord mathnormal" style="margin-right: 0.0037em;">α</span></span></span></span></span></td><td style="text-align: center;">WPW</td><td style="text-align: center;">Wolff-Parkinson-White syndrome</td></tr><tr><td style="text-align: center;">TOD</td><td style="text-align: center;">Target organ damage</td><td style="text-align: center;">XDR-TB</td><td style="text-align: center;">Extensively drug resistant-TB</td></tr><tr><td style="text-align: center;">TOF</td><td style="text-align: center;">Train-of-four</td><td style="text-align: center;">Z</td><td style="text-align: center;">Pyrazinamide</td></tr><tr><td style="text-align: center;">t-PA</td><td style="text-align: center;">Tissue plasminogen activator</td><td style="text-align: center;">ZE (syndrome)</td><td style="text-align: center;">Zollinger-Ellison (syndrome)</td></tr><tr><td style="text-align: center;">TPMT</td><td style="text-align: center;">Thiopurine methyl transferase</td><td style="text-align: center;"></td><td style="text-align: center;"></td></tr><tr><td style="text-align: center;">t.p.r.</td><td style="text-align: center;">Total peripheral resistance</td><td style="text-align: center;"></td><td style="text-align: center;"></td></tr><tr><td style="text-align: center;">TR</td><td style="text-align: center;">Thyroid hormone receptor</td><td style="text-align: center;"></td><td style="text-align: center;"></td></tr></tbody></table>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="general-pharmacological-principles">GENERAL PHARMACOLOGICAL PRINCIPLES<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#general-pharmacological-principles" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="chapter-1-br-introduction-routes-of-drug-administration">Chapter 1 &lt;br&gt; Introduction, Routes of Drug Administration<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#chapter-1-br-introduction-routes-of-drug-administration" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="introduction">INTRODUCTION<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#introduction" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="pharmacology">Pharmacology<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#pharmacology" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Pharmacology is the science of drugs (Greek: Pharmacon-drug; logos-discourse in). In a broad sense, it deals with interaction of exogenously administered chemical molecules with living systems, and any single chemical substance which can produce a biological response is a 'drug'. Pharmacology encompasses all aspects of knowledge about drugs, butmost importantly those that are relevant to effective and safe use of drugs for medicinal purposes.</p>
<p>For thousands of years most drugs were crude natural products of unknown composition and limited efficacy. Only the overt effects of these substances on the body were rather imprecisely known, but how the same were produced was entirely unknown. Animal experiments, primarily aimed at understanding physiological processes, were started in the 18th century. These were pioneered by F. Magendie and Claude Bernard, who also adapted them to study effects of certain drugs. Pharmacology as an experimental science was ushered by Rudolf Buchheim who founded the first institute of pharmacology in 1847 in Germany. In the later part of the 19th century, Oswald Schmiedeberg, regarded as the 'father of pharmacology', together with his many disciples like J Langley, T Frazer, P Ehrlich, AJ Clark, JJ Abel propounded some
of the fundamental concepts in pharmacology. Since then drugs have been purified, chemically characterized and a vast variety of highly potent and selective new drugs have been developed. The mechanism of action including molecular target of many drugs has been elucidated. This has been possible due to prolific growth of pharmacology which forms the backbone of rational therapeutics.</p>
<p>The two main divisions of pharmacology are pharmacodynamics and pharmacokinetics.
Pharmacodynamics (Greek: dynamis-power) -What the drug does to the body.</p>
<p>This includes physiological and biochemical effects of drugs and their mechanism of action at organ system/subcellular/macromolecular levels, e.g.-Adrenaline <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>→</mo></mrow><annotation encoding="application/x-tex">\rightarrow</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.3669em;"></span><span class="mrel">→</span></span></span></span></span> interaction with adrenoceptors <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>→</mo></mrow><annotation encoding="application/x-tex">\rightarrow</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.3669em;"></span><span class="mrel">→</span></span></span></span></span> G-protein mediated stimulation of cell membrane bound adenylyl cyclase <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>→</mo></mrow><annotation encoding="application/x-tex">\rightarrow</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.3669em;"></span><span class="mrel">→</span></span></span></span></span> increased intracellular cyclic <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mn>3</mn><mo mathvariant="normal" lspace="0em" rspace="0em">′</mo></msup><mo separator="true">,</mo><msup><mn>5</mn><mo mathvariant="normal" lspace="0em" rspace="0em">′</mo></msup><mrow><mi mathvariant="normal">A</mi><mi mathvariant="normal">M</mi><mi mathvariant="normal">P</mi></mrow><mo>→</mo></mrow><annotation encoding="application/x-tex">3^{\prime}, 5^{\prime} \mathrm{AMP} \rightarrow</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.9463em; vertical-align: -0.1944em;"></span><span class="mord"><span class="mord">3</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.7519em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">′</span></span></span></span></span></span></span></span></span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord"><span class="mord">5</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.7519em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">′</span></span></span></span></span></span></span></span></span><span class="mord"><span class="mord mathrm">AMP</span></span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">→</span></span></span></span></span> cardiac stimulation, hepatic glycogenolysis and hyperglycaemia, etc.
Pharmacokinetics (Greek: Kinesis-movement)-What the body does to the drug.</p>
<p>This refers to movement of the drug in and alteration of the drug by the body; includes absorption, distribution, binding/localization/storage, biotransformation and excretion of the drug, e.g. paracetamol is rapidly and almost completely absorbed orally attaining peak blood levels at <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>30</mn><mo>−</mo><mn>60</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">m</mi><mi mathvariant="normal">i</mi><mi mathvariant="normal">n</mi></mrow><mo separator="true">;</mo><mn>25</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">30-60 \mathrm{~min} ; 25 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">30</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.9444em; vertical-align: -0.1944em;"></span><span class="mord">60</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm">min</span></span><span class="mpunct">;</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord">25%</span></span></span></span></span> bound to plasma proteins,</p>
<p>widely and almost uniformly distributed in the body (volume of distribution <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>∼</mo><mn>1</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">L</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">\sim 1 \mathrm{~L} / \mathrm{kg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.3669em;"></span><span class="mrel">∼</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">1</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm">L</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span></span></span></span></span> ); extensively metabolized in the liver, primarily by glucuronide and sulfate conjugation into inactive metabolites which are excreted in urine; has a plasma half life <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo fence="true">(</mo><msup><mi mathvariant="normal">t</mi><mrow><mn>1</mn><mi mathvariant="normal">/</mi><mn>2</mn></mrow></msup><mo fence="true">)</mo></mrow><annotation encoding="application/x-tex">\left(\mathrm{t}^{1 / 2}\right)</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1.238em; vertical-align: -0.35em;"></span><span class="minner"><span class="mopen delimcenter" style="top: 0em;"><span class="delimsizing size1">(</span></span><span class="mord"><span class="mord mathrm">t</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.888em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1/2</span></span></span></span></span></span></span></span></span><span class="mclose delimcenter" style="top: 0em;"><span class="delimsizing size1">)</span></span></span></span></span></span></span> of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>2</mn><mo>−</mo><mn>3</mn></mrow><annotation encoding="application/x-tex">2-3</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">2</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">3</span></span></span></span></span> hours and a clearance value of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">l</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">i</mi><mi mathvariant="normal">n</mi></mrow></mrow><annotation encoding="application/x-tex">5 \mathrm{ml} / \mathrm{kg} / \mathrm{min}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">5</span><span class="mord"><span class="mord mathrm">ml</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm">min</span></span></span></span></span></span>.</p>
<p>Drug (French: Drogue-a dry herb) It is the single active chemical entity present in a medicine that is used for diagnosis, prevention, treatment/cure of a disease.</p>
<p>This disease oriented definition of drug does not include contraceptives or use of drugs for improvement of health. The WHO (1966) has given a more comprehensive definition-"Drug is any substance or product that is used or is intended to be used to modify or explore physiological systems or pathological states for the benefit of the recipient."</p>
<p>The term 'drugs' is being also used to mean addictive/abused/illicit substances. However, this restricted and derogatory sense usage is unfortunate degradation of a time honoured term, and 'drug' should refer to a substance that has some health promoting/therapeutic/ diagnostic application. Nevertheless, to avoid any misinterpretation, the term 'medicine' is being employed to designate such a substance in place of the term 'drug'.</p>
<p>Some other important aspects of pharmacology are:
Pharmacotherapeutics It is the application of pharmacological information together with knowledge of the disease for its prevention, mitigation or cure. Selection of the most appropriate drug, dosage and duration of treatment taking into account the stage of disease and the specific features of a patient are a part of pharmacotherapeutics.</p>
<p>Clinical pharmacology It is the scientific study of drugs (both old and new) in man. It includes pharmacodynamic and pharmacokinetic investigation in healthy volunteers as well as in patients. Evaluation of efficacy and safety
of drugs and comparative trials with other forms of treatment; surveillance of patterns of drug use, adverse effects, etc. are also part of clinical pharmacology.</p>
<p>The aim of clinical pharmacology is to generate data for optimum use of drugs and the practice of 'evidence based medicine'.</p>
<p>Chemotherapy It is the treatment of systemic infection/malignancy with specific drugs that have selective toxicity for the infecting organism/malignant cell with no/minimal effects on the host cells.
Drugs in general, can thus be divided into:
Pharmacodynamic agents These are designed to have pharmacodynamic effects in the recipient.</p>
<p>Chemotherapeutic agents These are designed to inhibit/kill invading parasites/malignant cell, but have no/minimal pharmacodynamic effects in the recipient.</p>
<p>Pharmacy It is the art and science of compounding and dispensing drugs or preparing suitable dosage forms for administration of drugs to man or animals. It includes collection, identification, purification, isolation, synthesis, standardization and quality control of medicinal substances. The large scale manufacture of drugs is called Pharmaceutics, which is primarily a technological science.</p>
<p>Toxicology It is the study of poisonous effect of drugs and other chemicals (household, environmental pollutant, industrial, agricultural, homicidal) with emphasis on detection, prevention and treatment of poisonings. It also includes the study of adverse effects of drugs, since the same substance can be a drug or a poison, depending on the dose.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="nature-of-drugs">NATURE OF DRUGS<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#nature-of-drugs" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>All drugs are chemical entities with simple or complex molecules. While majority are organic compounds, some are purely inorganic, like lithium carbonate, ferrous sulfate, magnesium hydroxide, etc. Organic drugs may be weakly</p>
<p>acidic (aspirin, penicillin) or weakly basic (morphine, chloroquine) or nonelectrolytes (alcohol, diethyl-ether). Most drugs are normally solids, e.g. paracetamol, propranolol, furosemide, ampicillin, etc., but some such as ethanol, glyceryl trinitrate, propofol, castor oil are liquids, and few like nitrous oxide are gaseous.</p>
<p>The molecular weight of majority of drugs falls in the range of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>100</mn><mo>−</mo><mn>1000</mn><mi mathvariant="normal">D</mi></mrow><annotation encoding="application/x-tex">100-1000 \mathrm{D}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">100</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord">1000</span><span class="mord mathrm">D</span></span></span></span></span>, because molecules smaller than 100 D do not generally have sufficiently specific features in terms of shape, size, configuration, chirality, distribution of charges, etc. to selectively bind to only one/ few closely related target biomolecules, to the exclusion of others. On the other hand, larger molecules than 1000 D do not readily pass through membranes/barriers in the body to reach the target sites in various tissues/cells. However, few drugs are as small as lithium ion (7D), and some like heparin ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>10</mn><mo>−</mo><mn>20</mn><mrow><mi mathvariant="normal">K</mi><mi mathvariant="normal">D</mi></mrow></mrow><annotation encoding="application/x-tex">10-20 \mathrm{KD}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">10</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord">20</span><span class="mord"><span class="mord mathrm">KD</span></span></span></span></span></span> ), gonadotropins ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&gt;</mo><mn>30</mn><mrow><mi mathvariant="normal">K</mi><mi mathvariant="normal">D</mi></mrow></mrow><annotation encoding="application/x-tex">&gt;30 \mathrm{KD}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&gt;</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord">30</span><span class="mord"><span class="mord mathrm">KD</span></span></span></span></span></span> ), enzymes, proteins, antibodies ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&gt;</mo><mn>50</mn></mrow><annotation encoding="application/x-tex">&gt;50</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&gt;</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">50</span></span></span></span></span> KD) are much bigger. Bulky molecule drugs have to be administered parenterally.</p>
<p>Drugs are generally perceived to be chemical substances foreign to the body (Xenobiotics). However, many endogenous chemicals like hormones, autacoids, metabolites and nutrients are also used as drugs. Chemical congeners of these metabolites/signal molecules are an important class of drugs which act by modifying the synthesis, storage, degradation or action of these metabolites/signal molecules.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="sources-of-drugs">SOURCES OF DRUGS<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#sources-of-drugs" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Drugs are obtained from a variety of sources:</p>
<ol>
<li>Plants Many plants contain biologically active substances and are the oldest source of drugs. Clues about medicinal plants were obtained from traditional systems of medicine prevalent in various parts of the world; e.g. use of opium, belladonna, ephedra, cinchona, curare, foxglove, sarpagandha, qinghaosu has been learnt from Egyptian, Greek, Aztec, Ayurvedic, Chinese and other systems of medicine. Chemically the active ingredients of plants fall in several categories:
a. Alkaloids: These are alkaline nitrogenous bases having potent activity, and are the most important category of vegetable origin drugs. Prominent examples are: morphine, atropine, ephedrine, nicotine, ergotamine, reserpine, quinine, vincristine, etc. They are mostly used as their water soluble hydrochloride/ sulfate salts.
b. Glycosides: These compounds consist of a heterocyclic nonsugar moiety (aglycone) linked to a sugar moiety through ether linkage. Cardiac glycosides (digoxin, ouabain) are the best known glycosidic drugs. The active principle of senna and similar plant purgatives are anthraquinone glycosides. Aminoglycosides (gentamicin, etc.) are antibiotics obtained from microorganisms, and have an aminosugar in place of a sugar moiety.
c. Oils: These are viscous, inflammable liquids, insoluble in water. Fixed (nonvolatile) oils are calorie yielding triglycerides of higher fatty acids; mostly used for food and as emollients, e.g. groundnut oil, coconut oil, sesame oil, etc. Castor oil is a stimulant purgative. Essential (volatile) oils, mostly obtained from flowers or leaves by steam distillation are aromatic (fragrant) terpene hydrocarbons that have no food value. They are used as flavouring agents, carminatives, counterirritants and astringents; examples are eucalyptus oil, pepermint oil, nilgiri oil, etc. Clove oil is used to allay dental pain. Menthol, thymol, camphor are volatile oils that are solids at room temperature.
Mineral oils are not plant products, but obtained from petroleum; liquid paraffin is a lubricant laxative, soft and hard paraffin are used as emollient and as ointment bases.
Other plant products like tanins are astringent; gums are demulcents and act as suspending agents in liquid dosage forms. Glycerine is a viscous, sweet liquid used as vehicle for gum/throat paint. Resins and balsams are used as antiseptic and in</li>
</ol>
<p>cough mixtures. The antimalarial drug artemisinin is a sesquiterpene endoperoxide obtained from a Chinese plant.
2. Animals Though animal parts have been used as cures since early times, it was exploration of activity of organ extracts in the late 19th and early 20th century that led to introduction of animal products into medicine, e.g. adrenaline, thyroxine, insulin, liver extract (vit. <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">B</mi><mn>12</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{B}_{12}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">B</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">12</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> ). Antisera and few vaccines are also produced from animals.
3. Microbes Most antibiotics are obtained from fungi, actinomycetes and bacteria, e.g. penicillin, gentamicin, tetracycline, erythromycin, polymyxin B, actinomycin D (anticancer). Some enzymes, e.g. diastase from a fungus and streptokinase from streptococci have a microbial source. Vaccines are produced by the use of microbes.
4. Minerals Few minerals, e.g. iron salts, calcium salts, lithium carbonate, magnesium/ aluminium hydroxide, iodine are used as medicinal substances.
5. Synthetic chemistry Synthetic chemistry made its debut in the 19th century, and is now the largest source of medicines. Synthetic drugs have the advantage of purity and uniformity of the product. They can be manufactured in any quantity as per need, in contrast to drugs from natural sources whose availability may be limited. Not only diverse congeners of naturally obtained drugs (atropine substitutes, adrenergic <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi>β</mi><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\beta_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.05278em;">β</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.0528em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> agonists, synthetic glucocorticoids/progestins/ cephalosporins, etc.) have been introduced to achieve greater selectivity of action or even novel type of activity, but many entirely synthetic families of drugs, e.g. benzodiazepines, thiazides, benzimidazoles, fluoroquinolones, etc. have been produced. Many drugs are being synthesized to target specific biomolecules, e.g. ACE inhibitors, glycoprotein IIb/IIIa receptor antagonists, HIV-reverse transcriptase inhibitors, etc. Synthetic drugs that are chiral can also be produced as single active enantiomer products, which may be therapeutically superior.
6. Biotechnology Several drugs, especially peptides and proteins are now produced by recombinant DNA technology, e.g. human growth hormone, human insulin, altaplase, interferon, etc. Monoclonal antibodies, regulator peptides, erythropoietin and other growth factors are the newer drugs of biotechnological origin. Protein therapeutics is rapidly expanding, because specifically designed and customized proteins can now be produced.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="drug-nomenclature">DRUG NOMENCLATURE<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#drug-nomenclature" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>A drug generally has three categories of names:
(a) Chemical name It describes the substance chemically, e.g. 1-(Isopropylamino)-3-(1-naphthyloxy) propan-2-ol for propranolol. This is cumbersome and not suitable for use in prescribing. A code name, e.g. RO 15-1788 (later named flumazenil) may be assigned by the manufacturer for convenience and simplicity before an approved name is coined.
(b) Non-proprietary name It is the name accepted by a competent scientific body/ authority, e.g. the United States Adopted Name (USAN) by the USAN council. Similarly, there is the British Approved name (BAN) of a drug. The non-proprietary names of newer drugs are kept uniform by an agreement to use the Recommended International Nonproprietary Name (rINN) in all member countries of the WHO. The BAN of older drugs as well has now been modified to be commensurate with rINN. However, many older drugs still have more than one non-proprietary names, e.g. 'meperidine' and 'pethidine' or 'lidocaine' and 'lignocaine' for the same drugs. Until the drug is included in a pharmacopoeia, the nonproprietary name may also be called the approved name. After its appearance in the official publication, it becomes the official name.</p>
<p>In common parlance, the term generic name is used in place of nonproprietary name. Etymologically this is incorrect: 'generic'</p>
<p>should be applied to the chemical or pharmacological group (or genus) of the compound, e.g. phenothiazines, tricyclic antidepressants, aminoglycoside antibiotics, etc. However, this misnomer is widely accepted and used even in official parlance.
(c) Proprietary (Brand) name It is the name assigned by the manufacturer(s) and is his property or trade mark. One drug may have multiple proprietary names, e.g. AMCARD, AMLOGARD, AMLOCOR, AMLONG, AMLOPIN, AMLOVAS, STAMLO for amlodipine from different manufacturers. Brand names are designed to be catchy, short, easy to remember and often suggestive, e.g. LOPRESOR suggesting drug for lowering blood pressure. Brand names generally differ in different countries, e.g. timolol maleate eye drops are marketed as TIMOPTIC in USA but as GlUCOMOL in India. Even the same manufacturer may market the same drug under different brand names in different countries. In addition, combined formulations have their own multiple brand names. This is responsible for much confusion in drug nomenclature.</p>
<p>There are many arguments for using the nonproprietary name in prescribing: uniformity, convenience, economy and better comprehension (propranolol, sotalol, timolol, pindolol, metoprolol, acebutolol, atenolol are all <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>β</mi></mrow><annotation encoding="application/x-tex">\beta</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mord mathnormal" style="margin-right: 0.05278em;">β</span></span></span></span></span> blockers, but their brand names have no such similarity). Drugs marketed under nonproprietary name (called generic products) are much cheaper than their branded counterparts, partly because the manufacturer invests a lot of money in promoting the brand name. However, when a drug is prescribed by the generic name, the chemist is free to dispense the generic product from any manufacturer, but not so when the drug is prescribed by a brand name. Thus, when it is important to ensure consistency of the product in terms of quality and bioavailability, etc. and especially when official control over quality of manufactured products is not rigorous, it is better to prescribe by the dependable brand name.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="drug-compendia">DRUG COMPENDIA<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#drug-compendia" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>These are compilations of information on drugs in the form of monographs; without going into the theoretical concepts, mechanisms of action and other aspects which help in understanding the subject. Pharmacopoeias and Formularies are broughtout by the Government in a country, hold legal status and are called official compendia. In addition, some non-official compendia are published by professional bodies, which are supplementary and dependable sources of information about drugs.</p>
<p>Pharmacopoeias They contain description of chemical structure, molecular weight, physical and chemical characteristics, solubility, identification and assay methods, standards of purity, storage conditions and dosage forms of officially approved drugs in a country. They are useful to drug manufacturers and regulatory authorities, but not to doctors, most of whom never see a pharmacopoeia. Examples are Indian (IP), British (BP), European (Eur P), United States (USP) pharmacopoeias.</p>
<p>Formularies Generally produced in easily carried booklet form, they list indications, dose, dosage forms, contraindications, precautions, adverse effects and storage of selected drugs that are available for medicinal use in a country. Drugs are categorized by their therapeutic class. Some rational fixed-dose drug combinations are included. A brief commentary on the drug class and clinical conditions in which they are used generally precedes specifics of individual drugs. Brief guidelines for treatment of selected conditions are provided. While British National Formulary (BNF) also lists brand names with costs, the National Formulary of India (NFI) does not include these. Most formularies have informative appendices as well. Formularies can be considerably helpful to prescribers.</p>
<p>Martindale: The Complete Drug Reference (Extrapharmacopoeia) Published every 2-3 years by the Royal Pharmaceutical Society of Great Britain, this non-official compendium is</p>
<p>an exhaustive and updated compilation of unbiased information on medicines used/registered all over the world. It includes new launches and contains pharmaceutical, pharmacological as well as therapeutic information on drugs, which can serve as a reliable reference book.</p>
<p>Physicians Desk Reference (PDR) and Drug: Facts and Comparisons (both from USA), etc. are other useful non-official compendia.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="essential-medicines-drugs-concept">ESSENTIAL MEDICINES (DRUGS) CONCEPT<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#essential-medicines-drugs-concept" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>The WHO has defined Essential Medicines (drugs) as "those that satisfy the priority healthcare needs of the population." They are selected with due regard to public health relevance, evidence on efficacy and safety, and comparative cost effectiveness. Essential medicines are intended to be available within the context of functioning health systems at all times and in adequate amounts, in appropriate dosage forms, with assured quality and adequate information, and at a price the individual and the community can afford.</p>
<p>It has been realized that only a handful of medicines out of the multitude available can meet the health care needs of majority of the people in any country, and that many well tested and cheaper medicines are equally (or more) efficacious and safe as their newer more expensive congeners. For optimum utilization of resources, governments (especially in developing countries) should concentrate on these medicines by identifying them as Essential medicines. The WHO has laid down criteria to guide selection of an essential medicine.*
(a) Adequate data on its efficacy and safety should be available from clinical studies.
(b) It should be available in a form in which quality, including bioavailability, and stability on storage can be assured.
(c) Its choice should depend upon pattern of prevalent diseases; availability of facilities and trained personnel;
financial resources; genetic, demographic and environmental factors.
(d) In case of two or more similar medicines, choice should be made on the basis of their relative efficacy, safety, quality, price and availability. Cost-benefit ratio should be a major consideration.
(e) Choice may also be influenced by comparative pharmacokinetic properties and local facilities for manufacture and storage.
(f) Most essential medicines should be single compounds. Fixed ratio combination products should be included only when dosage of each ingredient meets the requirements of a defined population group, and when the combination has a proven advantage in therapeutic effect, safety, adherence or in decreasing the emergence of drug resistance.
(g) Selection of essential medicines should be a continuous process which should take into account the changing priorities for public health action, epidemiological conditions as well as availability of better medicines/formulations and progress in pharmacological knowledge.
(h) Recently, it has been emphasized to select essential medicines based on rationally developed treatment guidelines.</p>
<p>To guide the member countries, the WHO brought out its first Model List of Essential Drugs along with their dosage forms and strengths in 1977 which could be adopted after suitable modifications according to local needs. This has been revised from time to time and the current is the 20th list (2017) <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow></mrow><mi mathvariant="normal">b</mi></msup></mrow><annotation encoding="application/x-tex">{ }^{\mathrm{b}}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8491em;"></span><span class="mord"><span class="mord"></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8491em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mathrm mtight">b</span></span></span></span></span></span></span></span></span></span></span></span></span> which has 433 medicines, including 25 fixed dose drug combinations (FDCs). India produced its National Essential Drugs List in 1996, and has revised it in 2011, and now in 2015 with the title "National List of Essential Medicines". <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow></mrow><mtext>c&nbsp;</mtext></msup></mrow><annotation encoding="application/x-tex">{ }^{\text {c }}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6644em;"></span><span class="mord"><span class="mord"></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.6644em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord text mtight"><span class="mord mtight">c&nbsp;</span></span></span></span></span></span></span></span></span></span></span></span></span></span> The latest list includes 376 medicines, of which 20 are FDCs. These medicines have been marked into 3 categories for being available at primary, secondary and tertiary levels of health care facility.</p>
<p>Adoption of the essential medicines list for procurement and supply of medicines, especially in the public sector healthcare system, has resulted in improved availability of medicines, cost saving and more rational use of drugs.</p>
<p><sup><a href="#user-content-fn-0" id="user-content-fnref-0" data-footnote-ref="true" aria-describedby="footnote-label">1</a></sup></p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="prescription-and-non-prescription-drugs">Prescription and non-prescription drugs<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#prescription-and-non-prescription-drugs" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>As per drug rules, majority of drugs including all antibiotics must be sold in retail only against a prescription issued to a patient by a registered medical practitioner. These are called 'prescription drugs', and in India they have been placed in the schedule <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>H</mi></mrow><annotation encoding="application/x-tex">H</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.08125em;">H</span></span></span></span></span> of the Drugs and Cosmetic Rules (1945) as amended from time to time. However, few drugs like simple analgesics (paracetamol aspirin), antacids, laxatives (senna, lactulose), vitamins, ferrous salts, etc. are considered relatively harmless, and can be procured without a prescription. These are 'non-prescription' or 'over-the-counter' (OTC) drugs; can be sold even by grocery stores.
Orphan Drugs These are drugs or biological products for diagnosis/treatment/ prevention of a rare disease or condition, or a more common disease (endemic only in resource poor countries or areas) for which there is no reasonable expectation that the cost of developing and marketing it will be recovered from the sales of that drug. As per Orphan Drug Amendment (1983) Act of USA, a rare disease/ condition is one that affects less than 0.2 million people in the USA. Though these drugs may be life saving for some patients, they are commercially difficult to obtain as a medicinal product. Governments in developed countries offer tax benefits and other incentives to pharmaceutical companies for developing and marketing orphan drugs. Orphan drug status has been awarded to many drugs in the USA, Europe and some other countries. Few examples of drugs granted 'Orphan Drug' status are listed in the box.</p>
<table><thead><tr><th style="text-align: left;">Abridged list of Orphan drugs</th><th style="text-align: left;"></th></tr></thead><tbody><tr><td style="text-align: left;">Azacitidine</td><td style="text-align: left;">Icatibant</td></tr><tr><td style="text-align: left;">Bevacizumab</td><td style="text-align: left;">Iloprost</td></tr><tr><td style="text-align: left;">Bortezomib</td><td style="text-align: left;">Nilotinib</td></tr><tr><td style="text-align: left;">Busulfan</td><td style="text-align: left;">Paromomycin</td></tr><tr><td style="text-align: left;">Carboprost</td><td style="text-align: left;">Rifaximin</td></tr><tr><td style="text-align: left;">Clofazimine</td><td style="text-align: left;">Rituximab</td></tr><tr><td style="text-align: left;">Colchicine</td><td style="text-align: left;">Sodium stibogluconate</td></tr><tr><td style="text-align: left;">Eltrombopag</td><td style="text-align: left;">Sodium thiosulfate</td></tr><tr><td style="text-align: left;">Fornivirsen</td><td style="text-align: left;">ThioTEPA</td></tr></tbody></table>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="dosage-forms-of-drugs">DOSAGE FORMS OF DRUGS<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#dosage-forms-of-drugs" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Dosage form is a product suitable for administration of a drug to a patient. Every active ingredient (drug) has to be formulated by adding other substances (excipients, diluents, preservatives,
vehicles, etc.) according to a specific recipe and packaged into a specific 'dosage form' such as tablet, elixir, ointment, injection vial, etc. which is then administered to the subject. The dosage form provides body to the drug, demarkates single doses, protects the active ingredient(s), and makes it suitable for administration in various ways. The important dosage forms are briefly described below.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="solid-dosage-forms">Solid dosage forms<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#solid-dosage-forms" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ol>
<li>Powders The drug is in a dry and finely pulverised state. If the drug is for oral administration, each dose has to be wrapped separately or packed in sachets; therefore this dosage form is inconvenient and unpopular except when the quantity is several grams, e.g. oral rehydration salts. Powders for topical application (dusting powders) are supplied as bulk powders in metallic or plastic containers with holes for sprinkling. Effervescent powders contain granulated sod. bicarbonate and citric or tartaric acid. They react when dissolved in water to liberate <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">C</mi><mi mathvariant="normal">O</mi></mrow><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{CO}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">CO</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> causing bubbling.</li>
<li>Tablets The drug is powdered or granulated, mixed with binding agents, and other excipients, and compressed/moulded into discoid, oblong or other shapes suitable for swallowing. The tablet may be plain or sugar coated or film coated. Other specialized types of tablets are:
Chewable tablets-can be chewed and swallowed, ingredients must be pleasent tasting.
Dispersible tablets - the tablet is dropped in a small quantity of water, wherein it disperses quickly; the solution is then gulped.
Sublingual tablets - put under the tongue, the drug is rapidly absorbed from the mouth.
Enteric coated tablet - the tablet is coated with a material that does not dissolve in the acidic medium of the stomach; the tablet disintegrates only on reaching the duodenum.
Sustained/Extended release tablets-These contain drug particles which are coated to</li>
</ol>
<p>dissolve at different rates. The active ingredient is made available for absorption over a longer period of time. The duration of action of short acting (2-6 hours) drugs can be extended to 12 hours or more.
Controlled release tablets-A semipermeable membrane controls the release of the drug prolonging its duration of action.
3. Pills These are archaic dosage forms in which the drug powder is mixed with honey/syrup to make a sticky mass. This is then rolled into spherical/oval bodies meant to be swallowed. The term is often loosely applied to tablets as well.
4. Capsules These are water soluble cylindrical containers made of gelatin which are filled with powdered or liquid medicament. The container dissolves on swallowing so that the drug is released in the stomach. Soft gelatine capsules dissolve very rapidly and generally contain liquid medicament. Enteric coated capsules are designed to dissolve only on reaching the ileum. Spansules are extended release capsules which are packed with granules of the drug having different coatings to dissolve over a range of time periods.
5. Lozenges These are tablet-like bodies of various shapes containing the drug along with a suitable gum, sweetening and flavouring agents. They are to be retained in the mouth and allowed to dissolve slowly, providing the drug for local action in the mouth and throat.
6. Suppositories These are conical bullet- shaped dosage forms for insertion into the anal canal, in which the drug is mixed with a mouldable firm base that melts at body temperature and releases the contained drug. Oval or suitably shaped bodies for vaginal insertion are called 'pessaries', while elongated pencil-like cones meant for insertion into male or female urethra are called bougies.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="liquid-dosage-forms">Liquid dosage forms<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#liquid-dosage-forms" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ol>
<li>
<p>Aqueous solutions They contain the drug dissolved in water, and may be meant for
oral, topical or parenteral administration. Oral drug solutions often contain sweetening and flavouring agents. Preservatives have to be mostly added because shelf-life of watery solutions is short.</p>
</li>
<li>
<p>Suspensions are dispersion of insoluble drugs in water with the help of a suspending agent. Emulsions are uniform mixtures of two immiscible liquids (mostly oil and water) in which droplets of one (dispersed phase) are suspended in the other (continuous phase) with the help of an amphiphilic emulsifying agent. Milk is a naturally occurring emulsion. Both suspensions and emulsions tend to settle down on keeping; should be shaken thoroughly before use.</p>
</li>
<li>
<p>Elixirs are hydro-alcoholic solutions of drugs, usually sweetened with syrup and flavoured by fruit extracts. Syrups have higher concentration of sugar and are thicker in consistency. Drugs that deteriorate in aqueous medium can be dispensed as 'dry syrups' which is reconstituted by adding water and shaking. The reconstituted syrup must be used within a few days. Linctus is a viscous syrupy liquid meant to be licked slowly for soothing the throat. It generally has menthol to impart cooling sensation, and an antitussive.</p>
</li>
<li>
<p>Drops These are relatively more concentrated solutions of medicaments meant for oral ingestion or external application to eye, nose or ear canal. Oral drops are the preferred dosage form for infants and young children. Eye/ nasal drops should be isotonic. Eye drops need sterilization. Drops are supplied in vials with a nozzle or alongwith a dropper for accurate dosing.</p>
</li>
<li>
<p>Lotions These are solutions, suspensions or emulsions meant for external application to the skin without rubbing. They generally have soothing, cooling, protective or emollient property and are better suited than creams or ointments for hairy skin. Liniments are similar preparations which generally contain counterirritants, and are to be rubbed on the skin to relieve pain and cause rubefaction.</p>
</li>
<li>
<p>Injections These are sterile solutions or suspensions in aqueous or oily medium for subcutaneous or intramuscular administration. Only aqueous solutions (not suspensions) are suitable for intravenous (i.v.) injection, because particles in suspension and oils injected i.v. can cause embolism. Injections are supplied in sealed glass ampoules or air tight rubber capped vials. Ampoules are broken just before injection, and usually contain a single dose. Drug from the vial is sucked in a syringe by piercing the rubber cap. Vials may be single or multi-dose. Drugs which are unstable in solution are supplied as dry powder vials. Sterile solvent is injected in the vial just before it is to be administered, and the dissolved/suspended drug is then sucked out into the syringe. Some drugs like insulin are also supplied in prefilled syringes and pen injectors. Large volume i.v. infusions are marketed in glass/polypropylene bottles.</p>
</li>
</ol>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="semisolid-dosage-forms">Semisolid dosage forms<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#semisolid-dosage-forms" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ol>
<li>Ointments These are greasy semisolid preparations meant for external application to the skin, eye, nasal mucosa, ear or anal canal. The drug is incorporated in an oily base, such as soft or hard paraffin, wool fat, bee's wax, etc. Ointments are not suitable for oozing surfaces, because they are more occlusive and donot allow evaporation of water. Rather they are good for dry, chronic lesions. Creams are similar to ointment but the base is a water in oil emulsion. The medicament is better absorbed into the skin from creams than from ointments, and creams are cosmetically more acceptable than ointments.</li>
<li>Pastes These are nongreasy preparations of thick consistency containing hydrophilic adhesive powders such as starch, prepared chalk, aluminium/magnesium hydroxide, zinc oxide, carboxy methylcellulose, etc. which swell by absorbing water. Pastes may contain viscous nonoily liquids like glycerol or propylene glycol. Pastes can be applied to inflamed or excoriated skin, oozing surfaces
and mucous membranes. Toothpastes are items of personal hygiene, and medicated toothpastes are extensively used in dentistry.</li>
<li>Gels The medicament is incorporated in a viscous colloidal solution of gelatin or similar material and is usually dispensed in collapsible tubes. They are meant for external application to the skin or mucosa and provide longer duration contact, but are nongreasy and washable with water. Gels are suitable for application to hairy skin, and are commonly applied to oral ulcers because they are better retained than aqueous solutions.</li>
</ol>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="inhalations">Inhalations<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#inhalations" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Drugs which are gases or volatile liquids can be administered by inhalation carried into air or oxygen with the help of a mouth piece, face mask, hood or endotracheal tube. Nonvolatile liquids and fine particle solids can be aerosolized using a metered dose inhaler, jet nebulizer, rotahaler or spinhaler for inhalation through the mouth. Pressurized metered dose inhalers (PMDIs) are hand-held devices which use a propellant, mostly hydrofluoroalkane (HFA), and deliver a specified dose of the drug in aerosol form per actuation. Jet nebulizers produce a mist of the drug solution generated by pressurized air or oxygen. Rotahaler is also a portable device in which a capsule (rotacap) containing very fine powder of the drug is punctured during actuation and the released particles are aerosolized by the inspiratory airflow of the patient. A propellant can also be used in some spin halers. Efficacy of the aerosolized drug depends on the particle size: 1-5 <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>μ</mi><mi mathvariant="normal">m</mi></mrow><annotation encoding="application/x-tex">\mu \mathrm{m}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.625em; vertical-align: -0.1944em;"></span><span class="mord mathnormal">μ</span><span class="mord mathrm">m</span></span></span></span></span> diameter particles deposit on the bronchioles and effectively deliver the drug. Larger particles settle on the oropharynx, while <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&lt;</mo><mn>1</mn><mi>μ</mi><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">m</mi></mrow></mrow><annotation encoding="application/x-tex">&lt;1 \mu \mathrm{~m}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&lt;</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">1</span><span class="mord mathnormal">μ</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm">m</span></span></span></span></span></span> particles donot settle anywhere and are exhaled out.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="routes-of-drug-administration">ROUTES OF DRUG ADMINISTRATION<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#routes-of-drug-administration" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Most drugs can be administered by a variety of routes. The choice of appropriate route in a given situation depends both on drug as well as patient related factors. Mostly common</p>
<p>sense considerations, feasibility and convenience dictate the route to be used.</p>
<p>Routes can be broadly divided into those for (a) Local action and (b) Systemic action.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="factors-governing-choice-of-route">Factors governing choice of route<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#factors-governing-choice-of-route" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ol>
<li>Physical and chemical properties of the drug (solid/liquid/gas; solubility, stability, pH , irritancy).</li>
<li>Site of desired action-localized and approachable or generalized and not approachable.</li>
<li>Rate and extent of absorption of the drug from different routes.</li>
<li>Effect of digestive juices and first pass metabolism on the drug.</li>
<li>Rapidity with which the response is desired (routine treatment or emergency).</li>
<li>Accuracy of dosage required (i.v. and inhalational can provide fine tuning).</li>
<li>Condition of the patient (unconscious, vomiting).</li>
</ol>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="local-routes">LOCAL ROUTES<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#local-routes" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>These routes can only be used for localized lesions at accessible sites and for drugs whose systemic absorption from these sites is minimal or absent. Thus, high concentrations are attained at the desired site without exposing the rest of the body. Systemic side effects or toxicity are consequently absent or minimal. For drugs (in suitable dosage forms) that are absorbed from these sites/routes, the same can serve as systemic route of administration, e.g. glyceryl trinitrate (GTN) applied on the skin as ointment or transdermal patch for angina pectoris. The local routes are:</p>
<ol>
<li>Topical This refers to external application of the drug to the surface for localized action. It is often more convenient as well as reassuring to the patient. Drugs can be efficiently delivered to the localized lesions on skin, oropharyngeal/ nasal mucosa, eyes, ear canal, anal canal or vagina in the form of lotion, ointment, cream, powder, rinse, paints, drops, spray, lozengens, suppositories or pesseries. Nonabsorbable drugs given orally for action on g.i. mucosa (sucralfate, vancomycin), inhalation of drugs for action on bronchi (salbutamol,
cromolyn sodium) and irrigating solutions/jellys (povidone iodine, lidocaine) applied to urethra are other forms of topical medication.</li>
<li>Deeper tissues Certain deep areas can be approached by using a syringe and needle, but the drug should be in such a form that systemic absorption is slow, e.g. intra-articular injection (hydrocortisone acetate in knee joint), infiltration around a nerve or intrathecal injection (lidocaine), retrobulbar injection (hydrocortisone acetate behind the eyeball).</li>
<li>Arterial supply Close intra-arterial injection is used for contrast media in angiography; anticancer drugs can be infused in femoral or brachial artery to localise the effect for limb malignancies.</li>
</ol>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="systemic-routes">SYSTEMIC ROUTES<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#systemic-routes" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>The drug administered through systemic routes is intended to be absorbed into the blood stream and distributed all over, including the site of action, through circulation (see Fig. 1.1).</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="1-oral">1. Oral<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#1-oral" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Oral ingestion is the oldest and commonest mode of drug administration. It is safer, more convenient, does not need assistance, noninvasive, often painless, the medicament need not be sterile and so is cheaper. Both solid dosage forms (powders, tablets, capsules, spansules, dragees, moulded tablets, gastrointestinal therapeutic sys-tems-GITs) and liquid dosage forms (elixirs, syrups, emulsions, mixtures) can be given orally.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="limitations-of-oral-route-of-administration">Limitations of oral route of administration<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#limitations-of-oral-route-of-administration" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Action of drugs is slower and thus not suitable for emergencies.</li>
<li>Unpalatable drugs (chloramphenicol) are difficult to administer; drug may be filled in capsules to circumvent this.</li>
<li>May cause nausea and vomiting.</li>
<li>Cannot be used for uncooperative/unconscious/ vomiting patient.</li>
<li>Absorption of the drug may be variable and erratic; certain drugs are not absorbed (streptomycin).</li>
<li>Others are destroyed by digestive juices (penicillin G, insulin) or in liver (GTN, testosterone, lidocaine).</li>
</ul>
<p><img src="assets/images/image-20251214-11ba9553.jpeg" alt="img-0.jpeg"></p>
<p>Fig. 1.1: Vascular pathway of drugs absorbed from various systemic routes of administration and sites of first pass metabolism
Note: Total drug absorbed orally is subjected to first pass metabolism in intestinal wall and liver, while approximately half of that absorbed from rectum passes through liver. Drug entering from any systemic route is exposed to first pass metabolism in lungs, but its extent is minor for most drugs.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="2-sublingual-s-i-or-buccal">2. Sublingual (s.I.) or buccal<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#2-sublingual-s-i-or-buccal" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>The tablet or pellet containing the drug is placed under the tongue or crushed in the mouth and spread over the buccal mucosa. Only lipid soluble and non-irritating drugs can be so administered. Absorption is relatively rapid-action can be produced in minutes. Though it is somewhat inconvenient, one can spit the drug after the desired effect has been obtained. The chief advantage is that liver is bypassed and drugs with high first pass metabolism can be absorbed directly into systemic circulation. Drugs given sublingually are-GTN, buprenorphine, desamino-oxytocin.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="3-rectal">3. Rectal<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#3-rectal" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Certain irritant and unpleasant drugs can be put into rectum as suppositories or retention enema for systemic effect. This route can also be used when the patient is having recurrent vomiting or is unconscious. However, it is rather inconvenient and embarrassing; absorption is slower, irregular and often unpredictable, though diazepam solution and paracetamol suppository are rapidly and dependably absorbed from the rectum in children. Drug absorbed into external haemorrhoidal veins (about 50%) bypasses liver, but not that absorbed into internal haemorrhoidal veins. Rectal inflammation can result from irritant drugs. Diazepam, indomethacin, paracetamol, ergotamine and few other drugs are some times given rectally.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="4-cutaneous">4. Cutaneous<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#4-cutaneous" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Highly lipid soluble drugs can be applied over the skin for slow and prolonged absorption. The liver is also bypassed. The drug can be incorporated in an ointment and applied over specified area of skin. Absorption of the drug can be enhanced by rubbing the preparation, by using an oily base and by an occlusive dressing.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="transdermal-therapeutic-systems-tts">Transdermal therapeutic systems (TTS)<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#transdermal-therapeutic-systems-tts" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>These are devices in the form of adhesive patches of various shapes and sizes <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo fence="true">(</mo><mn>5</mn><mo>−</mo><mn>20</mn><msup><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">c</mi><mi mathvariant="normal">m</mi></mrow><mn>2</mn></msup><mo fence="true">)</mo></mrow><annotation encoding="application/x-tex">\left(5-20 \mathrm{~cm}^{2}\right)</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1.2em; vertical-align: -0.35em;"></span><span class="minner"><span class="mopen delimcenter" style="top: 0em;"><span class="delimsizing size1">(</span></span><span class="mord">5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mord">20</span><span class="mord"><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm">cm</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8141em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span></span></span></span></span><span class="mclose delimcenter" style="top: 0em;"><span class="delimsizing size1">)</span></span></span></span></span></span></span> which deliver the contained drug at a constant rate into systemic circulation via the stratum corneum (Fig. 1.2). The drug (in solution or
bound to a polymer) is held in a reservoir between an occlusive backing film and a rate controlling micropore membrane, the under surface of which is smeared with an adhesive impregnated with priming dose of the drug. The adhesive layer is protected by another film that is to be peeled off just before application. The drug is delivered at the skin surface by diffusion for percutaneous absorption into circulation. The micropore membrane is such that rate of drug delivery to skin surface is less than the slowest rate of absorption from the skin. This offsets any variation in the rate of absorption according to the properties of different sites. As such, the drug is delivered at a constant and predictable rate irrespective of site of application. Usually chest, abdomen, upper arm, lower back, buttock or mastoid region are utilized.</p>
<p>Transdermal patches of GTN, fentanyl, nicotine and estradiol are available in India, while those of isosorbide dinitrate, hyoscine, and clonidine are marketed elsewhere. For different drugs, TTS have been designed to last for <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mo>−</mo><mn>3</mn></mrow><annotation encoding="application/x-tex">1-3</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">1</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">3</span></span></span></span></span> days. Though more expensive, they provide smooth plasma concentrations of the drug without fluctuations; minimize interindividual variations (drug is subjected to little first pass metabolism) and side effects. They are also more convenient-many patients prefer transdermal patches to oral tablets of the same drug; patient compliance is better. Local irritation and erythema occurs in some subjects, but is generally mild; can be minimized by changing the site of application each time by rotation.
<img src="assets/images/image-20251214-5c96a8d4.jpeg" alt="img-1.jpeg"></p>
<p>Fig. 1.2: Illustration of a transdermal drug delivery system</p>
<p>Discontinuation has been necessary in only <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>2</mn><mo>−</mo><mn>7</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">2-7 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">2</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">7%</span></span></span></span></span> cases.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="5-inhalation">5. Inhalation<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#5-inhalation" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Volatile liquids and gases are given by inhalation for systemic action, e.g. general anaesthetics. Absorption takes place from the vast surface of alveoli-action is very rapid. When administration is discontinued the drug diffuses back and is rapidly eliminated in expired air. Thus, controlled administration is possible with moment to moment adjustment. Irritant vapours (ether) cause inflammation of respiratory tract and increase secretion.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="6-nasal">6. Nasal<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#6-nasal" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>The mucous membrane of the nose can readily absorb many drugs; digestive juices and liver are bypassed. However, only certain drugs like GnRH agonists, calcitonin and desmopressin applied as a spray or nebulized solution have been used by this route. This route is being tried for some other peptide drugs like insulin, as well as to bypass the blood-brain barrier.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="7-parenteral">7. Parenteral<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#7-parenteral" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>(Par-beyond, enteral-intestinal)
Conventionally, parenteral refers to administration by injection which takes the drug directly into the tissue fluid or blood without having to cross the enteral mucosa. The limitations of oral administration are circumvented.</p>
<p>Drug action is faster and surer (valuable in emergencies). Gastric irritation and vomiting are not provoked. Parenteral routes can be employed even in unconscious, uncooperative or vomiting patient. There are no chances of interference by food or digestive juices. Liver is bypassed.</p>
<p>Disadvantages of parenteral routes are-the preparation has to be sterilized and is costlier, the technique is invasive and painful, assistance of another person is mostly needed (though self injection is possible, e.g. insulin by diabetics), there are chances of local tissue injury and, in general, parenteral route is more risky than oral. The important parenteral routes are:
(i) Subcutaneous (s.c.) The drug is deposited in the loose subcutaneous tissue which is richly supplied by nerves (irritant drugs cannot be injected) but is less vascular (absorption is slower than intramuscular). Only small volumes can be injected s.c. Self-injection is possible because deep penetration is not needed. This route should be avoided in shock patients who are vasoconstricted-absorption will be delayed. Repository (depot) preparations that are aqueous suspensions can be injected for prolonged action. Some special forms of this route are:
(a) Dermojet In this method needle is not used; a high velocity jet of drug solution is projected from a microfine orifice using a gun like implement. The solution passes through the superficial layers and gets deposited in the subcutaneous tissue. It is essentially painless and suited for mass inoculations.
(b) Pellet implantation The drug in the form of a solid pellet is introduced with a trochar and cannula. This provides sustained release of the drug over weeks and months, e.g. DOCA, testosterone.
(c) Sialistic (nonbiodegradable) and biodegradable implants Crystalline drug is packed in tubes or capsules made of suitable materials and implanted under the skin. Slow and uniform leaching of the drug occurs over months providing constant blood levels. The nonbiodegradable implant has to be removed later on but not the biodegradable one. This has been tried for hormones and contraceptives (e.g. NORPLANT).
(ii) Intramuscular (i.m.) The drug is injected in one of the large skeletal muscles-deltoid, triceps, gluteus maximus, rectus femoris, etc. Muscle is less richly supplied with sensory nerves (mild irritants can be injected) and is more vascular (absorption of drugs in aqueous solution is faster). It is less painful, but self injection is often impracticable because deep penetration is needed. Depot preparations (oily solutions, aqueous suspensions) can be injected</p>
<p>by this route. Intramuscular injections should be avoided in anticoagulant treated patients, because it can produce local haematoma.
(iii) Intravenous (i.v.) The drug is injected as a bolus (Greek: bolos-lump) or infused slowly over hours in one of the superficial veins. The drug reaches directly into the blood stream and effects are produced immediately (great value in emergency). The intima of veins is insensitive and drug gets diluted with blood, therefore, even highly irritant drugs can be injected i.v., but hazards are-thrombophlebitis of the injected vein and necrosis of adjoining tissues if extravasation occurs. These complications can be minimized by diluting the drug or injecting it into a running i.v. line. Only aqueous solutions (not suspensions, because drug particles can cause embolism) are to be
injected i.v. and there are no depot preparations for this route. Chances of causing air embolism is another risk. The dose of the drug required is smallest (bioavailability is <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>100</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">100 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">100%</span></span></span></span></span> ) and even large volumes can be infused. One big advantage with this route is-in case response is accurately measurable (e.g. BP) and the drug short acting (e.g. sodium nitroprusside), titration of the dose with the response is possible. However, this is the most risky route-vital organs like heart, brain, etc. get exposed to high concentrations of the drug.
(iv) Intradermal injection The drug is injected into the skin raising a bleb (e.g. BCG vaccine, sensitivity testing) or scarring/multiple puncture of the epidermis through a drop of the drug is done. This route is employed for specific purposes only.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="problem-directed-study">PROBLEM DIRECTED STUDY<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#problem-directed-study" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>1.1. A 5-year-old child is brought to the hospital with the complaint of fever, cough, breathlessness and chest pain. On examination he is found to be dull, but irritable with fast pulse <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo stretchy="false">(</mo><mn>116</mn><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">i</mi><mi mathvariant="normal">n</mi></mrow><mo stretchy="false">)</mo></mrow><annotation encoding="application/x-tex">(116 / \mathrm{min})</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mopen">(</span><span class="mord">116/</span><span class="mord"><span class="mord mathrm">min</span></span><span class="mclose">)</span></span></span></span></span>, rapid breathing (RR <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>50</mn><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">i</mi><mi mathvariant="normal">n</mi></mrow></mrow><annotation encoding="application/x-tex">50 / \mathrm{min}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">50/</span><span class="mord"><span class="mord mathrm">min</span></span></span></span></span></span> ) and indrawing of lower chest during inspiration, wheezing, crepitations and mild dehydration. Body temperature is <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mn>40</mn><mo lspace="0em" rspace="0em">∘</mo></msup><mi mathvariant="normal">C</mi><mrow><mo fence="true">(</mo><msup><mn>104</mn><mo lspace="0em" rspace="0em">∘</mo></msup><mi mathvariant="normal">F</mi><mo fence="true">)</mo></mrow></mrow><annotation encoding="application/x-tex">40^{\circ} \mathrm{C}\left(104^{\circ} \mathrm{F}\right)</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">4</span><span class="mord"><span class="mord">0</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.6741em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">∘</span></span></span></span></span></span></span></span></span><span class="mord mathrm">C</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="minner"><span class="mopen delimcenter" style="top: 0em;">(</span><span class="mord">10</span><span class="mord"><span class="mord">4</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.6741em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">∘</span></span></span></span></span></span></span></span></span><span class="mord mathrm">F</span><span class="mclose delimcenter" style="top: 0em;">)</span></span></span></span></span></span>. The paediatrician makes a provisional diagnosis of acute pneumonia and orders relevant haematological as well as bacteriological investigations. He decides to institute antibiotic therapy.
a. In case he selects an antibiotic which can be given orally as well as by i.m. or i.v. injection, which route of administration will be most appropriate in this case?
b. Should the paediatrician administer the antibiotic straight away or should he wait for the laboratory reports?
(see Appendix-1 for solution)</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="chapter-2-br-pharmacokinetics-membrane-transport-absorption-and-distribution-of-drugs">Chapter 2 &lt;br&gt; Pharmacokinetics: Membrane Transport, Absorption and Distribution of Drugs<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#chapter-2-br-pharmacokinetics-membrane-transport-absorption-and-distribution-of-drugs" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Pharmacokinetics is the quantitative study of drug movement in, through and out of the body. The overall scheme of pharmacokinetic processes is depicted in Fig. 2.1. The intensity of response is related to concentration of the drug at the site of action, which in turn is dependent on its pharmacokinetic properties. Pharmacokinetic considerations, therefore, determine the route(s) of administration, dose, latency of onset, time of peak action, duration of action and frequency of administration of a drug.</p>
<p>All pharmacokinetic processes involve transport of the drug across biological membranes.
Biological membrane This is a bilayer (about <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>100</mn><mover accent="true"><mi>A</mi><mo>˚</mo></mover></mrow><annotation encoding="application/x-tex">100 \AA</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.9468em;"></span><span class="mord">100</span><span class="mord accent"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.9468em;"><span style="top: -3em;"><span class="pstrut" style="height: 3em;"></span><span class="mord mathnormal">A</span></span><span style="top: -3.2523em;"><span class="pstrut" style="height: 3em;"></span><span class="accent-body" style="left: -0.2361em;"><span class="mord">˚</span></span></span></span></span></span></span></span></span></span></span> thick) of phospholipid and cholesterol molecules, the polar groups (glyceryl phosphate attached to ethanolamine/choline or hydroxyl group of cholesterol) of these are oriented at the two surfaces and the nonpolar hydrocarbon chains are embedded in the matrix to form a continuous sheet. This imparts high electrical resistance and relative impermeability to the membrane.
<img src="assets/images/image-20251214-a2359ab8.jpeg" alt="img-2.jpeg"></p>
<p>Fig. 2.1: Schematic depiction of pharmacokinetic processes</p>
<p><img src="assets/images/image-20251214-438fae79.jpeg" alt="img-3.jpeg"></p>
<p>Fig. 2.2: Illustration of the organisation of biological membrane</p>
<p>Extrinsic and intrinsic protein molecules are adsorbed on the lipid bilayer (Fig. 2.2). Glycoproteins or glycolipids are formed on the surface by attachment to polymeric sugars, aminosugars or sialic acids. The specific lipid and protein composition of different membranes differs according to the cell or the organelle type. The proteins are able to freely float through the membrane: associate and organize or vice versa. Some of the intrinsic ones, which extend through the full thickness of the membrane, surround fine aqueous pores. Paracellular spaces or channels also exist between certain epithelial/ endothelial cells. Other adsorbed proteins have enzymatic, carrier, receptor or signal transduction properties. Lipid molecules also are capable of lateral movement. Thus, biological membranes are highly dynamic structures.
Drugs are transported across the membranes by:
(a) Passive diffusion and filtration
(b) Specialized transport</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="passive-diffusion">Passive diffusion<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#passive-diffusion" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>The drug diffuses across the membrane in the direction of its concentration gradient (high to low), the membrane playing no active role in the process. This is the most important mechanism for majority of drugs; drugs are foreign substances (xenobiotics), and specialized mechanisms are developed by the body primarily for normal metabolites.
<img src="assets/images/image-20251214-1ceb2ee3.jpeg" alt="img-4.jpeg"></p>
<p>Fig. 2.3: Illustration of passive diffusion and filtration across the lipoidal biological membrane with aqueous pores</p>
<p>Lipid soluble drugs diffuse by dissolving in the lipoidal matrix of the membrane (Fig. 2.3), the rate of transport being proportional to the lipid : water partition coefficient of the drug. A more lipid-soluble drug attains higher concentration in the membrane and diffuses quickly. Also, greater the difference in the concentration of the drug on the two sides of the membrane, faster is its diffusion.
Influence of pH Most drugs are weak electrolytes, i.e. their ionization is pH dependent (contrast strong electrolytes that are nearly completely ionized at acidic as well as alkaline pH ). The ionization of a weak acid HA is given by the equation:</p>
<div class="math math-display"><span class="katex-display"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML" display="block"><semantics><mrow><mi>p</mi><mi>H</mi><mo>=</mo><mi>p</mi><mi>K</mi><mi>a</mi><mo>+</mo><mi>log</mi><mo>⁡</mo><mfrac><mrow><mo fence="true">[</mo><msup><mi mathvariant="normal">A</mi><mo lspace="0em" rspace="0em">−</mo></msup><mo fence="true">]</mo></mrow><mrow><mo stretchy="false">[</mo><mrow><mi mathvariant="normal">H</mi><mi mathvariant="normal">A</mi></mrow><mo stretchy="false">]</mo></mrow></mfrac></mrow><annotation encoding="application/x-tex">p H=p K a+\log \frac{\left[\mathrm{A}^{-}\right]}{[\mathrm{HA}]}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8778em; vertical-align: -0.1944em;"></span><span class="mord mathnormal">p</span><span class="mord mathnormal" style="margin-right: 0.08125em;">H</span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">=</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.8778em; vertical-align: -0.1944em;"></span><span class="mord mathnormal">p</span><span class="mord mathnormal" style="margin-right: 0.07153em;">K</span><span class="mord mathnormal">a</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">+</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 2.3843em; vertical-align: -0.936em;"></span><span class="mop">lo<span style="margin-right: 0.01389em;">g</span></span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord"><span class="mopen nulldelimiter"></span><span class="mfrac"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 1.4483em;"><span style="top: -2.314em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="mopen">[</span><span class="mord"><span class="mord mathrm">HA</span></span><span class="mclose">]</span></span></span><span style="top: -3.23em;"><span class="pstrut" style="height: 3em;"></span><span class="frac-line" style="border-bottom-width: 0.04em;"></span></span><span style="top: -3.677em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="minner"><span class="mopen delimcenter" style="top: 0em;">[</span><span class="mord"><span class="mord mathrm">A</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.7713em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">−</span></span></span></span></span></span></span></span></span><span class="mclose delimcenter" style="top: 0em;">]</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.936em;"><span></span></span></span></span></span><span class="mclose nulldelimiter"></span></span></span></span></span></span></div>
<p><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>p</mi><mi>K</mi><mi>a</mi></mrow><annotation encoding="application/x-tex">p K a</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8778em; vertical-align: -0.1944em;"></span><span class="mord mathnormal">p</span><span class="mord mathnormal" style="margin-right: 0.07153em;">K</span><span class="mord mathnormal">a</span></span></span></span></span> is the negative logarithm of acidic dissociation constant of the weak electrolyte. If the concentration of ionized drug <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo fence="true">[</mo><msup><mi mathvariant="normal">A</mi><mo lspace="0em" rspace="0em">−</mo></msup><mo fence="true">]</mo></mrow><annotation encoding="application/x-tex">\left[\mathrm{A}^{-}\right]</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1.0213em; vertical-align: -0.25em;"></span><span class="minner"><span class="mopen delimcenter" style="top: 0em;">[</span><span class="mord"><span class="mord mathrm">A</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.7713em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">−</span></span></span></span></span></span></span></span></span><span class="mclose delimcenter" style="top: 0em;">]</span></span></span></span></span></span>is equal to concentration of unionized drug [HA], then</p>
<div class="math math-display"><span class="katex-display"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML" display="block"><semantics><mrow><mfrac><mrow><mo fence="true">[</mo><msup><mi mathvariant="normal">A</mi><mo lspace="0em" rspace="0em">−</mo></msup><mo fence="true">]</mo></mrow><mrow><mo stretchy="false">[</mo><mrow><mi mathvariant="normal">H</mi><mi mathvariant="normal">A</mi></mrow><mo stretchy="false">]</mo></mrow></mfrac><mo>=</mo><mn>1</mn></mrow><annotation encoding="application/x-tex">\frac{\left[\mathrm{A}^{-}\right]}{[\mathrm{HA}]}=1</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 2.3843em; vertical-align: -0.936em;"></span><span class="mord"><span class="mopen nulldelimiter"></span><span class="mfrac"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 1.4483em;"><span style="top: -2.314em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="mopen">[</span><span class="mord"><span class="mord mathrm">HA</span></span><span class="mclose">]</span></span></span><span style="top: -3.23em;"><span class="pstrut" style="height: 3em;"></span><span class="frac-line" style="border-bottom-width: 0.04em;"></span></span><span style="top: -3.677em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="minner"><span class="mopen delimcenter" style="top: 0em;">[</span><span class="mord"><span class="mord mathrm">A</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.7713em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">−</span></span></span></span></span></span></span></span></span><span class="mclose delimcenter" style="top: 0em;">]</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.936em;"><span></span></span></span></span></span><span class="mclose nulldelimiter"></span></span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">=</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">1</span></span></span></span></span></div>
<p>since <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>log</mi><mo>⁡</mo><mn>1</mn></mrow><annotation encoding="application/x-tex">\log 1</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mop">lo<span style="margin-right: 0.01389em;">g</span></span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord">1</span></span></span></span></span> is 0 , under this condition</p>
<div class="math math-display"><span class="katex-display"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML" display="block"><semantics><mrow><mi>p</mi><mi>H</mi><mo>=</mo><mi>p</mi><mi>K</mi><mi>a</mi></mrow><annotation encoding="application/x-tex">p H=p K a</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8778em; vertical-align: -0.1944em;"></span><span class="mord mathnormal">p</span><span class="mord mathnormal" style="margin-right: 0.08125em;">H</span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">=</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.8778em; vertical-align: -0.1944em;"></span><span class="mord mathnormal">p</span><span class="mord mathnormal" style="margin-right: 0.07153em;">K</span><span class="mord mathnormal">a</span></span></span></span></span></div>
<p>Thus, <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>p</mi><mi>K</mi><mi>a</mi></mrow><annotation encoding="application/x-tex">p K a</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8778em; vertical-align: -0.1944em;"></span><span class="mord mathnormal">p</span><span class="mord mathnormal" style="margin-right: 0.07153em;">K</span><span class="mord mathnormal">a</span></span></span></span></span> is numerically equal to the pH at which the drug is <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>50</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">50 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">50%</span></span></span></span></span> ionized.</p>
<p>If pH is increased by 1 scale, then-</p>
<div class="math math-display"><span class="katex-display"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML" display="block"><semantics><mrow><mi>log</mi><mo>⁡</mo><mrow><mo fence="true">[</mo><msup><mi mathvariant="normal">A</mi><mo lspace="0em" rspace="0em">−</mo></msup><mo fence="true">]</mo></mrow><mi mathvariant="normal">/</mi><mo stretchy="false">[</mo><mrow><mi mathvariant="normal">H</mi><mi mathvariant="normal">A</mi></mrow><mo stretchy="false">]</mo><mo>=</mo><mn>1</mn><mspace width="1em"></mspace><mtext>&nbsp;or&nbsp;</mtext><mspace width="1em"></mspace><mrow><mo fence="true">[</mo><msup><mi mathvariant="normal">A</mi><mo lspace="0em" rspace="0em">−</mo></msup><mo fence="true">]</mo></mrow><mi mathvariant="normal">/</mi><mo stretchy="false">[</mo><mrow><mi mathvariant="normal">H</mi><mi mathvariant="normal">A</mi></mrow><mo stretchy="false">]</mo><mo>=</mo><mn>10</mn></mrow><annotation encoding="application/x-tex">\log \left[\mathrm{A}^{-}\right] /[\mathrm{HA}]=1 \quad \text { or } \quad\left[\mathrm{A}^{-}\right] /[\mathrm{HA}]=10</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1.2em; vertical-align: -0.35em;"></span><span class="mop">lo<span style="margin-right: 0.01389em;">g</span></span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="minner"><span class="mopen delimcenter" style="top: 0em;"><span class="delimsizing size1">[</span></span><span class="mord"><span class="mord mathrm">A</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8213em;"><span style="top: -3.113em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">−</span></span></span></span></span></span></span></span></span><span class="mclose delimcenter" style="top: 0em;"><span class="delimsizing size1">]</span></span></span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord">/</span><span class="mopen">[</span><span class="mord"><span class="mord mathrm">HA</span></span><span class="mclose">]</span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">=</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 1.2em; vertical-align: -0.35em;"></span><span class="mord">1</span><span class="mspace" style="margin-right: 1em;"></span><span class="mord text"><span class="mord">&nbsp;or&nbsp;</span></span><span class="mspace" style="margin-right: 1em;"></span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="minner"><span class="mopen delimcenter" style="top: 0em;"><span class="delimsizing size1">[</span></span><span class="mord"><span class="mord mathrm">A</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8213em;"><span style="top: -3.113em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">−</span></span></span></span></span></span></span></span></span><span class="mclose delimcenter" style="top: 0em;"><span class="delimsizing size1">]</span></span></span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord">/</span><span class="mopen">[</span><span class="mord"><span class="mord mathrm">HA</span></span><span class="mclose">]</span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">=</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">10</span></span></span></span></span></div>
<p>Similarly, if pH is reduced by 1 scale, then-</p>
<div class="math math-display"><span class="katex-display"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML" display="block"><semantics><mrow><mrow><mo fence="true">[</mo><msup><mi mathvariant="normal">A</mi><mo lspace="0em" rspace="0em">−</mo></msup><mo fence="true">]</mo></mrow><mi mathvariant="normal">/</mi><mo stretchy="false">[</mo><mrow><mi mathvariant="normal">H</mi><mi mathvariant="normal">A</mi></mrow><mo stretchy="false">]</mo><mo>=</mo><mn>1</mn><mi mathvariant="normal">/</mi><mn>10</mn></mrow><annotation encoding="application/x-tex">\left[\mathrm{A}^{-}\right] /[\mathrm{HA}]=1 / 10</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1.2em; vertical-align: -0.35em;"></span><span class="minner"><span class="mopen delimcenter" style="top: 0em;"><span class="delimsizing size1">[</span></span><span class="mord"><span class="mord mathrm">A</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8213em;"><span style="top: -3.113em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">−</span></span></span></span></span></span></span></span></span><span class="mclose delimcenter" style="top: 0em;"><span class="delimsizing size1">]</span></span></span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord">/</span><span class="mopen">[</span><span class="mord"><span class="mord mathrm">HA</span></span><span class="mclose">]</span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">=</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">1/10</span></span></span></span></span></div>
<p>Thus, weakly acidic drugs, which form salts with cations, e.g. sod. phenobarbitone, sod. sulfadiazine, pot. penicillin-V, etc. ionize more at alkaline pH and 1 scale change in pH causes 10 fold change in ionization.</p>
<p>Weakly basic drugs, which form salts with anions, e.g. atropine sulfate, ephedrine HCl , chloroquine phosphate, etc. conversely ionize more at acidic pH . Ions being lipid insoluble, do not diffuse and a pH difference across a membrane can cause differential distribution of weakly acidic and weakly basic drugs on the two sides (Fig. 2.4).
<img src="assets/images/image-20251214-c25b0b2f.jpeg" alt="img-5.jpeg"></p>
<p>Fig. 2.4: Influence of pH difference on two sides of a biological membrane on the steady-state distribution of a weakly acidic drug with <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>p</mi><mi>K</mi><mi>a</mi><mo>=</mo><mn>6</mn></mrow><annotation encoding="application/x-tex">p K a=6</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8778em; vertical-align: -0.1944em;"></span><span class="mord mathnormal">p</span><span class="mord mathnormal" style="margin-right: 0.07153em;">K</span><span class="mord mathnormal">a</span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">=</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">6</span></span></span></span></span></p>
<p>Implications of this consideration are:
(a) Acidic drugs, e.g. aspirin ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>p</mi><mi>K</mi><mi>a</mi><mn>3.5</mn></mrow><annotation encoding="application/x-tex">p K a 3.5</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8778em; vertical-align: -0.1944em;"></span><span class="mord mathnormal">p</span><span class="mord mathnormal" style="margin-right: 0.07153em;">K</span><span class="mord mathnormal">a</span><span class="mord">3.5</span></span></span></span></span> ) are largely unionized at acid gastric pH and are absorbed from stomach, while bases, e.g. atropine ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>p</mi><mi>K</mi><mi>a</mi><mn>10</mn></mrow><annotation encoding="application/x-tex">p K a 10</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8778em; vertical-align: -0.1944em;"></span><span class="mord mathnormal">p</span><span class="mord mathnormal" style="margin-right: 0.07153em;">K</span><span class="mord mathnormal">a</span><span class="mord">10</span></span></span></span></span> ) are largely ionized and are absorbed only when they reach the intestines. (b) The unionized form of acidic drugs which crosses the surface membrane of gastric mucosal cell, reverts to the ionized form within the cell
(pH 7.0) and then only slowly passes to the extracellular fluid. This is called ion trapping, i.e. a weak electrolyte crossing a membrane to encounter a pH from which it is not able to escape easily. This may contribute to gastric mucosal cell damage caused by aspirin.
(c) Basic drugs attain higher concentration intracellularly ( pH 7.0 vs 7.4 of plasma).
(d) Acidic drugs are ionized more in alkaline urine-do not back diffuse in the kidney tubules and are excreted faster. Accordingly, basic drugs are excreted faster if urine is acidified.
Lipid-soluble nonelectrolytes (e.g. ethanol, diethyl-ether) readily cross biological membranes and their transport is pH independent.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="filtration">Filtration<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#filtration" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Filtration is passage of drugs through aqueous pores in the membrane or through paracellular spaces. This can be accelerated if hydrodynamic flow of the solvent is occurring under hydrostatic or osmotic pressure gradient, e.g. across most capillaries including glomeruli. Lipid-insoluble drugs cross biological membranes by filtration if their molecular size is smaller than the diameter of the pores (Fig. 2.3). Majority of cells (intestinal mucosa, RBC, etc.) have very small pores ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>4</mn><mover accent="true"><mi>A</mi><mo>˚</mo></mover></mrow><annotation encoding="application/x-tex">4 \AA</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.9468em;"></span><span class="mord">4</span><span class="mord accent"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.9468em;"><span style="top: -3em;"><span class="pstrut" style="height: 3em;"></span><span class="mord mathnormal">A</span></span><span style="top: -3.2523em;"><span class="pstrut" style="height: 3em;"></span><span class="accent-body" style="left: -0.2361em;"><span class="mord">˚</span></span></span></span></span></span></span></span></span></span></span> ) and drugs with <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mrow><mi mathvariant="normal">M</mi><mi mathvariant="normal">W</mi></mrow><mo>&gt;</mo><mn>100</mn></mrow><annotation encoding="application/x-tex">\mathrm{MW}&gt;100</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7224em; vertical-align: -0.0391em;"></span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">MW</span></span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">&gt;</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">100</span></span></span></span></span> or 200 are not able to penetrate. However, capillaries (except those in brain) have large paracellular spaces <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo stretchy="false">(</mo><mn>40</mn><mover accent="true"><mi>A</mi><mo>˚</mo></mover></mrow><annotation encoding="application/x-tex">(40 \AA</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1.1968em; vertical-align: -0.25em;"></span><span class="mopen">(</span><span class="mord">40</span><span class="mord accent"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.9468em;"><span style="top: -3em;"><span class="pstrut" style="height: 3em;"></span><span class="mord mathnormal">A</span></span><span style="top: -3.2523em;"><span class="pstrut" style="height: 3em;"></span><span class="accent-body" style="left: -0.2361em;"><span class="mord">˚</span></span></span></span></span></span></span></span></span></span></span> ) and most drugs (even albumin) can filter through these (Fig. 2.8). As such, diffusion of drugs across capillaries is dependent on rate of blood flow through them rather than on lipid solubility of the drug or pH of the medium.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="specialized-transport">Specialized transport<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#specialized-transport" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>This can be carrier mediated or by vesicular transport (endocytosis, exocytosis).</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="carrier-transport">Carrier transport<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#carrier-transport" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>All cell membranes express a host of transmembrane proteins which serve as carriers or transporters for physiologically important ions,</p>
<p><img src="assets/images/image-20251214-f0a023d0.jpeg" alt="img-6.jpeg"></p>
<p>Fig. 2.5: Illustration of different types of carrier mediated transport across biological membrane
ABC—ATP-binding cassette transporter; SLC—Solute carrier transporter; M—Membrane
A. Facilitated diffusion: the carrier (SLC) binds and moves the poorly diffusible substrate along its concentration gradient (high to low) and does not require energy
B. Primary active transport: the carrier (ABC) derives energy directly by hydrolysing ATP and moves the substrate against its concentration gradient (low to high)
C. Symport: the carrier moves the substrate ' <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>A</mi></mrow><annotation encoding="application/x-tex">A</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal">A</span></span></span></span></span> ' against its concentration gradient by utilizing energy from downhill movement of another substrate ' <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>B</mi></mrow><annotation encoding="application/x-tex">B</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.05017em;">B</span></span></span></span></span> ' in the same direction
D. Antiport: the carrier moves the substrate ' <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>A</mi></mrow><annotation encoding="application/x-tex">A</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal">A</span></span></span></span></span> ' against its concentration gradient and is energized by the downhill movement of another substrate ' <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>B</mi></mrow><annotation encoding="application/x-tex">B</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.05017em;">B</span></span></span></span></span> ' in the opposite direction
nutrients, metabolites, transmitters, etc. across the membrane. At some sites, certain transporters also translocate xenobiotics, including drugs and their metabolites. In contrast to channels, which open for a finite time and allow passage of specific ions, transporters combine transiently with their substrate (ion or organic compound)-undergo a conformational change carrying the substrate to the other side of the membrane where the substrate dissociates and the transporter returns back to its original state (Fig. 2.5). Carrier transport is specific for the substrate (or the type of substrate, e.g. an organic anion), saturable, competitively inhibited by analogues which utilize the same transporter, and is much slower than the flux
through channels. Depending on requirement of energy, carrier transport is of two types:
a. Facilitated diffusion The transporter, belonging to the super-family of solute carrier (SLC) transporters, operates passively without needing energy and translocates the substrate in the direction of its electrochemical gradient, i.e. from higher to lower concentration (Fig. 2.5A). It merely facilitates permeation of a poorly diffusible substrate, e.g. the entry of glucose into muscle and fat cells by the glucose transporter GLUT 4.
b. Active transport It requires energy, is inhibited by metabolic poisons, and transports the solute against its electrochemical gradient (low to high), resulting in selective accumulation of the</p>
<p>substance on one side of the membrane. Drugs related to normal metabolites can utilize the transport processes meant for these, e.g. levodopa and methyl dopa are actively absorbed from the gut by the aromatic amino acid transporter. In addition, the body has developed some relatively nonselective transporters, like P-glycoprotein (P-gp), to deal with xenobiotics. Active transport can be primary or secondary depending on the source of the driving force.
i. Primary active transport Energy is obtained directly by the hydrolysis of ATP (Fig. 2.5B). The transporters belong to the superfamily of ATP binding cassettee (ABC) transporters whose intracellular loops have ATPase activity. They mediate only efflux of the solute from the cytoplasm, either to extracellular fluid or into an intracellular organelli (endoplasmic reticulum, mitochondria, etc.)</p>
<p>Encoded by the multidrug resistance 1 (MDR1) gene, P-gp is the most well known primary active transporter expressed in the intestinal mucosa, renal tubules, bile canaliculi, choroidal epithelium, astrocyte foot processes around brain capillaries (the blood-brain barrier), testicular and placental microvessels, which pumps out many drugs/ metabolites and thus limits their intestinal absorption, penetration into brain, testes and foetal tissues as well as promotes biliary and renal elimination. Many xenobiotics which induce or inhibit P-gp also have a similar effect on the drug metabolizing isoenzyme CYP3A4, indicating their synergistic role in detoxification of xenobiotics.</p>
<p>Other primary active transporters of pharmacological significance are multidrug resistance associated protein 2 (MRP 2) and breast cancer resistance protein (BCRP).
ii. Secondary active transport In this type of active transport effected by another set of SLC transporters, the energy to pump one solute is derived from the downhill movement of another solute (mostly <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">N</mi><mi mathvariant="normal">a</mi></mrow><mo lspace="0em" rspace="0em">+</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{Na}^{+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8446em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Na</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8446em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span>). When the concentration gradients are such that both the solutes move in the same direction (Fig. 2.5C), it is called symport or cotransport, but when they move in opposite directions (Fig. 2.5D), it is termed antiport or exchange transport. Metabolic energy (from hydrolysis of ATP) is spent in maintaining high transmembrane electrochemical gradient of the second solute (generally <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">N</mi><mi mathvariant="normal">a</mi></mrow><mo lspace="0em" rspace="0em">+</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{Na}^{+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8446em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Na</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8446em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span>). The SLC transporters mediate both uptake and efflux of drugs and metabolites.</p>
<p>The organic anion transporting polypeptide (OATP) and organic cation transporter (OCT), highly expressed in liver canaliculi and renal tubules, are secondary active transporters important in the metabolism and excretion of drugs and metabolites (especially glucuronides). The <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">N</mi><mi mathvariant="normal">a</mi></mrow><mo lspace="0em" rspace="0em">+</mo></msup><mo separator="true">,</mo><msup><mrow><mi mathvariant="normal">C</mi><mi mathvariant="normal">l</mi></mrow><mo lspace="0em" rspace="0em">−</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{Na}^{+}, \mathrm{Cl}^{-}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1.0501em; vertical-align: -0.1944em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Na</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8446em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Cl</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8557em;"><span style="top: -3.1473em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">−</span></span></span></span></span></span></span></span></span></span></span></span></span>dependent neurotransmitter transporters for norepinephrine, serotonin and dopamine (NET, SERT and DAT) are active SLC transporters that are targets for action of drugs like tricyclic antidepressants, selective serotonin reuptake inhibitors (SSRIs), cocaine, etc. Similarly, the Vesicular monoamine transporter (VMAT-2) of adrenergic and serotonergic storage vesicles transports catecholamines and 5-HT into the vesicles by exchanging with <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">H</mi><mo lspace="0em" rspace="0em">+</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{H}^{+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7713em;"></span><span class="mord"><span class="mord mathrm">H</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.7713em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span>ions, and is inhibited by reserpine. The absorption of glucose in intestines and renal tubules is through secondary active transport by sodium-glucose transporters (SGLT1 and SGLT2).</p>
<p>As indicated earlier, carrier transport (both facilitated diffusion and active transport) is saturable and follows the Michaelis-Menten kinetics. The maximal rate of transport is dependent on the density of the transporter in a particular membrane, and its rate constant <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo stretchy="false">(</mo><mrow><mi mathvariant="normal">K</mi><mi mathvariant="normal">m</mi></mrow><mo stretchy="false">)</mo></mrow><annotation encoding="application/x-tex">(\mathrm{Km})</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mopen">(</span><span class="mord"><span class="mord mathrm">Km</span></span><span class="mclose">)</span></span></span></span></span>, i.e. the substrate concentration at which rate of transport is half maximal, is governed by its affinity for the substrate. Genetic polymorphism can alter both the density and affinity of the transporter protein for different substrates and thus affect the pharmacokinetics of drugs. Moreover, tissue specific drug distribution can occur due to the presence of specific transporters in certain cells.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="vesicular-transport-endocytosis-exocytosis">Vesicular transport (endocytosis, exocytosis)<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#vesicular-transport-endocytosis-exocytosis" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Certain substances with very large or impermeable molecules are transported inside the cell (endocytosis) or extruded from it (exocytosis) by enclosing their particles into tiny vesicles. A binding protein located on the membrane complexes with the substance and initiates vesicle formation (Fig. 2.6). The vesicle then detaches from the membrane and may remain stored within the cell, or it may release the substance in the cytoplasm, or it may move to the opposite membrane fuse with it to release the substance across the cell (exocytosis).</p>
<p><img src="assets/images/image-20251214-2222adf1.jpeg" alt="img-7.jpeg"></p>
<p>Fig. 2.6: Illustration of vesicular transport (endocytosis and exocytosis).
Endocytosis: The large molecular particle (P) binds to a binding protein (B) on the surface of the cell. The membrane invaginates to form a vesicle which nicks off, and the vesicle may remain stored within the cell, or it may disintegrate to release the substance in the cytoplasm, or be extruded across the cell by exocytosis.
Exocytosis: The particle or the transmitter/hormone(T/H) stored within intracellular vesicles, generally as a complex with a storage protein (S), is secreted by exocytosis. On activation the vesicle translocates to and fuses with the membrane. All contents of the vesicle are then poured out in the extracellular space.</p>
<p>Vesicular transport is applicable to proteins and other big molecules, and contributes little to transport of most drugs, barring few like vit <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi>B</mi><mn>12</mn></msub></mrow><annotation encoding="application/x-tex">B_{12}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.05017em;">B</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.0502em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">12</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> which is absorbed from the gut after binding to intrinsic factor (a protein). Most hormones (insulin, etc.) and neurotransmitters, like noradrenaline, are secreted/released from the cell/nerve ending by exocytosis. Activation of the secretory cell/nerve ending prompts fusion of the storage vesicle to the surface membrane followed by extrusion of its contents into the extracellular space.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="absorption">ABSORPTION<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#absorption" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Absorption is movement of the drug from its site of administration into the circulation. Not only the fraction of the administered dose that gets absorbed, but also the rate of absorption is important. Except when given i.v., the drug has to cross biological membranes; absorption is governed by the above described principles. Other factors affecting absorption are:</p>
<p>Aqueous solubility Drugs given in solid form must dissolve in the aqueous biophase before they are absorbed. For poorly water soluble drugs (aspirin, griseofulvin) rate of dissolution governs rate of absorption. Ketoconazole dissolves at low pH : gastric acid is needed for its absorption. Obviously, a drug given as watery solution is absorbed faster than when the same is given in solid form or as oily solution.
Concentration Passive diffusion depends on concentration gradient; drug given as concentrated solution is absorbed faster than from dilute solution.
Area of absorbing surface Larger is the surface area, faster is the absorption.
Vascularity of the absorbing surface Blood circulation removes the drug from the site of absorption and maintains the concentration gradient across the absorbing surface. Increased blood flow hastens drug absorption just as wind hastens drying of clothes.
Route of administration This affects drug absorption, because each route has its own peculiarities.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="oral">Oral<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#oral" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>The effective barrier to orally administered drugs is the epithelial lining of the gastrointestinal tract, which is lipoidal. Nonionized lipid soluble drugs, e.g. ethanol are readily absorbed from stomach as well as intestine at rates proportional to their lipid : water partition coefficient. Acidic drugs, e.g. salicylates, barbiturates, etc. are predominantly unionized in the acid gastric juice and are absorbed from stomach, while basic drugs, e.g. morphine, quinine, etc. are largely ionized and are absorbed only on reaching the duodenum. However, even for acidic drugs absorption from stomach is slower, because the mucosa is thick, covered with mucus and the surface area is small. Absorbing surface area is much larger in the small intestine due to villi. Thus, faster gastric emptying accelerates drug absorption in general. Dissolution is a surface phenomenon, therefore, particle size
of the drug in solid dosage form governs rate of dissolution and in turn rate of absorption.</p>
<p>Presence of food dilutes the drug and retards absorption. Further, certain drugs form poorly absorbed complexes with food constituents, e.g. tetracyclines with calcium present in milk; moreover food delays gastric emptying. Thus, most drugs are absorbed better if taken in empty stomach. However, there are some exceptions, e.g. fatty food greatly enhances lumefantrine absorption. Highly ionized drugs, e.g. gentamicin, neostigmine are poorly absorbed when given orally.</p>
<p>Certain drugs are degraded in the gastrointestinal tract, e.g. penicillin G by acid, insulin by peptidases, and are ineffective orally. Enteric coated tablets (having acid resistant coating) and sustained release preparations (drug particles coated with slowly dissolving material) can be used to overcome acid lability, gastric irritancy and brief duration of action.</p>
<p>The oral absorption of certain drugs is low because a fraction of the absorbed drug is extruded back into the intestinal lumen by the efflux transporter P-gp located in the gut epithelium. The low oral bioavailability of digoxin and cyclosporine is partly accounted by this mechanism. Inhibitors of P-gp like quinidine, verapamil, erythromycin, etc. enhance, while P-gp inducers like rifampin and phenobarbitone reduce the oral bioavailability of these drugs.</p>
<p>Absorption of a drug can be affected by other concurrently ingested drugs. This may be a luminal effect: formation of insoluble complexes, e.g. tetracyclines and iron preparations with calcium salts and antacids, phenytoin with sucralfate. Such interaction can be minimized by administering the two drugs at <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>2</mn><mo>−</mo><mn>3</mn><mrow><mi mathvariant="normal">h</mi><mi mathvariant="normal">r</mi></mrow></mrow><annotation encoding="application/x-tex">2-3 \mathrm{hr}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">2</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6944em;"></span><span class="mord">3</span><span class="mord"><span class="mord mathrm">hr</span></span></span></span></span></span> intervals. Alteration of gut flora by antibiotics may disrupt the enterohepatic cycling of oral contraceptives and digoxin. Drugs can also alter absorption by gut wall effects: altering motility (anticholinergics, tricyclic antidepressants, opioids retard motility while metoclopramide enhances it) or causing mucosal damage (neomycin, methotrexate, vinblastine).</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="subcutaneous-and-intramuscular">Subcutaneous and Intramuscular<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#subcutaneous-and-intramuscular" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>By these routes the drug is deposited directly in the vicinity of the capillaries. Lipid soluble drugs pass readily across the whole surface of the capillary endothelium. Capillaries having large paracellular spaces do not obstruct absorption of even large lipid insoluble molecules or ions (Fig. 2.9A). Very large molecules are absorbed through lymphatics. Thus, many drugs not absorbed orally are absorbed parenterally. Absorption from s.c. site is slower than that from i.m. site, but both are generally faster and more consistent/ predictable than oral absorption. Application of heat and muscular exercise accelerate drug absorption by increasing blood flow, while vasoconstrictors, e.g. adrenaline injected with the drug (local anaesthetic) retard absorption. Incorporation of hyaluronidase facilitates drug absorption from s.c. injection by promoting spread. Many depot preparations, e.g. benzathine penicillin, protamine zinc insulin, depot progestins, etc. can be given by these routes.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="topical-sites-skin-cornea-mucous-membranes">Topical sites (skin, cornea, mucous membranes)<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#topical-sites-skin-cornea-mucous-membranes" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Systemic absorption after topical application depends primarily on lipid solubility of drugs. However, only few drugs significantly penetrate intact skin. Hyoscine, fentanyl, GTN, nicotine, testosterone, and estradiol (see p. 12) have been used in this manner. Corticosteroids applied over extensive areas of skin can produce systemic effects and pituitary-adrenal suppression. Absorption can be promoted by rubbing the drug incorporated in an olegenous base or by use of occlusive dressing which increases hydration of the skin. Organophosphate insecticides coming in contact with skin can produce systemic toxicity. Abraded surfaces readily absorb drugs, e.g. tannic acid applied over burnt skin has produced hepatic necrosis.</p>
<p>Cornea is permeable to lipid soluble, unionized physostigmine but not to highly ionized neostigmine. Drugs applied as eye drops may
get absorbed through the nasolacrimal duct, e.g. timolol eye drops can produce bradycardia and precipitate asthma. Mucous membranes of mouth, rectum, vagina absorb lipophilic drugs: estrogen cream applied vaginally has produced gynaecomastia in the male partner.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="bioavailability">Bioavailability<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#bioavailability" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Bioavailability refers to the rate and extent of absorption of a drug from a dosage form administered by any route, as determined by its concentration-time curve in blood or by its excretion in urine (Fig. 2.7). It is a measure of the fraction <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo stretchy="false">(</mo><mi>F</mi><mo stretchy="false">)</mo></mrow><annotation encoding="application/x-tex">(F)</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mopen">(</span><span class="mord mathnormal" style="margin-right: 0.13889em;">F</span><span class="mclose">)</span></span></span></span></span> of administered dose of a drug that reaches the systemic circulation in the unchanged form. Bioavailability of drug injected i.v. is <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>100</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">100 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">100%</span></span></span></span></span>, but is frequently lower after oral ingestion because-
(a) the drug may be incompletely absorbed.
(b) the absorbed drug may undergo first pass metabolism in the intestinal wall/liver or be excreted in bile.
<img src="assets/images/image-20251214-79bd125d.jpeg" alt="img-8.jpeg"></p>
<p>Fig. 2.7: Plasma concentration-time curves depicting bioavailability differences between three formulations of a drug containing the same amount
Note that formulation <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>B</mi></mrow><annotation encoding="application/x-tex">B</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.05017em;">B</span></span></span></span></span> is more slowly absorbed than <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>A</mi></mrow><annotation encoding="application/x-tex">A</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal">A</span></span></span></span></span>, and though ultimately both are absorbed to the same extent (area under the curve same), <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>B</mi></mrow><annotation encoding="application/x-tex">B</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.05017em;">B</span></span></span></span></span> may not produce therapeutic effect after a single dose; however average blood levels may be similar with both <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>A</mi></mrow><annotation encoding="application/x-tex">A</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal">A</span></span></span></span></span> and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>B</mi></mrow><annotation encoding="application/x-tex">B</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.05017em;">B</span></span></span></span></span> formulations when repeated doses are given; <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>C</mi></mrow><annotation encoding="application/x-tex">C</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.07153em;">C</span></span></span></span></span> is absorbed to a lesser extent—resulting in lower bioavailability</p>
<p>Incomplete bioavailability after s.c. or i.m. injection is less common, but may occur due to local binding of the drug.
Bioequivalence Oral formulations of a drug from different manufacturers or different batches from the same manufacturer may have the same amount of the drug (chemically equivalent) but may not yield the same blood levels-biologically inequivalent. Two preparations of a drug are considered bioequivalent when the rate and extent of bioavailability of the active drug from them is not significantly different under suitable test conditions.</p>
<p>Before a drug administered orally in solid dosage form can be absorbed, it must break into individual particles of the active drug (disintegration). Tablets and capsules contain a number of other materials-diluents, stabilizing agents, binders, lubricants, etc. The nature of these as well as details of the manufacture process, e.g. force used in compressing the tablet, may affect disintegration. The released drug must then dissolve in the aqueous gastrointestinal contents. The rate of dissolution is governed by the inherent solubility, particle size, crystal form and other physical properties of the drug. Differences in bioavailability may arise due to variations in disintegration and dissolution rates.</p>
<p>Differences in bioavailability are seen mostly with poorly soluble and slowly absorbed drugs. Reduction in particle size increases the rate of absorption of aspirin (microfine tablets). The amount of griseofulvin and spironolactone in the tablet can be reduced to half if the drug particle is microfined. There is no need to reduce the particle size of freely water soluble drugs, e.g. paracetamol.</p>
<p>Bioavailability variation assumes practical significance for drugs with low safety margin (digoxin) or where dosage needs precise control (oral hypoglycaemics, oral anticoagulants). It may also be responsible for success or failure of an antimicrobial regimen.</p>
<p>However, in the case of a large number of drugs bioavailability differences are negligible and the risks of changing from branded to generic
product or to another brand of the same drug have often been exaggerated.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="distribution">DISTRIBUTION<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#distribution" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Once a drug has gained access to the blood stream, it gets distributed to other tissues that initially had no drug, concentration gradient being in the direction of plasma to tissues. The extent of distribution of a drug and its pattern of tissue distribution depends on its:</p>
<ul>
<li>lipid solubility</li>
<li>ionization at physiological pH (a function of its pKa )</li>
<li>extent of binding to plasma and tissue proteins</li>
<li>presence of tissue-specific transporters</li>
<li>differences in regional blood flow.</li>
</ul>
<p>Movement of drug proceeds until an equilibrium is established between unbound drug in the plasma and the tissue fluids. Subsequently, there is a parallel decline in both due to elimination.
Apparent volume of distribution ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>V</mi></mrow><annotation encoding="application/x-tex">V</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.22222em;">V</span></span></span></span></span> ) Presuming that the body behaves as a single homogeneous compartment with volume <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>V</mi></mrow><annotation encoding="application/x-tex">V</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.22222em;">V</span></span></span></span></span> into which the drug gets immediately and uniformly distributed</p>
<div class="math math-display"><span class="katex-display"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML" display="block"><semantics><mrow><mi mathvariant="normal">V</mi><mo>=</mo><mfrac><mtext>&nbsp;dose&nbsp;administered&nbsp;i.v.&nbsp;</mtext><mtext>&nbsp;plasma&nbsp;concentration&nbsp;</mtext></mfrac></mrow><annotation encoding="application/x-tex">\mathrm{V}=\frac{\text { dose administered i.v. }}{\text { plasma concentration }}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathrm" style="margin-right: 0.01389em;">V</span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">=</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 2.2519em; vertical-align: -0.8804em;"></span><span class="mord"><span class="mopen nulldelimiter"></span><span class="mfrac"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 1.3714em;"><span style="top: -2.314em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="mord text"><span class="mord">&nbsp;plasma&nbsp;concentration&nbsp;</span></span></span></span><span style="top: -3.23em;"><span class="pstrut" style="height: 3em;"></span><span class="frac-line" style="border-bottom-width: 0.04em;"></span></span><span style="top: -3.677em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="mord text"><span class="mord">&nbsp;dose&nbsp;administered&nbsp;i.v.&nbsp;</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.8804em;"><span></span></span></span></span></span><span class="mclose nulldelimiter"></span></span></span></span></span></span></div>
<p>Since in the example shown in Fig. 2.8, the drug does not actually distribute into 20 L of body water, with the exclusion of the rest of it, this is only an apparent volume of distribution which can be defined as "the volume that would accommodate all the drug in the body, if the concentration throughout was the same as in plasma". Thus, it describes amount of the drug present in the body as a multiple of that contained in a unit volume of plasma. Considered together with drug clearance, this is a very useful pharmacokinetic concept.</p>
<p>Lipid-insoluble drugs do not enter cells<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>V</mi></mrow><annotation encoding="application/x-tex">V</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.22222em;">V</span></span></span></span></span> approximates extracellular fluid volume, e.g. streptomycin, gentamicin <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.25</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">L</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">0.25 \mathrm{~L} / \mathrm{kg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">0.25</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm">L</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span></span></span></span></span>.</p>
<p>Distribution is not only a matter of dilution, but also binding and sequestration. Drugs extensively bound to plasma proteins are largely</p>
<p><img src="assets/images/image-20251214-49f0433e.jpeg" alt="img-9.jpeg"></p>
<p>Fig. 2.8: Illustration of the concept of apparent volume of distribution <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo stretchy="false">(</mo><mi mathvariant="normal">V</mi><mo stretchy="false">)</mo></mrow><annotation encoding="application/x-tex">(\mathrm{V})</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mopen">(</span><span class="mord mathrm" style="margin-right: 0.01389em;">V</span><span class="mclose">)</span></span></span></span></span>
In this example, 1000 mg of drug injected i.v. produces steady-state plasma concentration of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>50</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mi mathvariant="normal">L</mi></mrow><annotation encoding="application/x-tex">50 \mathrm{mg} / \mathrm{L}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">50</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord mathrm">L</span></span></span></span></span>, apparent volume of distribution is 20 L
restricted to the vascular compartment and have low values of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>V</mi></mrow><annotation encoding="application/x-tex">V</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.22222em;">V</span></span></span></span></span>, e.g. diclofenac and warfarin ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>99</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">99 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">99%</span></span></span></span></span> bound) <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>V</mi><mo>=</mo><mn>0.15</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">L</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">V=0.15 \mathrm{~L} / \mathrm{kg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.22222em;">V</span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">=</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">0.15</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm">L</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span></span></span></span></span>.</p>
<p>A large value of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>V</mi></mrow><annotation encoding="application/x-tex">V</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.22222em;">V</span></span></span></span></span> indicates that larger quantity of drug is present in extravascular tissue. Drugs sequestrated in other tissues may have, <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>V</mi></mrow><annotation encoding="application/x-tex">V</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.22222em;">V</span></span></span></span></span> much more than total body water or even body mass, e.g. digoxin <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>6</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">L</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">6 \mathrm{~L} / \mathrm{kg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">6</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm">L</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span></span></span></span></span>, propranolol <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>4</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">L</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">4 \mathrm{~L} / \mathrm{kg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">4</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm">L</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span></span></span></span></span>, morphine <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>3.5</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">L</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">3.5 \mathrm{~L} / \mathrm{kg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">3.5</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm">L</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span></span></span></span></span>, because most of the drug is present in other tissues, and plasma concentration is low. Therefore, in case of poisoning, drugs with large volumes of distribution are not easily removed by haemodialysis.</p>
<p>Pathological states, e.g. congestive heart failure, uraemia, cirrhosis of liver, etc. can alter the <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>V</mi></mrow><annotation encoding="application/x-tex">V</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.22222em;">V</span></span></span></span></span> of many drugs by altering distribution of body water, permeability of membranes, binding proteins or by accumulation of metabolites that displace the drug from binding sites.</p>
<p>More precise multiple compartment models for drug distribution have been worked out, but the single compartment model, described above, is simple and fairly accurate for many drugs.
Redistribution Highly lipid-soluble drugs get initially distributed to organs with high blood flow, i.e. brain, heart, kidney, etc. Later, less vascular but more bulky tissues (muscle, fat) take up the</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="factors-governing-volume-of-drug-distribution">Factors governing volume of drug distribution<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#factors-governing-volume-of-drug-distribution" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Lipid: water partition coefficient of the drug</li>
<li>pKa value of the drug</li>
<li>Degree of plasma protein binding</li>
<li>Affinity for different tissues</li>
<li>Fat: lean body mass ratio, which can vary with age, sex, obesity, etc.</li>
<li>Diseases like CHF, uremia, cirrhosis
drug-plasma concentration falls and the drug is withdrawn from the highly perfused sites. If the site of action of the drug was in one of the highly perfused organs, redistribution results in termination of drug action. Greater the lipid solubility of the drug, faster is its redistribution. Anaesthetic action of thiopentone sod. injected i.v. is terminated in few minutes due to redistribution. A relatively short hypnotic action lasting 6-8 hours is exerted by oral diazepam or nitrazepam due to redistribution despite their elimination <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">t</mi><mrow><mn>1</mn><mi mathvariant="normal">/</mi><mn>2</mn></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{t}^{1 / 2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.888em;"></span><span class="mord"><span class="mord mathrm">t</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.888em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1/2</span></span></span></span></span></span></span></span></span></span></span></span></span> of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&gt;</mo><mn>30</mn><mrow><mi mathvariant="normal">h</mi><mi mathvariant="normal">r</mi></mrow></mrow><annotation encoding="application/x-tex">&gt;30 \mathrm{hr}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&gt;</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.6944em;"></span><span class="mord">30</span><span class="mord"><span class="mord mathrm">hr</span></span></span></span></span></span>. However, when the same drug is given repeatedly or continuously over long periods, the low perfusion high capacity sites get progressively filled up and the drug becomes longer acting.
Penetration into brain and CSF The capillary endothelial cells in brain have tight junctions and lack large paracellular spaces. Further, an investment of neural tissue (Fig. 2.9B) covers the capillaries. Together they constitute the so called blood-brain barrier (BBB). A similar bloodCSF barrier is located in the choroid plexus: capillaries are lined by choroidal epithelium having tight junctions. Both these barriers are lipoidal and limit the entry of nonlipid-soluble drugs, e.g. streptomycin, neostigmine, etc. Only lipid-soluble drugs, therefore, are able to penetrate and have action on the central nervous system. In addition, efflux transporters like P-gp and anion transporter (OATP) present in brain and choroidal vessels extrude many drugs that enter brain by other processes and serve to augment the protective barrier against potentially harmful xenobiotics. Dopamine does not enter brain but its precursor levodopa does; as such,</li>
</ul>
<p><img src="assets/images/image-20251214-57116848.jpeg" alt="img-10.jpeg"></p>
<p>Fig. 2.9: Passage of drugs across capillaries
A. Usual capillary with large paracellular spaces through which even large lipid-insoluble molecules diffuse
B. Capillary constituting blood brain or blood-CSF barrier. Tight junctions between capillary endothelial cells and investment of glial processes or choroidal epithelium do not allow passage of nonlipid-soluble molecules/ions
the latter is used in parkinsonism. Inflammation of meninges or brain increases permeability of these barriers. It has been proposed that some drugs accumulate in the brain by utilizing the transporters for endogenous substances.</p>
<p>There is also an enzymatic BBB: Monoamine oxidase (MAO), cholinesterase and some other enzymes are present in the capillary walls or in the cells lining them. They do not allow catecholamines, 5-HT, acetylcholine, etc. to enter brain in the active form.</p>
<p>The BBB is deficient at the CTZ in the medulla oblongata (even lipid-insoluble drugs are emetic) and at certain periventricular sites(anterior hypothalamus).</p>
<p>Exit of drugs from the CSF and brain, however, is not dependent on lipid-solubility and is rather unrestricted. This is due to bulk flow of CSF (alongwith the drug dissolved in it) back into blood through the arachnoid villi. Further, nonspecific organic anion and cation transport processes (similar to those in renal tubule) operate at the choroid plexus.
Passage across placenta Placental membranes are lipoidal and allow free passage of lipophilic drugs, while restricting hydrophilic drugs. The placental efflux P-gp and other transporters like BCRP, MRP3 also serve to
limit foetal exposure to maternally administered drugs. Placenta is a site for drug metabolism as well, which may lower/modify exposure of the foetus to the administered drug. However, restricted amounts of nonlipid-soluble drugs, when present in high concentration or for long periods in maternal circulation, gain access to the foetus. Some influx transporters also operate at the placenta. Thus, it is an incomplete barrier and almost any drug taken by the mother can affect the foetus or the newborn (drug taken just before delivery, e.g. morphine).</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="plasma-protein-binding">Plasma protein binding<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#plasma-protein-binding" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Most drugs possess physicochemical affinity for plasma proteins and get reversibly bound to these. Acidic drugs generally bind to plasma albumin and basic drugs to <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi>α</mi><mn>1</mn></msub></mrow><annotation encoding="application/x-tex">\alpha_{1}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5806em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.0037em;">α</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.0037em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> acid glycoprotein. Binding to albumin (which is more abundant) is quantitatively more important. Extent of binding depends on the individual compound; no generalization for a pharmacological or chemical class can be made (even small chemical change can markedly alter protein binding), for example the binding percentage of some benzodiazepines is:</p>
<table><thead><tr><th style="text-align: left;">Flurazepam</th><th style="text-align: left;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>10</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">10 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">10%</span></span></span></span></span></th><th style="text-align: left;">Alprazolam</th><th style="text-align: left;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>70</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">70 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">70%</span></span></span></span></span></th></tr></thead><tbody><tr><td style="text-align: left;">Lorazepam</td><td style="text-align: left;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>90</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">90 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">90%</span></span></span></span></span></td><td style="text-align: left;">Diazepam</td><td style="text-align: left;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>99</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">99 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">99%</span></span></span></span></span></td></tr></tbody></table>
<p>Increasing concentrations of the drug can progressively saturate the binding sites: fractional binding may be lower when large amounts of the drug are given. The generally expressed percentage binding refers to the usual therapeutic plasma concentrations of a drug. The clinically significant implications of plasma protein binding are:
(i) Highly plasma protein bound drugs are largely restricted to the vascular compartment because protein bound drug does not cross membranes (except through large paracellular spaces, such as in capillaries). They tend to have smaller volumes of distribution.</p>
<table><thead><tr><th style="text-align: left;">Drugs highly bound to plasma protein</th><th style="text-align: left;"></th></tr></thead><tbody><tr><td style="text-align: left;">To albumin</td><td style="text-align: left;">To <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi>α</mi><mn>1</mn></msub></mrow><annotation encoding="application/x-tex">\alpha_{1}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5806em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.0037em;">α</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.0037em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span>-acid glycoprotein</td></tr><tr><td style="text-align: left;">Barbiturates</td><td style="text-align: left;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>β</mi></mrow><annotation encoding="application/x-tex">\beta</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mord mathnormal" style="margin-right: 0.05278em;">β</span></span></span></span></span>-blockers</td></tr><tr><td style="text-align: left;">Benzodiazepines</td><td style="text-align: left;">Bupivacaine</td></tr><tr><td style="text-align: left;">NSAIDs</td><td style="text-align: left;">Lidocaine</td></tr><tr><td style="text-align: left;">Valproic acid</td><td style="text-align: left;">Disopyramide</td></tr><tr><td style="text-align: left;">Phenytoin</td><td style="text-align: left;">Imipramine</td></tr><tr><td style="text-align: left;">Penicillins</td><td style="text-align: left;">Methadone</td></tr><tr><td style="text-align: left;">Sulfonamides</td><td style="text-align: left;">Prazosin</td></tr><tr><td style="text-align: left;">Tetracyclines</td><td style="text-align: left;">Quinidine</td></tr><tr><td style="text-align: left;">Tolbutamide</td><td style="text-align: left;">Verapamil</td></tr><tr><td style="text-align: left;">Warfarin</td><td style="text-align: left;"></td></tr></tbody></table>
<p>(ii) The bound fraction is not available for action. However, it is in equilibrium with the free drug in plasma and dissociates when the concentration of the latter is reduced due to elimination. Plasma protein binding thus tantamounts to temporary storage of the drug.
(iii) High degree of protein binding generally makes the drug long acting, because bound fraction is not available for metabolism or excretion, unless it is actively extracted by liver or by kidney tubules. Glomerular filtration does not reduce the concentration of the free form in the efferent vessels, because water is also filtered. Active tubular secretion, however, removes the drug without the attendant solvent <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>→</mo></mrow><annotation encoding="application/x-tex">\rightarrow</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.3669em;"></span><span class="mrel">→</span></span></span></span></span> concentration of free drug falls <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>→</mo></mrow><annotation encoding="application/x-tex">\rightarrow</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.3669em;"></span><span class="mrel">→</span></span></span></span></span> bound drug dissociates and is eliminated resulting in a higher renal clearance value of the drug than the total renal blood flow (see Fig. 3.3).</p>
<p>The same is true of active transport of highly extracted drugs in liver. Plasma protein binding in this situation acts as a carrier mechanism and hastens drug elimination, e.g. excretion of penicillin (elimination <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">t</mi><mrow><mn>1</mn><mi mathvariant="normal">/</mi><mn>2</mn></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{t}^{1 / 2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.888em;"></span><span class="mord"><span class="mord mathrm">t</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.888em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1/2</span></span></span></span></span></span></span></span></span></span></span></span></span> is 30 min ); metabolism of lidocaine. Highly protein bound drugs are not removed by haemodialysis and need special techniques for treatment of poisoning.
(iv) The generally expressed plasma concentrations of the drug refer to bound as well as free drug. Degree of protein binding should be taken into account while relating these to concentrations of the drug that are active in vitro, e.g. MIC of an antimicrobial.
(v) One drug can bind to many sites on the albumin molecule. Conversely, more than one drug can bind to the same site. This can give rise to displacement interactions among drugs bound to the same site(s). The drug bound with higher affinity will displace that bound with lower affinity and tend to increase the concentration of its free form. This, however, is often transient because the displaced drug will diffuse into the tissues as well as get metabolized or excreted: the new steady-state free drug concentration is only marginally higher unless the displacement extends to tissue binding or there is concurrent inhibition of metabolism and/or excretion reducing drug clearance. The overall impact of many displacement interactions is minimal; except when the interaction is more complex. Moreover, two highly bound drugs do not necessarily displace each other-their binding sites may not overlap, e.g. probenecid and indomethacin are highly bound to albumin but do not displace each other. Similarly, acidic drugs do not generally displace basic drugs and vice versa.
(vi) In hypoalbuminemia, binding may be reduced and high concentrations of free drug may be attained, e.g. phenytoin and furosemide. Other diseases may also alter drug binding, e.g. phenytoin and pethidine binding is reduced in uraemia; propranolol binding is increased in pregnant women and in patients with inflammatory disease (acute phase reactant <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi>α</mi><mn>1</mn></msub></mrow><annotation encoding="application/x-tex">\alpha_{1}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5806em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.0037em;">α</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.0037em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> acidglycoprotein increases).</p>
<table><thead><tr><th style="text-align: left;">Drugs concentrated in tissues</th><th style="text-align: left;"></th></tr></thead><tbody><tr><td style="text-align: left;">Skeletal muscle, heart</td><td style="text-align: left;">- digoxin, emetine (bound to muscle proteins).</td></tr><tr><td style="text-align: left;">Liver</td><td style="text-align: left;">- chloroquine, tetracyclines, emetine, digoxin.</td></tr><tr><td style="text-align: left;">Kidney</td><td style="text-align: left;">- digoxin, chloroquine, emetine.</td></tr><tr><td style="text-align: left;">Thyroid</td><td style="text-align: left;">- iodine.</td></tr><tr><td style="text-align: left;">Brain</td><td style="text-align: left;">- chlorpromazine, acetazolamide, isoniazid.</td></tr><tr><td style="text-align: left;">Retina</td><td style="text-align: left;">- chloroquine (bound to nucleoproteins).</td></tr><tr><td style="text-align: left;">Iris</td><td style="text-align: left;">- ephedrine, atropine (bound to melanin).</td></tr><tr><td style="text-align: left;">Bone and teeth</td><td style="text-align: left;">- tetracyclines, heavy metals (bound to mucopolysaccharides of &lt;br&gt; connective tissue), bisphosphonates (bound to hydroxyapatite).</td></tr><tr><td style="text-align: left;">Adipose tissue</td><td style="text-align: left;">- thiopentone, ether, minocycline, phenoxybenzamine, DDT &lt;br&gt; dissolve in neutral fat due to high lipid-solubility; remain &lt;br&gt; stored due to poor blood supply of fat.</td></tr></tbody></table>
<p>Tissue storage Drugs may also accumulate in specific organs by active transport or get bound to specific tissue constituents (see box).</p>
<p>Drugs sequestrated in various tissues are unequally distributed, tend to have larger volume of distribution and longer duration of action. Some may exert local toxicity due to
high concentration, e.g. tetracyclines on bone and teeth, chloroquine on retina, streptomycin on vestibular apparatus, emetine on heart and skeletal muscle. Drugs may also selectively bind to specific intracellular organelle, e.g. tetracycline to mitochondria, chloroquine to nuclei.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="problem-directed-study">PROBLEM DIRECTED STUDY<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#problem-directed-study" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>2.1 A 60-year-old woman complained of weakness, lethargy and easy fatigability. Investigation showed that she had iron deficiency anaemia ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mrow><mi mathvariant="normal">H</mi><mi mathvariant="normal">b</mi></mrow><mn>.8</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">d</mi><mi mathvariant="normal">l</mi></mrow></mrow><annotation encoding="application/x-tex">\mathrm{Hb} .8 \mathrm{~g} / \mathrm{dl}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord"><span class="mord mathrm">Hb</span></span><span class="mord">.8</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm" style="margin-right: 0.01389em;">g</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm">dl</span></span></span></span></span></span> ). She was prescribed cap. ferrous fumarate 300 mg twice daily. She returned after one month with no improvement in symptoms. Her Hb . level was unchanged. On enquiry she revealed that she felt epigastric distress after taking the iron capsules, and had started taking antacid tablets along with the capsules.
(a) What could be the possible reason for her failure to respond to the oral iron medication?
2.2 A 50-year-old type-2 diabetes mellitus patient was maintained on tab. glibenclamide (a sulfonylurea) 5 mg twice daily. He developed toothache for which he took tab. aspirin 650 mg 6 hourly. After taking aspirin he experienced anxiety, sweating, palpitation, weakness, ataxia, and was behaving abnormally. These symptoms subsided when he was given a glass of glucose solution.
(a) What could be the explanation for his symptoms?
(b) Which alternative analgesic should have been taken?
(see Appendix-1 for solutions)</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="chapter-3-br-pharmacokinetics-metabolism-and-excretion-of-drugs-kinetics-of-elimination">Chapter 3 &lt;br&gt; Pharmacokinetics: Metabolism and Excretion of Drugs, Kinetics of Elimination<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#chapter-3-br-pharmacokinetics-metabolism-and-excretion-of-drugs-kinetics-of-elimination" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="biotransformation-metabolism">BIOTRANSFORMATION (Metabolism)<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#biotransformation-metabolism" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Biotransformation means chemical alteration of the drug in the body. It is needed to render nonpolar (lipid-soluble) compounds polar (lipid-insoluble) so that they are not reabsorbed in the renal tubules and are excreted. In the absence of metabolism, body will not be able to get rid of lipophylic substances, and they will become very long acting. Most hydrophilic drugs, e.g. streptomycin, neostigmine, pancuronium, etc. are little biotransformed and are largely excreted unchanged. Mechanisms which metabolize drugs (essentially foreign substances or Xenobiotics) have developed to protect the body from ingested toxins and other environmental chemicals.</p>
<p>The primary site for drug metabolism is liver; others are-kidney, intestine, lungs and plasma. Biotransformation of drugs may lead to the following.
(i) Inactivation Most drugs and their active metabolites are rendered inactive or less active, e.g. ibuprofen, paracetamol, lidocaine, chloramphenicol, propranolol and its active metabolite 4-hydroxypropranolol. Thus, biotransformation provides an alternative method of terminating drug action to excretion.
(ii) Active metabolite from an active drug Many drugs have been found to be partially converted to one or more active metabolite; the effects observed are the sumtotal of that due to the parent drug and its active metabolite(s) (see box).
(iii) Activation of inactive drug Few drugs are inactive as such and need conversion in the body to one or more active metabolites. Such a drug is called a prodrug (see box). The prodrug may offer advantages over the active form in being more stable, having better bioavailability or other desirable pharmacokinetic properties or less side effects and toxicity. Some prodrugs are activated selectively at the site of action.</p>
<table><thead><tr><th style="text-align: center;">Active drug</th><th style="text-align: center;">Active metabolite</th></tr></thead><tbody><tr><td style="text-align: center;">Morphine</td><td style="text-align: center;">- Morphine-6-glucuronide</td></tr><tr><td style="text-align: center;">Cefotaxime</td><td style="text-align: center;">- Desacetyl cefotaxime</td></tr><tr><td style="text-align: center;">Allopurinol</td><td style="text-align: center;">- Alloxanthine</td></tr><tr><td style="text-align: center;">Procainamide</td><td style="text-align: center;">- N-acetyl procainamide</td></tr><tr><td style="text-align: center;">Primidone</td><td style="text-align: center;">- Phenobarbitone, phenylethylmalonamide</td></tr><tr><td style="text-align: center;">Diazepam</td><td style="text-align: center;">- Desmethyl-diazepam, oxazepam</td></tr><tr><td style="text-align: center;">Digitoxin</td><td style="text-align: center;">- Digoxin</td></tr><tr><td style="text-align: center;">Imipramine</td><td style="text-align: center;">- Desipramine</td></tr><tr><td style="text-align: center;">Amitriptyline</td><td style="text-align: center;">- Nortriptyline</td></tr><tr><td style="text-align: center;">Codeine</td><td style="text-align: center;">- Morphine</td></tr><tr><td style="text-align: center;">Spironolactone</td><td style="text-align: center;">- Canrenone</td></tr><tr><td style="text-align: center;">Losartan</td><td style="text-align: center;">- E 3174</td></tr></tbody></table>
<p>Biotransformation reactions can be classified into:
(a) Nonsynthetic/Phase I/Functionalization reactions: a functional group ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>−</mo><mrow><mi mathvariant="normal">O</mi><mi mathvariant="normal">H</mi></mrow><mo separator="true">,</mo><mo>−</mo><mrow><mi mathvariant="normal">C</mi><mi mathvariant="normal">O</mi><mi mathvariant="normal">O</mi><mi mathvariant="normal">H</mi></mrow><mo separator="true">,</mo><mo>−</mo><mrow><mi mathvariant="normal">C</mi><mi mathvariant="normal">H</mi><mi mathvariant="normal">O</mi></mrow></mrow><annotation encoding="application/x-tex">-\mathrm{OH},-\mathrm{COOH},-\mathrm{CHO}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8778em; vertical-align: -0.1944em;"></span><span class="mord">−</span><span class="mord"><span class="mord mathrm">OH</span></span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord">−</span><span class="mord"><span class="mord mathrm">COOH</span></span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord">−</span><span class="mord"><span class="mord mathrm">CHO</span></span></span></span></span></span>, <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>−</mo><msub><mrow><mi mathvariant="normal">N</mi><mi mathvariant="normal">H</mi></mrow><mn>2</mn></msub><mo separator="true">,</mo><mo>−</mo><mrow><mi mathvariant="normal">S</mi><mi mathvariant="normal">H</mi></mrow><mo stretchy="false">)</mo></mrow><annotation encoding="application/x-tex">-\mathrm{NH}_{2},-\mathrm{SH})</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">−</span><span class="mord"><span class="mord"><span class="mord mathrm">NH</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord">−</span><span class="mord"><span class="mord mathrm">SH</span></span><span class="mclose">)</span></span></span></span></span> is generated or exposed-metabolite may be active or inactive.
(b) Synthetic/Conjugation/ Phase II reactions: an endogenous radical is conjugated to the drug-metabolite is mostly inactive; except few drugs, e.g. glucuronide conjugate of morphine and sulfate conjugate of minoxidil are active. Certain drugs already have functional groups and</p>
<p>are directly conjugated, while others undergo a phase I reaction first followed by a phase II reaction (see Fig. 3.1).</p>
<table><thead><tr><th style="text-align: center;">Prodrug</th><th style="text-align: center;"></th><th style="text-align: center;">Active form</th></tr></thead><tbody><tr><td style="text-align: center;">Levodopa</td><td style="text-align: center;">-</td><td style="text-align: center;">Dopamine</td></tr><tr><td style="text-align: center;">Enalapril</td><td style="text-align: center;">-</td><td style="text-align: center;">Enalaprilat</td></tr><tr><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>α</mi></mrow><annotation encoding="application/x-tex">\alpha</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.4306em;"></span><span class="mord mathnormal" style="margin-right: 0.0037em;">α</span></span></span></span></span>-Methyldopa</td><td style="text-align: center;">-</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>α</mi></mrow><annotation encoding="application/x-tex">\alpha</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.4306em;"></span><span class="mord mathnormal" style="margin-right: 0.0037em;">α</span></span></span></span></span>-methylnorepinephrine</td></tr><tr><td style="text-align: center;">Dipivefrine</td><td style="text-align: center;">-</td><td style="text-align: center;">Epinephrine</td></tr><tr><td style="text-align: center;">Proguanil</td><td style="text-align: center;">-</td><td style="text-align: center;">Cycloguanil</td></tr><tr><td style="text-align: center;">Prednisone</td><td style="text-align: center;">-</td><td style="text-align: center;">Prednisolone</td></tr><tr><td style="text-align: center;">Clopidogrel</td><td style="text-align: center;">-</td><td style="text-align: center;">Thiol metabolite</td></tr><tr><td style="text-align: center;">Bacampicillin</td><td style="text-align: center;">-</td><td style="text-align: center;">Ampicillin</td></tr><tr><td style="text-align: center;">Sulfasalazine</td><td style="text-align: center;">-</td><td style="text-align: center;">5-Aminosalicylic acid</td></tr><tr><td style="text-align: center;">Cyclophosphamide</td><td style="text-align: center;">-</td><td style="text-align: center;">Aldophosphamide, phosphoramide mustard, acrolein</td></tr><tr><td style="text-align: center;">Fluorouracil</td><td style="text-align: center;">-</td><td style="text-align: center;">Fluorouridine monophosphate</td></tr><tr><td style="text-align: center;">Mercaptopurine</td><td style="text-align: center;">-</td><td style="text-align: center;">Methylmercaptopurine ribonucleotide</td></tr><tr><td style="text-align: center;">Acyclovir</td><td style="text-align: center;">-</td><td style="text-align: center;">Acyclovir triphosphate</td></tr></tbody></table>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="nonsynthetic-reactions">Nonsynthetic reactions<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#nonsynthetic-reactions" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>(i) Oxidation This reaction involves addition of oxygen/negatively charged radical or removal of hydrogen/positively charged radical. Oxidations are the most important drug metabolizing reactions. Various oxidation reactions are:
hydroxylation; oxygenation at <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">C</mi><mo separator="true">,</mo><mi mathvariant="normal">N</mi></mrow><annotation encoding="application/x-tex">\mathrm{C}, \mathrm{N}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8778em; vertical-align: -0.1944em;"></span><span class="mord mathrm">C</span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord mathrm">N</span></span></span></span></span> or S atoms; N or O-dealkylation, oxidative deamination, etc.</p>
<p>In many cases the initial insertion of oxygen atom into the drug molecule produces short lived highly reactive quinone/epoxide/superoxide intermediates which then convert to more stable compounds.</p>
<p>Oxidative reactions are mostly carried out by a group of monooxygenases in the liver, which in the final step involve a cytochrome P-450 haemoprotein, NADPH, cytochrome P-450 reductase and molecular <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">O</mi><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{O}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">O</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span>. More than 100 cytochrome P-450 (CYP) isoenzymes differing in their affinity for various substrates (drugs), have been identified. The CYP isoenzymes important for drug metabolism in humans, along with their clinically relevant substrate drugs, inhibitors and inducers are listed in Table 3.1</p>
<p>Depending upon the extent of amino acid sequence homology, the cytochrome P-450 (CYP) isoenzymes are grouped into families designated by numerals ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mo separator="true">,</mo><mn>2</mn><mo separator="true">,</mo><mn>3</mn><mo>…</mo></mrow><annotation encoding="application/x-tex">1,2,3 \ldots</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">1</span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord">2</span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord">3</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="minner">…</span></span></span></span></span>. ), each having several sub-families designated by capital letters (A, B, C.....), while individual isoenzymes are again alloted numerals <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo stretchy="false">(</mo><mn>1</mn><mo separator="true">,</mo><mn>2</mn><mo separator="true">,</mo><mn>3</mn><mo>…</mo></mrow><annotation encoding="application/x-tex">(1,2,3 \ldots</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mopen">(</span><span class="mord">1</span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord">2</span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord">3</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="minner">…</span></span></span></span></span> ). In human beings, only a few members of three isoenzyme families (CYP 1, 2 and 3) carryout metabolism of most of the drugs, and many drugs such as tolbutamide, barbiturates, phenytoin, paracetamol are substrates for more than one isoform. The CYP isoenzymes important in man are:</p>
<p>CYP3A4/5 Carryout biotransformation of largest number (nearly <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>50</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">50 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">50%</span></span></span></span></span> ) of drugs. In addition to liver, these isoforms are expressed in intestine (responsible for first pass metabolism at this site) and kidney as well. Inhibition of this isoenzyme by erythromycin, clarithromycin, ketoconazole, itraconazole is responsible for the important drug interaction with terfenadine, astemizole and cisapride (see p. 181) which are its substrates. Verapamil, ritonavir and a constituent of grape fruit juice are other important inhibitors.</p>
<p>CYP2D6 This is the next most important CYP isoform which metabolizes nearly <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>20</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">20 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">20%</span></span></span></span></span> drugs including tricyclic antidepressants, selective serotonin reuptake inhibitors, many neuroleptics, antiarrhythmics, codeine, debrisoquine, metoprolol. Inhibition of this enzyme by quinidine results in failure of conversion of codeine to morphine <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>→</mo></mrow><annotation encoding="application/x-tex">\rightarrow</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.3669em;"></span><span class="mrel">→</span></span></span></span></span> analgesic effect of codeine is lost. Human subjects can be grouped into 'extensive' or 'poor' metabolizers of metoprolol and debrisoquin. The poor metabolizers have an altered CYP2D6 enzyme and exhibit low capacity to hydroxylate many drugs. An ultrarapid metabolizer genotype of CYP2D6 has also been identified.</p>
<p>CYP2C8/9 Important in the biotransformation of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&gt;</mo><mn>15</mn></mrow><annotation encoding="application/x-tex">&gt;15</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&gt;</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">15</span></span></span></span></span> commonly used drugs including phenytoin, carbamazepine, warfarin which are narrow safety margin drugs.</p>
<p>CYP2C19 Metabolizes <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&gt;</mo><mn>12</mn></mrow><annotation encoding="application/x-tex">&gt;12</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&gt;</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">12</span></span></span></span></span> frequently used drugs including omeprazole, lansoprazole, phenytoin, diazepam. Omeprazole and fluconazole are its inhibitors.</p>
<p>CYP1A1/2 Though this subfamily participates in the metabolism of only few drugs like theophylline, caffeine, paracetamol, carbamazepine, it is more important for activation of procarcinogens. Polycyclic hydrocarbons, cigarette smoke and charbroiled meat are its potent inducers.</p>
<p>CYP2E1 It catalyses oxidation of alcohol, holothane, and formation of minor metabolites of few drugs, notably the hepatotoxic N -acetyl benzoquinoneimine from paracetamol; chronic alcoholism induces this isoenzyme.</p>
<p>The relative amount of different cytochrome P-450s differs among species and among individuals of the same species. These differences</p>
<p>Table 3.1: Major drug metabolizing CYP450 isoenzymes in humans with their important substrate drugs, inhibitors and inducers</p>
<table><thead><tr><th style="text-align: center;">CYP-450 isoenzyme</th><th style="text-align: center;">Drugs metabolized</th><th style="text-align: center;">Inhibitors</th><th style="text-align: center;">Inducers</th></tr></thead><tbody><tr><td style="text-align: center;">CYP3A4 &lt;br&gt; CYP3A5</td><td style="text-align: center;">Terfenadine, Astemizole Cisapride, Losartan Carbamazepine, Hydrocortisone Paracetamol, Diazepam Buspirone, Mifepristone Ritonavir, Saquinavir Simvastatin, Quinidine Verapamil, Lidocaine Dapsone, Nevirapine</td><td style="text-align: center;">Erythromycin &lt;br&gt; Clarithromycin Ketoconazole Itraconazole Verapamil Ritonavir Fluoxetine Grape fruit juice</td><td style="text-align: center;">Barbiturates &lt;br&gt; Phenytoin &lt;br&gt; Carbamazepine &lt;br&gt; Rifampin &lt;br&gt; Glucocorticoids &lt;br&gt; Nevirapine</td></tr><tr><td style="text-align: center;">CYP2D6</td><td style="text-align: center;">Metoprolol, Debrisoquine Nebivolol, Amitryptyline Clomipramine, Fluoxetine Paroxetine, Venlafaxine Haloperidol, Clozapine Risperidone, Codeine Propafenone, Flecainide</td><td style="text-align: center;">Qunidine &lt;br&gt; Fluoxetine &lt;br&gt; Paroxetine</td><td style="text-align: center;">Phenobarbitone &lt;br&gt; Rifampin</td></tr><tr><td style="text-align: center;">CYP2C8 &lt;br&gt; CYP2C9</td><td style="text-align: center;">Phenytoin, Carbamazepine Warfarin, Tolbutamide Repaglinide, Pioglitazone Diclofenac, Ibuprofem Losartan</td><td style="text-align: center;">Fluvoxamine Fluconazole Gemfibrozil Trimethoprim</td><td style="text-align: center;">Phenobarbitone &lt;br&gt; Carbamazepine &lt;br&gt; Rifampin</td></tr><tr><td style="text-align: center;">CYP2C19</td><td style="text-align: center;">Omeprazole, Lansoprazole Amitriptyline, Citalopram Phenytoin, Diazepam Propranolol, Clopidogrel</td><td style="text-align: center;">Omeprazole &lt;br&gt; Fluconazole</td><td style="text-align: center;">Carbamazepine Rifampin</td></tr><tr><td style="text-align: center;">CYP1A1 &lt;br&gt; CYP1A2</td><td style="text-align: center;">Theophylline, Caffeine Paracetamol, Warfarin Carbamazepine</td><td style="text-align: center;">Fluvoxamine Fluoxetine</td><td style="text-align: center;">Polycyclic hydrocarbons Cigarette smoke Charbroiled meat Rifampin Carbamazepine</td></tr><tr><td style="text-align: center;">CYP2E1</td><td style="text-align: center;">Alcohol, Halothane &lt;br&gt; Paracetamol*</td><td style="text-align: center;">Disulfiram &lt;br&gt; Fomepizole</td><td style="text-align: center;">Chronic alcoholism Isoniazid</td></tr><tr><td style="text-align: center;">CYP2B6</td><td style="text-align: center;">Efavirenz, Nevirapine Cyclophosphamide, Methadone Sertraline, Clopidogrel</td><td style="text-align: center;">Paroxetine &lt;br&gt; Sertraline &lt;br&gt; Clopidogrel</td><td style="text-align: center;">Phenobarbitone Cyclophosphamide</td></tr></tbody></table>
<ul>
<li>Generates toxic metabolite N -acetyl-p-benzoquinoneimine (NABQI)
largely account for the marked interspecies and interindividual differences in rate of metabolism of drugs.</li>
</ul>
<p>Barbiturates, phenothiazines, imipramine, propranolol, ibuprofen, paracetamol, steroids, phenytoin, benzodiazepines, theophylline and many other drugs are oxidized in this way by CYP450. In addition few drugs like cimetidine, ranitidine, clozapine are oxidized at their <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">N</mi><mo separator="true">,</mo><mi mathvariant="normal">P</mi></mrow><annotation encoding="application/x-tex">\mathrm{N}, \mathrm{P}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8778em; vertical-align: -0.1944em;"></span><span class="mord mathrm">N</span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord mathrm">P</span></span></span></span></span> or S atoms by a group of flavin-monooxygenases
that are also located on hepatic endoplasmic reticulum, but are distinct from CYP enzymes. These enzymes are not susceptible to induction or inhibition by other drugs, and thus are not involved in drug interactions. Some other drugs, e.g. adrenaline, alcohol, mercaptopurine are oxidized by mitochondrial or cytoplasmic enzymes.
(ii) Reduction This reaction is the converse of oxidation and involves cytochrome P-450</p>
<p>enzymes working in the opposite direction. Alcohols, aldehydes, quinones are reduced. Drugs primarily reduced are chloralhydrate, chloramphenicol, halothane, warfarin.
(iii) Hydrolysis This is cleavage of drug molecule by taking up a molecule of water.</p>
<div class="math math-display"><span class="katex-display"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML" display="block"><semantics><mrow><mtext>&nbsp;Ester&nbsp;</mtext><mo>+</mo><msub><mi mathvariant="normal">H</mi><mn>2</mn></msub><mi mathvariant="normal">O</mi><mover><mo stretchy="true" minsize="3.0em">→</mo><mpadded width="+0.6em" lspace="0.3em"><mtext>&nbsp;esterase&nbsp;</mtext></mpadded></mover><mtext>&nbsp;Acid&nbsp;</mtext><mo>+</mo><mtext>&nbsp;Alcohol&nbsp;</mtext></mrow><annotation encoding="application/x-tex">\text { Ester }+\mathrm{H}_{2} \mathrm{O} \xrightarrow{\text { esterase }} \text { Acid }+ \text { Alcohol }</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7667em; vertical-align: -0.0833em;"></span><span class="mord text"><span class="mord">&nbsp;Ester&nbsp;</span></span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">+</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1.2026em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">H</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mord mathrm">O</span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel x-arrow"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 1.0526em;"><span style="top: -3.322em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight x-arrow-pad"><span class="mord mtight"><span class="mord text mtight"><span class="mord mtight">&nbsp;esterase&nbsp;</span></span></span></span></span><span class="svg-align" style="top: -2.689em;"><span class="pstrut" style="height: 2.7em;"></span><span class="hide-tail" style="height: 0.522em; min-width: 1.469em;"><svg xmlns="http://www.w3.org/2000/svg" width="400em" height="0.522em" viewBox="0 0 400000 522" preserveAspectRatio="xMaxYMin slice"><path d="M0 241v40h399891c-47.3 35.3-84 78-110 128
-16.7 32-27.7 63.7-33 95 0 1.3-.2 2.7-.5 4-.3 1.3-.5 2.3-.5 3 0 7.3 6.7 11 20
 11 8 0 13.2-.8 15.5-2.5 2.3-1.7 4.2-5.5 5.5-11.5 2-13.3 5.7-27 11-41 14.7-44.7
 39-84.5 73-119.5s73.7-60.2 119-75.5c6-2 9-5.7 9-11s-3-9-9-11c-45.3-15.3-85
-40.5-119-75.5s-58.3-74.8-73-119.5c-4.7-14-8.3-27.3-11-40-1.3-6.7-3.2-10.8-5.5
-12.5-2.3-1.7-7.5-2.5-15.5-2.5-14 0-21 3.7-21 11 0 2 2 10.3 6 25 20.7 83.3 67
 151.7 139 205zm0 0v40h399900v-40z"></path></svg></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.011em;"><span></span></span></span></span></span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.7778em; vertical-align: -0.0833em;"></span><span class="mord text"><span class="mord">&nbsp;Acid&nbsp;</span></span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">+</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6944em;"></span><span class="mord text"><span class="mord">&nbsp;Alcohol&nbsp;</span></span></span></span></span></span></div>
<p>Similarly, amides and polypeptides are hydrolysed by amidases and peptidases. In addition, there are epoxide hydrolases which detoxify epoxide metabolites of some drugs generated by CYP oxygenases. Hydrolysis occurs in liver, intestines, plasma and other tissues. Examples of hydrolysed drugs are choline esters, procaine, lidocaine, procainamide, aspirin, indomethacin, carbamazepine-epoxide, pethidine, oxytocin.
(iv) Cyclization This is formation of ring structure from a straight chain compound, e.g. cycloguanil from proguanil.
(v) Decyclization This implies opening up of ring structure of the cyclic drug molecule, such as barbiturates, phenytoin. This is generally a minor pathway.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="synthetic-reactions">Synthetic reactions<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#synthetic-reactions" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>These reactions involve conjugation of the drug or its phase I metabolite with an endogenous substrate, usually derived from carbohydrate or amino acid, to form a polar highly ionized organic acid, which is easily excreted in urine or bile. Conjugation reactions have high energy requirement and are generally faster than phase I reactions.
(i) Glucuronide conjugation This is the most important synthetic reaction carriedout by a group of UDP-glucuronosyl transferases (UGTs). Compounds with a hydroxyl or carboxylic acid group are easily conjugated with glucuronic acid which is derived from glucose. Examples arechloramphenicol, aspirin, paracetamol, diazepam, lorazepam, morphine, metronidazole. Not only drugs but endogenous substrates like bilirubin, steroidal hormones and thyroxine utilize this
pathway. Glucuronidation increases the molecular weight of the drug which favours its excretion in bile. Drug glucuronides excreted in bile can be hydrolysed by bacteria in the gut-the liberated drug is reabsorbed and undergoes the same fate. This enterohepatic cycling (see Fig. 3.2) of the drug prolongs its action, e.g. phenolphthalein, oral contraceptives.
(ii) Acetylation Compounds having amino or hydrazine residues are conjugated with the help of acetyl coenzyme-A, e.g. sulfonamides, isoniazid, PAS, dapsone, hydralazine, clonazepam, procainamide. Multiple genes control the N -acetyl transferases (NATs), and rate of acetylation shows genetic polymorphism (slow and fast acetylators).
(iii) Methylation The amines and phenols can be methylated by methyl transferases (MT); methionine and cysteine acting as methyl donors, e.g. adrenaline, histamine, nicotinic acid, methyldopa, captopril, mercaptopurine.
(iv) Sulfate conjugation The phenolic compounds and steroids are sulfated by sulfotransferases (SULTs), e.g. chloramphenicol, methyldopa, adrenal and sex steroids.
(v) Glycine conjugation Salicylates, nicotinic acid and other drugs having carboxylic acid group are conjugated with glycine, but this is not a major pathway of metabolism.
(vi) Glutathione conjugation This is carried out by glutathione-S-transferase (GST) forming a mercapturate. It is normally a minor pathway. However, it serves to inactivate highly reactive quinone or epoxide intermediates formed during metabolism of certain drugs, e.g. paracetamol. When large amount of such intermediates are formed (in poisoning or after enzyme induction), glutathione supply falls short-toxic adducts are formed with tissue constituents resulting in hepatic, renal and other tissue damage.
(vii) Ribonucleoside/nucleotide synthesis This pathway is important for the activation of many purine and pyrimidine antimetabolites used in cancer chemotherapy.</p>
<p><img src="assets/images/image-20251214-1eb265e2.jpeg" alt="img-11.jpeg"></p>
<p>Fig. 3.1: Simultaneous and/or sequential metabolism of a drug by phase I and phase II reactions</p>
<p>Most drugs are metabolized by multiple pathways, simultaneously or sequentially as illustrated in Fig. 3.1. Rates of reaction by different pathways often vary considerably. A variety of metabolites (some more, some less) of a drug may be produced. Stereoisomers of a drug may be metabolized differently and at different rates, e.g. S-warfarin rapidly undergoes ring oxidation, while R-warfarin is slowly degraded by sidechain reduction.</p>
<p>Only a few drugs are metabolized by enzymes of intermediary metabolism, e.g. alcohol by dehydrogenase, allopurinol by xanthine oxidase, succinylcholine and procaine by plasma cholinesterase, adrenaline by monoamine oxidase. Majority of drugs are acted on by relatively nonspecific enzymes which are directed to types of molecules rather than to specific drugs. The same enzyme can metabolize many drugs. The drug metabolising enzymes are divided into two types:</p>
<p>Microsomal enzymes These are located on smooth endoplasmic reticulum (a system of microtubules inside the cell), primarily in liver, also in kidney, intestinal mucosa and lungs. The monooxygenases, cytochrome P450, UGTs, epoxide hydrolases, etc. are microsomal enzymes.</p>
<p>They catalyse most of the oxidations, reductions, hydrolysis and glucuronide conjugation. Microsomal enzymes are inducible by drugs, certain dietary constituents, and other agencies.</p>
<p>Nonmicrosomal enzymes These are present in the cytoplasm and mitochondria of hepatic cells
as well as in other tissues including plasma. The esterases, amidases, some flavoprotein oxidases and most conjugases are nonmicrosomal. Reactions catalysed are:</p>
<p>Some oxidations and reductions, many hydrolytic reactions and all conjugations except glucuronidation.</p>
<p>The nonmicrosomal enzymes are not inducible but many show genetic polymorphism (acetyl transferase, pseudocholinesterase) similar to the microsomal enzymes.</p>
<p>Both microsomal and nonmicrosomal enzymes are deficient in the newborn, especially premature, making them more susceptible to many drugs, e.g. chloramphenicol, opioids. This deficit is made up in the first few months, more quickly in case of oxidation and other phase I reactions than in case of glucuronide and other conjugations which take 3 or more months to reach adult levels.</p>
<p>The amount and kind of drug metabolizing enzymes is controlled genetically and is also altered by diet, environmental factors. Thus, marked interspecies and interindividual differences are seen, e.g. cats are deficient in UGTs while dogs are deficient in NATs. Upto 6-fold difference in the rate of metabolism of a drug among normal human adults may be observed. This is one of the major causes of individual variation in drug response.</p>
<p>Hofmann elimination This refers to inactivation of the drug in the body fluids by spontaneous molecular rearrangement without the agency of any enzyme, e.g. atracurium.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="inhibition-of-drug-metabolism">Inhibition of Drug Metabolism<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#inhibition-of-drug-metabolism" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Azole antifungal drugs, macrolide antibiotics and some other drugs bind to the heme iron in CYP450 and inhibit the metabolism of many drugs, as well as some endogenous substances like steroids, bilirubin. One drug can competitively inhibit the metabolism of another if it utilizes the same enzyme or cofactors. However, such interactions are not as common as one would expect, because often different drugs are substrates for different CYP-450 isoenzymes. It is thus important to</p>
<p>know the CYP isoenzyme(s) that carry out the metabolism of a particular drug. A drug may be the substrate as well as inhibitor of the same CYP isoenzyme. In case the drug inhibits its own metabolism, the oral bioavailability is likely to increase (for high first pass metabolism drugs), while systemic clearance is likely to decrease, prolonging plasma half life. On chronic dosing, the oral bioavailability of verapamil is nearly doubled and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">t</mi><mrow><mn>1</mn><mi mathvariant="normal">/</mi><mn>2</mn></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{t}^{1 / 2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.888em;"></span><span class="mord"><span class="mord mathrm">t</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.888em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1/2</span></span></span></span></span></span></span></span></span></span></span></span></span> is prolonged, because it inhibits its own metabolism. A drug may also inhibit one isoenzyme while being itself a substrate of another isoenzyme, e.g. quinidine is metabolized mainly by CYP3A4 but inhibits CYP2D6. Moreover, majority of drugs, at therapeutic concentrations, are metabolized by non-saturation kinetics, i.e. the enzyme is present in excess. Clinically significant inhibition of drug metabolism occurs in case of drugs having affinity for the same isoenzyme, specially if they are metabolized by saturation kinetics or if kinetics changes from first order to zero order over the therapeutic range (capacity limited metabolism). The 'boosted' HIV-protease inhibitor (PI) strategy utilizes the potent CYP3A4 inhibitory action of low dose ritonavir to lower the dose of other PIs like atazanavir, lopinavir, saquinavir given concurrently. Obviously, inhibition of drug metabolism occurs in a dose related manner and can precipitate toxicity of the object drug (whose metabolism has been inhibited).</p>
<p>Because enzyme inhibition occurs by direct effect on the enzyme, it has a fast time course</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="drugs-that-inhibit-drug-metabolizing-enzymes">Drugs that inhibit drug metabolizing enzymes<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#drugs-that-inhibit-drug-metabolizing-enzymes" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<table><thead><tr><th style="text-align: left;">Allopurinol</th><th style="text-align: left;">Amiodarone</th></tr></thead><tbody><tr><td style="text-align: left;">Omeprazole</td><td style="text-align: left;">Propoxyphene</td></tr><tr><td style="text-align: left;">Erythromycin</td><td style="text-align: left;">Isoniazid</td></tr><tr><td style="text-align: left;">Clarithromycin</td><td style="text-align: left;">Cimetidine</td></tr><tr><td style="text-align: left;">Chloramphenicol</td><td style="text-align: left;">Quinidine</td></tr><tr><td style="text-align: left;">Ketoconazole</td><td style="text-align: left;">Disulfiram</td></tr><tr><td style="text-align: left;">Itraconazole</td><td style="text-align: left;">Diltiazem</td></tr><tr><td style="text-align: left;">Metronidazole</td><td style="text-align: left;">Verapamil</td></tr><tr><td style="text-align: left;">Ciprofloxacin</td><td style="text-align: left;">MAO inhibitors</td></tr><tr><td style="text-align: left;">Fluoxetine (and</td><td style="text-align: left;">Ritonavir (and other</td></tr><tr><td style="text-align: left;">other SSRIs)</td><td style="text-align: left;">HIV protease inhibitors)</td></tr></tbody></table>
<p>(within hours) compared to enzyme induction (see below).</p>
<p>Metabolism of drugs with high hepatic extraction is dependent on liver blood flow (blood flow limited metabolism). Propranolol reduces rate of lidocaine metabolism by decreasing hepatic blood flow. Some other drugs whose rate of metabolism is limited by hepatic blood flow are morphine, propranolol, verapamil and imipramine.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="microsomal-enzyme-induction">Microsomal Enzyme Induction<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#microsomal-enzyme-induction" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Many drugs, insecticides and carcinogens interact with DNA and increase the synthesis of microsomal enzyme protein, especially cytochrome P-450 and UGTs. As a result the rate of metabolism of inducing drug itself (autoinduction) and/or some other coadministered drugs is accelerated.</p>
<p>Different inducers are relatively selective for certain cytochrome P-450 isoenzyme families, e.g.:</p>
<ul>
<li>Anticonvulsants (phenobarbitone, phenytoin, carbamazepine), rifampin, glucocorticoids induce CYP3A isoenzymes.</li>
<li>Phenobarbitone and rifampin also induce CYP2D6 and CYP2C8/9.</li>
<li>Carbamazepine and rifampin, in addition, induce CYP2C19 and CYP1A1/2.</li>
<li>Isoniazid and chronic alcohol consumption induce CYP2E1.</li>
<li>Polycyclic hydrocarbons like 3-methylcholanthrene and benzopyrene found in cigarette smoke, charcoalbroiled meat, omeprazole and industrial pollutants induce CYP1A isoenzymes.</li>
<li>Other enzyme inducers are: chronic alcoholism, nevirapine, griseofulvin, DDT.
Since different CYP isoenzymes are involved in the metabolism of different drugs, every inducer increases biotransformation of certain drugs but not that of others. However, phenobarbitone like inducers of CYP3A and CYP2D6 affect the metabolism of a large number of drugs, because these isoenzymes act on many drugs. On the other hand</li>
</ul>
<p>induction by polycyclic hydrocarbons is limited to few drugs (like theophylline, warfarin) because CYP1A isoenzyme metabolizes only few drugs.</p>
<p>Induction involves microsomal enzymes in liver as well as other organs and increases the rate of metabolism by 2-4 fold. Induction takes <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>4</mn><mo>−</mo><mn>14</mn></mrow><annotation encoding="application/x-tex">4-14</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">4</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">14</span></span></span></span></span> days to reach its peak and is maintained till the inducing agent is being given. Thereafter the enzymes return to their original value over <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mo>−</mo><mn>3</mn></mrow><annotation encoding="application/x-tex">1-3</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">1</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">3</span></span></span></span></span> weeks.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="consequences-of-microsomal-enzyme-induction">Consequences of microsomal enzyme induction<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#consequences-of-microsomal-enzyme-induction" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ol>
<li>Decreased intensity and/or duration of action of drugs that are inactivated by metabolism, e.g. failure of contraception with oral contraceptives and loss of anti-HIV action of nevirapine due to rifampin coadministration.</li>
<li>Increased intensity of action of drugs that are activated by metabolism. Acute paracetamol toxicity is due to one of its metabolites-toxicity occurs at lower doses in patients receiving enzyme inducers.</li>
<li>Tolerance-if the drug induces its own metabolism (autoinduction), e.g. carbamazepine, rifampin; nevirapine dose needs to be doubled after 2 weeks.</li>
<li>Some endogenous substrates (steroids, bilirubin) are also metabolized faster.</li>
<li>Precipitation of acute intermittent porphyria: enzyme induction increases porphyrin synthesis by derepressing <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>δ</mi></mrow><annotation encoding="application/x-tex">\delta</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6944em;"></span><span class="mord mathnormal" style="margin-right: 0.03785em;">δ</span></span></span></span></span>-aminolevulinic acid synthetase. 6. Intermittent use of an inducer may interfere with adjustment of dose of another drug prescribed on regular basis, e.g. oral anticoagulants, oral hypoglycaemics, antiepileptics, antihypertensives.</li>
<li>Interference with chronic toxicity testing in animals.</li>
</ol>
<p>Drugs whose metabolism is significantly affected by enzyme induction are-phenytoin, carbamazepine, antidepressants, warfarin, tolbutamide, oral contraceptives, chloramphenicol, doxycycline, theophylline, griseofulvin, nevirapine.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="possible-uses-of-enzyme-induction">Possible uses of enzyme induction<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#possible-uses-of-enzyme-induction" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ol>
<li>Congenital nonhaemolytic jaundice: It is due to deficient glucuronidation of bilirubin; phenobarbitone hastens clearance of jaundice. 2. Cushing's syndrome: phenytoin may reduce the manifestations by enhancing degradation of adrenal steroids which are produced in excess. 3. Chronic poisonings: by faster metabolism of the accumulated poisonous substance.</li>
<li>Liver disease.</li>
</ol>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="first-pass-presystemic-metabolism">First-pass (Presystemic) Metabolism<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#first-pass-presystemic-metabolism" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>This refers to metabolism of a drug during its passage from the site of absorption into the systemic circulation. All orally administered drugs are exposed to drug metabolizing enzymes in the intestinal wall and liver (where they first reach through the portal vein). Presystemic metabolism in the gut and liver can be avoided by administering the drug through sublingual, transdermal or parenteral routes. However, limited presystemic metabolism can occur in the skin (transdermally administered drug) and in lungs (for drug reaching venous blood through any route). The extent of first pass metabolism differs for different drugs (Table 3.2) and is an important determinant of oral bioavailability.</p>
<p>A drug can also be excreted as such into bile. The hepatic extraction ratio <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo fence="true">(</mo><mi>E</mi><msub><mi>R</mi><mtext>Liver&nbsp;</mtext></msub><mo fence="true">)</mo></mrow><annotation encoding="application/x-tex">\left(E R_{\text {Liver }}\right)</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="minner"><span class="mopen delimcenter" style="top: 0em;">(</span><span class="mord mathnormal" style="margin-right: 0.05764em;">E</span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.00773em;">R</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3283em;"><span style="top: -2.55em; margin-left: -0.0077em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord text mtight"><span class="mord mtight">Liver&nbsp;</span></span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mclose delimcenter" style="top: 0em;">)</span></span></span></span></span></span> of a drug is the fraction of the absorbed drug prevented by the liver from reaching systemic circulation. Both presystemic metabolism as well as direct excretion into bile determine <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>E</mi><msub><mi>R</mi><mtext>Liver&nbsp;</mtext></msub></mrow><annotation encoding="application/x-tex">E R_{\text {Liver }}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord mathnormal" style="margin-right: 0.05764em;">E</span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.00773em;">R</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3283em;"><span style="top: -2.55em; margin-left: -0.0077em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord text mtight"><span class="mord mtight">Liver&nbsp;</span></span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span>, which is given by the equation:</p>
<div class="math math-display"><span class="katex-display"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML" display="block"><semantics><mrow><mi>E</mi><mi>R</mi><mo>=</mo><mfrac><mrow><mi>C</mi><msub><mi>L</mi><mtext>Liver&nbsp;</mtext></msub></mrow><mtext>&nbsp;Hepatic&nbsp;blood&nbsp;flow&nbsp;</mtext></mfrac></mrow><annotation encoding="application/x-tex">E R=\frac{C L_{\text {Liver }}}{\text { Hepatic blood flow }}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.00773em;">ER</span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">=</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 2.2408em; vertical-align: -0.8804em;"></span><span class="mord"><span class="mopen nulldelimiter"></span><span class="mfrac"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 1.3603em;"><span style="top: -2.314em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="mord text"><span class="mord">&nbsp;Hepatic&nbsp;blood&nbsp;flow&nbsp;</span></span></span></span><span style="top: -3.23em;"><span class="pstrut" style="height: 3em;"></span><span class="frac-line" style="border-bottom-width: 0.04em;"></span></span><span style="top: -3.677em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.07153em;">C</span><span class="mord"><span class="mord mathnormal">L</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3283em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord text mtight"><span class="mord mtight">Liver&nbsp;</span></span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.8804em;"><span></span></span></span></span></span><span class="mclose nulldelimiter"></span></span></span></span></span></span></div>
<p>Accordingly the systemic bioavailability <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo stretchy="false">(</mo><mi>F</mi><mo stretchy="false">)</mo></mrow><annotation encoding="application/x-tex">(F)</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mopen">(</span><span class="mord mathnormal" style="margin-right: 0.13889em;">F</span><span class="mclose">)</span></span></span></span></span> of an orally administered drug will be:</p>
<div class="math math-display"><span class="katex-display"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML" display="block"><semantics><mrow><mi>F</mi><mo>=</mo><mtext>&nbsp;fractional&nbsp;absorption&nbsp;</mtext><mo>×</mo><mo stretchy="false">(</mo><mi>I</mi><mo>−</mo><mi>E</mi><mi>R</mi><mo stretchy="false">)</mo></mrow><annotation encoding="application/x-tex">F=\text { fractional absorption } \times(I-E R)</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.13889em;">F</span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">=</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mord text"><span class="mord">&nbsp;fractional&nbsp;absorption&nbsp;</span></span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">×</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mopen">(</span><span class="mord mathnormal" style="margin-right: 0.07847em;">I</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord mathnormal" style="margin-right: 0.00773em;">ER</span><span class="mclose">)</span></span></span></span></span></div>
<p>When a drug with high first pass metabolism is given orally at higher dose to achieve therapeutic blood levels, the plasma concentration of its metabolites will be much higher compared to those resulting from parenteral dosing of the drug for the same therapeutic level. If the metabolites contribute to the adverse effects of the drug, oral dosing will be less safe than parenteral.</p>
<table><thead><tr><th style="text-align: center;">Low</th><th style="text-align: center;">Intermediate</th><th style="text-align: center;">High</th><th style="text-align: center;"></th></tr></thead><tbody><tr><td style="text-align: center;"></td><td style="text-align: center;"></td><td style="text-align: center;">not given orally</td><td style="text-align: center;">high oral dose</td></tr><tr><td style="text-align: center;">Phenobarbitone</td><td style="text-align: center;">Aspirin</td><td style="text-align: center;">Isoprenaline</td><td style="text-align: center;">Propranolol</td></tr><tr><td style="text-align: center;">Phenylbutazone</td><td style="text-align: center;">Quinidine</td><td style="text-align: center;">Lidocaine</td><td style="text-align: center;">Alprenolol</td></tr><tr><td style="text-align: center;">Tolbutamide</td><td style="text-align: center;">Desipramine</td><td style="text-align: center;">Hydrocortisone</td><td style="text-align: center;">Verapamil</td></tr><tr><td style="text-align: center;">Theophylline</td><td style="text-align: center;">Nortriptyline</td><td style="text-align: center;">Testosterone</td><td style="text-align: center;">Salbutamol</td></tr><tr><td style="text-align: center;">Pindolol</td><td style="text-align: center;">Chlorpromazine</td><td style="text-align: center;"></td><td style="text-align: center;">Glyceryl trinitrate</td></tr><tr><td style="text-align: center;">Diazepam</td><td style="text-align: center;">Pentazocine</td><td style="text-align: center;"></td><td style="text-align: center;">Morphine</td></tr><tr><td style="text-align: center;">Isosorbide mononitrate</td><td style="text-align: center;">Metoprolol</td><td style="text-align: center;"></td><td style="text-align: center;">Pethidine</td></tr></tbody></table>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="attributes-of-drugs-with-high-first-pass-metabolism">Attributes of drugs with high first pass metabolism:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#attributes-of-drugs-with-high-first-pass-metabolism" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>(a) Oral dose is considerably higher than sublingual or parenteral dose.
(b) There is marked individual variation in the oral dose due to differences in the extent of first pass metabolism.
(c) Oral bioavailability is apparently increased in patients with severe liver disease.
(d) Oral bioavailability of a drug is increased if another drug competing with it in first pass metabolism is given concurrently, e.g. chlorpromazine and propranolol.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="excretion">EXCRETION<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#excretion" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Excretion is the passage out of systemically absorbed drug. Drugs and their metabolites are excreted in:</p>
<ol>
<li>Urine Drug excretion in urine occurs via the kidney. It is the most important channel of excretion for majority of drugs (see below).</li>
<li>Faeces Apart from the unabsorbed fraction, most of the drug present in faeces is derived from bile. Liver actively transports into bile organic acids (especially drug glucuronides by OATP and MRP2), organic bases (by OCT), other lipophilic drugs (by P-gp) and steroids by distinct nonspecific active transport mechanisms. Relatively larger molecules (MW <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&gt;</mo><mn>300</mn></mrow><annotation encoding="application/x-tex">&gt;300</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&gt;</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">300</span></span></span></span></span> ) are preferentially eliminated in the bile. Most of the free drug in the gut, including that released by deconjugation of glucuronides
by enteric bacteria is reabsorbed (enterohepatic cycling) and ultimate excretion occurs in urine (Fig. 3.2). Only the remaining is excreted in the faeces. Enterohepatic cycling contributes to longer stay of the drug in the body. Drugs that attain high concentrations in bile include erythromycin, ampicillin, rifampin, tetracycline, oral contraceptives, vecuronium, phenolphthalein.</li>
</ol>
<p>Certain drugs are excreted directly in colon, e.g. anthracene purgatives, heavy metals.
3. Exhaled air Gases and volatile liquids (general anaesthetics, alcohol) are eliminated by lungs, irrespective of their lipid solubility. Alveolar transfer of the gas/vapour depends on its partial pressure in the blood. Lungs also serve to trap and extrude any particulate matter that enters circulation.
4. Saliva and sweat These are of minor importance for drug excretion. Lithium, pot. iodide, rifampin and heavy metals are present in these secretions in significant amounts. Most of the saliva along with the drug in it, is swallowed and meets the same fate as orally taken drug.
5. Milk The excretion of drug in milk is not important for the mother, but the suckling infant inadvertently receives the drug. Most drugs enter breast milk by passive diffusion. As such, more lipid soluble and less protein bound drugs cross better. Milk has a lower pH (7.0) than plasma, basic drugs are somewhat more concentrated in it. However, the total amount of</p>
<p><img src="assets/images/image-20251214-819264eb.jpeg" alt="img-12.jpeg"></p>
<p>Fig. 3.2: Enterohepatic cycling of drugs
In the liver many drgus (D), including steroids, are conjugated by the enzyme UDP-glucuronosyl transferases (UGTs) to form drug-glucuronide (DG). Part of the DG enters systemic circulation and is excreted into urine by the kidney through both glomerular filtration (GF) as well as active tubular secretion involving renal organic-anion transporting peptide (OATP).</p>
<p>Another part of DG is actively secreted into bile by the hepatic OATP. On reaching the gut lumen via bile, a major part of DG is deconjugated by bacterial hydrolytic enzymes (deconjugases) while the remaining is excreted into faeces. The released D is reabsorbed from the gut to again reach the liver through portal circulation and complete the enterohepatic cycle.
drug reaching the infant through breast feeding is generally small and majority of drugs can be given to lactating mothers without ill effects on the infant. Nevertheless, it is advisable to administer any drug to a lactating woman only when essential. Drugs that are safe, as well as those contraindicated during breast feeding or need special caution are given in Appendix-3 at the end of the book.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="renal-excretion">RENAL EXCRETION<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#renal-excretion" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>The kidney is responsible for excreting all water soluble substances. The amount of drug or its metabolites ultimately present in urine is the sum total of glomerular filtration, tubular reabsorption and tubular secretion (Fig. 3.3).</p>
<p>Net renal excretion
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>=</mo></mrow><annotation encoding="application/x-tex">=</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.3669em;"></span><span class="mrel">=</span></span></span></span></span>
(Glomerular filtration + tubular secretion) - tubular reabsorption</p>
<p>Glomerular filtration Glomerular capillaries have pores larger than usual; all nonprotein bound drug (whether lipid-soluble or insoluble) presented to the glomerulus is filtered. Thus, glomerular filtration of a drug depends on its plasma protein binding and renal blood flow. Glomerular filtration rate (g.f.r.), normally <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>∼</mo><mn>120</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">l</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">i</mi><mi mathvariant="normal">n</mi></mrow></mrow><annotation encoding="application/x-tex">\sim 120 \mathrm{ml} / \mathrm{min}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.3669em;"></span><span class="mrel">∼</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">120</span><span class="mord"><span class="mord mathrm">ml</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm">min</span></span></span></span></span></span>, declines progressively after the age of 50 , and is low in renal failure. Glomerular filtration of drugs declines in parallel.
Tubular reabsorption This occurs by passive diffusion and depends on the lipid solubility</p>
<p><img src="assets/images/image-20251214-a19f13bc.jpeg" alt="img-13.jpeg"></p>
<p>Fig. 3.3: Schematic depiction of glomerular filtration, tubular reabsorption and tubular secretion of drugs FD—free drug; BD—bound drug; UD—unionized drug; ID—ionized drug; Dx—actively secreted organic acid (or base) drug
and ionization of the drug at the existing urinary pH . Lipid-soluble drugs filtered at the glomerulus back diffuse in the tubules because <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>99</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">99 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">99%</span></span></span></span></span> of glomerular filtrate is reabsorbed, but nonlipid-soluble and highly ionized drugs are unable to do so. Thus, rate of excretion of such drugs, e.g. aminoglycoside antibiotics, quaternary ammonium compounds parallels g.f.r. (or creatinine clearance). Changes in urinary pH affect tubular reabsorption of drugs that are partially ionized-</p>
<ul>
<li>Weak bases ionize more and are less reabsorbed in acidic urine.</li>
<li>Weak acids ionize more and are less reabsorbed in alkaline urine.</li>
</ul>
<p>This principle is utilized for facilitating elimination of the drug in poisoning, i.e. urine is alkalinized in barbiturate and salicylate poisoning. Though elimination of weak bases (morphine, amphetamine) can be enhanced by acidifying urine, this is not practiced clinically, because acidosis can induce rhabdomyolysis, cardiotoxicity and actually worsen
outcome. The effect of changes in urinary pH on drug excretion is greatest for those having pKa values between 5 to 8 , because only in their case pH dependent passive reabsorption is significant.</p>
<p>Tubular secretion This is the active transfer of organic acids and bases by two separate classes of relatively nonspecific transporters (OAT and OCT) which operate in the proximal tubules. In addition, efflux transporters P-gp and MRP2 are located in the luminal membrane of proximal tubular cells. If renal clearance of a drug is greater than <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>120</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">m</mi><mi mathvariant="normal">L</mi></mrow><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">120 \mathrm{~mL} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">120</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm">mL</span></span><span class="mord">/</span></span></span></span></span> min (g.f.r.), additional tubular secretion can be assumed to be occurring.</p>
<p>Active transport of the drug across tubules reduces concentration of its free form in the tubular vessels and promotes dissociation of protein bound drug, which then becomes available for secretion (Fig. 3.3). Thus, protein binding, which is a hindrance for glomerular filtration of the drug, is not so (may even be facilitatory) to excretion by tubular secretion.
(a) Organic acid transport (through OATP) operates for penicillin, probenecid, uric acid, salicylates, indomethacin, sulfinpyrazone, nitrofurantoin, methotrexate, drug glucuronides and sulfates, etc.
(b) Organic base transport (through OCT) operates for thiazides, amiloride, triamterene, furosemide, quinine, procainamide, choline, cimetidine, etc.</p>
<p>Inherently both transport processes are bidirectional, i.e. they can transport their substrates from blood to tubular fluid and vice versa. However, for drugs and their metabolites (exogenous substances) secretion into the tubular lumen predominates, whereas an endogenous substrate like uric acid is predominantly reabsorbed.</p>
<p>Drugs utilizing the same active transport compete with each other. Probenecid is an organic acid which has high affinity for the tubular OATP. It blocks the active transport of both penicillin and uric acid, but whereas the net</p>
<p>excretion of the former is decreased, that of the latter is increased. This is because penicillin is primarily secreted while uric acid is primarily reabsorbed. Many drug interactions occur due to competition for tubular secretion, e.g.
(i) Aspirin blocks uricosuric action of probenecid and sulfinpyrazone and decrease tubular secretion of methotrexate.
(ii) Probenecid decreases the concentration of nitrofurantoin in urine, increases the duration of action of penicillin/ampicillin and impairs secretion of methotrexate.
(iii) Sulfinpyrazone inhibits excretion of tolbutamide.
(iv) Quinidine decreases renal and biliary clearance of digoxin by inhibiting efflux carrier P-gp.</p>
<p>Tubular transport mechanisms are not well developed at birth. As a result, duration of action of many drugs, e.g. penicillin, cephalosporins, aspirin is longer in neonates. These systems mature during infancy. Renal function again progressively declines after the age of 50 years; renal clearance of most drugs is substantially lower in the elderly ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&gt;</mo><mn>75</mn><mrow><mi mathvariant="normal">y</mi><mi mathvariant="normal">r</mi></mrow></mrow><annotation encoding="application/x-tex">&gt;75 \mathrm{yr}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&gt;</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">75</span><span class="mord"><span class="mord mathrm">yr</span></span></span></span></span></span> ).</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="kinetics-of-elimination">KINETICS OF ELIMINATION<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#kinetics-of-elimination" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>The knowledge of kinetics of elimination of a drug provides the basis for, as well as serves to devise rational dosage regimens and to modify them according to individual needs. There are three fundamental pharmacokinetic parameters, viz. bioavailability <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo stretchy="false">(</mo><mi>F</mi><mo stretchy="false">)</mo></mrow><annotation encoding="application/x-tex">(F)</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mopen">(</span><span class="mord mathnormal" style="margin-right: 0.13889em;">F</span><span class="mclose">)</span></span></span></span></span>, volume of distribution <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo stretchy="false">(</mo><mi>V</mi><mo stretchy="false">)</mo></mrow><annotation encoding="application/x-tex">(V)</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mopen">(</span><span class="mord mathnormal" style="margin-right: 0.22222em;">V</span><span class="mclose">)</span></span></span></span></span> and clearance <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo stretchy="false">(</mo><mi>C</mi><mi>L</mi><mo stretchy="false">)</mo></mrow><annotation encoding="application/x-tex">(C L)</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mopen">(</span><span class="mord mathnormal" style="margin-right: 0.07153em;">C</span><span class="mord mathnormal">L</span><span class="mclose">)</span></span></span></span></span> which must be understood. The first two have already been considered.</p>
<p>Drug elimination is the sumtotal of metabolic inactivation and excretion. As depicted in Fig. 2.1, drug is eliminated only from the central compartment (blood) which is in equilibrium with peripheral compartments including the site of action. Depending upon the ability of the body to eliminate a drug, a certain fraction of the central compartment may be considered to be totally 'cleared' of that drug in a given period of time to account for elimination over that period.
<img src="assets/images/image-20251214-ba873337.jpeg" alt="img-14.jpeg"></p>
<p>Fig. 3.4: Illustration of the concept of drug clearance. A fraction of the drug molecules present in plasma are removed on each passage through the organs of elimination. In the case shown, it requires 50 mL of plasma to account for the amount of drug being eliminated every minute: clearance is <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>50</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">m</mi><mi mathvariant="normal">L</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">i</mi><mi mathvariant="normal">n</mi></mrow></mrow><annotation encoding="application/x-tex">50 \mathrm{~mL} / \mathrm{min}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">50</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm">mL</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm">min</span></span></span></span></span></span></p>
<p>Clearance (CL) The clearance of a drug is the theoretical volume of plasma from which the drug is completely removed in unit time (analogy creatinine clearance; Fig. 3.4). It can be calculated as:</p>
<div class="math math-display"><span class="katex-display"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML" display="block"><semantics><mrow><mi>C</mi><mi>L</mi><mo>=</mo><mtext>&nbsp;Rate&nbsp;of&nbsp;elimination&nbsp;</mtext><mi mathvariant="normal">/</mi><mi>C</mi></mrow><annotation encoding="application/x-tex">C L=\text { Rate of elimination } / C</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.07153em;">C</span><span class="mord mathnormal">L</span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">=</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord text"><span class="mord">&nbsp;Rate&nbsp;of&nbsp;elimination&nbsp;</span></span><span class="mord">/</span><span class="mord mathnormal" style="margin-right: 0.07153em;">C</span></span></span></span></span></div>
<p>where <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>C</mi></mrow><annotation encoding="application/x-tex">C</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.07153em;">C</span></span></span></span></span> is the plasma concentration.
For majority of drugs the processes involved in elimination are not saturated over the clinically obtained concentrations, they follow:</p>
<p>First order kinetics The rate of elimination is directly proportional to the drug concentration, <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>C</mi><mi>L</mi></mrow><annotation encoding="application/x-tex">C L</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.07153em;">C</span><span class="mord mathnormal">L</span></span></span></span></span> remains constant; or a constant fraction of the drug present in the body is eliminated in unit time. This applies to majority of drugs which do not saturate the elimination processes (transporters, enzymes, blood flow, etc.) over the therapeutic concentration range. However, if the dose is high enough, elimination pathways of all drugs will get saturated.</p>
<p>Few drugs normally saturate eliminating mechanisms and are handled by-
Zero order kinetics The rate of elimination remains constant irrespective of drug concentration, <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>C</mi><mi>L</mi></mrow><annotation encoding="application/x-tex">C L</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.07153em;">C</span><span class="mord mathnormal">L</span></span></span></span></span> decreases with increase in concentration; or a constant amount of the drug is eliminated in unit time, e.g. ethyl alcohol. This</p>
<p>is also called capacity limited elimination or Michaelis-Menten elimination.</p>
<p>The elimination of some drugs approaches saturation over the therapeutic range, kinetics changes from first order to zero order at higher doses. As a result plasma concentration increases disproportionately with increase in dose (see Fig. 3.6), as occurs in case of phenytoin, tolbutamide, theophylline, warfarin. Since the dose rate-plasma concentration plot in this case is curved, it is also called 'nonlinear elimination'.</p>
<p>Blood flow dependent elimination For few drugs the eliminating capacity of an organ of elimination (kidney, liver) far exceeds the amount of drug normally presented to it by blood circulation. The elimination of such a drug becomes blood flow dependent. These highly extracted drugs are almost completely eliminated in a single passage through the organ of elimination.</p>
<p>Plasma half-life The Plasma half-life ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">t</mi><mrow><mn>1</mn><mi mathvariant="normal">/</mi><mn>2</mn></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{t}^{1 / 2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.888em;"></span><span class="mord"><span class="mord mathrm">t</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.888em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1/2</span></span></span></span></span></span></span></span></span></span></span></span></span> ) of a drug is the time taken for its plasma concentration to be reduced to half of its original value.</p>
<p>Taking the simplest case of a drug which has rapid one compartment distribution and first order elimination, and is given i.v. a semilog plasma concentration-time plot as shown in Fig. 3.5 is obtained. The plot has two slopes.</p>
<ul>
<li>initial rapidly declining ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>α</mi></mrow><annotation encoding="application/x-tex">\alpha</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.4306em;"></span><span class="mord mathnormal" style="margin-right: 0.0037em;">α</span></span></span></span></span> ) phase-due to distribution.</li>
<li>later less declined <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo stretchy="false">(</mo><mi>β</mi><mo stretchy="false">)</mo></mrow><annotation encoding="application/x-tex">(\beta)</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mopen">(</span><span class="mord mathnormal" style="margin-right: 0.05278em;">β</span><span class="mclose">)</span></span></span></span></span> phase-due to elimination.
At least two half-lives (distribution <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">t</mi><mrow><mn>1</mn><mi mathvariant="normal">/</mi><mn>2</mn></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{t}^{1 / 2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.888em;"></span><span class="mord"><span class="mord mathrm">t</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.888em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1/2</span></span></span></span></span></span></span></span></span></span></span></span></span> and elimination <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">t</mi><mrow><mn>1</mn><mi mathvariant="normal">/</mi><mn>2</mn></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{t}^{1 / 2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.888em;"></span><span class="mord"><span class="mord mathrm">t</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.888em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1/2</span></span></span></span></span></span></span></span></span></span></span></span></span> ) can be calculated from the two slopes. The elimination half life derived from the <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>β</mi></mrow><annotation encoding="application/x-tex">\beta</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mord mathnormal" style="margin-right: 0.05278em;">β</span></span></span></span></span> slope is simply called the 'half life' of the drug.</li>
</ul>
<p>Most drugs infact have multicompartment distribution and multiexponential decay of plasma concentration-time plot. Half-lives calculated from the terminal slopes (when plasma concentrations are very low) are exceptionally long, probably due to release of the drug from slow equilibrating tissues, enterohepatic circulation, etc. Only the <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">t</mi><mrow><mn>1</mn><mi mathvariant="normal">/</mi><mn>2</mn></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{t}^{1 / 2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.888em;"></span><span class="mord"><span class="mord mathrm">t</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.888em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1/2</span></span></span></span></span></span></span></span></span></span></span></span></span> calculated over the steady-state plasma concentration range is clinically relevant. It is this <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">t</mi><mrow><mn>1</mn><mi mathvariant="normal">/</mi><mn>2</mn></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{t}^{1 / 2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.888em;"></span><span class="mord"><span class="mord mathrm">t</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.888em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1/2</span></span></span></span></span></span></span></span></span></span></span></span></span> which is commonly mentioned.
<img src="assets/images/image-20251214-3d3e99c9.jpeg" alt="img-15.jpeg"></p>
<p>Fig. 3.5: Semilog plasma concentration-time plot of a drug eliminated by first order kinetics after intravenous injection</p>
<p>Since first order kinetics is an exponential process, mathematically, the elimination <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">t</mi><mrow><mn>1</mn><mi mathvariant="normal">/</mi><mn>2</mn></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{t}^{1 / 2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.888em;"></span><span class="mord"><span class="mord mathrm">t</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.888em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1/2</span></span></span></span></span></span></span></span></span></span></span></span></span> is</p>
<div class="math math-display"><span class="katex-display"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML" display="block"><semantics><mrow><msup><mi mathvariant="normal">t</mi><mrow><mn>1</mn><mi mathvariant="normal">/</mi><mn>2</mn></mrow></msup><mo>=</mo><mfrac><mrow><mi>ln</mi><mo>⁡</mo><mn>2</mn></mrow><mi>k</mi></mfrac></mrow><annotation encoding="application/x-tex">\mathrm{t}^{1 / 2}=\frac{\ln 2}{k}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.938em;"></span><span class="mord"><span class="mord mathrm">t</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.938em;"><span style="top: -3.113em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1/2</span></span></span></span></span></span></span></span></span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">=</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 2.0574em; vertical-align: -0.686em;"></span><span class="mord"><span class="mopen nulldelimiter"></span><span class="mfrac"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 1.3714em;"><span style="top: -2.314em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.03148em;">k</span></span></span><span style="top: -3.23em;"><span class="pstrut" style="height: 3em;"></span><span class="frac-line" style="border-bottom-width: 0.04em;"></span></span><span style="top: -3.677em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="mop">ln</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord">2</span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.686em;"><span></span></span></span></span></span><span class="mclose nulldelimiter"></span></span></span></span></span></span></div>
<p>Where <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>ln</mi><mo>⁡</mo><mn>2</mn></mrow><annotation encoding="application/x-tex">\ln 2</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6944em;"></span><span class="mop">ln</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord">2</span></span></span></span></span> is the natural logarithm of 2 (or 0.693 ) and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>k</mi></mrow><annotation encoding="application/x-tex">k</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6944em;"></span><span class="mord mathnormal" style="margin-right: 0.03148em;">k</span></span></span></span></span> is the elimination rate constant of the drug, i.e. the fraction of the total amount of drug in the body which is removed per unit time. For example, if 2 g of the drug is present in the body and 0.1 g is eliminated every hour, then</p>
<div class="math math-display"><span class="katex-display"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML" display="block"><semantics><mrow><mi>k</mi><mo>=</mo><mn>0.1</mn><mi mathvariant="normal">/</mi><mn>2</mn><mo>=</mo><mn>0.05</mn><mtext>&nbsp;or&nbsp;</mtext><mn>5</mn><mi mathvariant="normal">%</mi><mtext>&nbsp;per&nbsp;hour.&nbsp;</mtext></mrow><annotation encoding="application/x-tex">k=0.1 / 2=0.05 \text { or } 5 \% \text { per hour. }</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6944em;"></span><span class="mord mathnormal" style="margin-right: 0.03148em;">k</span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">=</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">0.1/2</span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">=</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.9444em; vertical-align: -0.1944em;"></span><span class="mord">0.05</span><span class="mord text"><span class="mord">&nbsp;or&nbsp;</span></span><span class="mord">5%</span><span class="mord text"><span class="mord">&nbsp;per&nbsp;hour.&nbsp;</span></span></span></span></span></span></div>
<p>It is calculated as:</p>
<div class="math math-display"><span class="katex-display"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML" display="block"><semantics><mrow><mi>k</mi><mo>=</mo><mfrac><mrow><mi>C</mi><mi>L</mi></mrow><mi>V</mi></mfrac></mrow><annotation encoding="application/x-tex">k=\frac{C L}{V}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6944em;"></span><span class="mord mathnormal" style="margin-right: 0.03148em;">k</span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">=</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 2.0463em; vertical-align: -0.686em;"></span><span class="mord"><span class="mopen nulldelimiter"></span><span class="mfrac"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 1.3603em;"><span style="top: -2.314em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.22222em;">V</span></span></span><span style="top: -3.23em;"><span class="pstrut" style="height: 3em;"></span><span class="frac-line" style="border-bottom-width: 0.04em;"></span></span><span style="top: -3.677em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.07153em;">C</span><span class="mord mathnormal">L</span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.686em;"><span></span></span></span></span></span><span class="mclose nulldelimiter"></span></span></span></span></span></span></div>
<p>therefore <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mspace width="1em"></mspace><msup><mi mathvariant="normal">t</mi><mrow><mn>1</mn><mi mathvariant="normal">/</mi><mn>2</mn></mrow></msup><mo>=</mo><mn>0.693</mn><mo>×</mo><mfrac><mi mathvariant="normal">V</mi><mrow><mi>C</mi><mi>L</mi></mrow></mfrac></mrow><annotation encoding="application/x-tex">\quad \mathrm{t}^{1 / 2}=0.693 \times \frac{\mathrm{V}}{C L}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.888em;"></span><span class="mspace" style="margin-right: 1em;"></span><span class="mord"><span class="mord mathrm">t</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.888em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1/2</span></span></span></span></span></span></span></span></span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">=</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">0.693</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">×</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1.2173em; vertical-align: -0.345em;"></span><span class="mord"><span class="mopen nulldelimiter"></span><span class="mfrac"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.8723em;"><span style="top: -2.655em;"><span class="pstrut" style="height: 3em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mathnormal mtight" style="margin-right: 0.07153em;">C</span><span class="mord mathnormal mtight">L</span></span></span></span><span style="top: -3.23em;"><span class="pstrut" style="height: 3em;"></span><span class="frac-line" style="border-bottom-width: 0.04em;"></span></span><span style="top: -3.394em;"><span class="pstrut" style="height: 3em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mathrm mtight" style="margin-right: 0.01389em;">V</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.345em;"><span></span></span></span></span></span><span class="mclose nulldelimiter"></span></span></span></span></span></span>
As such, half-life is a derived parameter from two variables <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>V</mi></mrow><annotation encoding="application/x-tex">V</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.22222em;">V</span></span></span></span></span> and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>C</mi><mi>L</mi></mrow><annotation encoding="application/x-tex">C L</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.07153em;">C</span><span class="mord mathnormal">L</span></span></span></span></span>, both of which may change independently. It, therefore, is not an exact index of drug elimination. Nevertheless,</p>
<p>it is a simple and useful guide to the sojourn of the drug in the body, i.e. after
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><msup><mi mathvariant="normal">t</mi><mrow><mn>1</mn><mi mathvariant="normal">/</mi><mn>2</mn></mrow></msup><mo>−</mo><mn>50</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">1 \mathrm{t}^{1 / 2}-50 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.9713em; vertical-align: -0.0833em;"></span><span class="mord">1</span><span class="mord"><span class="mord mathrm">t</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.888em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1/2</span></span></span></span></span></span></span></span></span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">50%</span></span></span></span></span> drug is eliminated.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>2</mn><msup><mi mathvariant="normal">t</mi><mrow><mn>1</mn><mi mathvariant="normal">/</mi><mn>2</mn></mrow></msup><mo>−</mo><mn>75</mn><mi mathvariant="normal">%</mi><mo stretchy="false">(</mo><mn>50</mn><mo>+</mo><mn>25</mn><mo stretchy="false">)</mo></mrow><annotation encoding="application/x-tex">2 \mathrm{t}^{1 / 2}-75 \%(50+25)</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.9713em; vertical-align: -0.0833em;"></span><span class="mord">2</span><span class="mord"><span class="mord mathrm">t</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.888em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1/2</span></span></span></span></span></span></span></span></span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">75%</span><span class="mopen">(</span><span class="mord">50</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">+</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">25</span><span class="mclose">)</span></span></span></span></span> drug is eliminated.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>3</mn><msup><mi mathvariant="normal">t</mi><mrow><mn>1</mn><mi mathvariant="normal">/</mi><mn>2</mn></mrow></msup><mo>−</mo><mn>87.5</mn><mi mathvariant="normal">%</mi><mo stretchy="false">(</mo><mn>50</mn><mo>+</mo><mn>25</mn><mo>+</mo><mn>12.5</mn><mo stretchy="false">)</mo></mrow><annotation encoding="application/x-tex">3 \mathrm{t}^{1 / 2}-87.5 \%(50+25+12.5)</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.9713em; vertical-align: -0.0833em;"></span><span class="mord">3</span><span class="mord"><span class="mord mathrm">t</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.888em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1/2</span></span></span></span></span></span></span></span></span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">87.5%</span><span class="mopen">(</span><span class="mord">50</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">+</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">25</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">+</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">12.5</span><span class="mclose">)</span></span></span></span></span> drug is eliminated.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>4</mn><msup><mi mathvariant="normal">t</mi><mrow><mn>1</mn><mi mathvariant="normal">/</mi><mn>2</mn></mrow></msup><mo>−</mo><mn>93.75</mn><mi mathvariant="normal">%</mi><mo stretchy="false">(</mo><mn>50</mn><mo>+</mo><mn>25</mn><mo>+</mo><mn>12.5</mn><mo>+</mo><mn>6.25</mn><mo stretchy="false">)</mo></mrow><annotation encoding="application/x-tex">4 \mathrm{t}^{1 / 2}-93.75 \%(50+25+12.5+6.25)</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.9713em; vertical-align: -0.0833em;"></span><span class="mord">4</span><span class="mord"><span class="mord mathrm">t</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.888em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1/2</span></span></span></span></span></span></span></span></span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">93.75%</span><span class="mopen">(</span><span class="mord">50</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">+</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">25</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">+</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">12.5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">+</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">6.25</span><span class="mclose">)</span></span></span></span></span> drug is eliminated.
Thus, nearly complete drug elimination occurs in <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>4</mn><mo>−</mo><mn>5</mn></mrow><annotation encoding="application/x-tex">4-5</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">4</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">5</span></span></span></span></span> half lives.
For drugs eliminated by-
First order kinetics- <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">t</mi><mrow><mn>1</mn><mi mathvariant="normal">/</mi><mn>2</mn></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{t}^{1 / 2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.888em;"></span><span class="mord"><span class="mord mathrm">t</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.888em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1/2</span></span></span></span></span></span></span></span></span></span></span></span></span> remains constant because <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>V</mi></mrow><annotation encoding="application/x-tex">V</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.22222em;">V</span></span></span></span></span> and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>C</mi><mi>L</mi></mrow><annotation encoding="application/x-tex">C L</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.07153em;">C</span><span class="mord mathnormal">L</span></span></span></span></span> do not change with dose.
Zero order kinetics- <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">t</mi><mrow><mn>1</mn><mi mathvariant="normal">/</mi><mn>2</mn></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{t}^{1 / 2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.888em;"></span><span class="mord"><span class="mord mathrm">t</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.888em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1/2</span></span></span></span></span></span></span></span></span></span></span></span></span> gets prolonged with dose because <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>C</mi><mi>L</mi></mrow><annotation encoding="application/x-tex">C L</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.07153em;">C</span><span class="mord mathnormal">L</span></span></span></span></span> progressively decreases as dose is increased. In fact, the concept of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">t</mi><mrow><mn>1</mn><mi mathvariant="normal">/</mi><mn>2</mn></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{t}^{1 / 2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.888em;"></span><span class="mord"><span class="mord mathrm">t</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.888em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1/2</span></span></span></span></span></span></span></span></span></span></span></span></span> is meaningless for such drugs, because, it is not a fixed value.</p>
<table><thead><tr><th style="text-align: left;">Half life of some representative drugs</th><th style="text-align: left;"></th><th style="text-align: left;"></th><th style="text-align: left;"></th></tr></thead><tbody><tr><td style="text-align: left;">Aspirin</td><td style="text-align: left;">4 hr</td><td style="text-align: left;">Digoxin</td><td style="text-align: left;">40 hr</td></tr><tr><td style="text-align: left;">Penicillin-G</td><td style="text-align: left;">30 &lt;br&gt; min</td><td style="text-align: left;">Digitoxin</td><td style="text-align: left;">7 days</td></tr><tr><td style="text-align: left;">Doxycycline</td><td style="text-align: left;">20 hr</td><td style="text-align: left;">Phenobarbitone</td><td style="text-align: left;">90 hr</td></tr></tbody></table>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="repeated-drug-administration">Repeated drug administration<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#repeated-drug-administration" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>When a drug is repeated at relatively short intervals, it accumulates in the body until elimination balances input and a steady state plasma concentration (Cpss) is attained-</p>
<div class="math math-display"><span class="katex-display"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML" display="block"><semantics><mrow><mtext>&nbsp;Cpss&nbsp;</mtext><mo>=</mo><mfrac><mtext>&nbsp;dose&nbsp;rate&nbsp;</mtext><mrow><mi>C</mi><mi>L</mi></mrow></mfrac></mrow><annotation encoding="application/x-tex">\text { Cpss }=\frac{\text { dose rate }}{C L}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8778em; vertical-align: -0.1944em;"></span><span class="mord text"><span class="mord">&nbsp;Cpss&nbsp;</span></span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">=</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 2.0574em; vertical-align: -0.686em;"></span><span class="mord"><span class="mopen nulldelimiter"></span><span class="mfrac"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 1.3714em;"><span style="top: -2.314em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.07153em;">C</span><span class="mord mathnormal">L</span></span></span><span style="top: -3.23em;"><span class="pstrut" style="height: 3em;"></span><span class="frac-line" style="border-bottom-width: 0.04em;"></span></span><span style="top: -3.677em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="mord text"><span class="mord">&nbsp;dose&nbsp;rate&nbsp;</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.686em;"><span></span></span></span></span></span><span class="mclose nulldelimiter"></span></span></span></span></span></span></div>
<p>From this equation it is implied that doubling the dose rate would double the average Cpss and so on. Further, if the therapeutic plasma concentration of the drug has been worked out and its <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>C</mi><mi>L</mi></mrow><annotation encoding="application/x-tex">C L</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.07153em;">C</span><span class="mord mathnormal">L</span></span></span></span></span> is known, the dose rate needed to achieve the target Cpss can be determined-</p>
<div class="math math-display"><span class="katex-display"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML" display="block"><semantics><mrow><mtext>&nbsp;Dose&nbsp;rate&nbsp;</mtext><mo>=</mo><mtext>&nbsp;target&nbsp;</mtext><mi>C</mi><mi>p</mi><mi>s</mi><mi>s</mi><mo>×</mo><mi>C</mi><mi>L</mi></mrow><annotation encoding="application/x-tex">\text { Dose rate }=\text { target } C p s s \times C L</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord text"><span class="mord">&nbsp;Dose&nbsp;rate&nbsp;</span></span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">=</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.8778em; vertical-align: -0.1944em;"></span><span class="mord text"><span class="mord">&nbsp;target&nbsp;</span></span><span class="mord mathnormal">Cp</span><span class="mord mathnormal">ss</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">×</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.07153em;">C</span><span class="mord mathnormal">L</span></span></span></span></span></div>
<p>After oral administration, often only a fraction <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo stretchy="false">(</mo><mi>F</mi><mo stretchy="false">)</mo></mrow><annotation encoding="application/x-tex">(F)</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mopen">(</span><span class="mord mathnormal" style="margin-right: 0.13889em;">F</span><span class="mclose">)</span></span></span></span></span> of the dose reaches systemic circulation in the active form. In such a case-</p>
<div class="math math-display"><span class="katex-display"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML" display="block"><semantics><mrow><mtext>&nbsp;Dose&nbsp;rate&nbsp;</mtext><mo>=</mo><mfrac><mrow><mtext>&nbsp;target&nbsp;</mtext><mi>C</mi><mi>p</mi><mi>s</mi><mi>s</mi><mo>×</mo><mi>C</mi><mi>L</mi></mrow><mi>F</mi></mfrac></mrow><annotation encoding="application/x-tex">\text { Dose rate }=\frac{\text { target } C p s s \times C L}{F}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord text"><span class="mord">&nbsp;Dose&nbsp;rate&nbsp;</span></span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">=</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 2.0463em; vertical-align: -0.686em;"></span><span class="mord"><span class="mopen nulldelimiter"></span><span class="mfrac"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 1.3603em;"><span style="top: -2.314em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.13889em;">F</span></span></span><span style="top: -3.23em;"><span class="pstrut" style="height: 3em;"></span><span class="frac-line" style="border-bottom-width: 0.04em;"></span></span><span style="top: -3.677em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="mord text"><span class="mord">&nbsp;target&nbsp;</span></span><span class="mord mathnormal">Cp</span><span class="mord mathnormal">ss</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">×</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mord mathnormal" style="margin-right: 0.07153em;">C</span><span class="mord mathnormal">L</span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.686em;"><span></span></span></span></span></span><span class="mclose nulldelimiter"></span></span></span></span></span></span></div>
<p>The dose rate-Cpss relationship is linear only in case of drugs eliminated by first order kinetics. For drugs (e.g. phenytoin) which follow Michaelis Menten kinetics, elimination changes from first order to zero order kinetics over the therapeutic range. Increase in their dose beyond saturation levels causes an increase in Cpss which is out of proportion to the change in dose rate (Fig. 3.6). In their case:</p>
<div class="math math-display"><span class="katex-display"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML" display="block"><semantics><mrow><mtext>&nbsp;Rate&nbsp;of&nbsp;drug&nbsp;elimination&nbsp;</mtext><mo>=</mo><mfrac><mrow><mrow><mo fence="true">(</mo><msub><mi>V</mi><mi>max</mi><mo>⁡</mo></msub><mo fence="true">)</mo></mrow><mo stretchy="false">(</mo><mi>C</mi><mo stretchy="false">)</mo></mrow><mrow><msub><mi>K</mi><mi>m</mi></msub><mo>+</mo><mi>C</mi></mrow></mfrac></mrow><annotation encoding="application/x-tex">\text { Rate of drug elimination }=\frac{\left(V_{\max }\right)(C)}{K_{m}+C}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mord text"><span class="mord">&nbsp;Rate&nbsp;of&nbsp;drug&nbsp;elimination&nbsp;</span></span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">=</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 2.263em; vertical-align: -0.836em;"></span><span class="mord"><span class="mopen nulldelimiter"></span><span class="mfrac"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 1.427em;"><span style="top: -2.314em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="mord"><span class="mord mathnormal" style="margin-right: 0.07153em;">K</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.1514em;"><span style="top: -2.55em; margin-left: -0.0715em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mathnormal mtight">m</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">+</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mord mathnormal" style="margin-right: 0.07153em;">C</span></span></span><span style="top: -3.23em;"><span class="pstrut" style="height: 3em;"></span><span class="frac-line" style="border-bottom-width: 0.04em;"></span></span><span style="top: -3.677em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="minner"><span class="mopen delimcenter" style="top: 0em;">(</span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.22222em;">V</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.1514em;"><span style="top: -2.55em; margin-left: -0.2222em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mop mtight"><span class="mtight">m</span><span class="mtight">a</span><span class="mtight">x</span></span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mclose delimcenter" style="top: 0em;">)</span></span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mopen">(</span><span class="mord mathnormal" style="margin-right: 0.07153em;">C</span><span class="mclose">)</span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.836em;"><span></span></span></span></span></span><span class="mclose nulldelimiter"></span></span></span></span></span></span></div>
<p>where <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>C</mi></mrow><annotation encoding="application/x-tex">C</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.07153em;">C</span></span></span></span></span> is the plasma concentration of the drug, <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi>V</mi><mi>max</mi><mo>⁡</mo></msub></mrow><annotation encoding="application/x-tex">V_{\max }</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.22222em;">V</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.1514em;"><span style="top: -2.55em; margin-left: -0.2222em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mop mtight"><span class="mtight">m</span><span class="mtight">a</span><span class="mtight">x</span></span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> is the maximum rate of drug elimination, and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi>K</mi><mi>m</mi></msub></mrow><annotation encoding="application/x-tex">K_{m}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.07153em;">K</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.1514em;"><span style="top: -2.55em; margin-left: -0.0715em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mathnormal mtight">m</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> is the plasma concentration at which elimination rate is half maximal.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="plateau-principle">Plateau principle<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#plateau-principle" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>When constant dose of a drug is repeated before the expiry of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>4</mn><msup><mi mathvariant="normal">t</mi><mrow><mn>1</mn><mi mathvariant="normal">/</mi><mn>2</mn></mrow></msup></mrow><annotation encoding="application/x-tex">4 \mathrm{t}^{1 / 2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.888em;"></span><span class="mord">4</span><span class="mord"><span class="mord mathrm">t</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.888em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1/2</span></span></span></span></span></span></span></span></span></span></span></span></span>, it would achieve higher peak concentration, because some remnant of the previous dose will be present in the body. This continues with every dose until progressively increasing rate of elimination (which increases with increase in concentration) balances the amount administered over the dose interval. Subsequently plasma concentration plateaus
<img src="assets/images/image-20251214-ae53c20d.jpeg" alt="img-16.jpeg"></p>
<p>Fig. 3.6: Relationship between dose rate and average steady-state plasma concentration of drugs eliminated by first order and Michaelis Menten (zero order) kinetics</p>
<p>and fluctuates about an average steady-state level. This is known as the plateau principle of drug accumulation. Steady-state is reached in 4-5 half lives unless dose interval is very much longer than <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">t</mi><mrow><mn>1</mn><mi mathvariant="normal">/</mi><mn>2</mn></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{t}^{1 / 2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.888em;"></span><span class="mord"><span class="mord mathrm">t</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.888em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1/2</span></span></span></span></span></span></span></span></span></span></span></span></span> (Fig. 3.7).
<img src="assets/images/image-20251214-510a4031.jpeg" alt="img-17.jpeg"></p>
<p>Fig. 3.7: Plateau principle of drug accumulation on repeated oral dosing.
Note. The area of the two shaded portions is equal
The amplitude of fluctuations in plasma concentration at steady-state depends on the dose interval relative to the <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">t</mi><mrow><mn>1</mn><mi mathvariant="normal">/</mi><mn>2</mn></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{t}^{1 / 2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.888em;"></span><span class="mord"><span class="mord mathrm">t</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.888em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1/2</span></span></span></span></span></span></span></span></span></span></span></span></span>, i.e. the difference between the maximum and minimum levels is less if smaller doses are repeated more frequently (dose rate remaining constant). Dose intervals are generally a compromise between what amplitude of fluctuations is clinically acceptable (because of loss of efficacy at troughs and side effects at peaks) and what frequency of dosing is convenient. However, if the dose rate is changed, a new average <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>C</mi><mi>p</mi><mi>s</mi><mi>s</mi></mrow><annotation encoding="application/x-tex">C p s s</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8778em; vertical-align: -0.1944em;"></span><span class="mord mathnormal">Cp</span><span class="mord mathnormal">ss</span></span></span></span></span> is attained over the next 4-5 half lives. When the drug is administered orally (absorption takes some time), average Cpss is approximately <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mi mathvariant="normal">/</mi><mn>3</mn></mrow><annotation encoding="application/x-tex">1 / 3</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">1/3</span></span></span></span></span> of the way between the minimal and maximal levels in a dose interval.
Target level strategy For drugs whose effects are not easily quantifiable and safety margin is not big, e.g. anticonvulsants, antidepressants, lithium, antiarrhythmics, theophylline, some antimicrobials, etc. or those given to prevent an event, it is best to aim at achieving a certain
plasma concentration which has been defined to be in the therapeutic range; such data are now available for most drugs of this type.</p>
<p>Drugs with short <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">t</mi><mrow><mn>1</mn><mi mathvariant="normal">/</mi><mn>2</mn></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{t}^{1 / 2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.888em;"></span><span class="mord"><span class="mord mathrm">t</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.888em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1/2</span></span></span></span></span></span></span></span></span></span></span></span></span> (upto <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>2</mn><mo>−</mo><mn>3</mn><mrow><mi mathvariant="normal">h</mi><mi mathvariant="normal">r</mi></mrow></mrow><annotation encoding="application/x-tex">2-3 \mathrm{hr}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">2</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6944em;"></span><span class="mord">3</span><span class="mord"><span class="mord mathrm">hr</span></span></span></span></span></span> ) administered at conventional intervals ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>6</mn><mo>−</mo><mn>12</mn><mrow><mi mathvariant="normal">h</mi><mi mathvariant="normal">r</mi></mrow></mrow><annotation encoding="application/x-tex">6-12 \mathrm{hr}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">6</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6944em;"></span><span class="mord">12</span><span class="mord"><span class="mord mathrm">hr</span></span></span></span></span></span> ) achieve the target levels only intermittently and fluctuations in plasma concentration are marked. In case of many drugs (penicillin, ampicillin, chloramphenicol, erythromycin, propranolol) this however is therapeutically acceptable.</p>
<p>For drugs with longer <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">t</mi><mrow><mn>1</mn><mi mathvariant="normal">/</mi><mn>2</mn></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{t}^{1 / 2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.888em;"></span><span class="mord"><span class="mord mathrm">t</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.888em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1/2</span></span></span></span></span></span></span></span></span></span></span></span></span> a dose that is sufficient to attain the target concentration after single administration, if repeated will accumulate according to plateau principle and produce toxicity later on. On the other hand, if the dosing is such as to attain target level at steady state, the therapeutic effect will be delayed by about 4 half lives (this may be clinically unacceptable). Such drugs are often administered by initial loading and subsequent maintenance doses.
Loading dose This is a single or few quickly repeated doses given in the beginning to attain target concentration rapidly. It may be calculated as-</p>
<div class="math math-display"><span class="katex-display"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML" display="block"><semantics><mrow><mtext>&nbsp;Loading&nbsp;dose&nbsp;</mtext><mo>=</mo><mfrac><mrow><mtext>&nbsp;target&nbsp;</mtext><mi>C</mi><mi>p</mi><mo>×</mo><mi>V</mi></mrow><mi>F</mi></mfrac></mrow><annotation encoding="application/x-tex">\text { Loading dose }=\frac{\text { target } C p \times V}{F}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mord text"><span class="mord">&nbsp;Loading&nbsp;dose&nbsp;</span></span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">=</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 2.0463em; vertical-align: -0.686em;"></span><span class="mord"><span class="mopen nulldelimiter"></span><span class="mfrac"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 1.3603em;"><span style="top: -2.314em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.13889em;">F</span></span></span><span style="top: -3.23em;"><span class="pstrut" style="height: 3em;"></span><span class="frac-line" style="border-bottom-width: 0.04em;"></span></span><span style="top: -3.677em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="mord text"><span class="mord">&nbsp;target&nbsp;</span></span><span class="mord mathnormal">Cp</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">×</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mord mathnormal" style="margin-right: 0.22222em;">V</span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.686em;"><span></span></span></span></span></span><span class="mclose nulldelimiter"></span></span></span></span></span></span></div>
<p>Thus, loading dose is governed only by <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>V</mi></mrow><annotation encoding="application/x-tex">V</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.22222em;">V</span></span></span></span></span> and not by CL or <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">t</mi><mrow><mn>1</mn><mi mathvariant="normal">/</mi><mn>2</mn></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{t}^{1 / 2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.888em;"></span><span class="mord"><span class="mord mathrm">t</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.888em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1/2</span></span></span></span></span></span></span></span></span></span></span></span></span>.
Maintenance dose This dose is one that is to be repeated at specified intervals after the attainment of target Cpss so as to maintain the same by balancing elimination. The maintenance dose rate is computed by equation (9) and is governed by <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>C</mi><mi>L</mi></mrow><annotation encoding="application/x-tex">C L</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.07153em;">C</span><span class="mord mathnormal">L</span></span></span></span></span> (or <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">t</mi><mrow><mn>1</mn><mi mathvariant="normal">/</mi><mn>2</mn></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{t}^{1 / 2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.888em;"></span><span class="mord"><span class="mord mathrm">t</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.888em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1/2</span></span></span></span></span></span></span></span></span></span></span></span></span> ) of the drug. If facilities for measurement of drug concentration are available, attainment of target level in a patient can be verified subsequently and dose rate adjusted if required.</p>
<p>Such two phase dosing provides rapid therapeutic effect with long term safety; frequently applied to digoxin, chloroquine, long-acting sulfonamides, doxycycline, amiodarone, etc. However, if there is no urgency, maintenance</p>
<p>doses can be given from the beginning. The concept of loading and maintenance dose is valid also for short <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">t</mi><mrow><mn>1</mn><mi mathvariant="normal">/</mi><mn>2</mn></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{t}^{1 / 2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.888em;"></span><span class="mord"><span class="mord mathrm">t</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.888em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1/2</span></span></span></span></span></span></span></span></span></span></span></span></span> drugs and i.v. administration in critically ill patients, e.g. lidocaine ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">t</mi><mrow><mn>1</mn><mi mathvariant="normal">/</mi><mn>2</mn></mrow></msup><mn>1.5</mn></mrow><annotation encoding="application/x-tex">\mathrm{t}^{1 / 2} 1.5</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.888em;"></span><span class="mord"><span class="mord mathrm">t</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.888em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1/2</span></span></span></span></span></span></span></span></span><span class="mord">1.5</span></span></span></span></span> hr ) used for cardiac arrhythmias is given as an i.v. bolus dose followed by slow i.v. infusion or intermittent fractional dosing.</p>
<p>Monitoring of plasma concentration of drugs It is clear from the above considerations that the Cpss of a drug attained in a given patient depends on its <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>F</mi><mo separator="true">,</mo><mi>V</mi></mrow><annotation encoding="application/x-tex">F, V</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8778em; vertical-align: -0.1944em;"></span><span class="mord mathnormal" style="margin-right: 0.13889em;">F</span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord mathnormal" style="margin-right: 0.22222em;">V</span></span></span></span></span> and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>C</mi><mi>L</mi></mrow><annotation encoding="application/x-tex">C L</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.07153em;">C</span><span class="mord mathnormal">L</span></span></span></span></span> in that patient. Because each of these parameters varies considerably among individuals, the actual Cpss in a patient may be <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mi mathvariant="normal">/</mi><mn>3</mn></mrow><annotation encoding="application/x-tex">1 / 3</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">1/3</span></span></span></span></span> to 3 times that calculated on the basis of population data. Measurement of plasma drug concentration can give an estimate of the pharmacokinetic variables in that patient and the magnitude of deviation from the 'average patient', so that appropriate adjustments in the dosage regimen can be made.</p>
<p>In case of drugs obeying first order kinetics:
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mtable rowspacing="0.25em" columnalign="right left" columnspacing="0em"><mtr><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow></mrow></mstyle></mtd><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow><mrow></mrow><mtext>&nbsp;Revised&nbsp;</mtext><mo>=</mo><mfrac><mrow><mtext>&nbsp;Previous&nbsp;dose&nbsp;rate&nbsp;</mtext><mo>×</mo><mtext>&nbsp;Target&nbsp;</mtext><mi>C</mi><mi>p</mi><mi>s</mi><mi>s</mi></mrow><mtext>&nbsp;dose&nbsp;rate&nbsp;</mtext></mfrac><mspace width="1em"></mspace><mtext>&nbsp;Measured&nbsp;</mtext><mi>C</mi><mi>p</mi><mi>s</mi><mi>s</mi><mi mathvariant="normal">.</mi><mi mathvariant="normal">.</mi><mi mathvariant="normal">.</mi><mo stretchy="false">(</mo><mn>12</mn><mo stretchy="false">)</mo></mrow></mstyle></mtd></mtr></mtable><annotation encoding="application/x-tex">\begin{aligned} &amp; \text { Revised }=\frac{\text { Previous dose rate } \times \text { Target } C p s s}{\text { dose rate }} \quad \text { Measured } C p s s . . .(12)\end{aligned}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 2.3574em; vertical-align: -0.9287em;"></span><span class="mord"><span class="mtable"><span class="col-align-r"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 1.4287em;"><span style="top: -3.4287em;"><span class="pstrut" style="height: 3.3714em;"></span><span class="mord"></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.9287em;"><span></span></span></span></span></span><span class="col-align-l"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 1.4287em;"><span style="top: -3.4287em;"><span class="pstrut" style="height: 3.3714em;"></span><span class="mord"><span class="mord"></span><span class="mord text"><span class="mord">&nbsp;Revised&nbsp;</span></span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">=</span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mord"><span class="mopen nulldelimiter"></span><span class="mfrac"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 1.3714em;"><span style="top: -2.314em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="mord text"><span class="mord">&nbsp;dose&nbsp;rate&nbsp;</span></span></span></span><span style="top: -3.23em;"><span class="pstrut" style="height: 3em;"></span><span class="frac-line" style="border-bottom-width: 0.04em;"></span></span><span style="top: -3.677em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="mord text"><span class="mord">&nbsp;Previous&nbsp;dose&nbsp;rate&nbsp;</span></span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">×</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mord text"><span class="mord">&nbsp;Target&nbsp;</span></span><span class="mord mathnormal">Cp</span><span class="mord mathnormal">ss</span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.686em;"><span></span></span></span></span></span><span class="mclose nulldelimiter"></span></span><span class="mspace" style="margin-right: 1em;"></span><span class="mord text"><span class="mord">&nbsp;Measured&nbsp;</span></span><span class="mord mathnormal">Cp</span><span class="mord mathnormal">ss</span><span class="mord">...</span><span class="mopen">(</span><span class="mord">12</span><span class="mclose">)</span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.9287em;"><span></span></span></span></span></span></span></span></span></span></span></span>
Therapeutic drug monitoring (TDM) is particularly useful in the following situations:</p>
<ol>
<li>Drugs with low safety margin, e.g. -digoxin, anticonvulsants, antiarrhythmics, theophylline, aminoglycoside antibiotics, lithium, tricyclic antidepressants.</li>
<li>If individual variations are large, e.g.-antidepressants, lithium.</li>
<li>Potentially toxic drugs used in the presence of renal failure, e.g. -aminoglycoside antibiotics, vancomycin.</li>
<li>In case of poisoning.</li>
<li>In case of failure of response without any apparent reason, e.g. -antimicrobials.</li>
<li>To check patient compliance, e.g. -psychopharmacological agents.</li>
</ol>
<p>Selection of the correct interval between drug administration and drawing of blood sample for TDM is critical,
and depends on the purpose of TDM as well as the nature of the drug.
a. When the purpose is dose adjustment: In case of drugs which need to act continuously (relatively long-acting drugs), it is prudent to measure the trough steady-state blood levels, i.e. just prior to the next dose, because this is governed by both <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>V</mi></mrow><annotation encoding="application/x-tex">V</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.22222em;">V</span></span></span></span></span> and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>C</mi><mi>L</mi></mrow><annotation encoding="application/x-tex">C L</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.07153em;">C</span><span class="mord mathnormal">L</span></span></span></span></span>. On the other hand, for short-acting drugs which achieve therapeutic levels only intermittently (e.g. ampicillin, gentamicin), sampling is done in the immediate post-absorptive phase (usually after 1-2 hours of oral/i.m. dosing) to reflect the peak levels.
b. In case of poisoning: Blood for drug level estimation should be taken at the earliest to confirm the poisoning and to assess its seriousness. It should then be repeated at intervals to estimate the drug clearance in the affected patient, and the need to hasten elimination (e.g. by haemodialysis).
c. For checking compliance to medication: Even random blood sampling can be informative.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="monitoring-of-plasma-concentration-is-of-no-value-for">Monitoring of plasma concentration is of no value for<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#monitoring-of-plasma-concentration-is-of-no-value-for" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ol>
<li>Drugs whose response is easily measurable, e.g.- antihypertensives, hypoglycaemics, diuretics, oral anticoagulants, inhalational general anaesthetics.</li>
<li>Drugs activated in the body, e.g.-levodopa.</li>
<li>'Hit and run drugs' (whose effect lasts much longer than the drug itself), e.g.-reserpine, guanethidine, MAO inhibitors, omeprazole.</li>
<li>Drugs with irreversible action, e.g.-organophosphate anticholinesterases, phenoxybenzamine.</li>
</ol>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="prolongation-of-drug-action">PROLONGATION OF DRUG ACTION<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#prolongation-of-drug-action" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>It is sometimes advantageous to modify a drug in such a way that it acts for a longer period. By doing so:
(i) Frequency of administration is reducedmore convenient.
(ii) Improved patient compliance-a single morning dose is less likely to be forgotten/omitted than a 6 or 8 hourly regimen; a monthly or quarterly administered contraceptive over one that has to be taken daily.
(iii) Large fluctuations in plasma concentration are avoided-side effects related to high peak</p>
<p>plasma level just after a dose (e.g. nifedipine) would be minimized; better round-the-clock control of blood sugar level, etc.
(iv) Drug effect could be maintained overnight without disturbing sleep, e.g. antiasthmatics, anticonvulsants, etc.</p>
<p>However, all drugs do not need to be made long acting, e.g. those used for brief therapeutic effect (sleep-inducing hypnotic, headache remedy) or those with inherently long duration of action (doxycycline, omeprazole, digoxin, amlodipine). Drugs with <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">t</mi><mrow><mn>1</mn><mi mathvariant="normal">/</mi><mn>2</mn></mrow></msup><mo>≤</mo><mn>4</mn><mrow><mi mathvariant="normal">h</mi><mi mathvariant="normal">r</mi></mrow></mrow><annotation encoding="application/x-tex">\mathrm{t}^{1 / 2} \leq 4 \mathrm{hr}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1.024em; vertical-align: -0.136em;"></span><span class="mord"><span class="mord mathrm">t</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.888em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1/2</span></span></span></span></span></span></span></span></span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">≤</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.6944em;"></span><span class="mord">4</span><span class="mord"><span class="mord mathrm">hr</span></span></span></span></span></span> are suitable for controlled release formulations, while there is no need of such formulations for drugs with <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">t</mi><mrow><mn>1</mn><mi mathvariant="normal">/</mi><mn>2</mn></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{t}^{1 / 2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.888em;"></span><span class="mord"><span class="mord mathrm">t</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.888em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1/2</span></span></span></span></span></span></span></span></span></span></span></span></span> <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>≥</mo><mn>12</mn><mrow><mi mathvariant="normal">h</mi><mi mathvariant="normal">r</mi></mrow></mrow><annotation encoding="application/x-tex">\geq 12 \mathrm{hr}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7719em; vertical-align: -0.136em;"></span><span class="mrel">≥</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.6944em;"></span><span class="mord">12</span><span class="mord"><span class="mord mathrm">hr</span></span></span></span></span></span>. Methods utilized for prolonging drug action are summarised below. Some of these have already been described.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="1-by-prolonging-absorption-from-site-of-administration">1. By prolonging absorption from site of administration<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#1-by-prolonging-absorption-from-site-of-administration" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>(a) Oral Sustained release tablets, spansule capsules, etc.; drug particles are coated with resins, plastic materials or other substances which temporally disperse release of the active ingredient in the g.i.t. Another technique (controlled release tablet/capsule; Fig. 3.8) utilizes a semipermeable membrane to control the release of drug from the dosage form. Such preparations prolong the action by 4 to 8 hours and no more, because in that time drug particles reach the colon. Also, the drug release pattern and consequently the attained blood levels of
<img src="assets/images/image-20251214-132aac52.jpeg" alt="img-18.jpeg"></p>
<p>Fig. 3.8: Pattern of drug release from oral controlled release tablet/capsule; <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>30</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">30 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">30%</span></span></span></span></span> of the dose outside the semipermeable membrane is released immediately, while <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>70</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">70 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">70%</span></span></span></span></span> of the dose is released slowly through the membrane over the next 4-8 hours
the drug may be more variable than the regular tablet of the same drug.
(b) Parenteral The s.c. and i.m. injection of drug in insoluble form (benzathine penicillin, lente insulin) or as oily solution (depot progestins); pellet implantation, sialistic and biodegradable implants can provide for its absorption over a couple of days to several months or even years. Inclusion of a vasoconstrictor with the drug also delays absorption (adrenaline with local anaesthetics).
(c) Transdermal drug delivery systems The drug impregnated in adhesive patches, strips or as ointment applied on skin is utilized in some cases to prolong drug action, e.g. GTN (see p. 12).</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="2-by-increasing-plasma-protein-binding">2. By increasing plasma protein binding<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#2-by-increasing-plasma-protein-binding" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Drug congeners have been prepared which are highly bound to plasma protein and are slowly released in the free active form, e.g. sulfadoxine.
3. By retarding rate of metabolism Small chemical modification can markedly affect the rate of metabolism without affecting the biological action, e.g. addition of ethinyl group to estradiol (ethinyl estradiol) makes it longer acting and suitable for use as oral contraceptive. Inhibition of specific enzyme by one drug can prolong the action of another drug, e.g. allopurinol inhibits the degradation of 6-mercaptopurine, ritonavir boosts the levels of atazanavir/lopinavir/saquinavir, cilastatin protects imipenem from degradation in kidney.
4. By retarding renal excretion The tubular secretion of drug being an active process, can be suppressed by a competing substance, e.g. probenecid prolongs duration of action of penicillin, ampicillin and amoxicillin.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="targeted-drug-delivery-devices">Targeted drug delivery devices<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#targeted-drug-delivery-devices" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Some new devices have been invented (and many are under development) to localise and prolong the delivery of the contained drug to a specific target organ. The ones already in use are:</p>
<ol>
<li>Liposomes These are unilamellar or bilamellar nano-vesicles <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo stretchy="false">(</mo><mn>60</mn><mo>−</mo><mn>80</mn><mrow><mi mathvariant="normal">n</mi><mi mathvariant="normal">M</mi></mrow><mo stretchy="false">)</mo></mrow><annotation encoding="application/x-tex">(60-80 \mathrm{nM})</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mopen">(</span><span class="mord">60</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">80</span><span class="mord"><span class="mord mathrm">nM</span></span><span class="mclose">)</span></span></span></span></span> produced by sonication of lecithin or other biodegradable phospholipids. Since liposomes injected i.v. are selectively taken up by reticuloendothelial cells, especially liver and spleen, and some malignant cells, the drug incorporated in them gets selectively delivered to these cells. Liposomal amphotericin B is being used in Kala azar and some serious cases of systemic mycosis. Antibody tagging of liposomes is being tried as a means to target other specific tissues.</li>
<li>Drug releasing implants The implant is coated with the drug using special techniques and then placed in the target organ to provide prolonged delivery of minute quantities of the drug by slow release. Progestin impregnated intrauterine contraceptive device (IUCD) affords protection for upto 5 years. It is also being tried for other gynaecological problems. Antithrombotic drug coated stents (devices placed in the thrombosed coronary artery after balloon angioplasty to keep it patent) are in use to prevent restenosis and failure of angioplasty.</li>
</ol>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="problem-directed-study">PROBLEM DIRECTED STUDY<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#problem-directed-study" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>3.1 A 30 -year-old mother of 2 children weighing 60 kg was taking combined oral contraceptive pill containing levonorgestrel 0.15 mg + ethinylestradiol <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>30</mn><mi>μ</mi><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">30 \mu \mathrm{~g}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">30</span><span class="mord mathnormal">μ</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm" style="margin-right: 0.01389em;">g</span></span></span></span></span></span> per day cyclically ( 3 weeks treatment -1 week gap). She developed fever with cough and was diagnosed as a case of pulmonary tuberculosis after sputum smear examination. She was put on isoniazid ( 300 <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mo stretchy="false">)</mo><mo>+</mo></mrow><annotation encoding="application/x-tex">\mathrm{mg})+</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mclose">)</span><span class="mord">+</span></span></span></span></span> rifampin <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo stretchy="false">(</mo><mn>600</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mo stretchy="false">)</mo><mo>+</mo></mrow><annotation encoding="application/x-tex">(600 \mathrm{mg})+</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mopen">(</span><span class="mord">600</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mclose">)</span><span class="mord">+</span></span></span></span></span> pyrazinamide <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo stretchy="false">(</mo><mn>1.5</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">g</mi></mrow><mo stretchy="false">)</mo><mo>+</mo></mrow><annotation encoding="application/x-tex">(1.5 \mathrm{~g})+</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mopen">(</span><span class="mord">1.5</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm" style="margin-right: 0.01389em;">g</span></span><span class="mclose">)</span><span class="mord">+</span></span></span></span></span> ethambutol <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo stretchy="false">(</mo><mn>1.0</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">g</mi></mrow><mo stretchy="false">)</mo></mrow><annotation encoding="application/x-tex">(1.0 \mathrm{~g})</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mopen">(</span><span class="mord">1.0</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm" style="margin-right: 0.01389em;">g</span></span><span class="mclose">)</span></span></span></span></span> daily for 2 months, followed by isoniazid <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo stretchy="false">(</mo><mn>600</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mo stretchy="false">)</mo><mo>+</mo></mrow><annotation encoding="application/x-tex">(600 \mathrm{mg})+</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mopen">(</span><span class="mord">600</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mclose">)</span><span class="mord">+</span></span></span></span></span> rifampin <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo stretchy="false">(</mo><mn>600</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mo stretchy="false">)</mo></mrow><annotation encoding="application/x-tex">(600 \mathrm{mg})</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mopen">(</span><span class="mord">600</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mclose">)</span></span></span></span></span> thrice weekly. In the 3rd month she failed to have the usual withdrawal bleeding during the gap period of contraceptive cycle. After 10 days her urinary pregnancy test was found to be positive.
(a) What could be the reason for failure of the oral contraceptive?
(b) What precaution could have prevented the unwanted pregnancy?
3.2 A 20 -year-old patient weighing 60 kg has to be prescribed an antiepileptic drug (available as 200 and 400 mg tablets) for generalized tonic-clonic seizures. The pharmacokinetic parameters and therapeutic plasma concentration of the selected drug are:</p>
<p>Target steady-state plasma concentration (Cpss) -6 mg/L
Oral bioavailability ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>F</mi></mrow><annotation encoding="application/x-tex">F</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.13889em;">F</span></span></span></span></span> ) <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>−</mo><mn>70</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">-70 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.0833em;"></span><span class="mord">−</span><span class="mord">70%</span></span></span></span></span>
Volume of distribution (V) <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>−</mo><mn>1.4</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">L</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">-1.4 \mathrm{~L} / \mathrm{kg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">−</span><span class="mord">1.4</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm">L</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span></span></span></span></span>
Clearance (CL) <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>−</mo><mn>80</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">l</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">h</mi><mi mathvariant="normal">r</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">-80 \mathrm{ml} / \mathrm{hr} / \mathrm{kg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">−</span><span class="mord">80</span><span class="mord"><span class="mord mathrm">ml</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm">hr</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span></span></span></span></span>
Plasma half life ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">t</mi><mn>1</mn><mi mathvariant="normal">/</mi><mn>2</mn></mrow><annotation encoding="application/x-tex">\mathrm{t} 1 / 2</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord mathrm">t</span><span class="mord">1/2</span></span></span></span></span> ) - 15 hours
What should be the loading dose and the daily maintenance dose of the drug for this patient? (see Appendix-1 for solutions)</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="chapter-4-mechanism-of-drug-action-receptor-pharmacology">Chapter 4 Mechanism of Drug Action; Receptor Pharmacology<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#chapter-4-mechanism-of-drug-action-receptor-pharmacology" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Pharmacodynamics is the study of drug effects. It starts with describing what the drugs do, and goes on to explain how they do it. Thus, it attempts to elucidate the complete action-effect sequence and the dose-effect relationship. Modification of the action of one drug by another drug is also an aspect of pharmacodynamics.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="principles-of-drug-action">PRINCIPLES OF DRUG ACTION<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#principles-of-drug-action" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Drugs (except those gene based) do not impart new functions to any system, organ or cell; they only alter the pace of ongoing activity. However, this alone can have profound medicinal as well as toxicological impact, the basic types of drug action can be broadly classed as:</p>
<ol>
<li>Stimulation It refers to selective enhancement of the level of activity of specialized cells, e.g. adrenaline stimulates heart, pilocarpine stimulates salivary glands. However, excessive stimulation is often followed by depression of that function, e.g. high dose of picrotoxin, a central nervous system (CNS) stimulant, produces convulsions followed by coma and respiratory depression.</li>
<li>Depression It means selective diminution of activity of specialized cells, e.g. barbiturates depress CNS, quinidine depresses heart, omeprazole depresses gastric acid secretion. Certain drugs stimulate one type of cells but depress the other, e.g. acetylcholine stimulates intestinal smooth muscle but depresses SA node in heart. Thus, most drugs cannot be simply classed as stimulants or depressants.</li>
<li>Irritation This connotes a nonselective, often noxious effect and is particularly applied to less specialized cells (epithelium, connective tissue). Strong irritation results in inflammation, corrosion, necrosis and morphological damage. This may result in diminution or loss of function.</li>
<li>Replacement This refers to the use of natural metabolites, hormones or their congeners in deficiency states, e.g. levodopa in parkinsonism, insulin in diabetes mellitus, iron in anaemia.</li>
<li>Cytotoxic action Selective cytotoxic action on invading parasites or cancer cells, attenuating them without significantly affecting the host cells is utilized for cure/ palliation of infections and neoplasms, e.g. penicillin, chloroquine, zidovudine, cyclophosphamide, etc.</li>
</ol>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="mechanism-of-drug-action">MECHANISM OF DRUG ACTION<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#mechanism-of-drug-action" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Only a handful of drugs act by virtue of their simple physical or chemical property; examples are:</p>
<ul>
<li>Bulk laxatives (ispaghula)—physical mass</li>
<li>Dimethicone, petroleum jelly-physical form, opacity</li>
<li>Paraamino benzoic acid-absorption of UV rays</li>
<li>Activated charcoal-adsorptive property</li>
<li>Mannitol, mag. sulfate-osmotic activity</li>
<li><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow></mrow><mn>131</mn></msup><mi mathvariant="normal">I</mi></mrow><annotation encoding="application/x-tex">{ }^{131} \mathrm{I}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8141em;"></span><span class="mord"><span class="mord"></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8141em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">131</span></span></span></span></span></span></span></span></span><span class="mord mathrm">I</span></span></span></span></span> and other radioisotopes-radioactivity</li>
<li>Antacids-neutralization of gastric HCl</li>
<li>Pot. permanganate-oxidizing property</li>
<li>Chelating agents (EDTA, dimercaprol)-chelation of heavy metals.</li>
<li>Cholestyramine-sequestration of bile acids and cholesterol in the gut</li>
<li>Mesna-Scavenging of vasicotoxic reactive metabolites of cyclophosphamide
Majority of drugs produce their effects by interacting with a discrete target biomolecules, which usually are proteins. Such mechanism confers selectivity of action to the drug. Functional proteins that are targets of drug action</li>
</ul>
<p>can be grouped into four major categories, viz. enzymes, ion channels, transporters and receptors (see Fig. 4.1). However, a few drugs do act on other proteins (e.g. colchicine, vinca alkaloids,
<img src="assets/images/image-20251214-f1982f6e.jpeg" alt="img-19.jpeg"></p>
<p>Fig. 4.1: Four major types of biomacromolecular targets of drug action.
(A) Enzyme; (B) Transmembrane ion channel; (C) Membrane bound transporter; (D) Receptor (see text for description)
taxanes bind to the structural protein tubulin) or on nucleic acids (alkylating agents).</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="i-enzymes">I. ENZYMES<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#i-enzymes" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Almost all biological reactions are carried out under catalytic influence of enzymes; hence, enzymes are a very important target of drug action. Drugs can either increase or decrease the rate of enzymatically mediated reactions. However, in physiological systems enzyme activities are often optimally set. Thus, stimulation of enzymes by drugs, that are truly foreign substances, is unusual. Enzyme stimulation is relevant to some natural metabolites only, e.g. pyridoxine acts as a cofactor and increases decarboxylase activity. Several enzymes are stimulated through receptors and second messengers, e.g. adrenaline stimulates hepatic glycogen phosphorylase through <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>β</mi></mrow><annotation encoding="application/x-tex">\beta</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mord mathnormal" style="margin-right: 0.05278em;">β</span></span></span></span></span> receptors and cyclic AMP. Stimulation of an enzyme increases its affinity for the substrate so that rate constant <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo stretchy="false">(</mo><mi>k</mi><mi>M</mi><mo stretchy="false">)</mo></mrow><annotation encoding="application/x-tex">(k M)</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mopen">(</span><span class="mord mathnormal" style="margin-right: 0.03148em;">k</span><span class="mord mathnormal" style="margin-right: 0.10903em;">M</span><span class="mclose">)</span></span></span></span></span> of the reaction is lowered (Fig. 4.2).</p>
<p>Apparent increase in enzyme activity can also occur by enzyme induction, i.e. synthesis
<img src="assets/images/image-20251214-c39818f7.jpeg" alt="img-20.jpeg"></p>
<p>Fig. 4.2: Effect of enzyme induction, stimulation and inhibition on kinetics of enzyme reaction
Vmax-Maximum velocity of reaction; Vmax (s) of stimulated enzyme; Vmax (i)-in presence of noncompetitive inhibitor; <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>k</mi><mi>M</mi></mrow><annotation encoding="application/x-tex">k M</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6944em;"></span><span class="mord mathnormal" style="margin-right: 0.03148em;">k</span><span class="mord mathnormal" style="margin-right: 0.10903em;">M</span></span></span></span></span>-rate constant of the reaction; <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>k</mi><mi>M</mi><mo stretchy="false">(</mo><mi>s</mi><mo stretchy="false">)</mo></mrow><annotation encoding="application/x-tex">k M(s)</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord mathnormal" style="margin-right: 0.03148em;">k</span><span class="mord mathnormal" style="margin-right: 0.10903em;">M</span><span class="mopen">(</span><span class="mord mathnormal">s</span><span class="mclose">)</span></span></span></span></span>-of stimulated enzyme; <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>k</mi><mi>M</mi><mo stretchy="false">(</mo><mi>i</mi><mo stretchy="false">)</mo></mrow><annotation encoding="application/x-tex">k M(i)</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord mathnormal" style="margin-right: 0.03148em;">k</span><span class="mord mathnormal" style="margin-right: 0.10903em;">M</span><span class="mopen">(</span><span class="mord mathnormal">i</span><span class="mclose">)</span></span></span></span></span>-in presence of competitive inhibitor
Note: Enzyme induction and noncompetitive inhibition do not change the affinity of the enzyme ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>k</mi><mi>M</mi></mrow><annotation encoding="application/x-tex">k M</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6944em;"></span><span class="mord mathnormal" style="margin-right: 0.03148em;">k</span><span class="mord mathnormal" style="margin-right: 0.10903em;">M</span></span></span></span></span> is unaltered), whereas enzyme stimulation and competitive inhibition respectively decrease and increase the <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>k</mi><mi>M</mi></mrow><annotation encoding="application/x-tex">k M</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6944em;"></span><span class="mord mathnormal" style="margin-right: 0.03148em;">k</span><span class="mord mathnormal" style="margin-right: 0.10903em;">M</span></span></span></span></span>.</p>
<table><thead><tr><th style="text-align: left;">Enzyme</th><th style="text-align: left;">Endogenous substrate</th><th style="text-align: left;">Competitive inhibitor</th></tr></thead><tbody><tr><td style="text-align: left;">Cholinesterase</td><td style="text-align: left;">Acetylcholine</td><td style="text-align: left;">Physostigmine, Neostigmine</td></tr><tr><td style="text-align: left;">Monoamine-oxidase A (MAO-A)</td><td style="text-align: left;">Catecholamines</td><td style="text-align: left;">Moclobemide</td></tr><tr><td style="text-align: left;">Dopa decarboxylase</td><td style="text-align: left;">Levodopa</td><td style="text-align: left;">Carbidopa, Benserazide</td></tr><tr><td style="text-align: left;">Xanthine oxidase</td><td style="text-align: left;">Hypoxanthine</td><td style="text-align: left;">Allopurinol</td></tr><tr><td style="text-align: left;">Angiotensin converting enzyme (ACE)</td><td style="text-align: left;">Angiotensin-1</td><td style="text-align: left;">Captopril</td></tr><tr><td style="text-align: left;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mrow><mi mathvariant="normal">S</mi><mi mathvariant="normal">i</mi></mrow><mo>−</mo></mrow><annotation encoding="application/x-tex">\mathrm{Si}-</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7667em; vertical-align: -0.0833em;"></span><span class="mord"><span class="mord mathrm">Si</span></span><span class="mord">−</span></span></span></span></span> Reductase</td><td style="text-align: left;">Testosterone</td><td style="text-align: left;">Finasteride</td></tr><tr><td style="text-align: left;">Aromatase</td><td style="text-align: left;">Testosterone, Androstenedione</td><td style="text-align: left;">Letrozole, Anastrozole</td></tr><tr><td style="text-align: left;">Bacterial folate synthase</td><td style="text-align: left;">Para-amino benzoic acid (PABA)</td><td style="text-align: left;">Sulfadiazine</td></tr></tbody></table>
<p>of more enzyme protein. This cannot be called stimulation because the <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>k</mi><mi>M</mi></mrow><annotation encoding="application/x-tex">k M</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6944em;"></span><span class="mord mathnormal" style="margin-right: 0.03148em;">k</span><span class="mord mathnormal" style="margin-right: 0.10903em;">M</span></span></span></span></span> does not change. Many drugs induce microsomal enzymes (see p. 33).</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="enzyme-inhibition">Enzyme inhibition<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#enzyme-inhibition" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Some chemicals (heavy metal salts, strong acids and alkalies, formaldehyde, phenol, etc.) denature proteins and inhibit all enzymes nonselectively. They have limited medicinal value restricted to external application only. However, selective inhibition of a particular enzyme is a common mode of drug action. Such inhibition is either competitive or noncompetitive.
(i) Competitive (equilibrium type) The drug being structurally similar competes with the normal substrate for the catalytic binding site of the enzyme so that the product is not formed or a nonfunctional product is formed (Fig. 4.1A), and a new equilibrium is achieved in the presence of the drug. Such inhibitors increase the <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>k</mi><mi>M</mi></mrow><annotation encoding="application/x-tex">k M</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6944em;"></span><span class="mord mathnormal" style="margin-right: 0.03148em;">k</span><span class="mord mathnormal" style="margin-right: 0.10903em;">M</span></span></span></span></span> but the Vmax remains unchanged (Fig. 4.2), i.e. higher concentration of the substrate is required to achieve <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mi mathvariant="normal">/</mi><mn>2</mn></mrow><annotation encoding="application/x-tex">1 / 2</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">1/2</span></span></span></span></span> maximal reaction velocity, but if substrate concentration is sufficiently increased, it can displace the inhibitor and the same maximal reaction velocity can be attained. Examples are given in the box above.</p>
<p>A nonequilibrium type of enzyme inhibition can also occur with drugs which react with the same catalytic site of the enzyme but either form strong covalent bonds or have such high affinity for the enzyme that the normal substrate is not able to displace the inhibitor, e.g.</p>
<ul>
<li>Organophosphates react covalently with the esteretic site of the enzyme cholinesterase.</li>
<li>Methotrexate has 50,000 times higher affinity for dihydrofolate reductase than the normal substrate DHFA.
In these situations, <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>k</mi><mi>M</mi></mrow><annotation encoding="application/x-tex">k M</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6944em;"></span><span class="mord mathnormal" style="margin-right: 0.03148em;">k</span><span class="mord mathnormal" style="margin-right: 0.10903em;">M</span></span></span></span></span> is increased and Vmax is reduced.
(ii) Noncompetitive The inhibitor reacts with an adjacent site and not with the catalytic site, but alters the enzyme in such a way that it loses its catalytic property. Thus, <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>k</mi><mi>M</mi></mrow><annotation encoding="application/x-tex">k M</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6944em;"></span><span class="mord mathnormal" style="margin-right: 0.03148em;">k</span><span class="mord mathnormal" style="margin-right: 0.10903em;">M</span></span></span></span></span> is unchanged but Vmax is reduced. Examples are given in the box.</li>
</ul>
<table><thead><tr><th style="text-align: left;">Noncompetitive inhibitor</th><th style="text-align: left;">Enzyme</th><th style="text-align: left;"></th></tr></thead><tbody><tr><td style="text-align: left;">Acetazolamide</td><td style="text-align: left;">-</td><td style="text-align: left;">Carbonic anhydrase</td></tr><tr><td style="text-align: left;">Aspirin, indomethacin</td><td style="text-align: left;">-</td><td style="text-align: left;">Cyclooxygenase</td></tr><tr><td style="text-align: left;">Disulfiram</td><td style="text-align: left;">- Aldehyde &lt;br&gt; dehydrogenase</td><td style="text-align: left;"></td></tr><tr><td style="text-align: left;">Omeprazole</td><td style="text-align: left;">-</td><td style="text-align: left;">H<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>⋅</mo></mrow><annotation encoding="application/x-tex">\cdot</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.4445em;"></span><span class="mord">⋅</span></span></span></span></span> K<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>⋅</mo></mrow><annotation encoding="application/x-tex">\cdot</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.4445em;"></span><span class="mord">⋅</span></span></span></span></span> ATPase</td></tr><tr><td style="text-align: left;">Digoxin</td><td style="text-align: left;">-</td><td style="text-align: left;">Na<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>⋅</mo></mrow><annotation encoding="application/x-tex">\cdot</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.4445em;"></span><span class="mord">⋅</span></span></span></span></span> K<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>⋅</mo></mrow><annotation encoding="application/x-tex">\cdot</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.4445em;"></span><span class="mord">⋅</span></span></span></span></span> ATPase</td></tr><tr><td style="text-align: left;">Theophylline</td><td style="text-align: left;">-</td><td style="text-align: left;">Phosphodiesterase</td></tr><tr><td style="text-align: left;">Propylthiouracil</td><td style="text-align: left;">-</td><td style="text-align: left;">Peroxidase in thyroid</td></tr><tr><td style="text-align: left;">Lovastatin</td><td style="text-align: left;">-</td><td style="text-align: left;">HMG-CoA reductase</td></tr><tr><td style="text-align: left;">Sildenafil</td><td style="text-align: left;">-</td><td style="text-align: left;">Phosphodiesterase-5</td></tr></tbody></table>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="ii-ion-channels">II. ION CHANNELS<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#ii-ion-channels" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Proteins which act as ion selective channels participate in transmembrane signaling and regulate intracellular ionic composition. This makes them a common target of drug action (Fig. 4.1B). Drugs can affect ion channels, some of which actually are receptors, because they are operated by specific signal molecules either directly and are called ligand gated channels</p>
<p>(e.g. nicotinic receptor, see Fig. 4.4) or through G-proteins and are termed G-protein regulated channels (e.g. cardiac <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi>β</mi><mn>1</mn></msub></mrow><annotation encoding="application/x-tex">\beta_{1}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.05278em;">β</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.0528em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> adrenergic receptor activated <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">C</mi><mi mathvariant="normal">a</mi></mrow><mrow><mn>2</mn><mo>+</mo></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{Ca}^{2+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8873em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Ca</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8873em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span> channel, see Table 4.1). Drugs can also act on voltage operated and stretch sensitive channels by directly binding to the channel and affecting ion movement through it, e.g. local anaesthetics which obstruct voltage sensitive <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">N</mi><mi mathvariant="normal">a</mi></mrow><mo lspace="0em" rspace="0em">+</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{Na}^{+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8446em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Na</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8446em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span>channels (see Ch. 26). In addition, certain drugs modulate opening and closing of the channels, e.g.:</p>
<ul>
<li>Quinidine blocks myocardial <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">N</mi><mi mathvariant="normal">a</mi></mrow><mo lspace="0em" rspace="0em">+</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{Na}^{+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8446em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Na</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8446em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span>channels.</li>
<li>Dofetilide and amiodarone block myocardial delayed rectifier <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">K</mi><mo lspace="0em" rspace="0em">+</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{K}^{+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7713em;"></span><span class="mord"><span class="mord mathrm">K</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.7713em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span>channel.</li>
<li>Nifedipine blocks L-type of voltage sensitive <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">C</mi><mi mathvariant="normal">a</mi></mrow><mrow><mn>2</mn><mo>+</mo></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{Ca}^{2+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8873em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Ca</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8873em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span> channel.</li>
<li>Nicorandil opens ATP-sensitive <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">K</mi><mo lspace="0em" rspace="0em">+</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{K}^{+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7713em;"></span><span class="mord"><span class="mord mathrm">K</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.7713em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span>channels.</li>
<li>Sulfonylurea hypoglycaemics inhibit pancreatic ATP-sensitive <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">K</mi><mo lspace="0em" rspace="0em">+</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{K}^{+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7713em;"></span><span class="mord"><span class="mord mathrm">K</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.7713em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span>channels (see Fig. 19.6).</li>
<li>Amiloride inhibits renal epithelial <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">N</mi><mi mathvariant="normal">a</mi></mrow><mo lspace="0em" rspace="0em">+</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{Na}^{+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8446em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Na</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8446em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span>channels (see Fig. 42.3).</li>
<li>Phenytoin modulates (prolongs the inactivated state of) voltage sensitive neuronal <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">N</mi><mi mathvariant="normal">a</mi></mrow><mo lspace="0em" rspace="0em">+</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{Na}^{+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8446em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Na</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8446em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span>channel (Fig. 30.1).</li>
<li>Ethosuximide inhibits T-type of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">C</mi><mi mathvariant="normal">a</mi></mrow><mrow><mn>2</mn><mo>+</mo></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{Ca}^{2+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8873em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Ca</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8873em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span> channels in thalamic neurones.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="iii-transporters">III. TRANSPORTERS<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#iii-transporters" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Several substrates are translocated across membranes by binding to specific transporters (carriers) which either facilitate diffusion in the direction of the concentration gradient or pump the metabolite/ion against the concentration gradient using metabolic energy (see p. 18-19; Fig. 2.5). Many drugs produce their action by directly interacting with the solute carrier (SLC) class of transporter proteins to inhibit the ongoing physiological transport of the metabolite/ion (Fig. 4.1C). Examples are:</p>
<ul>
<li>Desipramine and cocaine block neuronal reuptake of noradrenaline by interacting with norepinephrine transporter (NET) as depicted in Fig. 9.4.</li>
<li>Fluoxetine (and other SSRIs) inhibit neuronal reuptake of 5-HT by interacting with serotonin transporter (SERT), Fig. 33.1.</li>
<li>Amphetamines selectively block dopamine reuptake in brain neurons by dopamine transporter (DAT).</li>
<li>Reserpine blocks the vesicular reuptake of noradrenaline and 5-HT by the vesicular monoamine transporter (VMAT-2), see Fig. 9.4.</li>
<li>Hemicholinium blocks choline uptake into cholinergic neurones and depletes acetylcholine (see Fig. 7.1).</li>
<li>The anticonvulsant tiagabine acts by inhibiting reuptake of GABA into brain neurones by GABA transporter GAT1 (see Fig. 30.1).</li>
<li>Furosemide inhibits the <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">N</mi><mi mathvariant="normal">a</mi></mrow><mo lspace="0em" rspace="0em">+</mo></msup><msup><mi mathvariant="normal">K</mi><mo lspace="0em" rspace="0em">+</mo></msup><mn>2</mn><msup><mrow><mi mathvariant="normal">C</mi><mi mathvariant="normal">l</mi></mrow><mo lspace="0em" rspace="0em">−</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{Na}^{+} \mathrm{K}^{+} 2 \mathrm{Cl}^{-}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8557em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Na</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8446em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span><span class="mord"><span class="mord mathrm">K</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.7713em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span><span class="mord">2</span><span class="mord"><span class="mord"><span class="mord mathrm">Cl</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8557em;"><span style="top: -3.1473em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">−</span></span></span></span></span></span></span></span></span></span></span></span></span>cotransporter in the ascending limb of loop of Henle (see Fig. 42.1).</li>
<li>Hydrochlorothiazide inhibits the <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">N</mi><mi mathvariant="normal">a</mi></mrow><mo lspace="0em" rspace="0em">+</mo></msup><msup><mrow><mi mathvariant="normal">C</mi><mi mathvariant="normal">l</mi></mrow><mo lspace="0em" rspace="0em">−</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{Na}^{+} \mathrm{Cl}^{-}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8557em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Na</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8446em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span><span class="mord"><span class="mord"><span class="mord mathrm">Cl</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8557em;"><span style="top: -3.1473em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">−</span></span></span></span></span></span></span></span></span></span></span></span></span> symporter in the early distal tubule (see Fig. 42.2).</li>
<li>Probenecid inhibits active transport of organic acids (uric acid, penicillin) in renal tubules by interacting with organic anion transporter (OAT).</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="iv-receptors">IV. RECEPTORS<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#iv-receptors" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>The largest number of drugs do not bind directly to the effectors, viz. enzymes, channels, transporters, structural proteins, template biomolecules, etc. but act through specific regulatory macromolecules which control the above listed effectors. These regulatory macromolecules or the sites on them which associate with and interact with the drug are called 'receptors'.
Receptor: It is defined as a macromolecule or binding site located on the surface or inside the effector cell that serves to recognize the signal molecule/drug and initiate the response to it, but itself has no other function.</p>
<p>Though, in a broad sense all types of target biomolecules, including the effectors (enzymes, channels, transporters, etc.) with which a drug can bind to produce its action have been denoted as 'receptors' by some authors, such designation tends to steal the specific meaning of this important term.</p>
<p>If so applied, xanthine oxidase would be the 'receptor' for allopurinol, L-type <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">C</mi><mi mathvariant="normal">a</mi></mrow><mrow><mn>2</mn><mo>+</mo></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{Ca}^{2+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8873em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Ca</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8873em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span> channel would be the 'receptor' for nifedipine, serotonin transporter (SERT) would be the 'receptor' for fluoxetine; a connotation not in consonence with the general understanding of the term 'receptor'. It is therefore better to reserve the term 'receptor' for purely regulatory macromolecules which combine with and mediate the action of signal molecules including drugs.</p>
<p>The following terms are used in describing drug-receptor interaction:
Agonist An agent which activates a receptor to produce an effect similar to that of the physiological signal molecule.
Inverse agonist An agent which activates a receptor to produce an effect in the opposite direction to that of the agonist.
Antagonist An agent which prevents the action of an agonist on a receptor or the subsequent response, but does not have any effect of its own.
Partial agonist An agent which activates a receptor to produce submaximal effect but antagonizes the action of a full agonist.
Ligand (Latin: ligare-to bind) Any molecule which attaches selectively to particular receptors or sites. The term only indicates affinity or ability to bind without regard to functional change: agonists and competitive antagonists are both ligands of the same receptor.</p>
<p>The overall scheme of drug action through receptors is depicted in Fig. 4.1D.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="basic-evidences-for-drug-action-through-receptors">Basic evidences for drug action through receptors<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#basic-evidences-for-drug-action-through-receptors" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>(i) Many drugs exhibit structural specificity of action, i.e. specific chemical configuration is associated with a particular action, e.g. isopropyl substitution on the ethylamine side chain of sympathetic drugs produces compounds with marked cardiac and bronchial activity-most <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>β</mi></mrow><annotation encoding="application/x-tex">\beta</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mord mathnormal" style="margin-right: 0.05278em;">β</span></span></span></span></span> adrenergic agonists and antagonists have this substitution. A 3 carbon internitrogen separation in the side chain of phenothiazines results in antidopaminergic-antipsychotic compounds, whereas 2 carbon separation produces anticholinergic-antihistaminic compounds. Further, chiral drugs show stereospecificity in action, e.g. levo noradrenaline is 10 times more potent than dextro noradrenaline; <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>d</mi></mrow><annotation encoding="application/x-tex">d</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6944em;"></span><span class="mord mathnormal">d</span></span></span></span></span>-propranolol is about 100 times less potent in blocking <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>β</mi></mrow><annotation encoding="application/x-tex">\beta</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mord mathnormal" style="margin-right: 0.05278em;">β</span></span></span></span></span> receptors than the <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>l</mi></mrow><annotation encoding="application/x-tex">l</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6944em;"></span><span class="mord mathnormal" style="margin-right: 0.01968em;">l</span></span></span></span></span>-isomer, but both are equipotent local anaesthetics.</p>
<p>Thus, the cell must have some mechanism to recognize a particular chemical configuration and three dimensional structure.
<img src="assets/images/image-20251214-812e3d65.jpeg" alt="img-21.jpeg">
<img src="assets/images/image-20251214-bd300809.jpeg" alt="img-22.jpeg">
(ii) Competitive antagonism is seen between specific agonists and antagonists. Langley in 1878 was so impressed by the mutual antagonism among two alkaloids pilocarpine and atropine that he proposed that both reacted with the same 'receptive substance' on the cell. Ehrlich (1900) observed quantitative neutralization between toxins and antitoxins and designated 'receptor' to be the anchoring group of the protoplasmic molecule for the administered compound.
(iii) It was calculated by Clark that adrenaline and acetylcholine produce their maximal effect on frog's heart by occupying only <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mi mathvariant="normal">/</mi><mn>6000</mn></mrow><annotation encoding="application/x-tex">1 / 6000</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">1/6000</span></span></span></span></span> th of the cardiac cell surface-thus, special regions of reactivity to such drugs must be present on the cell.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="receptor-occupation-theory">Receptor occupation theory<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#receptor-occupation-theory" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>After studying quantitative aspects of drug action, Clark (1937) propounded a theory of drug action based on occupation of receptors by specific drugs and that the pace of a cellular function can be altered by interaction of these receptors with drugs which, in fact, are small molecular ligands. He perceived the interaction between the two molecular species, viz. drug <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo stretchy="false">(</mo><mi>D</mi><mo stretchy="false">)</mo></mrow><annotation encoding="application/x-tex">(D)</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mopen">(</span><span class="mord mathnormal" style="margin-right: 0.02778em;">D</span><span class="mclose">)</span></span></span></span></span> and receptor <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo stretchy="false">(</mo><mi>R</mi><mo stretchy="false">)</mo></mrow><annotation encoding="application/x-tex">(R)</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mopen">(</span><span class="mord mathnormal" style="margin-right: 0.00773em;">R</span><span class="mclose">)</span></span></span></span></span> to be governed by the law of mass action, and the effect <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo stretchy="false">(</mo><mi>E</mi><mo stretchy="false">)</mo></mrow><annotation encoding="application/x-tex">(E)</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mopen">(</span><span class="mord mathnormal" style="margin-right: 0.05764em;">E</span><span class="mclose">)</span></span></span></span></span> to be a direct function of the drug-receptor complex <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo stretchy="false">(</mo><mi>D</mi><mi>R</mi><mo stretchy="false">)</mo></mrow><annotation encoding="application/x-tex">(D R)</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mopen">(</span><span class="mord mathnormal" style="margin-right: 0.02778em;">D</span><span class="mord mathnormal" style="margin-right: 0.00773em;">R</span><span class="mclose">)</span></span></span></span></span> formed:</p>
<div class="math math-display"><span class="katex-display"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML" display="block"><semantics><mrow><mi>D</mi><mo>+</mo><mi>R</mi><mi><munder><mo><mo><mover><mo><mo>⇄</mo></mo><msub><mi>K</mi><mn>1</mn></msub></mover></mo></mo><msub><mi>K</mi><mn>2</mn></msub></munder></mi><mi>D</mi><mi>R</mi><mo>⟶</mo><mi>E</mi><mo>…</mo><mo stretchy="false">(</mo><mn>1</mn><mo stretchy="false">)</mo></mrow><annotation encoding="application/x-tex">D+R \underset{K_{2}}{\stackrel{K_{1}}{\rightleftarrows}} D R \longrightarrow E \ldots(1)</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7667em; vertical-align: -0.0833em;"></span><span class="mord mathnormal" style="margin-right: 0.02778em;">D</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">+</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 2.4897em; vertical-align: -1.0223em;"></span><span class="mord mathnormal" style="margin-right: 0.00773em;">R</span><span class="mord"><span class="mop op-limits"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 1.4673em;"><span style="top: -2.6451em; margin-left: 0em;"><span class="pstrut" style="height: 3.4673em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight"><span class="mord mathnormal mtight" style="margin-right: 0.07153em;">K</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3173em;"><span style="top: -2.357em; margin-left: -0.0715em; margin-right: 0.0714em;"><span class="pstrut" style="height: 2.5em;"></span><span class="sizing reset-size3 size1 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.143em;"><span></span></span></span></span></span></span></span></span></span><span style="top: -3.4673em;"><span class="pstrut" style="height: 3.4673em;"></span><span><span class="mop"><span class="mrel"><span class="mop op-limits"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 1.4673em;"><span style="top: -3.0029em;"><span class="pstrut" style="height: 3em;"></span><span><span class="mop amsrm">⇄</span></span></span><span style="top: -3.889em; margin-left: 0em;"><span class="pstrut" style="height: 3em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight"><span class="mord mathnormal mtight" style="margin-right: 0.07153em;">K</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3173em;"><span style="top: -2.357em; margin-left: -0.0715em; margin-right: 0.0714em;"><span class="pstrut" style="height: 2.5em;"></span><span class="sizing reset-size3 size1 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.143em;"><span></span></span></span></span></span></span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.1779em;"><span></span></span></span></span></span></span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 1.0223em;"><span></span></span></span></span></span></span><span class="mord mathnormal" style="margin-right: 0.02778em;">D</span><span class="mord mathnormal" style="margin-right: 0.00773em;">R</span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">⟶</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord mathnormal" style="margin-right: 0.05764em;">E</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="minner">…</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mopen">(</span><span class="mord">1</span><span class="mclose">)</span></span></span></span></span></div>
<p>Subsequently, it was realized that occupation of the receptor is essential but not itself sufficient to elicit a response; the agonist must also be able to activate (induce a conformational change in) the receptor. The ability to bind</p>
<p>with the receptor designated as affinity, and the capacity to induce a functional change in the receptor designated as intrinsic activity (IA) or efficacy are independent properties.
Affinity of a drug for a receptor determines its concetration around the receptor required to form a certain number of drug-receptor associations (DRs). Higher affinity implies that the same number of DRs will be formed at lower concentrations of the drug, compared to another drug which has lower affinity.
Intrinsic activity of a drug is a measure of its ability to induce a functional change in the receptor which could vary from 0 to 1 (nil to maximal).</p>
<p>Competitive antagonists occupy the receptor but do not activate it, while certain drugs are partial agonists which occupy and submaximally activate the receptor. An all or none action is not a must at the receptor. A theoretical quantity (S) denoting strength of stimulus imparted to the cell was interposed in the Clark's equation:</p>
<div class="math math-display"><span class="katex-display"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML" display="block"><semantics><mrow><mi>D</mi><mo>+</mo><mi>R</mi><mi><munder><mo><mo><mover><mo><mo>⇄</mo></mo><msub><mi>K</mi><mn>1</mn></msub></mover></mo></mo><msub><mi>K</mi><mn>2</mn></msub></munder></mi><mi>D</mi><mi>R</mi><mover><mo stretchy="true" minsize="3.0em">→</mo><mpadded width="+0.6em" lspace="0.3em"><mtext>&nbsp;WWW&nbsp;</mtext></mpadded></mover><mi>S</mi><mo>⟶</mo><mi>E</mi><mo>…</mo><mo stretchy="false">(</mo><mn>2</mn><mo stretchy="false">)</mo></mrow><annotation encoding="application/x-tex">D+R \underset{K_{2}}{\stackrel{K_{1}}{\rightleftarrows}} D R \xrightarrow{\text { WWW }} S \longrightarrow E \ldots(2)</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7667em; vertical-align: -0.0833em;"></span><span class="mord mathnormal" style="margin-right: 0.02778em;">D</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">+</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 2.4897em; vertical-align: -1.0223em;"></span><span class="mord mathnormal" style="margin-right: 0.00773em;">R</span><span class="mord"><span class="mop op-limits"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 1.4673em;"><span style="top: -2.6451em; margin-left: 0em;"><span class="pstrut" style="height: 3.4673em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight"><span class="mord mathnormal mtight" style="margin-right: 0.07153em;">K</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3173em;"><span style="top: -2.357em; margin-left: -0.0715em; margin-right: 0.0714em;"><span class="pstrut" style="height: 2.5em;"></span><span class="sizing reset-size3 size1 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.143em;"><span></span></span></span></span></span></span></span></span></span><span style="top: -3.4673em;"><span class="pstrut" style="height: 3.4673em;"></span><span><span class="mop"><span class="mrel"><span class="mop op-limits"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 1.4673em;"><span style="top: -3.0029em;"><span class="pstrut" style="height: 3em;"></span><span><span class="mop amsrm">⇄</span></span></span><span style="top: -3.889em; margin-left: 0em;"><span class="pstrut" style="height: 3em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight"><span class="mord mathnormal mtight" style="margin-right: 0.07153em;">K</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3173em;"><span style="top: -2.357em; margin-left: -0.0715em; margin-right: 0.0714em;"><span class="pstrut" style="height: 2.5em;"></span><span class="sizing reset-size3 size1 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.143em;"><span></span></span></span></span></span></span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.1779em;"><span></span></span></span></span></span></span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 1.0223em;"><span></span></span></span></span></span></span><span class="mord mathnormal" style="margin-right: 0.02778em;">D</span><span class="mord mathnormal" style="margin-right: 0.00773em;">R</span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel x-arrow"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 1.1003em;"><span style="top: -3.322em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight x-arrow-pad"><span class="mord mtight"><span class="mord text mtight"><span class="mord mtight">&nbsp;WWW&nbsp;</span></span></span></span></span><span class="svg-align" style="top: -2.689em;"><span class="pstrut" style="height: 2.7em;"></span><span class="hide-tail" style="height: 0.522em; min-width: 1.469em;"><svg xmlns="http://www.w3.org/2000/svg" width="400em" height="0.522em" viewBox="0 0 400000 522" preserveAspectRatio="xMaxYMin slice"><path d="M0 241v40h399891c-47.3 35.3-84 78-110 128
-16.7 32-27.7 63.7-33 95 0 1.3-.2 2.7-.5 4-.3 1.3-.5 2.3-.5 3 0 7.3 6.7 11 20
 11 8 0 13.2-.8 15.5-2.5 2.3-1.7 4.2-5.5 5.5-11.5 2-13.3 5.7-27 11-41 14.7-44.7
 39-84.5 73-119.5s73.7-60.2 119-75.5c6-2 9-5.7 9-11s-3-9-9-11c-45.3-15.3-85
-40.5-119-75.5s-58.3-74.8-73-119.5c-4.7-14-8.3-27.3-11-40-1.3-6.7-3.2-10.8-5.5
-12.5-2.3-1.7-7.5-2.5-15.5-2.5-14 0-21 3.7-21 11 0 2 2 10.3 6 25 20.7 83.3 67
 151.7 139 205zm0 0v40h399900v-40z"></path></svg></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.011em;"><span></span></span></span></span></span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.6943em; vertical-align: -0.011em;"></span><span class="mord mathnormal" style="margin-right: 0.05764em;">S</span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">⟶</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord mathnormal" style="margin-right: 0.05764em;">E</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="minner">…</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mopen">(</span><span class="mord">2</span><span class="mclose">)</span></span></span></span></span></div>
<p>Depending on the agonist, DR could generate a stronger or weaker S, probably as a function of the degree of conformational change brought about by the agonist in the receptor. Accordingly:
Agonists have both affinity and maximal intrinsic activity (IA <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>=</mo><mn>1</mn></mrow><annotation encoding="application/x-tex">=1</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.3669em;"></span><span class="mrel">=</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">1</span></span></span></span></span> ), e.g. adrenaline, histamine, morphine.
Competitive antagonists have affinity but no intrinsic activity (IA <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>=</mo><mn>0</mn></mrow><annotation encoding="application/x-tex">=0</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.3669em;"></span><span class="mrel">=</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">0</span></span></span></span></span> ), e.g. propranolol, atropine, chlorpheniramine, naloxone.
Partial agonists have affinity and submaximal intrinsic activity (IA between 0 and 1), e.g. dichloroisoproterenol (on <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>β</mi></mrow><annotation encoding="application/x-tex">\beta</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mord mathnormal" style="margin-right: 0.05278em;">β</span></span></span></span></span> adrenergic receptor), buspirone on <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mo>−</mo><msub><mrow><mi mathvariant="normal">H</mi><mi mathvariant="normal">T</mi></mrow><mrow><mn>1</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">A</mi></mrow></mrow></msub></mrow><annotation encoding="application/x-tex">5-\mathrm{HT}_{1 \mathrm{~A}}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">HT</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3283em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span><span class="mord mtight"><span class="mspace nobreak mtight"><span class="mtight">&nbsp;</span></span><span class="mord mathrm mtight">A</span></span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> receptor.</p>
<p>The lower ceiling response to a partial agonist is not because of lower affinity for the receptor. In fact some partial agonists have higher affinity and are dose-to-dose more potent than the full agonist, e.g. buprenorphine is 25 times more potent than morphine (full agonist
of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>μ</mi></mrow><annotation encoding="application/x-tex">\mu</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.625em; vertical-align: -0.1944em;"></span><span class="mord mathnormal">μ</span></span></span></span></span> opioid receptor) but is a partial agonist and cannot relieve very severe pain or deeply depress respiration.</p>
<p>Partial agonists also antagonize the effects of a full agonist, because they occupy a large population of the receptors (while producing small response) and leave fewer receptors to interact with the full agonist. As such, buprenorphine precipitates withdrawal symptoms in a highly morphine dependent subject, but can substitute for it at lower levels of morphine dependence.
Inverse agonists have affinity but intrinsic activity with a minus sign (IA between 0 and -1 ). Inverse agonism is manifest only in case of some receptors which show certain degree of Constitutive activation, i.e. they are partially active even in the basal state (complete absence of any agonist). In other words they are tonically active. The benzodiazepine receptor (see Fig. 29.3) is one such receptor, and DMCM is its inverse agonist. However, majority of receptors (like the NM nicotinic receptor) are totally inactive in the absence of an agonist, and there is no scope for inverse agonism.</p>
<p>It has also been demonstrated that many full agonists can produce maximal response even while occupying <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&lt;</mo><mn>1</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">&lt;1 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&lt;</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">1%</span></span></span></span></span> of the available receptors. A large receptor reserve exists in their case, or a number of spare receptors are present. On the other hand, for certain drugs, the total number of receptors may limit the maximal response, and there are no space receptors.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="the-two-state-receptor-model">The two-state receptor model<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#the-two-state-receptor-model" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>An attractive alternative model for explaining the action of agonists, antagonists, partial agonists and inverse agonists has been proposed.</p>
<p>The receptor is believed to exist in two interchangeable states: <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>R</mi><mi>a</mi></mrow><annotation encoding="application/x-tex">R a</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.00773em;">R</span><span class="mord mathnormal">a</span></span></span></span></span> (active) and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>R</mi><mi>i</mi></mrow><annotation encoding="application/x-tex">R i</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.00773em;">R</span><span class="mord mathnormal">i</span></span></span></span></span> (inactive) which are in equilibrium. In the case of majority of receptors, the <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>R</mi><mi>i</mi></mrow><annotation encoding="application/x-tex">R i</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.00773em;">R</span><span class="mord mathnormal">i</span></span></span></span></span> state is favoured at equilibrium-no/very weak signal is generated in the absence of the agonist-the receptor exhibits no constitutive activation (Fig. 4.3I). The agonist (A) binds preferentially to the <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>R</mi><mi>a</mi></mrow><annotation encoding="application/x-tex">R a</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.00773em;">R</span><span class="mord mathnormal">a</span></span></span></span></span> conformation and shifts the equilibrium <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>→</mo><mi>R</mi><mi>a</mi></mrow><annotation encoding="application/x-tex">\rightarrow R a</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.3669em;"></span><span class="mrel">→</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.00773em;">R</span><span class="mord mathnormal">a</span></span></span></span></span></p>
<p>predominates and a response is generated (Fig. 4.3II) depending on the concentration of A . The competitive antagonist (B) binds to <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>R</mi><mi>a</mi></mrow><annotation encoding="application/x-tex">R a</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.00773em;">R</span><span class="mord mathnormal">a</span></span></span></span></span> and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>R</mi><mi>i</mi></mrow><annotation encoding="application/x-tex">R i</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.00773em;">R</span><span class="mord mathnormal">i</span></span></span></span></span> with equal affinity <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>→</mo></mrow><annotation encoding="application/x-tex">\rightarrow</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.3669em;"></span><span class="mrel">→</span></span></span></span></span> the equilibrium is not altered <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>→</mo></mrow><annotation encoding="application/x-tex">\rightarrow</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.3669em;"></span><span class="mrel">→</span></span></span></span></span> no response is generated (Fig. 4.3 III), and when the agonist is applied fewer <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>R</mi><mi>a</mi></mrow><annotation encoding="application/x-tex">R a</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.00773em;">R</span><span class="mord mathnormal">a</span></span></span></span></span> are available to bind it-response to agonist is decreased. If an agonist has only slightly greater affinity for <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>R</mi><mi>a</mi></mrow><annotation encoding="application/x-tex">R a</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.00773em;">R</span><span class="mord mathnormal">a</span></span></span></span></span> than for <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>R</mi><mi>i</mi></mrow><annotation encoding="application/x-tex">R i</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.00773em;">R</span><span class="mord mathnormal">i</span></span></span></span></span>, the equilibrium is only modestly shifted towards <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>R</mi><mi>a</mi></mrow><annotation encoding="application/x-tex">R a</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.00773em;">R</span><span class="mord mathnormal">a</span></span></span></span></span> (Fig. 4.3 IV) even at saturating concentrations <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>→</mo></mrow><annotation encoding="application/x-tex">\rightarrow</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.3669em;"></span><span class="mrel">→</span></span></span></span></span> a submaximal response is produced and the drug is called a partial agonist (C). The inverse agonist (D) has high affinity for the <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>R</mi><mi>i</mi></mrow><annotation encoding="application/x-tex">R i</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.00773em;">R</span><span class="mord mathnormal">i</span></span></span></span></span> state (Fig. 4.3V), therefore it can produce an opposite response, provided the resting equilibrium was in favour of the <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>R</mi><mi>a</mi></mrow><annotation encoding="application/x-tex">R a</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.00773em;">R</span><span class="mord mathnormal">a</span></span></span></span></span> state. Certain ion channel receptors such as benzodiazepine receptor and some Gprotein coupled receptors like histamine <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">H</mi><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{H}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">H</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span>,
<img src="assets/images/image-20251214-6df96621.jpeg" alt="img-23.jpeg"></p>
<p>Fig. 4.3: Illustration of the two-state receptor model (see text for explanation)
angiotensin <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">A</mi><mi mathvariant="normal">T</mi></mrow><mn>1</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{AT}_{1}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">AT</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span>, adrenergic <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi>β</mi><mn>1</mn></msub></mrow><annotation encoding="application/x-tex">\beta_{1}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.05278em;">β</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.0528em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> and cannabinoid receptors exhibit constitutive activation, i.e. an appreciable intensity signal is generated even in the basal state (no agonist present). In their case the inverse agonist stabilizes the receptor in the inactive conformation resulting in an opposite response. Only few inverse agonists are known at present.</p>
<p>This model provides an explanation for the phenomenon of positive cooperativity often seen with neurotransmitters, and is supported by studies of conformational mutants of the receptor with altered equilibrium. However, receptors are now known to be capable of adopting not just two, but multiple active and inactive conformations favoured by different ligands.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="nature-of-receptors">Nature of receptors<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#nature-of-receptors" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Receptors are regulatory macromolecules, mostly proteins, though nucleic acids may also serve as receptors. Hundreds of receptor proteins have been isolated, purified, cloned and their primary amino acid (AA) sequence has been worked out. Molecular cloning has also helped in obtaining the receptor protein in larger quantity to study its structure and properties, and in subclassifying receptors. The cell surface receptors with their coupling and effector proteins are considered to be floating in a sea of membrane lipids; the folding, orientation and topography of the system being determined by interactions between the lipophilic and hydrophilic domains of the peptide chains with solvent molecules (water on one side and lipids on the other). Nonpolar portions of the AA chain tend to bury within the membrane, while polar groups tend to come out in the aqueous medium. In such a delicately balanced system, it is not difficult to visualize that a small molecular ligand binding to one site in the receptor molecule could be capable of tripping the balance (by altering distribution of charges, etc.) and bringing about conformational changes at distant sites. Each of the five major families of receptors (described later) have a well defined common structural motif, while the individual receptors</p>
<p>differ in the details of amino acid sequencing, length of intra/extracellular loops, etc. Majority of receptor molecules are made up of several non-identical subunits (heteropolymeric), and agonist binding has been shown to bring about changes in their quaternary structure or relative alignment of the subunits, e.g. on activation the subunits of nicotinic receptor move apart opening a centrally located cation channel.</p>
<p>Many clinically useful drugs act upon physiological receptors which mediate responses to transmitters, hormones, autacoids and other endogenous signal molecules; examples are cholinergic, adrenergic, histaminergic, steroid, leukotriene, insulin and other such receptors. In addition, now some truly drug receptors have been described for which there are no known physiological ligands, e.g. benzodiazepine receptor, sulfonylurea receptor. Receptors for which no endogenous mediator or ligand is at present known are called 'Orphan receptors'. They, nevertheless, may prove to be targets for novel drugs yet to be developed.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="receptor-subtypes">Receptor subtypes<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#receptor-subtypes" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>The delineation of multiple types and subtypes of receptors for signal molecules has played an important role in the development of a number of targeted and more selective drugs. Even at an early stage of evolution of receptor pharmacology, it was observed that actions of acetylcholine could be grouped into 'muscarinic' and 'nicotinic' depending upon whether they were mimicked by the then known alkaloids muscarine or nicotine. Accordingly, they were said to be mediated by two types of cholinergic receptors, viz. muscarinic (M) or nicotinic <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo stretchy="false">(</mo><mi mathvariant="normal">N</mi><mo stretchy="false">)</mo></mrow><annotation encoding="application/x-tex">(\mathrm{N})</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mopen">(</span><span class="mord mathrm">N</span><span class="mclose">)</span></span></span></span></span>; a concept strengthened by the finding that muscarinic actions were blocked by atropine, while nicotinic actions were blocked by curare. In a landmark study, Ahlquist (1948) divided adrenergic receptors into ' <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>α</mi></mrow><annotation encoding="application/x-tex">\alpha</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.4306em;"></span><span class="mord mathnormal" style="margin-right: 0.0037em;">α</span></span></span></span></span> ' and ' <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>β</mi></mrow><annotation encoding="application/x-tex">\beta</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mord mathnormal" style="margin-right: 0.05278em;">β</span></span></span></span></span> ' on the basis of two distinct rankorder of potencies of adrenergic agonists. These receptors have now been further subdivided <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mrow><mo fence="true">(</mo><msub><mi mathvariant="normal">M</mi><mn>1</mn></msub><mo separator="true">,</mo><msub><mi mathvariant="normal">M</mi><mn>2</mn></msub><mo>…</mo><mi mathvariant="normal">.</mi><msub><mi mathvariant="normal">M</mi><mi mathvariant="normal">T</mi></msub><mo fence="true">)</mo></mrow><mo separator="true">,</mo><mrow><mo fence="true">(</mo><msub><mi mathvariant="normal">N</mi><mi mathvariant="normal">M</mi></msub></mrow></mrow><annotation encoding="application/x-tex">\left(\mathrm{M}_{1}, \mathrm{M}_{2} \ldots . \mathrm{M}_{\mathrm{T}}\right),\left(\mathrm{N}_{\mathrm{M}}\right.</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="minner"><span class="mopen delimcenter" style="top: 0em;">(</span><span class="mord"><span class="mord mathrm">M</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord"><span class="mord mathrm">M</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="minner">…</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord">.</span><span class="mord"><span class="mord mathrm">M</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3283em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mathrm mtight">T</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mclose delimcenter" style="top: 0em;">)</span></span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="minner"><span class="mopen delimcenter" style="top: 0em;">(</span><span class="mord"><span class="mord mathrm">N</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3283em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mathrm mtight">M</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mclose nulldelimiter"></span></span></span></span></span></span>, <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mrow><msub><mi mathvariant="normal">N</mi><mi mathvariant="normal">N</mi></msub><mo fence="true">)</mo></mrow><mrow><mo fence="true">(</mo><msub><mi>α</mi><mn>1</mn></msub><mo separator="true">,</mo><msub><mi>α</mi><mn>2</mn></msub><mo fence="true">)</mo></mrow><mrow><mo fence="true">(</mo><msub><mi>β</mi><mn>1</mn></msub><mo separator="true">,</mo><msub><mi>β</mi><mn>2</mn></msub><mo separator="true">,</mo><msub><mi>β</mi><mn>3</mn></msub><mo fence="true">)</mo></mrow></mrow><annotation encoding="application/x-tex">\left.\mathrm{N}_{\mathrm{N}}\right)\left(\alpha_{1}, \alpha_{2}\right)\left(\beta_{1}, \beta_{2}, \beta_{3}\right)</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="minner"><span class="mopen nulldelimiter"></span><span class="mord"><span class="mord mathrm">N</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3283em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mathrm mtight">N</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mclose delimcenter" style="top: 0em;">)</span></span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="minner"><span class="mopen delimcenter" style="top: 0em;">(</span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.0037em;">α</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.0037em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.0037em;">α</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.0037em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mclose delimcenter" style="top: 0em;">)</span></span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="minner"><span class="mopen delimcenter" style="top: 0em;">(</span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.05278em;">β</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.0528em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.05278em;">β</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.0528em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.05278em;">β</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.0528em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">3</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mclose delimcenter" style="top: 0em;">)</span></span></span></span></span></span>. Multiple subtypes of
receptors for practically all transmitters, autacoids, hormones, etc. are now known and have paved the way for introduction of numerous clinically superior drugs. In many cases, receptor classification has provided sound explanation for differences observed in the actions of closely related drugs.</p>
<p>The following criteria have been utilized in classifying receptors:
a. Pharmacological criteria Classification is based on relative potencies of selective agonists and antagonists. This is the classical and oldest approach with direct clinical bearing; was used in delineating M and N cholinergic, <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>α</mi></mrow><annotation encoding="application/x-tex">\alpha</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.4306em;"></span><span class="mord mathnormal" style="margin-right: 0.0037em;">α</span></span></span></span></span> and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>β</mi></mrow><annotation encoding="application/x-tex">\beta</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mord mathnormal" style="margin-right: 0.05278em;">β</span></span></span></span></span> adrenergic, <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">H</mi><mn>1</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{H}_{1}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">H</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">H</mi><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{H}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">H</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> histaminergic receptors, etc.
b. Tissue distribution The relative organ/tissue distribution is the basis for designating the subtype, e.g. the cardiac <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>β</mi></mrow><annotation encoding="application/x-tex">\beta</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mord mathnormal" style="margin-right: 0.05278em;">β</span></span></span></span></span> adrenergic receptors as <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi>β</mi><mn>1</mn></msub></mrow><annotation encoding="application/x-tex">\beta_{1}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.05278em;">β</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.0528em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span>, while bronchial as <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi>β</mi><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\beta_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.05278em;">β</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.0528em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span>. This division was confirmed by selective agonists and antagonists as well as by molecular cloning.
c. Ligand binding Measurement of specific binding of high affinity radio-labelled ligand to cellular fragments (usually membranes) in vitro, and its displacement by various selective agonists/antagonists is used to delineate receptor subtypes. Multiple 5-HT receptors were distinguished by this approach. Autoradiography has helped in mapping distribution of receptor subtypes in the brain and other organs.
d. Transducer pathway Receptor subtypes may be distinguished by the mechanism through which their activation is linked to the response, e.g. M cholinergic receptor acts through G-proteins, while N cholinergic receptor gates influx of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">N</mi><mi mathvariant="normal">a</mi></mrow><mo lspace="0em" rspace="0em">+</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{Na}^{+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8446em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Na</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8446em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span>ions; <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>α</mi></mrow><annotation encoding="application/x-tex">\alpha</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.4306em;"></span><span class="mord mathnormal" style="margin-right: 0.0037em;">α</span></span></span></span></span> adrenergic receptor acts via <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">I</mi><mi mathvariant="normal">P</mi></mrow><mn>3</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{IP}_{3}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">IP</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">3</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span>-DAG pathway and by decreasing cAMP, while <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>β</mi></mrow><annotation encoding="application/x-tex">\beta</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mord mathnormal" style="margin-right: 0.05278em;">β</span></span></span></span></span> adrenergic receptor increases cAMP; <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">G</mi><mi mathvariant="normal">A</mi><mi mathvariant="normal">B</mi><mi mathvariant="normal">A</mi></mrow><mi mathvariant="normal">A</mi></msub></mrow><annotation encoding="application/x-tex">\mathrm{GABA}_{\mathrm{A}}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">GABA</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3283em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mathrm mtight">A</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> receptor is a ligand gated <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">C</mi><mi mathvariant="normal">l</mi></mrow><mo lspace="0em" rspace="0em">−</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{Cl}^{-}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8557em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Cl</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8557em;"><span style="top: -3.1473em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">−</span></span></span></span></span></span></span></span></span></span></span></span></span>channel, while <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">G</mi><mi mathvariant="normal">A</mi><mi mathvariant="normal">B</mi><mi mathvariant="normal">A</mi></mrow><mi mathvariant="normal">B</mi></msub></mrow><annotation encoding="application/x-tex">\mathrm{GABA}_{\mathrm{B}}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">GABA</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3283em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mathrm mtight">B</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> receptor increases <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">K</mi><mo lspace="0em" rspace="0em">+</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{K}^{+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7713em;"></span><span class="mord"><span class="mord mathrm">K</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.7713em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span>conductance through a G-protein.
e. Molecular cloning The receptor protein is cloned and its detailed amino acid sequence as well as three dimentional structure is worked out. Subtypes are designated on the basis of sequence homology. This approach has in the recent years resulted in a flood of receptor subtypes and several isoforms (which do not differ in ligand selectivity) of each subtype. The functional significance of many of these subtypes/isoforms is dubious. Even receptors without known ligands (orphan receptors) have been described.</p>
<p>Application of so many approaches has thrown up several detailed, confusing and often conflicting classifications of receptors in the past. However, a consensus receptor classification is now decided on a continuing basis by an expert group of the International Union of Pharmacological Sciences (IUPHAR).</p>
<p>Silent receptors These are sites which bind specific drugs but no pharmacological response is elicited. They are better called inert binding sites or sites of loss, e.g. plasma proteins which have binding sites for many drugs. To avoid confusion, the term receptor should be restricted to those regulatory binding sites which are capable of generating a response.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="action-effect-sequence">ACTION-EFFECT SEQUENCE<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#action-effect-sequence" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>'Drug action' and 'drug effect' are often loosely used interchangeably, but are not synonymous. Drug action It is the initial combination of the drug with its receptor resulting in a conformational change in the latter (in case of agonists), or prevention of conformational change through exclusion of the agonist (in case of antagonists).
Drug effect It is the ultimate change in biological function brought about as a consequence of drug action, through a series of intermediate steps (transducer).</p>
<p>Receptors subserve two essential functions, viz, recognition of the specific ligand molecule and transduction of the signal into a response. Accordingly, the receptor molecule has a ligand binding domain (spatially and energetically suitable for binding the specific ligand) and an effector domain (Fig. 4.4) which undergoes a functional conformational change. These domains have now actually been identified in some receptors. The perturbation in the receptor molecule is variously translated into the response. The sequential relationship between drug action, transducer and drug effect can be seen in Fig. 4.1D and 4.6.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="transducer-mechanisms">TRANSDUCER MECHANISMS<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#transducer-mechanisms" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Considerable progress has been made in the understanding of transducer mechanisms which in most instances have been found to be highly complex multistep processes that provide for
<img src="assets/images/image-20251214-cefc1318.jpeg" alt="img-24.jpeg"></p>
<p>Fig. 4.4: Diagrammatic representation of receptor mediated operation of membrane ion channel In case of nicotinic cholinergic receptor, the molecule ( 8 nm in diameter) is composed of 5 subunits ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>2</mn><mi>α</mi><mo>+</mo><mi>β</mi><mo>+</mo><mi>γ</mi><mo>+</mo><mi>δ</mi></mrow><annotation encoding="application/x-tex">2 \alpha+\beta+\gamma+\delta</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">2</span><span class="mord mathnormal" style="margin-right: 0.0037em;">α</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">+</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mord mathnormal" style="margin-right: 0.05278em;">β</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">+</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.7778em; vertical-align: -0.1944em;"></span><span class="mord mathnormal" style="margin-right: 0.05556em;">γ</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">+</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6944em;"></span><span class="mord mathnormal" style="margin-right: 0.03785em;">δ</span></span></span></span></span> ) enclosing a transmembrane ion channel within the <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>α</mi></mrow><annotation encoding="application/x-tex">\alpha</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.4306em;"></span><span class="mord mathnormal" style="margin-right: 0.0037em;">α</span></span></span></span></span> subunit. Normally the channel is closed (A). When two molecules of acetylcholine bind to the two <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>α</mi></mrow><annotation encoding="application/x-tex">\alpha</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.4306em;"></span><span class="mord mathnormal" style="margin-right: 0.0037em;">α</span></span></span></span></span> subunits (B), all subunits move apart opening the central pore to 0.7 nm , enough to allow passage of partially hydrated <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">N</mi><mi mathvariant="normal">a</mi></mrow><mo lspace="0em" rspace="0em">+</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{Na}^{+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8446em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Na</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8446em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span>ions. Anions are blocked from passage through the channel by positive charges lining it.
In other cases, <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">K</mi><mo lspace="0em" rspace="0em">+</mo></msup><mo separator="true">,</mo><msup><mrow><mi mathvariant="normal">C</mi><mi mathvariant="normal">a</mi></mrow><mrow><mn>2</mn><mo>+</mo></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{K}^{+}, \mathrm{Ca}^{2+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1.0818em; vertical-align: -0.1944em;"></span><span class="mord"><span class="mord mathrm">K</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.7713em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Ca</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8873em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span> or <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">C</mi><mi mathvariant="normal">l</mi></mrow><mo lspace="0em" rspace="0em">−</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{Cl}^{-}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8557em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Cl</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8557em;"><span style="top: -3.1473em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">−</span></span></span></span></span></span></span></span></span></span></span></span></span>ions move through the channel depending on its ion selectivity.</p>
<p><img src="assets/images/image-20251214-7e096f27.jpeg" alt="img-25.jpeg"></p>
<p>Fig. 4.5: Diagrammatic representation of G-protein coupled receptor molecule
The receptor consists of 7 membrane spanning helical segments of hydrophobic amino acids. The intervening segments connecting the helices form 3 loops on either side of the membrane. The amino terminus of the chain lies on the extracellular face, while the carboxy terminus is on the cytosolic side. The approximate location of the agonist and G-protein binding sites is indicated.
amplification of the signal, as well as integration of concurrently received extra- and intra-cellular signals at each step. Because only a handful of transducer pathways are shared by a large number of receptors, the cell is able to generate an integrated response reflecting the sum total of diverse signal inputs. The transducer mechanisms can be grouped into 5 major categories. Receptors falling in one category also possess considerable structural homology, and belong to one super-family of receptors.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="1-g-protein-coupled-receptors-gpcrs">1. G-protein coupled receptors (GPCRs)<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#1-g-protein-coupled-receptors-gpcrs" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>These are a large family of cell membrane receptors which are linked to the effector (enzyme/channel/transporter) through one or more GTP-activated proteins (G-proteins) for response effectuation. All such receptors have a common pattern of structural organization (Fig. 4.5). The molecule has <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>7</mn><mi>α</mi></mrow><annotation encoding="application/x-tex">7 \alpha</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">7</span><span class="mord mathnormal" style="margin-right: 0.0037em;">α</span></span></span></span></span>-helical membrane spanning hydrophobic amino acid (AA) segments which run into 3 extracellular and 3 intracellular loops. The agonist binding site is located somewhere between the helices on
the extracellular face, while another recognition site formed by cytosolic segments binds the coupling G-protein. The G-proteins float in the membrane with their exposed domain lying in the cytosol, and are heterotrimeric in composition ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>α</mi><mo separator="true">,</mo><mi>β</mi></mrow><annotation encoding="application/x-tex">\alpha, \beta</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mord mathnormal" style="margin-right: 0.0037em;">α</span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord mathnormal" style="margin-right: 0.05278em;">β</span></span></span></span></span> and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>γ</mi></mrow><annotation encoding="application/x-tex">\gamma</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.625em; vertical-align: -0.1944em;"></span><span class="mord mathnormal" style="margin-right: 0.05556em;">γ</span></span></span></span></span> subunits). In the inactive state GDP is bound to the <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>α</mi></mrow><annotation encoding="application/x-tex">\alpha</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.4306em;"></span><span class="mord mathnormal" style="margin-right: 0.0037em;">α</span></span></span></span></span> subunit at the exposed domain; activation through the receptor leads to displacement of GDP by GTP. The activated <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>α</mi></mrow><annotation encoding="application/x-tex">\alpha</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.4306em;"></span><span class="mord mathnormal" style="margin-right: 0.0037em;">α</span></span></span></span></span>-subunit carrying GTP dissociates from the other two subunits and either activates or inhibits the effector. The <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>β</mi><mi>γ</mi></mrow><annotation encoding="application/x-tex">\beta \gamma</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mord mathnormal" style="margin-right: 0.05278em;">β</span><span class="mord mathnormal" style="margin-right: 0.05556em;">γ</span></span></span></span></span> diamer has also been shown to activate receptor-operated <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">K</mi><mo lspace="0em" rspace="0em">+</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{K}^{+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7713em;"></span><span class="mord"><span class="mord mathrm">K</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.7713em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span> channels, to inhibit voltage gated <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">C</mi><mi mathvariant="normal">a</mi></mrow><mrow><mn>2</mn><mo>+</mo></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{Ca}^{2+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8873em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Ca</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8873em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span> channels and to promote GPCR desensitization at higher rates of activation.
A number of G proteins distinguished by their <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>α</mi></mrow><annotation encoding="application/x-tex">\alpha</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.4306em;"></span><span class="mord mathnormal" style="margin-right: 0.0037em;">α</span></span></span></span></span> subunits have been described. The important ones with their action on the effector are:</p>
<p>Gs : Adenylyl cyclase activation, <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">C</mi><mi mathvariant="normal">a</mi></mrow><mrow><mn>2</mn><mo>+</mo></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{Ca}^{2+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8873em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Ca</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8873em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span> channel opening
Gi : Adenylyl cyclase inhibition, <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">K</mi><mo lspace="0em" rspace="0em">+</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{K}^{+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7713em;"></span><span class="mord"><span class="mord mathrm">K</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.7713em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span>channel opening
Go : <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">C</mi><mi mathvariant="normal">a</mi></mrow><mrow><mn>2</mn><mo>+</mo></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{Ca}^{2+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8873em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Ca</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8873em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span> channel inhibition
Gq : Phospholipase C activation
A limited number of G-proteins are shared between different receptors and one receptor can utilize more than one G-protein (agonist pleotropy), e.g. the following couplers have been associated with different receptors.</p>
<table><thead><tr><th style="text-align: left;">Receptor</th><th style="text-align: left;">Coupler</th></tr></thead><tbody><tr><td style="text-align: left;">Muscarinic <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">M</mi><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{M}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">M</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span></td><td style="text-align: left;">Gi, Go</td></tr><tr><td style="text-align: left;">Muscarinic <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">M</mi><mn>1</mn></msub><mo separator="true">,</mo><msub><mi mathvariant="normal">M</mi><mn>3</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{M}_{1}, \mathrm{M}_{3}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8778em; vertical-align: -0.1944em;"></span><span class="mord"><span class="mord mathrm">M</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord"><span class="mord mathrm">M</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">3</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span></td><td style="text-align: left;">Gq</td></tr><tr><td style="text-align: left;">Dopamine D2</td><td style="text-align: left;">Gi, Go</td></tr><tr><td style="text-align: left;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>β</mi></mrow><annotation encoding="application/x-tex">\beta</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mord mathnormal" style="margin-right: 0.05278em;">β</span></span></span></span></span>-adrenergic</td><td style="text-align: left;">Gs</td></tr><tr><td style="text-align: left;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi>α</mi><mn>1</mn></msub></mrow><annotation encoding="application/x-tex">\alpha_{1}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5806em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.0037em;">α</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.0037em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span>-adrenergic</td><td style="text-align: left;">Gq</td></tr><tr><td style="text-align: left;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi>α</mi><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\alpha_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5806em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.0037em;">α</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.0037em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span>-adrenergic</td><td style="text-align: left;">Gi, Go</td></tr><tr><td style="text-align: left;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">G</mi><mi mathvariant="normal">A</mi><mi mathvariant="normal">B</mi><mi mathvariant="normal">A</mi></mrow><mi mathvariant="normal">B</mi></msub></mrow><annotation encoding="application/x-tex">\mathrm{GABA}_{\mathrm{B}}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">GABA</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3283em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mathrm mtight">B</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span></td><td style="text-align: left;">Gi, Go</td></tr><tr><td style="text-align: left;">Serotonin 5-HT <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow></mrow><mn>1</mn></msub></mrow><annotation encoding="application/x-tex">{ }_{1}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.4511em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span></td><td style="text-align: left;">Gi, Go</td></tr><tr><td style="text-align: left;">Serotonin 5-HT <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow></mrow><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">{ }_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.4511em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span></td><td style="text-align: left;">Gq</td></tr><tr><td style="text-align: left;">Prostanoid</td><td style="text-align: left;">Gs, Gi, Gq</td></tr></tbody></table>
<p>In addition, Gs is the coupler for histamine <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">H</mi><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{H}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">H</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> serotonin <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><msub><mrow><mi mathvariant="normal">H</mi><mi mathvariant="normal">T</mi></mrow><mrow><mn>4</mn><mo>−</mo><mn>7</mn></mrow></msub></mrow><annotation encoding="application/x-tex">5 \mathrm{HT}_{4-7}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8917em; vertical-align: -0.2083em;"></span><span class="mord">5</span><span class="mord"><span class="mord"><span class="mord mathrm">HT</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">4</span><span class="mbin mtight">−</span><span class="mord mtight">7</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.2083em;"><span></span></span></span></span></span></span></span></span></span></span>, glucagon, thyrotropin (TSH) and many other hormones, while Gi is utilized by</p>
<p>opioid, cannabinoid and some other receptors. Moreover, a receptor can utilize different biochemical pathways in different tissues.</p>
<p>The <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>α</mi></mrow><annotation encoding="application/x-tex">\alpha</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.4306em;"></span><span class="mord mathnormal" style="margin-right: 0.0037em;">α</span></span></span></span></span>-subunit has GTPase activity: the bound GTP is slowly hydrolysed to GDP: the <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>α</mi></mrow><annotation encoding="application/x-tex">\alpha</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.4306em;"></span><span class="mord mathnormal" style="margin-right: 0.0037em;">α</span></span></span></span></span>-subunit then dissociates from the effector to rejoin its other subunits, but not before the effector has been activated/ inhibited for several seconds (much longer than the life-time of the activated receptor, which is in milliseconds) and the signal has been greatly amplified. The rate of GTP hydrolysis by the <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>α</mi></mrow><annotation encoding="application/x-tex">\alpha</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.4306em;"></span><span class="mord mathnormal" style="margin-right: 0.0037em;">α</span></span></span></span></span> subunit and thus the period for which it remains activated is regulated by another protein called 'regulator of G protein signaling' (RGS). The onset time of response through GPCRs is in seconds.</p>
<p>There are three major effector pathways (Table 4.1) through which GPCRs function.
(a) Adenylyl cyclase: cAMP pathway Activation of AC results in intracellular accumulation of second messenger cAMP (Fig. 4.6) which functions mainly through cAMP-dependent protein kinase <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo fence="true">(</mo><msub><mrow><mi mathvariant="normal">P</mi><mi mathvariant="normal">K</mi></mrow><mi mathvariant="normal">A</mi></msub><mo fence="true">)</mo></mrow><annotation encoding="application/x-tex">\left(\mathrm{PK}_{\mathrm{A}}\right)</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="minner"><span class="mopen delimcenter" style="top: 0em;">(</span><span class="mord"><span class="mord"><span class="mord mathrm">PK</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3283em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mathrm mtight">A</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mclose delimcenter" style="top: 0em;">)</span></span></span></span></span></span>. The <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">P</mi><mi mathvariant="normal">K</mi></mrow><mi mathvariant="normal">A</mi></msub></mrow><annotation encoding="application/x-tex">\mathrm{PK}_{\mathrm{A}}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">PK</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3283em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mathrm mtight">A</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> phosphorylates and alters the function of many enzymes, ion channels, transporters, transcription factors and structural proteins to manifest as increased contractility/impulse generation (heart), relaxation (smooth muscle), glycogenolysis, lipolysis,
inhibition of secretion/mediator release, modulation of junctional transmission, water conservation by kidney, steroid hormone synthesis, etc. In addition, cAMP directly opens a specific type of membrane <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">C</mi><mi mathvariant="normal">a</mi></mrow><mrow><mn>2</mn><mo>+</mo></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{Ca}^{2+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8873em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Ca</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8873em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span> channel called cyclic nucleotide gated channel (CNG) in the heart, brain and kidney. The other mediators of cellular actions of cAMP are: cAMP response element binding protein (CREB) which is a transcription factor, cAMP regulated guanine nucleotide exchange factors called EPACs and certain transporters. Responses opposite to the above are produced when AC is inhibited through inhibitory Gi-protein.</p>
<p>The action of cAMP is terminated intracellularly by phosphodiesterases (PDEs) which hydrolyse it to 5-AMP. Some isoforms of PDE <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo fence="true">(</mo><msub><mrow><mi mathvariant="normal">P</mi><mi mathvariant="normal">D</mi><mi mathvariant="normal">E</mi></mrow><mn>3</mn></msub><mo separator="true">,</mo><msub><mrow><mi mathvariant="normal">P</mi><mi mathvariant="normal">D</mi><mi mathvariant="normal">E</mi></mrow><mn>4</mn></msub><mo fence="true">)</mo></mrow><annotation encoding="application/x-tex">\left(\mathrm{PDE}_{3}, \mathrm{PDE}_{4}\right)</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="minner"><span class="mopen delimcenter" style="top: 0em;">(</span><span class="mord"><span class="mord"><span class="mord mathrm">PDE</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">3</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">PDE</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">4</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mclose delimcenter" style="top: 0em;">)</span></span></span></span></span></span> are selective for cAMP, while <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">P</mi><mi mathvariant="normal">D</mi><mi mathvariant="normal">E</mi></mrow><mn>5</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{PDE}_{5}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">PDE</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">5</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> is selective for cGMP.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="cyclic-gmp-cgmp-as-a-second-messenger">Cyclic GMP (cGMP) as a second messenger<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#cyclic-gmp-cgmp-as-a-second-messenger" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>In contrast to cAMP, the cGMP serves as an intracellular second messenger only in a limited number of tissues, such as vascular smooth muscle, intestinal mucosal cell and kidney. In these tissues it respectively mediates relaxation, inhibition of salt and water absorption as well</p>
<p>Table 4.1: Major functional pathways of G-protein coupled receptor transduction</p>
<table><thead><tr><th style="text-align: center;">Adenylyl cyclase: cAMP</th><th style="text-align: center;"></th><th style="text-align: center;">Phospholipase<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>I</mi><msub><mi>P</mi><mn>2</mn></msub><mi mathvariant="normal">/</mi><mi>D</mi><mi>A</mi><mi>G</mi></mrow><annotation encoding="application/x-tex">I P_{2} / D A G</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord mathnormal" style="margin-right: 0.07847em;">I</span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.13889em;">P</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.1389em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mord">/</span><span class="mord mathnormal" style="margin-right: 0.02778em;">D</span><span class="mord mathnormal">A</span><span class="mord mathnormal">G</span></span></span></span></span></th><th style="text-align: center;">Channel regulation</th><th style="text-align: center;"></th><th style="text-align: center;"></th></tr></thead><tbody><tr><td style="text-align: center;">activation</td><td style="text-align: center;">inhibition</td><td style="text-align: center;">activation</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">C</mi><mi mathvariant="normal">a</mi></mrow><mrow><mn>2</mn><mo>+</mo></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{Ca}^{2+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8873em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Ca</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8873em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span> opening</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">C</mi><mi mathvariant="normal">a</mi></mrow><mrow><mn>2</mn><mo>+</mo></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{Ca}^{2+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8873em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Ca</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8873em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span> closing</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">K</mi><mo lspace="0em" rspace="0em">+</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{K}^{+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7713em;"></span><span class="mord"><span class="mord mathrm">K</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.7713em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span>opening</td></tr><tr><td style="text-align: center;">Adrenergic- <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>β</mi></mrow><annotation encoding="application/x-tex">\beta</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mord mathnormal" style="margin-right: 0.05278em;">β</span></span></span></span></span></td><td style="text-align: center;">Adrenergic- <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi>α</mi><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\alpha_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5806em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.0037em;">α</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.0037em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span></td><td style="text-align: center;">Adrenergic- <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi>α</mi><mn>1</mn></msub></mrow><annotation encoding="application/x-tex">\alpha_{1}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5806em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.0037em;">α</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.0037em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span></td><td style="text-align: center;">Adrenergic- <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi>β</mi><mn>1</mn></msub></mrow><annotation encoding="application/x-tex">\beta_{1}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.05278em;">β</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.0528em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span></td><td style="text-align: center;">Dopamine-D2</td><td style="text-align: center;">Adrenergic- <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi>α</mi><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\alpha_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5806em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.0037em;">α</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.0037em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span></td></tr><tr><td style="text-align: center;">Histamine- <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">H</mi><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{H}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">H</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span></td><td style="text-align: center;">Muscarinic- <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">M</mi><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{M}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">M</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span></td><td style="text-align: center;">Histamine- <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">H</mi><mn>1</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{H}_{1}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">H</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span></td><td style="text-align: center;"></td><td style="text-align: center;">GABA <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow></mrow><mi>B</mi></msub></mrow><annotation encoding="application/x-tex">_{B}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.4783em; vertical-align: -0.15em;"></span><span class="mord"><span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3283em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mathnormal mtight" style="margin-right: 0.05017em;">B</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span></td><td style="text-align: center;">Muscarinic- <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">M</mi><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{M}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">M</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span></td></tr><tr><td style="text-align: center;">Dopamine-D1</td><td style="text-align: center;">Dopamine-D2</td><td style="text-align: center;">Muscarinic- <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">M</mi><mn>1</mn></msub><mo separator="true">,</mo><msub><mi mathvariant="normal">M</mi><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{M}_{1}, \mathrm{M}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8778em; vertical-align: -0.1944em;"></span><span class="mord"><span class="mord mathrm">M</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord"><span class="mord mathrm">M</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span></td><td style="text-align: center;"></td><td style="text-align: center;">Opioid- <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>κ</mi></mrow><annotation encoding="application/x-tex">\kappa</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.4306em;"></span><span class="mord mathnormal">κ</span></span></span></span></span></td><td style="text-align: center;">Dopamine-D2</td></tr><tr><td style="text-align: center;">Glucagon</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mo>−</mo><msub><mrow><mi mathvariant="normal">H</mi><mi mathvariant="normal">T</mi></mrow><mn>1</mn></msub></mrow><annotation encoding="application/x-tex">5-\mathrm{HT}_{1}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">HT</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mo>−</mo><msub><mrow><mi mathvariant="normal">H</mi><mi mathvariant="normal">T</mi></mrow><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">5-\mathrm{HT}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">HT</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span></td><td style="text-align: center;"></td><td style="text-align: center;">Adenosine-A <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow></mrow><mn>1</mn></msub></mrow><annotation encoding="application/x-tex">{ }_{1}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.4511em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mo>−</mo><msub><mrow><mi mathvariant="normal">H</mi><mi mathvariant="normal">T</mi></mrow><mrow><mn>1</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">A</mi></mrow></mrow></msub></mrow><annotation encoding="application/x-tex">5-\mathrm{HT}_{1 \mathrm{~A}}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">HT</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3283em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span><span class="mord mtight"><span class="mspace nobreak mtight"><span class="mtight">&nbsp;</span></span><span class="mord mathrm mtight">A</span></span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span></td></tr><tr><td style="text-align: center;">FSH &amp; LH</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">G</mi><mi mathvariant="normal">A</mi><mi mathvariant="normal">B</mi><mi mathvariant="normal">A</mi></mrow><mi>B</mi></msub></mrow><annotation encoding="application/x-tex">\mathrm{GABA}_{B}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">GABA</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3283em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mathnormal mtight" style="margin-right: 0.05017em;">B</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span></td><td style="text-align: center;">Vasopressin-Oxytocin</td><td style="text-align: center;"></td><td style="text-align: center;">Somatostatin</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">G</mi><mi mathvariant="normal">A</mi><mi mathvariant="normal">B</mi><mi mathvariant="normal">A</mi></mrow><mi>B</mi></msub></mrow><annotation encoding="application/x-tex">\mathrm{GABA}_{B}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">GABA</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3283em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mathnormal mtight" style="margin-right: 0.05017em;">B</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span></td></tr><tr><td style="text-align: center;">ACTH</td><td style="text-align: center;">Opioid- <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>μ</mi><mo separator="true">,</mo><mi>δ</mi></mrow><annotation encoding="application/x-tex">\mu, \delta</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mord mathnormal">μ</span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord mathnormal" style="margin-right: 0.03785em;">δ</span></span></span></span></span></td><td style="text-align: center;">Bradykinin- <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">B</mi><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{B}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">B</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span></td><td style="text-align: center;"></td><td style="text-align: center;"></td><td style="text-align: center;">Opioid- <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>μ</mi><mo separator="true">,</mo><mi>δ</mi></mrow><annotation encoding="application/x-tex">\mu, \delta</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mord mathnormal">μ</span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord mathnormal" style="margin-right: 0.03785em;">δ</span></span></span></span></span></td></tr><tr><td style="text-align: center;">TSH</td><td style="text-align: center;">Angiotensin-AT <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow></mrow><mn>1</mn></msub></mrow><annotation encoding="application/x-tex">{ }_{1}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.4511em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span></td><td style="text-align: center;">Angiotensin-AT <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow></mrow><mn>1</mn></msub></mrow><annotation encoding="application/x-tex">{ }_{1}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.4511em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span></td><td style="text-align: center;"></td><td style="text-align: center;"></td><td style="text-align: center;">Adenosine- <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">A</mi><mn>1</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{A}_{1}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">A</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span></td></tr><tr><td style="text-align: center;">Prostaglandin-EP <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow></mrow><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">{ }_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.4511em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span></td><td style="text-align: center;">Prostaglandin-EP <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow></mrow><mn>3</mn></msub></mrow><annotation encoding="application/x-tex">{ }_{3}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.4511em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">3</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span></td><td style="text-align: center;">Prostaglandin-FP <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow></mrow><mn>1</mn></msub></mrow><annotation encoding="application/x-tex">{ }_{1}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.4511em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">E</mi><mi mathvariant="normal">P</mi></mrow><mn>1</mn></msub><mo separator="true">,</mo><msub><mrow><mi mathvariant="normal">E</mi><mi mathvariant="normal">P</mi></mrow><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{EP}_{1}, \mathrm{EP}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8778em; vertical-align: -0.1944em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">EP</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">EP</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span></td><td style="text-align: center;"></td><td style="text-align: center;"></td><td style="text-align: center;"></td></tr><tr><td style="text-align: center;">Prostacyclin-IP</td><td style="text-align: center;">Somatostatin</td><td style="text-align: center;">Thromboxane-TP</td><td style="text-align: center;"></td><td style="text-align: center;"></td><td style="text-align: center;"></td></tr><tr><td style="text-align: center;">Adenosine- <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">A</mi><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{A}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">A</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span></td><td style="text-align: center;">Adenosine- <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">A</mi><mn>1</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{A}_{1}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">A</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span></td><td style="text-align: center;">Leukotriene BLT <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow></mrow><mrow><mn>1</mn><mtext>&nbsp;exa&nbsp;</mtext></mrow></msub></mrow><annotation encoding="application/x-tex">{ }_{1 \text { exa }}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.4511em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span><span class="mord text mtight"><span class="mord mtight">&nbsp;exa&nbsp;</span></span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> LT</td><td style="text-align: center;"></td><td style="text-align: center;"></td><td style="text-align: center;"></td></tr><tr><td style="text-align: center;"></td><td style="text-align: center;"></td><td style="text-align: center;">Cholecystokinin- &lt;br&gt; Gastrin</td><td style="text-align: center;"></td><td style="text-align: center;"></td><td style="text-align: center;"></td></tr><tr><td style="text-align: center;"></td><td style="text-align: center;"></td><td style="text-align: center;">PAF</td><td style="text-align: center;"></td><td style="text-align: center;"></td><td style="text-align: center;"></td></tr></tbody></table>
<p><img src="assets/images/image-20251214-c12118a8.jpeg" alt="img-26.jpeg"></p>
<p>Fig. 4.6: The action-effect sequence of two G-protein coupled ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>β</mi></mrow><annotation encoding="application/x-tex">\beta</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mord mathnormal" style="margin-right: 0.05278em;">β</span></span></span></span></span> adrenergic and muscarinic <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">M</mi><mi mathvariant="normal">p</mi></msub></mrow><annotation encoding="application/x-tex">\mathrm{M}_{\mathrm{p}}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.9694em; vertical-align: -0.2861em;"></span><span class="mord"><span class="mord mathrm">M</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.1514em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mathrm mtight">p</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.2861em;"><span></span></span></span></span></span></span></span></span></span></span> ) receptor activation in myocardial cell
Adrenaline (Adr) binds to <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>β</mi></mrow><annotation encoding="application/x-tex">\beta</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mord mathnormal" style="margin-right: 0.05278em;">β</span></span></span></span></span>-adrenergic receptor ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>β</mi><mo>−</mo><mi mathvariant="normal">R</mi></mrow><annotation encoding="application/x-tex">\beta-\mathrm{R}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mord mathnormal" style="margin-right: 0.05278em;">β</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathrm">R</span></span></span></span></span> ) on the cell surface inducing a conformational change which permits interaction of the G-protein binding site with the stimulatory G-protein (Gs). The activated <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>α</mi></mrow><annotation encoding="application/x-tex">\alpha</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.4306em;"></span><span class="mord mathnormal" style="margin-right: 0.0037em;">α</span></span></span></span></span> subunit of Gs now binds GTP (in place of GDP), and dissociates from the <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>β</mi><mi>γ</mi></mrow><annotation encoding="application/x-tex">\beta \gamma</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mord mathnormal" style="margin-right: 0.05278em;">β</span><span class="mord mathnormal" style="margin-right: 0.05556em;">γ</span></span></span></span></span> dimer as well as from the receptor. The Gs <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>α</mi></mrow><annotation encoding="application/x-tex">\alpha</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.4306em;"></span><span class="mord mathnormal" style="margin-right: 0.0037em;">α</span></span></span></span></span> carrying bound GTP associates with and activates the enzyme adenylyl cyclase (AC) located on the cytosolic side of the membrane: ATP is hydrolysed to cAMP which then phosphorylates and thus activates cAMP dependent protein kinase ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">P</mi><mi mathvariant="normal">K</mi></mrow><mi mathvariant="normal">A</mi></msub></mrow><annotation encoding="application/x-tex">\mathrm{PK}_{\mathrm{A}}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">PK</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3283em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mathrm mtight">A</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> ). The <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">P</mi><mi mathvariant="normal">K</mi></mrow><mi mathvariant="normal">A</mi></msub></mrow><annotation encoding="application/x-tex">\mathrm{PK}_{\mathrm{A}}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">PK</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3283em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mathrm mtight">A</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> in turn phosphorylates many functional proteins including troponin and phospholamban, so that they interact with <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">C</mi><mi mathvariant="normal">a</mi></mrow><mrow><mn>2</mn><mo>+</mo></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{Ca}^{2+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8873em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Ca</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8873em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span>, respectively resulting in increased force of contraction and faster relaxation. Calcium is made available by entry from outside (direct activation of myocardial membrane <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">C</mi><mi mathvariant="normal">a</mi></mrow><mrow><mn>2</mn><mo>+</mo></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{Ca}^{2+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8873em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Ca</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8873em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span> channels by <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mrow><mi mathvariant="normal">G</mi><mi mathvariant="normal">s</mi></mrow><mi>α</mi></mrow><annotation encoding="application/x-tex">\mathrm{Gs} \alpha</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord"><span class="mord mathrm">Gs</span></span><span class="mord mathnormal" style="margin-right: 0.0037em;">α</span></span></span></span></span> and through their phosphorylation by <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">P</mi><mi mathvariant="normal">K</mi></mrow><mi mathvariant="normal">A</mi></msub></mrow><annotation encoding="application/x-tex">\mathrm{PK}_{\mathrm{A}}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">PK</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3283em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mathrm mtight">A</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> ) as well as from intracellular stores.</p>
<p>One of the other proteins phosphorylated by cAMP is phosphorylase kinase which then activates the enzyme phosphorylase resulting in breakdown of glycogen to be utilized as energy source for increased contractility.</p>
<p>Action of acetylcholine (ACh) on muscarinic <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">M</mi><mi mathvariant="normal">p</mi></msub></mrow><annotation encoding="application/x-tex">\mathrm{M}_{\mathrm{p}}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.9694em; vertical-align: -0.2861em;"></span><span class="mord"><span class="mord mathrm">M</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.1514em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mathrm mtight">p</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.2861em;"><span></span></span></span></span></span></span></span></span></span></span> receptor <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo fence="true">(</mo><msub><mi mathvariant="normal">M</mi><mi mathvariant="normal">p</mi></msub><mo>−</mo><mi mathvariant="normal">R</mi><mo fence="true">)</mo></mrow><annotation encoding="application/x-tex">\left(\mathrm{M}_{\mathrm{p}}-\mathrm{R}\right)</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1.0361em; vertical-align: -0.2861em;"></span><span class="minner"><span class="mopen delimcenter" style="top: 0em;">(</span><span class="mord"><span class="mord mathrm">M</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.1514em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mathrm mtight">p</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.2861em;"><span></span></span></span></span></span></span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mord mathrm">R</span><span class="mclose delimcenter" style="top: 0em;">)</span></span></span></span></span></span>, also located in the myocardial membrane, similarly activates an inhibitory G-protein (Gi). The GTP carrying active Gi <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>α</mi></mrow><annotation encoding="application/x-tex">\alpha</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.4306em;"></span><span class="mord mathnormal" style="margin-right: 0.0037em;">α</span></span></span></span></span> subunit inhibits AC, and opposes its activation by <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mrow><mi mathvariant="normal">G</mi><mi mathvariant="normal">s</mi></mrow><mi>α</mi></mrow><annotation encoding="application/x-tex">\mathrm{Gs} \alpha</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord"><span class="mord mathrm">Gs</span></span><span class="mord mathnormal" style="margin-right: 0.0037em;">α</span></span></span></span></span>. The <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>β</mi><mi>γ</mi></mrow><annotation encoding="application/x-tex">\beta \gamma</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mord mathnormal" style="margin-right: 0.05278em;">β</span><span class="mord mathnormal" style="margin-right: 0.05556em;">γ</span></span></span></span></span> dimer of Gi activates membrane <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">K</mi><mo lspace="0em" rspace="0em">+</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{K}^{+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7713em;"></span><span class="mord"><span class="mord mathrm">K</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.7713em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span>channels causing hyperpolarization which depresses impulse generation.
as anion secretion, and natriuresis (mainly due to reduced proximal tubular <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">N</mi><mi mathvariant="normal">a</mi></mrow><mo lspace="0em" rspace="0em">+</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{Na}^{+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8446em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Na</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8446em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span>reabsorption).</p>
<p>There are two principal forms of guanylyl cyclases (GC) which generate cGMP, one cell membrane bound and the other cytosolic. However, none of these is regulated by a GPCR. The cell membrane bound GC is regulated by a
transmembrane enzyme-linked receptor (described on p.58) for atrial natriuretic peptide (ANP). The cytosolic soluble GC in vascular smooth muscle is activated by nitric oxide (NO). After generation by the vascular endothelium NO diffuses into the adjacent smooth muscle cell and stimulates the soluble GC. Increased</p>
<p><img src="assets/images/image-20251214-89af597b.jpeg" alt="img-27.jpeg"></p>
<p>Fig. 4.7: The important steps of phospholipase <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">c</mi><mi>β</mi><mo stretchy="false">(</mo><mrow><mi mathvariant="normal">P</mi><mi mathvariant="normal">L</mi><mi mathvariant="normal">c</mi></mrow><mi>β</mi><mo stretchy="false">)</mo></mrow><annotation encoding="application/x-tex">\mathrm{c} \beta(\mathrm{PLc} \beta)</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord mathrm">c</span><span class="mord mathnormal" style="margin-right: 0.05278em;">β</span><span class="mopen">(</span><span class="mord"><span class="mord mathrm">PLc</span></span><span class="mord mathnormal" style="margin-right: 0.05278em;">β</span><span class="mclose">)</span></span></span></span></span> pathway of response effectuation (in smooth muscle) The agonist, e.g. histamine binds to its <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">H</mi><mn>1</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{H}_{1}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">H</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> receptor <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo fence="true">(</mo><msub><mi mathvariant="normal">H</mi><mn>1</mn></msub><mi mathvariant="normal">R</mi><mo fence="true">)</mo></mrow><annotation encoding="application/x-tex">\left(\mathrm{H}_{1} \mathrm{R}\right)</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="minner"><span class="mopen delimcenter" style="top: 0em;">(</span><span class="mord"><span class="mord mathrm">H</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mord mathrm">R</span><span class="mclose delimcenter" style="top: 0em;">)</span></span></span></span></span></span> and activates the G-protein <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">G</mi><mi mathvariant="normal">q</mi></msub></mrow><annotation encoding="application/x-tex">\mathrm{G}_{\mathrm{q}}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.9694em; vertical-align: -0.2861em;"></span><span class="mord"><span class="mord mathrm">G</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.1514em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mathrm mtight">q</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.2861em;"><span></span></span></span></span></span></span></span></span></span></span>. Its <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>α</mi></mrow><annotation encoding="application/x-tex">\alpha</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.4306em;"></span><span class="mord mathnormal" style="margin-right: 0.0037em;">α</span></span></span></span></span> subunit binds GTP in place of GDP, dissociates from the receptor as well as from <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi>β</mi><mn>7</mn></msub></mrow><annotation encoding="application/x-tex">\beta_{7}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.05278em;">β</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.0528em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">7</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> dimer to activate membrane bound <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mrow><mi mathvariant="normal">P</mi><mi mathvariant="normal">L</mi><mi mathvariant="normal">c</mi></mrow><mi>β</mi></mrow><annotation encoding="application/x-tex">\mathrm{PLc} \beta</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mord"><span class="mord mathrm">PLc</span></span><span class="mord mathnormal" style="margin-right: 0.05278em;">β</span></span></span></span></span> that hydrolyses phosphatidyl inositol 4, 5-bisphosphate <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo fence="true">(</mo><msub><mrow><mi mathvariant="normal">P</mi><mi mathvariant="normal">I</mi><mi mathvariant="normal">P</mi></mrow><mn>2</mn></msub><mo fence="true">)</mo></mrow><annotation encoding="application/x-tex">\left(\mathrm{PIP}_{2}\right)</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="minner"><span class="mopen delimcenter" style="top: 0em;">(</span><span class="mord"><span class="mord"><span class="mord mathrm">PIP</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mclose delimcenter" style="top: 0em;">)</span></span></span></span></span></span>, a membrane bound phospholipid. The products inositol 1, 4, 5-trisphosphate <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo fence="true">(</mo><msub><mrow><mi mathvariant="normal">I</mi><mi mathvariant="normal">P</mi></mrow><mn>3</mn></msub><mo fence="true">)</mo></mrow><annotation encoding="application/x-tex">\left(\mathrm{IP}_{3}\right)</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="minner"><span class="mopen delimcenter" style="top: 0em;">(</span><span class="mord"><span class="mord"><span class="mord mathrm">IP</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">3</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mclose delimcenter" style="top: 0em;">)</span></span></span></span></span></span> and diacylglycerol (DAG) act as second messengers. The primary action of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">I</mi><mi mathvariant="normal">P</mi></mrow><mn>3</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{IP}_{3}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">IP</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">3</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> is facilitation of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">C</mi><mi mathvariant="normal">a</mi></mrow><mrow><mn>2</mn><mo>+</mo></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{Ca}^{2+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8873em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Ca</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8873em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span> mobilization from intracellular organellar pools, while DAG in conjunction with <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">C</mi><mi mathvariant="normal">a</mi></mrow><mrow><mn>2</mn><mo>+</mo></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{Ca}^{2+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8873em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Ca</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8873em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span> activates protein kinase C (PKc) which phosphorylates and alters the activity of a number of functional and structural proteins. Cytosolic <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">C</mi><mi mathvariant="normal">a</mi></mrow><mrow><mn>2</mn><mo>+</mo></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{Ca}^{2+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8873em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Ca</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8873em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span> is a veritable messenger: combines with calmodulin (CAM) to activate myosin light chain kinase (MLCK) inducing contraction, and another important regulator calcium-calmodulin protein kinase (CCPK). Several other effectors are regulated by <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">C</mi><mi mathvariant="normal">a</mi></mrow><mrow><mn>2</mn><mo>+</mo></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{Ca}^{2+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8873em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Ca</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8873em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span> in a CAM dependent or CAM- independent manner. Cytosolic <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">C</mi><mi mathvariant="normal">a</mi></mrow><mrow><mn>2</mn><mo>+</mo></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{Ca}^{2+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8873em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Ca</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8873em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span> is recycled by uptake into the endoplasmic reticulum as well as effluxed by membrane <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">C</mi><mi mathvariant="normal">a</mi></mrow><mrow><mn>2</mn><mo>+</mo></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{Ca}^{2+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8873em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Ca</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8873em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span> pump.
cGMP dephosphorylates myosin light chain kinase (MLCK) through PKG and induces relaxation (see Fig. 40.3). This pathway is utilized by glyceryl trinitrate, sod. nitroprusside, etc.
(b) Phospholipase C: IP <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow></mrow><mn>3</mn></msub></mrow><annotation encoding="application/x-tex">{ }_{3}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.4511em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">3</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span>-DAG pathway Activation of phospholipase <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">C</mi><mi>β</mi></msub><mrow><mo fence="true">(</mo><mrow><mi mathvariant="normal">P</mi><mi mathvariant="normal">L</mi><mi mathvariant="normal">c</mi></mrow><mi>β</mi><mo fence="true">)</mo></mrow></mrow><annotation encoding="application/x-tex">\mathrm{C}_{\beta}\left(\mathrm{PLc} \beta\right)</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1.0361em; vertical-align: -0.2861em;"></span><span class="mord"><span class="mord mathrm">C</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3361em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mathnormal mtight" style="margin-right: 0.05278em;">β</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.2861em;"><span></span></span></span></span></span></span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="minner"><span class="mopen delimcenter" style="top: 0em;">(</span><span class="mord"><span class="mord mathrm">PLc</span></span><span class="mord mathnormal" style="margin-right: 0.05278em;">β</span><span class="mclose delimcenter" style="top: 0em;">)</span></span></span></span></span></span> by the activated GTP carrying <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>α</mi></mrow><annotation encoding="application/x-tex">\alpha</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.4306em;"></span><span class="mord mathnormal" style="margin-right: 0.0037em;">α</span></span></span></span></span> subunit of Gq hydrolyses the membrane phospholipid phosphatidyl inositol 4,5-bisphosphate <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo fence="true">(</mo><msub><mrow><mi mathvariant="normal">P</mi><mi mathvariant="normal">I</mi><mi mathvariant="normal">P</mi></mrow><mn>2</mn></msub><mo fence="true">)</mo></mrow><annotation encoding="application/x-tex">\left(\mathrm{PIP}_{2}\right)</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="minner"><span class="mopen delimcenter" style="top: 0em;">(</span><span class="mord"><span class="mord"><span class="mord mathrm">PIP</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mclose delimcenter" style="top: 0em;">)</span></span></span></span></span></span> to generate the second messengers inositol 1,4,5-trisphosphate <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo fence="true">(</mo><msub><mrow><mi mathvariant="normal">I</mi><mi mathvariant="normal">P</mi></mrow><mn>3</mn></msub><mo fence="true">)</mo></mrow><annotation encoding="application/x-tex">\left(\mathrm{IP}_{3}\right)</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="minner"><span class="mopen delimcenter" style="top: 0em;">(</span><span class="mord"><span class="mord"><span class="mord mathrm">IP</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">3</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mclose delimcenter" style="top: 0em;">)</span></span></span></span></span></span> and diacylglycerol (DAG). The <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">I</mi><mi mathvariant="normal">P</mi></mrow><mn>3</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{IP}_{3}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">IP</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">3</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> being water soluble diffuses to the cytosol and mobilizes <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">C</mi><mi mathvariant="normal">a</mi></mrow><mrow><mn>2</mn><mo>+</mo></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{Ca}^{2+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8873em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Ca</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8873em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span> from endoplasmic reticular depots
(Fig. 4.7). The lipophilic DAG remains within the membrane, but recruits protein kinase C (PKc) and activates it with the help of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">C</mi><mi mathvariant="normal">a</mi></mrow><mrow><mn>2</mn><mo>+</mo></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{Ca}^{2+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8873em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Ca</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8873em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span>. The activated PKc phosphorylates many intracellular proteins (depending on the type of effector cell) and mediates various physiological responses. So that it can serve signaling functions, the cytosolic concentration of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">C</mi><mi mathvariant="normal">a</mi></mrow><mrow><mn>2</mn><mo>+</mo></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{Ca}^{2+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8873em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Ca</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8873em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span> is kept very low ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>∼</mo><mn>100</mn><mrow><mi mathvariant="normal">n</mi><mi mathvariant="normal">M</mi></mrow></mrow><annotation encoding="application/x-tex">\sim 100 \mathrm{nM}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.3669em;"></span><span class="mrel">∼</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord">100</span><span class="mord"><span class="mord mathrm">nM</span></span></span></span></span></span> ) by specific pumps located at the plasma membrane and at the endoplasmic reticulum. Triggered by <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">I</mi><mi mathvariant="normal">P</mi></mrow><mn>3</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{IP}_{3}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">IP</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">3</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span>, the released <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">C</mi><mi mathvariant="normal">a</mi></mrow><mrow><mn>2</mn><mo>+</mo></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{Ca}^{2+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8873em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Ca</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8873em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span> (third messenger in this setting) acts as a highly versatile regulator acting</p>
<p>through calmodulin (CAM), PKc and other effectors-mediates/modulates smooth muscle, contraction, glandular secretion/transmitter release, eicosanoid synthesis, neuronal excitability, intracellular movements, membrane function, metabolism, cell proliferation, etc. Signaling in this pathway is terminated by degradation of the second messengers. The <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">I</mi><mi mathvariant="normal">P</mi></mrow><mn>3</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{IP}_{3}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">IP</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">3</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> is dephosphorylated to inositol which is reutilized in the synthesis of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">P</mi><mi mathvariant="normal">I</mi><mi mathvariant="normal">P</mi></mrow><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{PIP}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">PIP</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> (see Fig. 32.1), while DAG is partly converted back to phospholipids, and partly deacylated to arachidonic acid.</p>
<p>Intracellular <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">C</mi><mi mathvariant="normal">a</mi></mrow><mrow><mn>2</mn><mo>+</mo></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{Ca}^{2+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8873em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Ca</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8873em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span> release has been found to occur in waves <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo fence="true">(</mo><msup><mrow><mi mathvariant="normal">C</mi><mi mathvariant="normal">a</mi></mrow><mrow><mn>2</mn><mo>+</mo></mrow></msup></mrow><annotation encoding="application/x-tex">\left(\mathrm{Ca}^{2+}\right.</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1.2373em; vertical-align: -0.35em;"></span><span class="minner"><span class="mopen delimcenter" style="top: 0em;"><span class="delimsizing size1">(</span></span><span class="mord"><span class="mord"><span class="mord mathrm">Ca</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8873em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span><span class="mord mtight">+</span></span></span></span></span></span></span></span></span><span class="mclose nulldelimiter"></span></span></span></span></span></span> mediated <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">C</mi><mi mathvariant="normal">a</mi></mrow><mrow><mn>2</mn><mo>+</mo></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{Ca}^{2+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8873em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Ca</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8873em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span> release from successive pools facilitated by inositol 1, 3, 4, 5-tetrakisphosphate- <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">I</mi><mi mathvariant="normal">P</mi></mrow><mn>3</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{IP}_{3}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">IP</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">3</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> ) and exhibits a variety of agonist and concentration dependent oscillatory patterns. The activation of different effectors may depend on the amplitude and pattern of these oscillations. Thus, the same intracellular messenger can trigger different responses depending on the nature and strength of the extracellular signal.
(c) Channel regulation The activated Gproteins (Gs, Gi, Go) can also open or inhibit ionic channels specific for <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">C</mi><mi mathvariant="normal">a</mi></mrow><mrow><mn>2</mn><mo>+</mo></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{Ca}^{2+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8873em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Ca</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8873em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span> and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">K</mi><mo lspace="0em" rspace="0em">+</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{K}^{+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7713em;"></span><span class="mord"><span class="mord mathrm">K</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.7713em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span>, without the intervention of any second messenger like cAMP or <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">I</mi><mi mathvariant="normal">P</mi></mrow><mn>3</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{IP}_{3}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">IP</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">3</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span>, and bring about hyperpolarization/depolarization/changes in intracellular <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">C</mi><mi mathvariant="normal">a</mi></mrow><mrow><mn>2</mn><mo>+</mo></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{Ca}^{2+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8873em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Ca</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8873em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span> concentration. The Gs opens <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">C</mi><mi mathvariant="normal">a</mi></mrow><mrow><mn>2</mn><mo>+</mo></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{Ca}^{2+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8873em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Ca</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8873em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span> channels in myocardium and skeletal muscles, while Gi and Go open <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">K</mi><mo lspace="0em" rspace="0em">+</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{K}^{+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7713em;"></span><span class="mord"><span class="mord mathrm">K</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.7713em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span>channels in heart and smooth muscle as well as inhibit neuronal <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">C</mi><mi mathvariant="normal">a</mi></mrow><mrow><mn>2</mn><mo>+</mo></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{Ca}^{2+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8873em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Ca</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8873em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span> channels. Direct channel regulation is mostly the function of the <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>β</mi><mi>γ</mi></mrow><annotation encoding="application/x-tex">\beta \gamma</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mord mathnormal" style="margin-right: 0.05278em;">β</span><span class="mord mathnormal" style="margin-right: 0.05556em;">γ</span></span></span></span></span> dimer of the dissociated G protein. Physiological responses like changes in inotropy, chronotropy, transmitter release, neuronal activity and smooth muscle relaxation follow. Receptors found to regulate ionic channels through G-proteins are listed in Table 4.1.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="2-ion-channel-receptors">2. Ion channel receptors<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#2-ion-channel-receptors" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>These cell surface receptors, also called ligand gated ion channels, enclose ion selective channels (for <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">N</mi><mi mathvariant="normal">a</mi></mrow><mo lspace="0em" rspace="0em">+</mo></msup><mo separator="true">,</mo><msup><mi mathvariant="normal">K</mi><mo lspace="0em" rspace="0em">+</mo></msup><mo separator="true">,</mo><msup><mrow><mi mathvariant="normal">C</mi><mi mathvariant="normal">a</mi></mrow><mrow><mn>2</mn><mo>+</mo></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{Na}^{+}, \mathrm{K}^{+}, \mathrm{Ca}^{2+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1.0818em; vertical-align: -0.1944em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Na</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8446em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord"><span class="mord mathrm">K</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.7713em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Ca</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8873em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span> or <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">C</mi><mi mathvariant="normal">l</mi></mrow><mo lspace="0em" rspace="0em">−</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{Cl}^{-}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8557em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Cl</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8557em;"><span style="top: -3.1473em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">−</span></span></span></span></span></span></span></span></span></span></span></span></span>) within their molecules. Agonist binding opens the channel (Fig. 4.4) and causes depolarization/hyperpolarization/changes in cytosolic ionic composition, depending on the ion that flows through. The
nicotinic cholinergic, <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">G</mi><mi mathvariant="normal">A</mi><mi mathvariant="normal">B</mi><mi mathvariant="normal">A</mi></mrow><mi mathvariant="normal">A</mi></msub></mrow><annotation encoding="application/x-tex">\mathrm{GABA}_{\mathrm{A}}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">GABA</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3283em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mathrm mtight">A</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span>, glycine (inhibitory AA), excitatory AA-glutamate (kainate, NMDA and AMPA) and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><msub><mrow><mi mathvariant="normal">H</mi><mi mathvariant="normal">T</mi></mrow><mn>3</mn></msub></mrow><annotation encoding="application/x-tex">5 \mathrm{HT}_{3}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord">5</span><span class="mord"><span class="mord"><span class="mord mathrm">HT</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">3</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> receptors fall in this category, and a large number of clinically useful drugs act through this type of receptors.</p>
<p>The receptor is usually a pentameric protein; all subunits, in addition to large intra- and extracellular segments, generally have four membrane spanning helical domains. The subunits are mostly arranged round the channel like a rosette and the <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>α</mi></mrow><annotation encoding="application/x-tex">\alpha</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.4306em;"></span><span class="mord mathnormal" style="margin-right: 0.0037em;">α</span></span></span></span></span> subunits usually bear the agonist binding sites.</p>
<p>Certain receptor-operated (or ligand-gated) ion channels also have secondary ligands which bind to an allosteric site and modulate the gating of the channel by the primary ligand, e.g. the benzodiazepine receptor modulates <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">G</mi><mi mathvariant="normal">A</mi><mi mathvariant="normal">B</mi><mi mathvariant="normal">A</mi></mrow><mi mathvariant="normal">A</mi></msub></mrow><annotation encoding="application/x-tex">\mathrm{GABA}_{\mathrm{A}}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">GABA</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3283em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mathrm mtight">A</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> gated <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">C</mi><mi mathvariant="normal">l</mi></mrow><mo lspace="0em" rspace="0em">−</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{Cl}^{-}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8557em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Cl</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8557em;"><span style="top: -3.1473em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">−</span></span></span></span></span></span></span></span></span></span></span></span></span>channel.</p>
<p>Thus, in these receptors the agonist directly operates ion channels, without the intervention of any coupling protein or second messenger. The onset and offset of responses through this class of receptors is the fastest (in milliseconds).</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="3-transmembrane-enzyme-linked-receptors">3. Transmembrane enzyme-linked receptors<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#3-transmembrane-enzyme-linked-receptors" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>This class of receptors are utilized primarily by peptide hormones, and are made up of a large extracellular ligand binding domain connected through a single transmembrane helical peptide chain to an intracellular subunit having enzymatic property. The enzyme at the cytosolic side is generally a protein kinase, but can also be guanylyl cyclase in few cases. The commonest protein kinases are the ones which phosphorylate tyrosine residues on the substrate proteins and are called 'receptor tyrosine kinases' (RTKs), see Fig. 4.8. Examples are-insulin, epidermal growth factor (EGF), nerve growth factor (NGF) and many other growth factor receptors. Inhibitors of specific RTKs involved in growth factor signaling are a new class of targeted anticancer drugs. However, the transforming growth factor (TGF) receptor and few others are serine/threonine kinases-</p>
<p><img src="assets/images/image-20251214-fd3c2150.jpeg" alt="img-28.jpeg"></p>
<p>Fig. 4.8: Model of receptor tyrosine kinase, an enzymelinked receptor
On binding the peptide hormone to the extracellular domains, the monomeric receptors move laterally in the membrane and form dimers. Dimerization activates tyrosine-kinase (RTK) activity of the intracellular domains so that they phosphorylate tyrosine (t) residues on each other, as well as on several <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">S</mi><mi mathvariant="normal">H</mi></mrow><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{SH}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">SH</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> domain substrate proteins <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo fence="true">(</mo><msub><mrow><mi mathvariant="normal">S</mi><mi mathvariant="normal">H</mi></mrow><mn>2</mn></msub><mo>−</mo><mrow><mi mathvariant="normal">P</mi><mi mathvariant="normal">r</mi></mrow><mo fence="true">)</mo></mrow><annotation encoding="application/x-tex">\left(\mathrm{SH}_{2}-\mathrm{Pr}\right)</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="minner"><span class="mopen delimcenter" style="top: 0em;">(</span><span class="mord"><span class="mord"><span class="mord mathrm">SH</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mord"><span class="mord mathrm">Pr</span></span><span class="mclose delimcenter" style="top: 0em;">)</span></span></span></span></span></span>. The phosphorylated substrate proteins then perform downstream signaling function.
<img src="assets/images/image-20251214-a1d25301.jpeg" alt="img-29.jpeg"></p>
<p>Fig. 4.9: Model of transmembrane JAK-STAT binding receptor
The intracellular domain of these receptors lacks intrinsic protein kinase activity. Cytokines/hormones binding to the extracellular domain induce receptor dimerization which activates the intracellular domain to bind free moving JAK (Janus Kinase) molecules. The activated JAK phosphorylate tyrosine residues on the receptor which then binds another protein STAT (signal transducer and activator of transcription). Tyrosine residues of STAT also get phosphorylated by JAK. The phosphorylated STAT dimerize, dissociate from the receptor and move to the nucleus to regulate transcription of target genes.
which phosphorylate serine/threonine residues of the target proteins.</p>
<p>In the unliganded monomeric state, the kinase remains inactive. Hormone binding induces dimerization of receptor molecules, brings about conformation changes which activate the kinase to autophosphorylate tyrosine residues on each other, increasing their affinity for binding substrate proteins which have <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">S</mi><mi mathvariant="normal">H</mi></mrow><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{SH}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">SH</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> domains. These are then phosphorylated and released to carry forward the cascade of phosphorylations leading to the response.</p>
<p>A large number of intracellular signaling proteins have <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">S</mi><mi mathvariant="normal">H</mi></mrow><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{SH}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">SH</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> domains. Thus, by controlling phosphorylation of key enzymes, ion channels, transporters, etc. the RTKs are able to regulate diverse cellular functions including metabolic reactions, cell growth and differentiation. One of the <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">S</mi><mi mathvariant="normal">H</mi></mrow><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{SH}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">SH</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> domain enzymes is phospholipase <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">c</mi><mi>γ</mi><mrow><mo fence="true">(</mo><msub><mrow><mi mathvariant="normal">P</mi><mi mathvariant="normal">L</mi><mi mathvariant="normal">c</mi></mrow><mi>γ</mi></msub><mo fence="true">)</mo></mrow></mrow><annotation encoding="application/x-tex">\mathrm{c} \gamma\left(\mathrm{PLc}_{\gamma}\right)</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1.0361em; vertical-align: -0.2861em;"></span><span class="mord mathrm">c</span><span class="mord mathnormal" style="margin-right: 0.05556em;">γ</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="minner"><span class="mopen delimcenter" style="top: 0em;">(</span><span class="mord"><span class="mord"><span class="mord mathrm">PLc</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.1514em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mathnormal mtight" style="margin-right: 0.05556em;">γ</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.2861em;"><span></span></span></span></span></span></span><span class="mclose delimcenter" style="top: 0em;">)</span></span></span></span></span></span> which is activated by certain RTKs, and which, like <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mrow><mi mathvariant="normal">P</mi><mi mathvariant="normal">L</mi><mi mathvariant="normal">c</mi></mrow><mi>β</mi></mrow><annotation encoding="application/x-tex">\mathrm{PLc} \beta</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mord"><span class="mord mathrm">PLc</span></span><span class="mord mathnormal" style="margin-right: 0.05278em;">β</span></span></span></span></span>, generates <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">I</mi><mi mathvariant="normal">P</mi></mrow><mn>3</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{IP}_{3}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">IP</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">3</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> and DAG as second messengers for response effectuation.</p>
<p>The transmembrane enzyme-linked receptors transduce responses in a matter of few minutes to few hours.</p>
<p>Another feature of this class of receptors is that their dimerization also promotes receptor internalization, degradation in lysosomes and down regulation if activation is fast enough. Mutations interfering with such down-regulation contribute to development of certain malignancies.</p>
<p>In place of protein kinase the enzyme can also be guanylyl cyclase (GC), as in the case of atrial natriuretic peptide (ANP). Agonist activation of the receptor generates cGMP in the cytosol as a second messenger, which in turn activates cGMP-dependent protein kinase <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo fence="true">(</mo><msub><mrow><mi mathvariant="normal">P</mi><mi mathvariant="normal">K</mi></mrow><mi mathvariant="normal">G</mi></msub><mo fence="true">)</mo></mrow><annotation encoding="application/x-tex">\left(\mathrm{PK}_{\mathrm{G}}\right)</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="minner"><span class="mopen delimcenter" style="top: 0em;">(</span><span class="mord"><span class="mord"><span class="mord mathrm">PK</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3283em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mathrm mtight">G</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mclose delimcenter" style="top: 0em;">)</span></span></span></span></span></span> and modulates cellular activity.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="4-transmembrane-jak-stat-binding-receptors">4. Transmembrane JAK-STAT binding receptors<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#4-transmembrane-jak-stat-binding-receptors" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>These receptors differ from RTKs in not having any intrinsic catalytic domain. Agonist-induced dimerization alters the intracellular domain</p>
<p>conformation to increase its affinity for a cytosolic tyrosine protein kinase JAK (Janus Kinase). On binding, JAK gets activated and phosphorylates tyrosine residues of the receptor, which now bind another free moving protein STAT (signal transducer and activator of transcription). This is also phosphorylated by JAK. Pairs of phosphorylated STAT dimerize and translocate to the nucleus to regulate gene transcription resulting in a biological response. Many cytokines, growth hormone, prolactin, interferons, etc. act through this type of receptor.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="5-receptors-regulating-gene-expression-transcription-factors-nuclear-receptors">5. Receptors regulating gene expression (Transcription factors, Nuclear receptors)<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#5-receptors-regulating-gene-expression-transcription-factors-nuclear-receptors" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>In contrast to the above 4 classes of receptors, these are intracellular (cytoplasmic or nuclear) soluble proteins which respond to lipid soluble chemical messengers that penetrate the cell (Fig. 4.10). The receptor protein (specific for each hormone/regulator) is inherently capable of binding to specific genes, but its attached proteins HSP-90 and may be some others prevent it from adopting the configuration needed for binding to DNA. When the hormone binds near the carboxy terminus of the receptor, the restricting proteins (HSP-90, etc.) are released, the receptor dimerizes and the DNA binding regulatory segment located in the middle of the molecule folds into the functionally active configuration. The liganded receptor dimer moves to the nucleus and binds other co-activator/co-repressor proteins which have a modulatory influence on its capacity to alter gene function. The whole complex then attaches to specific DNA sequences (hormone response elements) of the target genes and facilitates or represses their expression so that specific mRNA is synthesized/repressed on the template of the gene. This mRNA moves to the ribosomes and directs synthesis of specific proteins which regulate activity of the target cells.</p>
<p>All steroidal hormones (glucocorticoids, mineralocorticoids, androgens, estrogens, progesterone), thyroxine, vit D and vit A
function in this manner. Different steroidal hormones affect different target cells and produce different effects because each one binds to its own receptor and directs a unique pattern of synthesis of specific proteins. The specificity as to which hormone will be bound is provided by the hormone binding domain, while that as to which gene will be activated or repressed is a function of the DNA binding/N-terminus domain. Different ligands of the same nuclear receptor have been found to induce ligand-specific conformations of the receptor so that different combinations of co-activators and co-repressors may be bound in different target tissues, e.g. selective estrogen receptor modulators (SERMs) tamoxifen and raloxifene have differing patterns of action on various estrogenic target organs. Chimeric receptors have also been produced which respond to one hormone, but produce the effects of the other hormone.</p>
<p>This transduction mechanism is the slowest in its time course of action (takes hours) because adequate quantity of the effector protein will have to be produced before the response occurs. The effects also generally out last the signal (hormone), because majority of the generated effector proteins have slow turnover, and persist in the body even after the hormone has been eliminated.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="regulation-of-receptors">Regulation of receptors<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#regulation-of-receptors" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Receptors exist in a dynamic state; their density and efficacy to elicit the response is subject to regulation by the level of on-going activity, feedback from their own signal output and other physiopathological influences, e.g. estrogens increase the density of oxytocin receptors on the myometrium. The sensitivity of uterus to contractile action of oxytocin increases progressively during the third trimester of pregnancy, especially near term. In tonically active systems, prolonged deprivation of the agonist (by denervation or continued use of an antagonist or a drug which reduces input) results in supersensitivity of the receptor as well as the effector system to the agonist. This has</p>
<p><img src="assets/images/image-20251214-1aa09722.jpeg" alt="img-30.jpeg"></p>
<p>Fig. 4.10: Operational scheme of intracellular (glucocorticoid) receptor
The glucocorticoid (G) penetrates the cell membrane and binds to the glucocorticoid receptor (GR) protein that normally resides in the cytoplasm in association with heat shock protein 90 (HSP90) <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>±</mo></mrow><annotation encoding="application/x-tex">\pm</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">±</span></span></span></span></span> other proteins. The GR has a steroid binding domain near the carboxy terminus and a mid-region DNA binding domain joined by a 'hinge region'. The DNA binding domain has two 'zinc fingers', each made up of a loop of amino acids with chelated zinc ion. Binding of the steroid to GR dissociates the complexed proteins (HSP90, etc) removing their inhibitory influence on it. A dimerization region that overlaps the steroid binding domain is exposed, promoting dimerization of the occupied receptor. The steroid bound receptor dimer translocates to the nucleus, binds coactivator/corepressor proteins and interacts with specific DNA sequences called 'glucocorticoid responsive elements' (GREs) within the regulatory region of appropriate genes. The expression of these genes is consequently altered resulting in promotion (or suppression) of their transcription. The specific mRNA thus produced is directed to the ribosome where the message is translated into a specific pattern of protein synthesis, which inturn modifies cell function.</p>
<p>clinical relevance in clonidine/CNS depressant/ opioid withdrawal syndromes, sudden discontinuation of propranolol in angina pectoris, etc. The mechanisms involved may be unmasking of receptors or their proliferation (up regulation) or accentuation of signal amplification by the transducer.</p>
<p>Conversely, continued/intense receptor stimulation causes desensitization or refractoriness: the receptor becomes less efficient in transducing response to the agonist. This can be easily demonstrated experimentally (Fig. 4.11); clinical examples are bronchial asthma patients treated continuously with <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>β</mi></mrow><annotation encoding="application/x-tex">\beta</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mord mathnormal" style="margin-right: 0.05278em;">β</span></span></span></span></span> adrenergic agonists and parkinsonian patients treated with high doses of levodopa gradually become less responsive. The changes may be brought about by:
(i) Masking or internalization of the receptor (it becomes inaccessible to the agonist) or impaired coupling of the transducer to the receptor. In this case refractoriness develops as well as fades quickly.</p>
<p>In the case of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>β</mi></mrow><annotation encoding="application/x-tex">\beta</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mord mathnormal" style="margin-right: 0.05278em;">β</span></span></span></span></span> adrenergic receptor, it has been found that high rate of agonist binding promotes phosphorylation of its serine residues near the intracellular carboxy
<img src="assets/images/image-20251214-22271616.jpeg" alt="img-31.jpeg"></p>
<p>Fig. 4.11: Illustration of the phenomenon of desensitization
Contractile responses of frog's rectus abdominis muscle to acetylcholine. Note that shortly after exposure to a high (100 fold) dose of the agonist, the response is markedly attenuated, but is regained if sufficient time is allowed to elapse.
terminus by an enzyme <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>β</mi></mrow><annotation encoding="application/x-tex">\beta</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mord mathnormal" style="margin-right: 0.05278em;">β</span></span></span></span></span> adrenergic receptor kinase ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>β</mi></mrow><annotation encoding="application/x-tex">\beta</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mord mathnormal" style="margin-right: 0.05278em;">β</span></span></span></span></span> ARK), allowing it to bind a protein called <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>β</mi></mrow><annotation encoding="application/x-tex">\beta</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mord mathnormal" style="margin-right: 0.05278em;">β</span></span></span></span></span>-arrestin ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>β</mi></mrow><annotation encoding="application/x-tex">\beta</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mord mathnormal" style="margin-right: 0.05278em;">β</span></span></span></span></span>-arr) which hinders its interaction with <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mrow><mi mathvariant="normal">G</mi><mi mathvariant="normal">s</mi></mrow><mo>→</mo></mrow><annotation encoding="application/x-tex">\mathrm{Gs} \rightarrow</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord"><span class="mord mathrm">Gs</span></span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">→</span></span></span></span></span> receptor transduction is impaired. When the <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>β</mi></mrow><annotation encoding="application/x-tex">\beta</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mord mathnormal" style="margin-right: 0.05278em;">β</span></span></span></span></span>-agonist is removed, the serine residues are dephosphorylated by cellular phosphatases, and receptor mediated activation of Gs is restored. However, in case of excessive/prolonged activation, the phosphorylated <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>β</mi></mrow><annotation encoding="application/x-tex">\beta</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mord mathnormal" style="margin-right: 0.05278em;">β</span></span></span></span></span> adrenergic GPCR is internalized and largely moved to the lysosomes, where they are degraded, rather than returning back to the surface membrane. This results in receptor down regulation.
(ii) Decreased synthesis/increased destruction of the receptor (down regulation): refractoriness develops over weeks or months and recedes slowly. Receptor down regulation is particularly exhibited by the tyrosine kinase receptors and some GPCRs. Similarly, the transducer and effector proteins are also up or down regulated.</p>
<p>Some times response to all agonists which act through different receptors but produce the same overt effect (e.g. histamine and acetylcholine both contract intestinal smooth muscle) is decreased by exposure to any one of these agonists (heterologous desensitization), showing that mechanisms of response effectuation have become less efficient. However, often desensitization is limited to agonists of the same receptor that is being repeatedly activated (homologous desensitization).</p>
<p>Both homologous and heterologous desensitization has been observed in the case of GPCRs. The BARK <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>β</mi></mrow><annotation encoding="application/x-tex">\beta</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mord mathnormal" style="margin-right: 0.05278em;">β</span></span></span></span></span>-arrestin mechanism described above produces homologous desensitization. The GPCRs transduce many responses by activating <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">P</mi><mi mathvariant="normal">K</mi></mrow><mi mathvariant="normal">A</mi></msub></mrow><annotation encoding="application/x-tex">\mathrm{PK}_{\mathrm{A}}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">PK</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3283em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mathrm mtight">A</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">P</mi><mi mathvariant="normal">K</mi></mrow><mi mathvariant="normal">C</mi></msub></mrow><annotation encoding="application/x-tex">\mathrm{PK}_{\mathrm{C}}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">PK</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3283em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mathrm mtight">C</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span>. These kinases phosphorylate many GPCRs rather nonselectively (at a site different from that of BARK) and hinder their interaction with G-proteins, resulting in heterologous desensitization.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="functions-of-receptors">Functions of receptors<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#functions-of-receptors" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>These can be summarized as:
(a) To propagate regulatory signals from outside to inside the effector cell when the molecular species carrying the signal cannot itself penetrate the cell membrane.
(b) To amplify the signal.
(c) To integrate various extracellular and intracellular regulatory signals.
(d) To adapt to short term and long term changes in the regulatory melieu and maintain homeostasis.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="nonreceptor-mediated-drug-action">Nonreceptor-mediated drug action<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#nonreceptor-mediated-drug-action" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>This refers to drugs which do not act by binding to specific regulatory macromolecules. Drug action by purely physical or chemical means, interactions with small molecules or ions (antacids, chelating agents, cholestyramine, etc.), as well as direct interaction with enzymes, ionic channels and transporters has already been described. In addition, there are drugs like alkylating agents which react covalently with several critical biomolecules, especially nucleic acids, and have cytotoxic property useful in the treatment of cancer. Another important class of drugs are the antimetabolites (purine/pyrimidine analogues) which lead to production of nonfunctional or dysfunctional cellular components that exert antineoplastic, antiviral and immunosuppressant activity.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="dose-response-relationship">DOSE-RESPONSE RELATIONSHIP<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#dose-response-relationship" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>When a drug is administered systemically, the dose-response relationship has two components: dose-plasma concentration relationship and plasma concentration-response relationship. The former is determined by pharmacokinetic considerations and ordinarily, descriptions of dose-response relationship refer to the latter, which can be more easily studied in vitro.</p>
<p>Generally, the intensity of response increases with increase in dose (or more precisely concentration at the receptor), but at higher doses, the increase in response progressively becomes less marked and the dose-response curve is a rectangular hyperbola (Fig. 4.12). This is because drug-receptor interaction obeys law of mass action, which is described by the equation (3) and is applicable to interaction between any two molecules having a given affinity for each other.</p>
<div class="math math-display"><span class="katex-display"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML" display="block"><semantics><mrow><mi mathvariant="normal">E</mi><mo>=</mo><mfrac><mrow><mi mathvariant="normal">E</mi><mi>m</mi><mi>a</mi><mi>x</mi><mo>×</mo><mo stretchy="false">[</mo><mi mathvariant="normal">D</mi><mo stretchy="false">]</mo></mrow><mrow><msub><mi mathvariant="normal">K</mi><mi mathvariant="normal">D</mi></msub><mo>+</mo><mo stretchy="false">[</mo><mi mathvariant="normal">D</mi><mo stretchy="false">]</mo></mrow></mfrac></mrow><annotation encoding="application/x-tex">\mathrm{E}=\frac{\mathrm{E} m a x \times[\mathrm{D}]}{\mathrm{K}_{\mathrm{D}}+[\mathrm{D}]}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathrm">E</span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">=</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 2.363em; vertical-align: -0.936em;"></span><span class="mord"><span class="mopen nulldelimiter"></span><span class="mfrac"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 1.427em;"><span style="top: -2.314em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">K</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3283em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mathrm mtight">D</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">+</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mopen">[</span><span class="mord mathrm">D</span><span class="mclose">]</span></span></span><span style="top: -3.23em;"><span class="pstrut" style="height: 3em;"></span><span class="frac-line" style="border-bottom-width: 0.04em;"></span></span><span style="top: -3.677em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="mord mathrm">E</span><span class="mord mathnormal">ma</span><span class="mord mathnormal">x</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">×</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mopen">[</span><span class="mord mathrm">D</span><span class="mclose">]</span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.936em;"><span></span></span></span></span></span><span class="mclose nulldelimiter"></span></span></span></span></span></span></div>
<p>Where E is the observed effect at a dose [D] of the drug, Emax is the maximal response, <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi>K</mi><mi>D</mi></msub></mrow><annotation encoding="application/x-tex">K_{D}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.07153em;">K</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3283em;"><span style="top: -2.55em; margin-left: -0.0715em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mathnormal mtight" style="margin-right: 0.02778em;">D</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> is the dissociation constant of the drug-receptor
<img src="assets/images/image-20251214-c0a682fc.jpeg" alt="img-32.jpeg"></p>
<p>Fig. 4.12: Dose-response and log dose-response curves
complex, which is a measure of the affinity between the two, and is equal to the dose of the drug at which half maximal response is produced. If the dose is plotted on a logarithmic scale, the curve becomes sigmoid and a linear relationship between log of dose and the response is seen in the intermediate ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>30</mn><mo>−</mo><mn>70</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">30-70 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">30</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">70%</span></span></span></span></span> response) zone, as can be predicted from equation (3). This is not peculiar to drugs. In fact all stimuli are graded biologically by the fractional change in stimulus intensity, e.g. 1 kg and 2 kg weights held in two hands can be easily differentiated, but not 10 kg and 11 kg weights. Though the absolute difference in both cases remains 1 kg , there is a <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>100</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">100 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">100%</span></span></span></span></span> fractional change in the former case but only <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>10</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">10 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">10%</span></span></span></span></span> change in the latter case. In other words, response is proportional to an exponential function (log) of the dose.
Other advantages of plotting log dose-response curves (DRC) are:</p>
<ul>
<li>A wide range of drug doses can be easily displayed on a graph.</li>
<li>Comparison between agonists and study of antagonists becomes easier.
The log dose-response curve (DRC) can be characterized by its shape (slope and maxima) and position on the dose axis.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="drug-potency-and-efficacy">Drug potency and efficacy<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#drug-potency-and-efficacy" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>The position of DRC on the dose axis is the index of drug potency which refers to the</p>
<p>amount of drug needed to produce a certain response. A DRC positioned rightward indicates lower potency (Fig. 4.13). Relative potency is often more meaningful than absolute potency, and is generally defined by comparing the dose (concentration) of the two agonists at which they elicit half maximal response <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo fence="true">(</mo><msub><mrow><mi mathvariant="normal">E</mi><mi mathvariant="normal">C</mi></mrow><mn>50</mn></msub><mo fence="true">)</mo></mrow><annotation encoding="application/x-tex">\left(\mathrm{EC}_{50}\right)</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="minner"><span class="mopen delimcenter" style="top: 0em;">(</span><span class="mord"><span class="mord"><span class="mord mathrm">EC</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">50</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mclose delimcenter" style="top: 0em;">)</span></span></span></span></span></span>. Thus, if 10 mg of morphine <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>=</mo><mn>100</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">=100 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.3669em;"></span><span class="mrel">=</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">100</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span> of pethidine as analgesic, morphine is 10 times more potent than pethidine. However, a higher potency, in itself, does not confer clinical superiority unless the potency for therapeutic effect is selectively increased over potency for adverse effect. Drug potency is clearly a factor in choosing the dose of a drug.</p>
<p>The upper limit of DRC is the index of drug efficacy and refers to the maximal response that can be elicited by the drug, e.g. morphine produces a degree of analgesia not obtainable with any dose of aspirin-morphine is more efficacious than aspirin. Efficacy is a more decisive factor in the choice of a drug.
<img src="assets/images/image-20251214-6d8fa740.jpeg" alt="img-33.jpeg"></p>
<p>Fig. 4.13: Illustration of drug potency and drug efficacy. Dose-response curve of four drugs producing the same qualitative effect
Note:
Drug B is less potent but equally efficacious as drug <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>A</mi></mrow><annotation encoding="application/x-tex">A</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal">A</span></span></span></span></span>. Drug <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>C</mi></mrow><annotation encoding="application/x-tex">C</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.07153em;">C</span></span></span></span></span> is less potent and less efficacious than drug <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>A</mi></mrow><annotation encoding="application/x-tex">A</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal">A</span></span></span></span></span>. Drug D is more potent than drugs <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>A</mi><mo separator="true">,</mo><mi>B</mi><mo separator="true">,</mo><mi mathvariant="normal">&amp;</mi><mi>C</mi></mrow><annotation encoding="application/x-tex">A, B, \&amp; C</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mord mathnormal">A</span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord mathnormal" style="margin-right: 0.05017em;">B</span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord">&amp;</span><span class="mord mathnormal" style="margin-right: 0.07153em;">C</span></span></span></span></span>, but less effica -cious than drugs <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>A</mi><mi mathvariant="normal">&amp;</mi><mi>B</mi></mrow><annotation encoding="application/x-tex">A \&amp; B</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6944em;"></span><span class="mord mathnormal">A</span><span class="mord">&amp;</span><span class="mord mathnormal" style="margin-right: 0.05017em;">B</span></span></span></span></span>, and equally efficacious as drug <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>C</mi></mrow><annotation encoding="application/x-tex">C</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.07153em;">C</span></span></span></span></span>.</p>
<p>Often the terms 'drug potency' and 'drug efficacy' are used interchangeably, but these are not synonymous and refer to different characteristics of the drug. The two can vary independently:
(a) Aspirin is less potent as well as less efficacious analgesic than morphine.
(b) Pethidine is less potent but equally efficacious analgesic as morphine.
(c) Furosemide is less potent but more efficacious diuretic than metolazone.
(d) Diazepam is more potent but less efficacious CNS depressant than pentobarbitone.</p>
<p>Depending on the type of drug, both higher efficacy (as in the case of furosemide confering utility for mobilizing edema fluid and in renal failure) or lower efficacy (as in the case of diazepam confering safety in over-dose) could be clinically advantageous.</p>
<p>The slope of the DRC is also important. A steep slope indicates that a moderate increase in dose will markedly increase the response (dose needs individualization), while a flat one implies that little increase in response will occur over a wide dose range (standard doses can be given to most patients). Hydralazine has a steep, while hydrochlorothiazide has a flat DRC of antihypertensive effect (Fig. 4.14).
<img src="assets/images/image-20251214-1bd01ef1.jpeg" alt="img-34.jpeg"></p>
<p>Fig. 4.14: Steep and flat dose-response curves illustrated by antihypertensive effect of hydralazine and hydrochlorothiazide</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="therapeutic-efficacy">Therapeutic efficacy<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#therapeutic-efficacy" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>The 'therapeutic efficacy' or 'clinical effectiveness' is a composite attribute of a drug different from the foregoing pharmacological description of 'potency' and 'efficacy'. It depends not only on the relative potency and efficacy of the drug, but on many pharmacokinetic and pathophysiological variables as well. It is often expressed in terms of (a) degree of benefit/relief afforded by the drug (in the recommended dose range) i.e. graded dose-response relationship. For example, the degree of relief in parkinsonian symptoms afforded by levodopa-carbidopa is much greater than that possible with trihexyphenidyl: the former has higher therapeutic efficacy than the latter.</p>
<p>The other method of expressing therapeutic efficacy is in terms of (b) success rate in achieving a defined therapeutic end point, i.e. quantal dose-response relationship, e.g. an antibiotic which cures <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>95</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">95 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">95%</span></span></span></span></span> cases of gonorrhoea is a more efficacious antigonococcal drug than one which cures only <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>75</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">75 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">75%</span></span></span></span></span> patients. Similarly, a drug which makes a higher percentage of epileptic patients totally seizure free than another drug, is the more therapeutically effective antiepileptic.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="drug-selectivity">Drug selectivity<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#drug-selectivity" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Drugs seldom produce just one action: the DRCs for different effects of a drug may be different. The extent of separation of DRCs of a drug for different effects is a measure of its selectivity, e.g. the DRCs for bronchodilatation and cardiac stimulation (Fig. 4.15) are quite similar in case of isoprenaline, but far apart in case of salbutamol-the latter is a more selective bronchodilator drug.</p>
<p>The gap between the therapeutic effect DRC and the adverse effect DRC defines the safety margin or the therapeutic index of a drug. In experimental animals, therapeutic index is often calculated as:
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mtable rowspacing="0.25em" columnalign="right left" columnspacing="0em"><mtr><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow></mrow></mstyle></mtd><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow><mrow></mrow><mtext>&nbsp;Therapeutic&nbsp;index&nbsp;</mtext><mo>=</mo><mfrac><mtext>&nbsp;median&nbsp;lethal&nbsp;dose&nbsp;</mtext><mtext>&nbsp;median&nbsp;effective&nbsp;dose&nbsp;</mtext></mfrac></mrow></mstyle></mtd></mtr></mtable><annotation encoding="application/x-tex">\begin{aligned} &amp; \text { Therapeutic index }=\frac{\text { median lethal dose }}{\text { median effective dose }} \end{aligned}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 2.3574em; vertical-align: -0.9287em;"></span><span class="mord"><span class="mtable"><span class="col-align-r"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 1.4287em;"><span style="top: -3.4287em;"><span class="pstrut" style="height: 3.3714em;"></span><span class="mord"></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.9287em;"><span></span></span></span></span></span><span class="col-align-l"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 1.4287em;"><span style="top: -3.4287em;"><span class="pstrut" style="height: 3.3714em;"></span><span class="mord"><span class="mord"></span><span class="mord text"><span class="mord">&nbsp;Therapeutic&nbsp;index&nbsp;</span></span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">=</span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mord"><span class="mopen nulldelimiter"></span><span class="mfrac"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 1.3714em;"><span style="top: -2.314em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="mord text"><span class="mord">&nbsp;median&nbsp;effective&nbsp;dose&nbsp;</span></span></span></span><span style="top: -3.23em;"><span class="pstrut" style="height: 3em;"></span><span class="frac-line" style="border-bottom-width: 0.04em;"></span></span><span style="top: -3.677em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="mord text"><span class="mord">&nbsp;median&nbsp;lethal&nbsp;dose&nbsp;</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.686em;"><span></span></span></span></span></span><span class="mclose nulldelimiter"></span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.9287em;"><span></span></span></span></span></span></span></span></span></span></span></span>
<img src="assets/images/image-20251214-4f759fd0.jpeg" alt="img-35.jpeg"></p>
<p>Fig. 4.15: Illustration of drug selectivity
Log dose-response curves of salbutamol for bronchodilatation (A) and cardiac stimulation (D)
Log dose-response curves of isoprenaline for bronchodilatation (B) and cardiac stimulation (C)</p>
<div class="math math-display"><span class="katex-display"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML" display="block"><semantics><mrow><mtext>&nbsp;or&nbsp;</mtext><mfrac><mrow><mi>L</mi><msub><mi>D</mi><mn>50</mn></msub></mrow><mrow><mi>E</mi><msub><mi>D</mi><mn>50</mn></msub></mrow></mfrac></mrow><annotation encoding="application/x-tex">\text { or } \frac{L D_{50}}{E D_{50}}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 2.1963em; vertical-align: -0.836em;"></span><span class="mord text"><span class="mord">&nbsp;or&nbsp;</span></span><span class="mord"><span class="mopen nulldelimiter"></span><span class="mfrac"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 1.3603em;"><span style="top: -2.314em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.05764em;">E</span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.02778em;">D</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.0278em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">50</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span><span style="top: -3.23em;"><span class="pstrut" style="height: 3em;"></span><span class="frac-line" style="border-bottom-width: 0.04em;"></span></span><span style="top: -3.677em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="mord mathnormal">L</span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.02778em;">D</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.0278em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">50</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.836em;"><span></span></span></span></span></span><span class="mclose nulldelimiter"></span></span></span></span></span></span></div>
<p>where: Median effective dose <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo fence="true">(</mo><msub><mrow><mi mathvariant="normal">E</mi><mi mathvariant="normal">D</mi></mrow><mn>50</mn></msub><mo fence="true">)</mo></mrow><annotation encoding="application/x-tex">\left(\mathrm{ED}_{50}\right)</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="minner"><span class="mopen delimcenter" style="top: 0em;">(</span><span class="mord"><span class="mord"><span class="mord mathrm">ED</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">50</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mclose delimcenter" style="top: 0em;">)</span></span></span></span></span></span> is the dose which produces the specified effect in <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>50</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">50 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">50%</span></span></span></span></span> individuals and median lethal dose <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo fence="true">(</mo><msub><mrow><mi mathvariant="normal">L</mi><mi mathvariant="normal">D</mi></mrow><mn>50</mn></msub><mo fence="true">)</mo></mrow><annotation encoding="application/x-tex">\left(\mathrm{LD}_{50}\right)</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="minner"><span class="mopen delimcenter" style="top: 0em;">(</span><span class="mord"><span class="mord"><span class="mord mathrm">LD</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">50</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mclose delimcenter" style="top: 0em;">)</span></span></span></span></span></span> is the dose which kills <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>50</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">50 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">50%</span></span></span></span></span> of the recipients.</p>
<p>But this is irrelevant in the clinical set up where the therapeutic range, also called the 'therapeutic window' is bounded by the dose which produces minimal therapeutic effect and the dose which produces maximal acceptable adverse effect (Fig. 4.16). Because of individual variability, the effective dose for some subjects may be toxic for others; defining the therapeutic range for many drugs is a challenging task. A drug may be capable of inducing a higher therapeutic response (have higher efficacy) but development of intolerable adverse effects may preclude use of higher doses, e.g. prednisolone in bronchial asthma.
Risk-benefit ratio This term is very frequently used, and conveys a judgement on the estimated harm (adverse effects, cost, inconvenience) vs expected advantages (relief of symptoms, cure, reduction of complications/mortality, improvement in quality of life). A drug should be</p>
<p><img src="assets/images/image-20251214-082167ff.jpeg" alt="img-36.jpeg"></p>
<p>Fig. 4.16: Illustrative dose-response curves for therapeutic effect and adverse effect of the same drug
prescribed only when the benefits outweigh the risks. However, risk-benefit ratio can hardly ever be accurately measured for each instance of drug use, because 'risk' is the probability of harm; and harm has to be qualified by its nature, quantum, time-course (transient to lifelong) as well as the value that the particular patient attaches to it. None of these can be precisely ascertained beforehand in an individual patient. As such, the physician has to rely on data from use of drugs in large populations (pharmacoepidemiology) and his own experience of the drug and the patient.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="drug-specificity">Drug specificity<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#drug-specificity" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Specificity of a drug refers to the range of actions produced by it. Certain drugs produce just one or a limited number of actions, while others have widespread effects on many organs of the body. Specificity is governed by:
(a) whether a drug acts on a single receptor/ target or on many targets, and
(b) how widely the target is distributed in the body.
Omeprazole (and other proton pump inhibitors) is an example of a highly specific drug. The singular perceptible action in therapeutic doses is inhibition of gastric acid secretion,
because it acts only on one target molecule <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">H</mi><mo lspace="0em" rspace="0em">+</mo></msup><msup><mi mathvariant="normal">K</mi><mo lspace="0em" rspace="0em">+</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{H}^{+} \mathrm{K}^{+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7713em;"></span><span class="mord"><span class="mord mathrm">H</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.7713em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span><span class="mord"><span class="mord mathrm">K</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.7713em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span>ATPase (proton pump) which is localized to the gastric parietal cells. An example of a drug acting on multiple targets is chlorpromazine which has antagonistic action on dopamine D2, <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>α</mi></mrow><annotation encoding="application/x-tex">\alpha</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.4306em;"></span><span class="mord mathnormal" style="margin-right: 0.0037em;">α</span></span></span></span></span>-adrenergic, muscarinic cholinergic, histamine <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">H</mi><mn>1</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{H}_{1}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">H</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> and some <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mo>−</mo><mrow><mi mathvariant="normal">H</mi><mi mathvariant="normal">T</mi></mrow></mrow><annotation encoding="application/x-tex">5-\mathrm{HT}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord"><span class="mord mathrm">HT</span></span></span></span></span></span> receptors. It also has <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">N</mi><mi mathvariant="normal">a</mi></mrow><mo lspace="0em" rspace="0em">+</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{Na}^{+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8446em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Na</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8446em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span>channel blocking action. As a result, it produces a wide range of actions. Another case is dexamethasone which is an agonist only of glucocorticoid receptor, but produces effects involving many organs and tissues, because the glucocorticoid receptor is expressed by practically every cell of the body. Drugs with all grades of specificity are available.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="drug-synergism-and-antagonism">DRUG SYNERGISM AND ANTAGONISM<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#drug-synergism-and-antagonism" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>When two or more drugs are given simultaneously or in quick succession, they may be either indifferent to each other or exhibit synergism or antagonism. The interaction may take place at pharmacokinetic level (see Ch. 2 and 3) or at pharmacodynamic level.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="synergism">SYNERGISM<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#synergism" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>(Greek: Syn-together; ergon—work)
When the action of one drug is facilitated or increased by the other, they are said to be synergistic. In a synergistic pair, both the drugs can have action in the same direction or given alone one may be inactive but still enhance the action of the other when given together. Synergism can be:
(a) Additive The effect of the two drugs is in the same direction and simply adds up: effect of drugs <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">A</mi><mo>+</mo><mi mathvariant="normal">B</mi><mo>=</mo></mrow><annotation encoding="application/x-tex">\mathrm{A}+\mathrm{B}=</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7667em; vertical-align: -0.0833em;"></span><span class="mord mathrm">A</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">+</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathrm">B</span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">=</span></span></span></span></span> effect of drug <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">A</mi><mo>+</mo></mrow><annotation encoding="application/x-tex">\mathrm{A}+</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7667em; vertical-align: -0.0833em;"></span><span class="mord mathrm">A</span><span class="mord">+</span></span></span></span></span> effect of drug B</p>
<p>Side effects of the components of an additive pair may be different-do not add up. Thus, the combination is better tolerated than higher dose of one component.</p>
<table><thead><tr><th style="text-align: left;">Additive drug combinations</th><th style="text-align: left;"></th></tr></thead><tbody><tr><td style="text-align: left;">Aspirin + paracetamol</td><td style="text-align: left;">as analgesic/antipyretic</td></tr><tr><td style="text-align: left;">Nitrous oxide + halothane</td><td style="text-align: left;">as general anaesthetic</td></tr><tr><td style="text-align: left;">Amlodipine + atenolol</td><td style="text-align: left;">as antihypertensive</td></tr><tr><td style="text-align: left;">Glibenclamide + &lt;br&gt; metformin</td><td style="text-align: left;">as hypoglycaemic</td></tr><tr><td style="text-align: left;">Ephedrine + theophylline</td><td style="text-align: left;">as bronchodilator</td></tr></tbody></table>
<p>(b) Supraadditive (potentiation) The effect of combination is greater than the individual effects of the components:
effect of drug <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">A</mi><mo>+</mo><mi mathvariant="normal">B</mi><mo>&gt;</mo></mrow><annotation encoding="application/x-tex">\mathrm{A}+\mathrm{B}&gt;</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7667em; vertical-align: -0.0833em;"></span><span class="mord mathrm">A</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">+</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.7224em; vertical-align: -0.0391em;"></span><span class="mord mathrm">B</span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">&gt;</span></span></span></span></span> effect of drug <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">A</mi><mo>+</mo></mrow><annotation encoding="application/x-tex">\mathrm{A}+</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7667em; vertical-align: -0.0833em;"></span><span class="mord mathrm">A</span><span class="mord">+</span></span></span></span></span> effect of drug B
This is always the case when one component given alone produces no effect, but enhances the effect of the other (potentiation). Examples are given in the box. Additive synergism and potentiation are depicted diagrammatically in Fig. 4.17.</p>
<table><thead><tr><th style="text-align: left;">Supraadditive drug combinations</th><th style="text-align: left;"></th></tr></thead><tbody><tr><td style="text-align: left;">Drug pair</td><td style="text-align: left;">Basis of potentiation</td></tr><tr><td style="text-align: left;">Acetylcholine +</td><td style="text-align: left;">Inhibition of break</td></tr><tr><td style="text-align: left;">physostigmine</td><td style="text-align: left;">down</td></tr><tr><td style="text-align: left;">Levodopa + carbidopa/</td><td style="text-align: left;">Inhibition of peripheral</td></tr><tr><td style="text-align: left;">benserazide</td><td style="text-align: left;">metabolism</td></tr><tr><td style="text-align: left;">Adrenaline + cocaine/</td><td style="text-align: left;">Inhibition of</td></tr><tr><td style="text-align: left;">desipramine</td><td style="text-align: left;">neuronal uptake</td></tr><tr><td style="text-align: left;">Sulfamethoxazole +</td><td style="text-align: left;">Sequential blockade</td></tr><tr><td style="text-align: left;">trimethoprim</td><td style="text-align: left;"></td></tr><tr><td style="text-align: left;">Antihypertensives</td><td style="text-align: left;">Tackling two</td></tr><tr><td style="text-align: left;">(enalapril+</td><td style="text-align: left;">contributory factors</td></tr><tr><td style="text-align: left;">hydrochlorothiazide)</td><td style="text-align: left;"></td></tr><tr><td style="text-align: left;">Tyramine + MAO</td><td style="text-align: left;">Increasing releaseable</td></tr><tr><td style="text-align: left;">inhibitors</td><td style="text-align: left;">CA store</td></tr></tbody></table>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="antagonism">ANTAGONISM<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#antagonism" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>When one drug decreases or abolishes the action of another, they are said to be antagonistic: effect of drugs <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">A</mi><mo>+</mo><mi mathvariant="normal">B</mi><mo>&lt;</mo></mrow><annotation encoding="application/x-tex">\mathrm{A}+\mathrm{B}&lt;</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7667em; vertical-align: -0.0833em;"></span><span class="mord mathrm">A</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">+</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.7224em; vertical-align: -0.0391em;"></span><span class="mord mathrm">B</span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">&lt;</span></span></span></span></span> effect of drug <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">A</mi><mo>+</mo></mrow><annotation encoding="application/x-tex">\mathrm{A}+</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7667em; vertical-align: -0.0833em;"></span><span class="mord mathrm">A</span><span class="mord">+</span></span></span></span></span> effect of drug B
Usually in an antagonistic pair one drug is inactive as such but decreases the effect of the other. Depending on the mechanism involved, antagonism may be:
<img src="assets/images/image-20251214-b65abf16.jpeg" alt="img-37.jpeg"></p>
<p>Fig. 4.17: Log dose-response curves of a drug ' <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>A</mi></mrow><annotation encoding="application/x-tex">A</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal">A</span></span></span></span></span> ' depicting additive synergism (in purple) and potentiation (Supra-additive synergism) in blue.
A: An agonist drug.
B: Another agonist in a fixed submaximal dose producing <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>40</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">40 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">40%</span></span></span></span></span> response.
C: A potentiating drug which itself has no agonistic activity.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="a-physical-antagonism">(a) Physical antagonism<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#a-physical-antagonism" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Based on the physical property of the drugs, e.g. charcoal adsorbs alkaloids and can prevent their absorption-used in alkaloidal poisonings.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="b-chemical-antagonism">(b) Chemical antagonism<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#b-chemical-antagonism" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>The two drugs react chemically and form an inactive product, e.g.</p>
<ul>
<li><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">K</mi><mi mathvariant="normal">M</mi><mi mathvariant="normal">n</mi><mi mathvariant="normal">O</mi></mrow><mn>4</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{KMnO}_{4}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">KMnO</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">4</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> oxidizes alkaloids-used for gastric lavage in poisoning.</li>
<li>Tannins + alkaloids-insoluble alkaloidal tannate is formed.</li>
<li>Chelating agents (BAL, Cal. disod. edetate) complex toxic metals (As, Pb ).</li>
<li>Nitrites form methaemoglobin which reacts with cyanide radical.
Drugs may react when mixed in the same syringe or infusion bottle:</li>
<li>Thiopentone sod. + succinylcholine chloride</li>
<li>Penicillin-G sod. + succinylcholine chloride</li>
<li>Heparin + penicillin/tetracyclines/streptomycin/hydrocortisone</li>
</ul>
<p>(c) Physiological/functional antagonism</p>
<p>The two drugs act on different receptors or by different mechanisms, but have opposite overt effects on the same physiological function, i.e. have pharmacological effects in opposite direction, e.g.</p>
<ul>
<li>Histamine and adrenaline on bronchial muscles and on BP.</li>
<li>Hydrochlorothiazide and amiloride on urinary <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">K</mi><mo lspace="0em" rspace="0em">+</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{K}^{+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7713em;"></span><span class="mord"><span class="mord mathrm">K</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.7713em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span>excretion.</li>
<li>Glucagon and insulin on blood sugar level.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="d-receptor-antagonism">(d) Receptor antagonism<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#d-receptor-antagonism" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>One drug (antagonist) blocks the receptor action of the other (agonist). This is a very important mechanism of drug action, because physiological signal molecules act through their receptors, blockade of which can produce specific and often profound pharmacological effects. Receptor antagonists are selective (relatively), i.e. an anticholinergic will oppose contraction of intestinal smooth muscle induced by cholinergic agonists, but not that induced by histamine or 5-HT (they act through a different set of receptors). Receptor antagonism can be competitive or noncompetitive.
Competitive antagonism (equilibrium type) The antagonist is chemically similar to the agonist, competes with it (Fig. <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>4.18</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">A</mi></mrow><mo separator="true">,</mo><mi mathvariant="normal">D</mi></mrow><annotation encoding="application/x-tex">4.18 \mathrm{~A}, \mathrm{D}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8778em; vertical-align: -0.1944em;"></span><span class="mord">4.18</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm">A</span></span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord mathrm">D</span></span></span></span></span> ) and binds to the same site to the exclusion of the agonist molecules. Because the antagonist has affinity but no intrinsic activity (see p. 50), no response is produced and the <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>log</mi><mo>⁡</mo></mrow><annotation encoding="application/x-tex">\log</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mop">lo<span style="margin-right: 0.01389em;">g</span></span></span></span></span></span> DRC of the agonist is shifted to the right. Since antagonist binding is reversible and depends on the relative concentration of the agonist and antagonist molecules, higher concentration of the agonist progressively overcomes the block-a parallel shift of the agonist DRC with no suppression of maximal response is obtained (Fig. 4.19A). The extent of shift is dependent on the affinity and concentration of the antagonist.</p>
<p>A partial agonist (Fig. 4.18 C), having affinity for the same receptor, also competes with and
<img src="assets/images/image-20251214-56aca34b.jpeg" alt="img-38.jpeg"></p>
<p>Fig. 4.18: Illustration of sites of action of agonists and antagonists (A), and the action of full agonist (B), partial agonist (C), competitive antagonist (D) and noncompetitive antagonist ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>E</mi></mrow><annotation encoding="application/x-tex">E</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.05764em;">E</span></span></span></span></span> ) on the receptor
antagonizes a full agonist, while producing a submaximal response of its own.
Noncompetitive antagonism The antagonist is chemically unrelated to the agonist, binds to a different allosteric site altering the receptor in such a way that it is unable to combine with the agonist (Fig. 4.18E), or is unable to transduce</p>
<p><img src="assets/images/image-20251214-74a03d95.jpeg" alt="img-39.jpeg"></p>
<p>Fig. 4.19: Dose-response curves showing competitive (a) and noncompetitive (b) antagonism A-agonist, B-competitive antagonist, C—noncompetitive antagonist
the response, so that the downstream chain of events are uncoupled. This is also called allosteric antagonism. Because the agonist and the antagonist are combining with different sites, there is no competition between them-even high agonist concentration is unable to reverse the block completely. Increasing concentrations of the antagonist progressively flatten the agonist DRC (Fig. 4.19B). Noncompetitive antagonists have been produced experimentally, but are not in clinical use.</p>
<p>Nonequilibrium antagonism Certain antagonists bind to the receptor with strong (covalent) bonds or dissociate from it slowly (due to very high affinity) so that agonist molecules are unable to reduce receptor occupancy of the antagonist molecules-law of mass action cannot apply-an irreversible or nonequilibrium antagonism is produced. The agonist DRC is shifted to the right and the maximal response is lowered (if spare receptors are few). Since in this situation the agonist molecules are not able to compete</p>
<table><thead><tr><th style="text-align: center;">Competitive (equilibrium type)</th><th style="text-align: center;">Noncompetitive</th></tr></thead><tbody><tr><td style="text-align: center;">1. Antagonist binds with the same receptor as the agonist</td><td style="text-align: center;">Binds to another site of receptor</td></tr><tr><td style="text-align: center;">2. Antagonist resembles chemically with the agonist</td><td style="text-align: center;">Does not resemble</td></tr><tr><td style="text-align: center;">3. Parallel rightward shift of agonist DRC</td><td style="text-align: center;">Flattening of agonist DRC</td></tr><tr><td style="text-align: center;">4. The same maximal response can be attained by increasing dose of agonist (surmountable antagonism)</td><td style="text-align: center;">Maximal response is suppressed (unsurmountable antagonism)</td></tr><tr><td style="text-align: center;">5. Intensity of response depends on the concentration of both agonist and antagonist</td><td style="text-align: center;">Maximal response depends only on the concentration of antagonist</td></tr><tr><td style="text-align: center;">6. Examples: ACh—Atropine Morphine-Naloxone</td><td style="text-align: center;">Diazepam-Bicuculline</td></tr></tbody></table>
<p>with the antagonist molecules and flattening of agonist DRC is a feature of noncompetitive antagonism; nonequilibrium antagonism has also been called 'a type of noncompetitive antagonism'. Phenoxybenzamine is a non-
equilibrium antagonist of adrenaline at the <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>α</mi></mrow><annotation encoding="application/x-tex">\alpha</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.4306em;"></span><span class="mord mathnormal" style="margin-right: 0.0037em;">α</span></span></span></span></span> adrenergic receptors.</p>
<p>Features of competitive and noncompetitive antagonism are compared on previous page.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="problem-directed-study">PROBLEM DIRECTED STUDY<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#problem-directed-study" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>4.1 A patient being treated with methotrexate (Mtx) developed oral ulceration, megaloblastic anaemia and other toxic symptoms. Given that (i) Mtx acts by inhibiting the enzyme dihydrofolate reductase (DHFRase) which generates the essential coenzyme tetrahydrofolic acid (THFA) from dihydrofolic acid (DHFA) needed for one carbon transfer reactions, (ii) Mtx binds to the catalytic site of DHFRase with an affinity 50,000 times greater than the natural substrate DHFA, and that (iii) two forms of folate viz. folic acid and folinic acid (N5 formyl THFA) are available for therapeutic use:
(a) Which type of enzyme inhibition will be produced by Mtx?
(b) Which form of folate should be used to treat Mtx toxicity?
(see Appendix-1 for solution)</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="aspects-of-pharmacotherapy-br-chapter-5-br-clinical-pharmacology-and-drug-development">Aspects of Pharmacotherapy, &lt;br&gt; Chapter 5 &lt;br&gt; Clinical Pharmacology and Drug Development<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#aspects-of-pharmacotherapy-br-chapter-5-br-clinical-pharmacology-and-drug-development" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Pharmaco- (drug) therapy is dynamic and an ever evolving science. It requires understanding of the drug, the disease, the patient and the milieu in which it is undertaken. As such, in addition to knowledge of drug action, mechanisms and pharmacokinetics, several aspects like drug dosage, sources of variability in drug response, pharmacogenetics, influence of disease on drug action, etc. are important for otimum drug therapy.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="drug-dosage">DRUG DOSAGE<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#drug-dosage" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>'Dose' is the appropriate amount of a drug needed to produce a certain degree of response in a given patient.</p>
<p>Accordingly, dose of a drug has to be qualified in terms of the chosen response, e.g. the analgesic dose of aspirin for headache is <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.3</mn><mo>−</mo><mn>0.6</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">0.3-0.6 \mathrm{~g}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">0.3</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">0.6</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm" style="margin-right: 0.01389em;">g</span></span></span></span></span></span>, its antiplatelet dose is <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>60</mn><mo>−</mo><mn>150</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">60-150 \mathrm{mg} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">60</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">150</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span></span></span></span></span> day, while its antiinflammatory dose for rheumatoid arthritis is <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>3</mn><mo>−</mo><mn>5</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">3-5 \mathrm{~g}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">3</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">5</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm" style="margin-right: 0.01389em;">g</span></span></span></span></span></span> per day. Similarly there could be a prophylactic dose, a therapeutic dose or a toxic dose of the same drug.</p>
<p>The dose of a drug is governed by its inherent potency, i.e. the concentration at which it should be present at the target site, and its pharmacokinetic characteristics. The recommended doses are based on population data and cater to an 'average' patient. However, individual patients may not be 'average' in respect to a number of pharmacokinetic and pharmacodynamic parameters, emphasizing the need for individualizing drug dose. The strategies adopted for different types of drugs and conditions are:</p>
<ol>
<li>Standard dose The same dose is appropriate for most patients-individual variations are minor or the drug has a wide safety margin so that a large enough dose can be given to cover them, e.g. oral contraceptives, penicillin, chloroquine, mebendazole, hydrochlorothiazide.</li>
<li>Regulated dose The drug modifies a finely regulated body function which can be easily measured. The dosage is accurately adjusted by repeated measurement of the affected physiological parameter, e.g. antihypertensives, hypoglycaemics, anticoagulants, diuretics, general anaesthetics. In their case, measurement of plasma drug concentration is not needed.</li>
<li>Target level dose (see p. 41) The response is not easily measurable but has been demonstrated to be obtained at a certain range of drug concentration in plasma. An empirical dose aimed at attaining the target level is given in the beginning and adjustments are made later by actual monitoring of plasma concentrations. When facilities for drug level monitoring are not available, crude adjustments are made by observing the patient at relatively long intervals, e.g. antidepressants, antiepileptics, digoxin, theophylline.</li>
<li>Titrated dose The dose needed to produce maximal therapeutic effect cannot be given because of intolerable adverse effects. Optimal dose is arrived at by titrating it with an acceptable level of adverse effect. Low initial dose and</li>
</ol>
<p>upward titration (in most non-critical situations) or high initial dose and downward titration (in critical situations) can be practised. Often a compromise between submaximal therapeutic effect but tolerable side effects can be struck, e.g. anticancer drugs, corticosteroids, levodopa.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="fixed-dose-combinations-fdcs-of-drugs">Fixed dose combinations (FDCs) of drugs<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#fixed-dose-combinations-fdcs-of-drugs" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>A large number of pharmaceutical preparations contain two or more drugs in a fixed dose ratio. Advantages offered by these are:</p>
<ol>
<li>Convenience and better patient compli-ance-when all the components present in the FDC are actually needed by the patient and their amounts are appropriate. It may also be cost saving compared to both/all the components administered separately.</li>
<li>Certain drug combinations are synergistic, e.g. sulfamethoxazole + trimethoprim; levodopa + carbidopa/benserazide; combination oral contraceptives, isoniazid + rifampin.</li>
<li>The therapeutic effect of two components being same may add up while the side effects being different may not. For this the components of the FDC should act by different mechanisms, e.g. amlodipine + atenolol as antihypertensive.</li>
<li>The side effect of one component may be counteracted by the other, e.g. a thiazide + a potassium sparing diuretic. However, the amount of the latter may not be sufficient in all cases.</li>
<li>Combined formulation ensures that a single drug will not be administered. This is important in the treatment of tuberculosis, HIV-AIDS and falciparum malaria.
Before prescribing a combination, the physician must consider whether any of the ingredients is unnecessary; if it is, the combination should not be prescribed. It can never be justified that a drug is given to a patient who does not need it in order to provide him another, one that he needs.</li>
</ol>
<p>There are many inbuilt disadvantages of FDCs:</p>
<ol>
<li>The patient may not actually need all the drugs present in a combination: he is subjected to additional side effects and expense (often due to ignorance of the physician about the exact composition of the combined formulations).</li>
<li>The dose of most drugs needs to be adjusted and individualised. When a combined formulation is used, this cannot be done without altering the dose of the other component(s). However, few combinations are available at more than one dose ratios, e.g. levodopa <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo stretchy="false">(</mo><mn>100</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mo stretchy="false">)</mo><mo>+</mo></mrow><annotation encoding="application/x-tex">(100 \mathrm{mg})+</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mopen">(</span><span class="mord">100</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mclose">)</span><span class="mord">+</span></span></span></span></span> Carbidopa ( 10 mg or 25 mg ), amoxicillin ( 250 mg or 500 mg<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo stretchy="false">)</mo><mo>+</mo></mrow><annotation encoding="application/x-tex">)+</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mclose">)</span><span class="mord">+</span></span></span></span></span> clavulanic acid <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo stretchy="false">(</mo><mn>125</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mo stretchy="false">)</mo></mrow><annotation encoding="application/x-tex">(125 \mathrm{mg})</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mopen">(</span><span class="mord">125</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mclose">)</span></span></span></span></span>.</li>
<li>The time course of action of the components may be different: administering them at the same intervals may be inappropriate.</li>
<li>Altered renal or hepatic function of the patient may differently affect the pharmacokinetics of the components.</li>
<li>Adverse effect, when it occurs, cannot be easily ascribed to the particular drug causing it.</li>
<li>Contraindication to one component (allergy, other conditions) contraindicates the whole product.</li>
<li>Confusion of therapeutic aims and false sense of superiority of two drugs over one is fostered, specially in case of antimicrobials whose combinations should be avoided. Corticosteroids should never be combined with any other drug meant for internal use. Drug combinations that are banned in India are listed in Appendix-4.
Thus, only a handful of FDCs are rational and justified, while far too many are produced and vigorously promoted by the pharmaceutical industry. In fact, the latest (2017) WHO essential medicines list incorporates only 25 FDCs, and the NLEM (2015) of India has only 20 FDCs. In addition to the previously banned FDCs, recently 344 other irrational FDCs have been banned in India.</li>
</ol>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="factors-modifying-drug-action">FACTORS MODIFYING DRUG ACTION<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#factors-modifying-drug-action" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Variation in response to the same dose of a drug between different patients and even in the same patient on different occasions is a rule rather than exception. One or more of the following categories of differences among individuals are responsible for the variations in drug response:
(1) Individuals differ in pharmacokinetic handling of drugs: attain varying plasma/target site concentration of the drug. This is more marked for drugs disposed by metabolism (e.g. propranolol) than for drugs excreted unchanged (e.g. atenolol).
(2) Variations in number or state of receptors, coupling proteins or other components of response effectuation.
(3) Variations in neurogenic/hormonal tone or concentrations of specific constituents, e.g. atropine tachycardia depends on vagal tone, propranolol bradycardia depends on sympathetic tone, captopril hypotension depends on body <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">N</mi><mi mathvariant="normal">a</mi></mrow><mo lspace="0em" rspace="0em">+</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{Na}^{+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8446em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Na</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8446em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span>status.</p>
<p>A multitude of host and external factors influence drug response. They fall in two categories viz genetic and nongenetic including all environmental, circumstantial and personal variables. Though individual variation cannot be totally accounted for by these factors, their understanding can guide the choice of appropriate drug and dose for an individual patient. However, final adjustments have to be made by observing the response in a given patient on a given occasion.
The factors modify drug action either:
(a) Quantitatively The plasma concentration and/or the action of the drug is increased or decreased. Most of the factors introduce this type of change and can be dealt with by adjustment of drug dosage.
(b) Qualitatively The type of response is altered, e.g. drug allergy or idiosyncrasy. This
is less common but often precludes further use of that drug in the affected patient.
The various factors are discussed below-</p>
<ol>
<li>Body size It influences the concentration of the drug attained at the site of action. The average adult dose refers to individuals of medium built. For exceptionally obese or lean individuals and for children dose may be calculated on body weight (BW) basis:
Individual dose <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>=</mo><mfrac><mrow><mtext>&nbsp;BW&nbsp;</mtext><mo stretchy="false">(</mo><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow><mo stretchy="false">)</mo></mrow><mn>70</mn></mfrac><mo>×</mo></mrow><annotation encoding="application/x-tex">=\frac{\text { BW }(\mathrm{kg})}{70} \times</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.3669em;"></span><span class="mrel">=</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 1.355em; vertical-align: -0.345em;"></span><span class="mord"><span class="mopen nulldelimiter"></span><span class="mfrac"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 1.01em;"><span style="top: -2.655em;"><span class="pstrut" style="height: 3em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">70</span></span></span></span><span style="top: -3.23em;"><span class="pstrut" style="height: 3em;"></span><span class="frac-line" style="border-bottom-width: 0.04em;"></span></span><span style="top: -3.485em;"><span class="pstrut" style="height: 3em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord text mtight"><span class="mord mtight">&nbsp;BW&nbsp;</span></span><span class="mopen mtight">(</span><span class="mord mtight"><span class="mord mathrm mtight" style="margin-right: 0.01389em;">kg</span></span><span class="mclose mtight">)</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.345em;"><span></span></span></span></span></span><span class="mclose nulldelimiter"></span></span><span class="mord">×</span></span></span></span></span> average adult dose
It has been argued that body surface area (BSA) provides a more accurate basis for dose calculation, because total body water, extracellular fluid volume and metabolic activity are better paralleled by BSA.
Individual dose <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>=</mo><mfrac><mrow><mtext>&nbsp;BSA&nbsp;</mtext><mrow><mo fence="true">(</mo><msup><mi mathvariant="normal">m</mi><mn>2</mn></msup><mo fence="true">)</mo></mrow></mrow><mn>1.7</mn></mfrac><mo>×</mo></mrow><annotation encoding="application/x-tex">=\frac{\text { BSA }\left(\mathrm{m}^{2}\right)}{1.7} \times</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.3669em;"></span><span class="mrel">=</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 1.655em; vertical-align: -0.345em;"></span><span class="mord"><span class="mopen nulldelimiter"></span><span class="mfrac"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 1.31em;"><span style="top: -2.655em;"><span class="pstrut" style="height: 3em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1.7</span></span></span></span><span style="top: -3.23em;"><span class="pstrut" style="height: 3em;"></span><span class="frac-line" style="border-bottom-width: 0.04em;"></span></span><span style="top: -3.6125em;"><span class="pstrut" style="height: 3em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord text mtight"><span class="mord mtight">&nbsp;BSA&nbsp;</span></span><span class="minner mtight"><span class="mopen sizing reset-size3 size6 mtight delimcenter" style="top: 0.075em;"><span class="mtight">(</span></span><span class="mord mtight"><span class="mord mathrm mtight">m</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8913em;"><span style="top: -2.931em; margin-right: 0.0714em;"><span class="pstrut" style="height: 2.5em;"></span><span class="sizing reset-size3 size1 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span></span></span></span></span><span class="mclose sizing reset-size3 size6 mtight delimcenter" style="top: 0.075em;"><span class="mtight">)</span></span></span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.345em;"><span></span></span></span></span></span><span class="mclose nulldelimiter"></span></span><span class="mord">×</span></span></span></span></span> average adult dose
The BSA of an individual can be calculated from Dubois formula:
BSA <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mrow><mo fence="true">(</mo><msup><mi mathvariant="normal">m</mi><mn>2</mn></msup><mo fence="true">)</mo></mrow><mo>=</mo></mrow><annotation encoding="application/x-tex">\left(\mathrm{m}^{2}\right)=</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1.2em; vertical-align: -0.35em;"></span><span class="minner"><span class="mopen delimcenter" style="top: 0em;"><span class="delimsizing size1">(</span></span><span class="mord"><span class="mord mathrm">m</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8141em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span></span></span></span></span><span class="mclose delimcenter" style="top: 0em;"><span class="delimsizing size1">)</span></span></span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">=</span></span></span></span></span>
BW <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo stretchy="false">(</mo><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow><msup><mo stretchy="false">)</mo><mn>0.425</mn></msup><mo>×</mo></mrow><annotation encoding="application/x-tex">(\mathrm{kg})^{0.425} \times</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1.0641em; vertical-align: -0.25em;"></span><span class="mopen">(</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span><span class="mclose"><span class="mclose">)</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8141em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">0.425</span></span></span></span></span></span></span></span></span><span class="mord">×</span></span></span></span></span> Height <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo stretchy="false">(</mo><mrow><mi mathvariant="normal">c</mi><mi mathvariant="normal">m</mi></mrow><msup><mo stretchy="false">)</mo><mn>0.725</mn></msup><mo>×</mo><mn>0.007184</mn></mrow><annotation encoding="application/x-tex">(\mathrm{cm})^{0.725} \times 0.007184</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1.0641em; vertical-align: -0.25em;"></span><span class="mopen">(</span><span class="mord"><span class="mord mathrm">cm</span></span><span class="mclose"><span class="mclose">)</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8141em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">0.725</span></span></span></span></span></span></span></span></span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">×</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">0.007184</span></span></span></span></span>
or obtained from chart-form or slide-rule nomograms based on BW and height.</li>
</ol>
<p>However, dose recommendations in terms of BSA are available only for anticancer and a handful of other drugs: for the rest BW has been used as the index. Thus, prescribing on BSA basis suffers from lack of data base, is more cumbersome and has not thrived, except in few cases.
2. Age The dose of a drug for children is often calculated from the adult dose. Some age based formulae for calculating child dose from the adult dose have been framed, but are not in use now. Child dose is better calculated more accurately on BW basis. For many drugs, manufacturers give dosage recommendations on <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">\mathrm{mg} / \mathrm{kg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span></span></span></span></span> basis. Average figures for children are given in the chart below.</p>
<table><thead><tr><th style="text-align: center;">Age</th><th style="text-align: center;">Body weight (Kg)*</th><th style="text-align: center;"></th><th style="text-align: center;">% of &lt;br&gt; Adult dose</th></tr></thead><tbody><tr><td style="text-align: center;"></td><td style="text-align: center;">Boys</td><td style="text-align: center;">Girls</td><td style="text-align: center;"></td></tr><tr><td style="text-align: center;">Newborn</td><td style="text-align: center;">3.5</td><td style="text-align: center;">3.4</td><td style="text-align: center;">12.5</td></tr><tr><td style="text-align: center;">1 month</td><td style="text-align: center;">4.8</td><td style="text-align: center;">4.5</td><td style="text-align: center;">15</td></tr><tr><td style="text-align: center;">3 months</td><td style="text-align: center;">6.4</td><td style="text-align: center;">5.8</td><td style="text-align: center;">18</td></tr><tr><td style="text-align: center;">6 months</td><td style="text-align: center;">8.1</td><td style="text-align: center;">7.4</td><td style="text-align: center;">22</td></tr><tr><td style="text-align: center;">1 year</td><td style="text-align: center;">10.5</td><td style="text-align: center;">9.7</td><td style="text-align: center;">25</td></tr><tr><td style="text-align: center;">3 years</td><td style="text-align: center;">14.3</td><td style="text-align: center;">13.8</td><td style="text-align: center;">33</td></tr><tr><td style="text-align: center;">5 years</td><td style="text-align: center;">18.5</td><td style="text-align: center;">18.2</td><td style="text-align: center;">40</td></tr><tr><td style="text-align: center;">7 years</td><td style="text-align: center;">23.1</td><td style="text-align: center;">22.9</td><td style="text-align: center;">50</td></tr><tr><td style="text-align: center;">9 years</td><td style="text-align: center;">28.7</td><td style="text-align: center;">29.1</td><td style="text-align: center;">60</td></tr><tr><td style="text-align: center;">12 years</td><td style="text-align: center;">40.7</td><td style="text-align: center;">41.8</td><td style="text-align: center;">75</td></tr></tbody></table>
<p>*50th percentile body weight of Indian boys and girls as per CDC 2000 guidelines.</p>
<p>However, infants and children are not small adults. They have important physiological differences from adults. The newborn has low g.f.r. and tubular transport is immature. As such, the <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">t</mi><mrow><mn>1</mn><mi mathvariant="normal">/</mi><mn>2</mn></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{t}^{1 / 2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.888em;"></span><span class="mord"><span class="mord mathrm">t</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.888em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1/2</span></span></span></span></span></span></span></span></span></span></span></span></span> of drugs excreted by glomerular filtration (gentamicin) and tubular secretion (penicillin) is prolonged by 3 to 5 times. Glomerular filtration reaches adult rates by 5 month of age and tubular secretion takes about 7 months to mature. Similarly, hepatic drug metabolizing system is inadequate in newborns -chloramphenicol can produce gray baby syndrome (see Ch. 53). Blood-brain barrier is more permeable-drugs attain higher concentration in the CNS (easy entry of unconjugated bilirubin in brain causes kernicterus). These defects are exaggerated in the premature infant. Drug absorption may also be altered in infants because of lower gastric acidity and slower intestinal transit. Transdermal absorption however, is faster because infant skin is thin and more permeable. Rectal absorption is fast and more predictable in infants and young children. Taking advantage of this fact, diazepam solution is given rectally to control febrile seizures in children <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&lt;</mo><mn>5</mn></mrow><annotation encoding="application/x-tex">&lt;5</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&lt;</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">5</span></span></span></span></span> years. Therefore, infant doses must be learned as such and not derived from any formula.</p>
<p>After the first year of life, drug metabolism is often faster than in adults. Accordingly, the <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">t</mi><mrow><mn>1</mn><mi mathvariant="normal">/</mi><mn>2</mn></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{t}^{1 / 2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.888em;"></span><span class="mord"><span class="mord mathrm">t</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.888em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1/2</span></span></span></span></span></span></span></span></span></span></span></span></span> of theophylline, phenytoin, carbamazepine is shorter in children than in adults. Also, higher per kg dose is needed in children for drugs which are primarily excreted unchanged by
kidney, e.g. daily dose of digoxin is about 8-12 <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>μ</mi><mi mathvariant="normal">g</mi><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">\mu \mathrm{g} / \mathrm{kg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord mathnormal">μ</span><span class="mord mathrm" style="margin-right: 0.01389em;">g</span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span></span></span></span></span> compared to adult dose of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>3</mn><mo>−</mo><mn>5</mn><mi>μ</mi><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">3-5 \mu \mathrm{~g} / \mathrm{kg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">3</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">5</span><span class="mord mathnormal">μ</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm" style="margin-right: 0.01389em;">g</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span></span></span></span></span>.</p>
<p>Solid dosage forms and metered dose inhalers are difficult to administer to young children.</p>
<p>Children are growing and are susceptible to special adverse effects of drugs, e.g. suppression of growth can occur with corticosteroids; androgens may promote early fusion of epiphysis resulting in stunting of stature; tetracyclines get deposited in growing teeth and discolour/deform them. Dystonic reactions to phenothiazines are more common in children.
Elderly In the elderly, renal function progressively declines (intact nephron loss) so that g.f.r. is <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>∼</mo><mn>75</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">\sim 75 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.3669em;"></span><span class="mrel">∼</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">75%</span></span></span></span></span> at 50 years and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>∼</mo><mn>50</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">\sim 50 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.3669em;"></span><span class="mrel">∼</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">50%</span></span></span></span></span> at 75 years age compared to young adults. Drug doses have to be reduced, e.g. daily dose of streptomycin is 0.75 g after 50 years and 0.5 g after 70 years of age compared to 1 g for young adults. There is also a reduction in the hepatic microsomal drug metabolizing activity and liver blood flow: oral bioavailability of drugs with high hepatic extraction is generally increased, but the overall effects on drug metabolism are not uniform. Due to lower renal as well as metabolic clearance, the elderly are prone to develop cumulative toxicity while receiving prolonged medication. Other affected aspects of drug handling are:</p>
<ul>
<li>slower absorption due to reduced gut motility as well as blood flow to intestines,</li>
<li>lesser plasma protein binding due to lower plasma albumin,</li>
<li>increased or decreased volume of distribution of lipophilic and hydrophilic drugs respectively.
Aged are relatively intolerant to digitalis. The responsiveness of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>β</mi></mrow><annotation encoding="application/x-tex">\beta</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mord mathnormal" style="margin-right: 0.05278em;">β</span></span></span></span></span> adrenergic receptors to both agonists and antagonists is reduced in the elderly and sensitivity to other drugs also may be altered. Due to prostatism in elderly males, even mild anticholinergic activity of the drug can accentuate bladder voiding difficulty. Elderly are also likely to be on multiple drug therapy for hypertension, ischaemic heart disease, diabetes, arthritis, etc.</li>
</ul>
<p>which increases many fold the chances of drug interactions. They are more prone to develop postural instability, giddiness and mental confusion. In general, the incidence of adverse drug reactions is much higher in the elderly.
3. Sex Females have smaller body size and require doses that are on the lower side of the range. Subjective effects of drugs may differ in females because of their mental makeup. Maintenance treatment of heart failure with digoxin is reported to be associated with higher mortality among women than among men. A number of antihypertensives (clonidine, methyldopa, <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>β</mi></mrow><annotation encoding="application/x-tex">\beta</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mord mathnormal" style="margin-right: 0.05278em;">β</span></span></span></span></span>-blockers, diuretics) have potential to interfere with sexual function in males but not in females. Gynaecomastia is a side effect (of ketoconazole, metoclopramide, chlorpromazine, digitalis) that can occur only in men. Ketoconazole causes loss of libido in men but not in women. Obviously androgens are unacceptable to women and estrogens to men. In women consideration must also be given to menstruation, pregnancy and lactation.</p>
<p>Drugs given during pregnancy can affect the foetus (see Ch. 6 and Appendix-2). There are marked and progressive physiological changes during pregnancy, especially in the third trimester, which can alter drug disposition.
(i) Gastrointestinal motility is reduced <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>→</mo></mrow><annotation encoding="application/x-tex">\rightarrow</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.3669em;"></span><span class="mrel">→</span></span></span></span></span> delayed absorption of orally administered drug.
(ii) Plasma and extracellular fluid volume expands-volume of drug distribution may increase.
(iii) While plasma albumin level falls, that of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi>α</mi><mn>1</mn></msub></mrow><annotation encoding="application/x-tex">\alpha_{1}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5806em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.0037em;">α</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.0037em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> acid glycoprotein increases-the unbound fraction of acidic drugs increases but that of basic drugs decreases.
(iv) Renal blood flow increases markedly-polar drugs are eliminated faster.
(v) Hepatic microsomal enzymes undergo induc-tion-many drugs are metabolized faster.
Thus, the overall effect on drug disposition is complex and often difficult to predict.
4. Species and race There are many examples of differences in responsiveness to
drugs among different species; rabbits are resistant to atropine, rats and mice are resistant to digitalis and rat is more sensitive to curare than cat. These differences are important while extrapolating results from experimental animals to man.</p>
<p>Among human beings some racial differences have been observed, e.g. blacks require higher and Mongols require lower concentrations of atropine and ephedrine to dilate their pupil. <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>β</mi></mrow><annotation encoding="application/x-tex">\beta</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mord mathnormal" style="margin-right: 0.05278em;">β</span></span></span></span></span>-blockers are less effective as antihypertensive in Afro-Caribbeans. Considering the widespread use of chloramphenicol in India and Hong Kong between 1950-1980, relatively few cases of aplastic anaemia have been reported compared to its incidence in the west. Similarly, quiniodochlor related cases of subacute myelooptic neuropathy (SMON) occurred in epidemic proportion in Japan, but there is no confirmed report of its occurrence in India despite extensive use.
5. Genetics The dose of a drug to produce the same effect may vary by 4-6 fold among different individuals. All key determinants of drug response, viz. transporters, metabolizing enzymes, ion channels, receptors with their couplers and effectors are controlled genetically. Hence, a great deal of individual variability can be traced to the genetic composition of the subject.
Pharmacogenetics The study of genetic basis for variability in drug response is called 'Pharmacogenetics'. It deals with genetic influences on drug action as well as on drug handling by the body. As the genomic technology has advanced and the human genome project has been undertaken, gene libraries and huge data bases (like 'pharmacogenetics and pharmacogenomics knowledge base', 'Human genome variation database', etc.) have been created aiming at improving precision in drug therapy. Pharmacogenomics is the use of genetic information to guide the choice of drug and dose on an individual basis.</p>
<p>A relationship is drawn between how a patient responds to a drug with his genetic makeup.</p>
<p>The purpose is to identify individuals who are either more likely or less likely to respond to a drug, as well as those who require altered dose of certain drugs. Attempt is made to define the genetic basis of an individual's profile of drug response and to predict the best treatment option for him/her. So far, this has been applied largely to patients with known genetic abnormalities, but the goal is 'personalized medicine' on a wide scale. However, the basis of a large proportion of genetic variability still remains unexplained.</p>
<p>A continuous variation with bell-shaped Gaussian frequency distribution is seen in the case of most drugs. In addition, there are some specific genetic defects which lead to discontinuous variation in drug responses, e.g.-</p>
<ol>
<li>Atypical pseudocholinesterase results in prolonged succinylcholine apnoea.</li>
<li>G-6PD deficiency is responsible for haemolysis with primaquine and other oxidizing drugs. This X-linked monogenic trait is more common in the Mediterranean, African and Southeast Asian races. The haemolysis is largely dose related. Several variants of the G-6PD gene occur in the population resulting in differing severity of haemolysis triggered by different oxidizing drugs. Haemolysis is severe in homozygous deficient individuals of certain genotypes. Important drugs reported to cause haemolysis in G-6PD deficient subjects are listed in the box.</li>
</ol>
<table><thead><tr><th style="text-align: center;">Drugs with potential <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow></mrow><mo lspace="0em" rspace="0em">∗</mo></msup></mrow><annotation encoding="application/x-tex">{ }^{*}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6887em;"></span><span class="mord"><span class="mord"></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.6887em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">∗</span></span></span></span></span></span></span></span></span></span></span></span></span> to cause haemolysis in G-6PD deficient individuals</th><th style="text-align: center;"></th></tr></thead><tbody><tr><td style="text-align: center;">Primaquine</td><td style="text-align: center;">Nalidixic acid</td></tr><tr><td style="text-align: center;">Chloroquine</td><td style="text-align: center;">Fluoroquinolones</td></tr><tr><td style="text-align: center;">Quinine/Quinidine</td><td style="text-align: center;">Chloramphenicol</td></tr><tr><td style="text-align: center;">Proguanil</td><td style="text-align: center;">Nitrofurantoin</td></tr><tr><td style="text-align: center;">Pyrimethamine</td><td style="text-align: center;">Furazolidone</td></tr><tr><td style="text-align: center;">Dapsone</td><td style="text-align: center;">Menadione</td></tr><tr><td style="text-align: center;">Sulfonamides</td><td style="text-align: center;">Methyldopa</td></tr><tr><td style="text-align: center;">Cotrimoxazole</td><td style="text-align: center;">Hydralazine</td></tr><tr><td style="text-align: center;">Sulfasalazine</td><td style="text-align: center;">Procainamide</td></tr><tr><td style="text-align: center;">Sulfonylureas</td><td style="text-align: center;">Probenecid</td></tr><tr><td style="text-align: center;">Thiazide diuretics</td><td style="text-align: center;">Colchicine</td></tr><tr><td style="text-align: center;">Aspirin</td><td style="text-align: center;">Methylene blue</td></tr></tbody></table>
<p><sup><a href="#user-content-fn-0" id="user-content-fnref-0-2" data-footnote-ref="true" aria-describedby="footnote-label">1</a></sup>3. The low activity CYP2C9 variants metabolize warfarin at a slow rate and are at higher risk of bleeding.
4. Thiopurine methyl transferase (TPMT) deficiency increases risk of severe bone marrow toxicity of 6-mercaptopurine and azathioprine.
5. Irinotecan induced neutropenia and diarrhoea is more in patients with UGT1A1 *28 allele of glucuronyl transferase.
6. Severe 5-fluorouracil toxicity occurs in patients with dihydropyrimidine dehydrogenase (DPD) deficiency.
7. Over expression of P-gp results in tumour resistance to many cancer chemotherapeutic drugs, because it pumps out the drug from the tumour cells.
8. Polymorphism of N-acetyl transferase 2 (NAT2) gene results in rapid and slow acetylator status. Isoniazid neuropathy, procainamide and hydralazine induced lupus occurs mainly in slow acetylators.
9. Acute intermittent porphyria-precipitated by barbiturates is due to genetic defect in repression of porphyrin synthesis.
10. CYP2D6 abnormality causes poor metoprolol/ debrisoquin metabolizer status. Since several antidepressants and antipsychotics also are substrates of CYP2D6, deficient patients are more likely to experience their toxicity. Codeine fails to produce analgesia in CYP2D6 deficient, because this enzyme generates morphine from codeine.
11. Malignant hyperthermia after halothane is due to abnormal <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">C</mi><mi mathvariant="normal">a</mi></mrow><mrow><mn>2</mn><mo>+</mo></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{Ca}^{2+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8873em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Ca</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8873em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span> release channel (ryanodine receptor) in the sarcoplasmic reticulum of skeletal muscles.
12. Inability to hydroxylate phenytoin results in toxicity at usual doses.
13. Resistance to coumarin anticoagulants is due to an abnormal enzyme vitamin K epoxide reductase (VKOR) that regenerates the reduced form of vit. K. This form has low affinity for the coumarins.
14. Attack of angle closure glaucoma is precipitated by mydriatics in individuals with narrow iridocorneal angle.</p>
<p>Genetic variability in drug response could be due to single gene mutation or polygenic. Genotype to phenotype predictability is much better in monogenic phenotypic traits such as G-6PD, CYP2D6, TPMT, etc., than for multigenic traits, which are clinically less significant. Majority of gene polymorphisms are due to substitution of a single base pair by another. When found in the population at a frequency of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&gt;</mo><mn>1</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">&gt;1 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&gt;</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">1%</span></span></span></span></span>, these are called 'Single neuclcotide polymorphisms' (SNPs). Gene polymorphisms are often encountered at different frequencies among different ethnic/geographical groups.</p>
<p>Despite accumulation of considerable pharmacogenomic data and the fact that genotyping of the individual needs to be done only once, its practical application in routine patient care is at present limited due to prerequirement of multiple drug specific genotypic screening. Simple spot tests for some, e.g. G-6 PD deficiency are currently in use.
6. Route of administration Route of administration governs the speed and intensity of drug response (see Ch. 1). Parenteral administration is often resorted to for more rapid, more pronounced and more predictable drug action. A drug may have entirely different uses through different routes, e.g. magnesium sulfate given orally causes purgation, applied on sprained joints it decreases swelling, while intravenously it produces CNS depression and hypotension.
7. Environmental factors and time of administration Several environmental factors affect drug responses. Exposure to insecticides, carcinogens, tobacco smoke and consumption of charcoal broiled meat are well known to induce drug metabolism. Type of diet and temporal relation between drug ingestion and meals can alter drug absorption, e.g. food interferes with absorption of ampicillin, but a fatty meal enhances absorption of griseofulvin and lumefantrine. Subjective effects of a drug may be markedly influenced by the setup in which it is taken. Hypnotics taken at night and in quiet, familiar surroundings may work more easily. Statins cause greater inhibition of
cholesterol synthesis when taken in the late evening. It has been shown that corticosteroids taken as a single morning dose cause less pituitary-adrenal suppression.
8. Psychological factor Efficacy of a drug can be affected by the patient's beliefs, attitudes and expectations. This is particularly applicable to centrally acting drugs, e.g. a nervous and anxious patient requires more general anaesthetic; alcohol generally impairs performance but if punishment (which induces anxiety) is introduced, it may actually improve performance by relieving anxiety.
Placebo This is an inert substance which is given in the garb of a medicine. It works by psychodynamic rather than pharmacodynamic means and often produces responses equivalent to the active drug. Some individuals are more suggestible and easily respond to a placebo: and are called 'placebo reactors'. Placebos are used in two situations:</p>
<ol>
<li>As a control device in clinical trial of drugs (dummy medication).</li>
<li>To treat a patient who, in the opinion of the physician, does not require an active drug. Placebo is a Latin word meaning 'I shall please'. A patient responds to the whole therapeutic setting; placebo-effect largely depends on the physician-patient relationship.</li>
</ol>
<p>Placebos do induce physiological responses, e.g. they can release endorphins in brain-causing analgesia. Naloxone, an opioid antagonist, blocks placebo analgesia. When an active drug is administered, it produces effects both due to its pharmacodynamic action as well as the psychodynamic effect of the act of medication. Placebo effects can thus supplement pharmacological effects of active medicines. However, placebo effects are highly variable even in the same individual, e.g. a placebo may induce sleep on the first night, but not subsequently. Thus, it has a very limited role in practical therapeutics. Substances commonly used as placebo are lactose tablets/capsules and distilled water injection. Multivitamin preparations are often misused as placebos when no medication is needed.</p>
<p>Nocebo It is the converse of placebo, and refers to negative psychodynamic effect evoked by the pessimistic attitude of the patient, or by loss of faith in the medication and/or the physician. Nocebo effect can oppose the therapeutic effect of active medication.
9. Pathological states Not only drugs modify disease processes, several diseases can influence drug disposition and drug action:
Gastrointestinal (g.i.) diseases Certain g.i. diseases can alter absorption of orally administered drugs. The changes are complex and drug absorption can increase or decrease, e.g. in coeliac disease absorption of amoxicillin is decreased but that of cephalexin and cotrimoxazole is increased. Thus, malabsorption syndrome does not necessarily reduce absorption of all drugs. Gastric stasis occurring during migraine attack retards the absorption of ingested drugs. Achlorhydria decreases aspirin absorption by favouring its ionization. NSAIDs can aggravate peptic ulcer disease.
Liver disease Liver disease (especially cirrhosis) can influence drug disposition in several ways:</p>
<ul>
<li>Bioavailability of drugs having high first pass metabolism (see Ch. 3) is increased due to loss of hepatocellular function and portocaval shunting.</li>
<li>Serum albumin is reduced-protein binding of acidic drugs (diclofenac, warfarin, etc.) is reduced and more drug is present in the free form.</li>
<li>Metabolism and elimination of some drugs (morphine, lidocaine, propranolol) is decreased-their dose should be reduced. Alternative drugs that do not depend on hepatic metabolism for elimination and/or have shorter <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">t</mi><mrow><mn>1</mn><mi mathvariant="normal">/</mi><mn>2</mn></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{t}^{1 / 2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.888em;"></span><span class="mord"><span class="mord mathrm">t</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.888em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1/2</span></span></span></span></span></span></span></span></span></span></span></span></span> should be preferred, e.g. oxazepam or lorazepam in place of diazepam; atenolol as <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>β</mi></mrow><annotation encoding="application/x-tex">\beta</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mord mathnormal" style="margin-right: 0.05278em;">β</span></span></span></span></span>-blocker.</li>
<li>Prodrugs needing hepatic metabolism for activation, e.g. bacampicillin are less effective and should be avoided.
The changes in drug metabolism due to liver disease are complex and there is no simple test (like creatinine clearance for renal disease) to estimate the extent of alteration
in drug disposition. Moreover, the kinetics of different drugs is affected to different extents.</li>
</ul>
<p>Not only disposition, but action as well of certain drugs may be altered in liver disease, e.g.</p>
<ul>
<li>The sensitivity of brain to depressant action of morphine and barbiturates is markedly increased in cirrhotics-normal doses can produce coma.</li>
<li>Brisk diuresis can precipitate mental changes in patients with impending hepatic encephalopathy, because diuretics cause hypokalemic alkalosis which favours conversion of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msubsup><mrow><mi mathvariant="normal">N</mi><mi mathvariant="normal">H</mi></mrow><mn>4</mn><mo lspace="0em" rspace="0em">+</mo></msubsup></mrow><annotation encoding="application/x-tex">\mathrm{NH}_{4}^{+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1.0916em; vertical-align: -0.247em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">NH</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.8446em;"><span style="top: -2.453em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">4</span></span></span></span><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.247em;"><span></span></span></span></span></span></span></span></span></span></span> to <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">N</mi><mi mathvariant="normal">H</mi></mrow><mn>3</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{NH}_{3}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">NH</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">3</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span>. Ammonia enters brain easily and causes mental derangement.</li>
<li>Oral anticoagulants can markedly prolong prothrombin time, because clotting factors are already low.</li>
<li>Fluid retaining action of phenylbutazone (other NSAIDs as well), and lactic acidosis due to metformin are accentuated.
Hepatotoxic drugs should be avoided in liver disease.
Kidney disease It markedly affects the pharmacokinetics of many drugs as well as alters the effects of some drugs.</li>
</ul>
<p>Clearance of drugs that are primarily excreted unchanged (aminoglycosides, digoxin, phenobarbitone) is reduced parallel to decrease in creatinine clearance <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo fence="true">(</mo><msub><mrow><mi mathvariant="normal">C</mi><mi mathvariant="normal">L</mi></mrow><mrow><mi mathvariant="normal">c</mi><mi mathvariant="normal">r</mi></mrow></msub><mo fence="true">)</mo></mrow><annotation encoding="application/x-tex">\left(\mathrm{CL}_{\mathrm{cr}}\right)</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="minner"><span class="mopen delimcenter" style="top: 0em;">(</span><span class="mord"><span class="mord"><span class="mord mathrm">CL</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.1514em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight"><span class="mord mathrm mtight">cr</span></span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mclose delimcenter" style="top: 0em;">)</span></span></span></span></span></span>. Loading dose of such a drug is not altered (unless edema is present), but maintenance doses should be reduced or dose interval prolonged proportionately. A rough guideline is given in the box:</p>
<table><thead><tr><th style="text-align: left;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">C</mi><mi mathvariant="normal">L</mi></mrow><mrow><mi mathvariant="normal">c</mi><mi mathvariant="normal">r</mi></mrow></msub></mrow><annotation encoding="application/x-tex">\mathrm{CL}_{\mathrm{cr}}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">CL</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.1514em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight"><span class="mord mathrm mtight">cr</span></span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> (patient)</th><th style="text-align: center;">Dose rate to be reduced to</th></tr></thead><tbody><tr><td style="text-align: left;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>50</mn><mo>−</mo><mn>70</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">l</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">i</mi><mi mathvariant="normal">n</mi></mrow></mrow><annotation encoding="application/x-tex">50-70 \mathrm{ml} / \mathrm{min}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">50</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">70</span><span class="mord"><span class="mord mathrm">ml</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm">min</span></span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>70</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">70 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">70%</span></span></span></span></span></td></tr><tr><td style="text-align: left;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>30</mn><mo>−</mo><mn>50</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">l</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">i</mi><mi mathvariant="normal">n</mi></mrow></mrow><annotation encoding="application/x-tex">30-50 \mathrm{ml} / \mathrm{min}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">30</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">50</span><span class="mord"><span class="mord mathrm">ml</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm">min</span></span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>50</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">50 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">50%</span></span></span></span></span></td></tr><tr><td style="text-align: left;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>10</mn><mo>−</mo><mn>30</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">l</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">i</mi><mi mathvariant="normal">n</mi></mrow></mrow><annotation encoding="application/x-tex">10-30 \mathrm{ml} / \mathrm{min}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">10</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">30</span><span class="mord"><span class="mord mathrm">ml</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm">min</span></span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>30</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">30 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">30%</span></span></span></span></span></td></tr><tr><td style="text-align: left;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mo>−</mo><mn>10</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">l</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">i</mi><mi mathvariant="normal">n</mi></mrow></mrow><annotation encoding="application/x-tex">5-10 \mathrm{ml} / \mathrm{min}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">10</span><span class="mord"><span class="mord mathrm">ml</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm">min</span></span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>20</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">20 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">20%</span></span></span></span></span></td></tr></tbody></table>
<p>Dose rate of drugs only partly excreted unchanged in urine also needs reduction, but to lesser extents. If the <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">t</mi><mrow><mn>1</mn><mi mathvariant="normal">/</mi><mn>2</mn></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{t}^{1 / 2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.888em;"></span><span class="mord"><span class="mord mathrm">t</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.888em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1/2</span></span></span></span></span></span></span></span></span></span></span></span></span> of the drug is prolonged, attainment of steady-state plasma concentration with maintenance doses is delayed proportionately.</p>
<p>Plasma proteins, especially albumin, are often low or altered in structure in patients with renal disease-binding of acidic drugs is reduced, but that of basic drugs is not much affected.</p>
<p>The permeability of blood-brain barrier is increased in renal failure; opiates, barbiturates, phenothiazines, benzodiazepines, etc. produce more CNS depression. Pethidine should be avoided because its metabolite nor-pethidine can accumulate on repeated dosing and cause seizures. The target organ sensitivity may also be increased. Antihypertensive drugs produce greater postural hypotension in patients with renal insufficiency.</p>
<p>Certain drugs worsen the existing clinical condition in renal failure, e.g.</p>
<ul>
<li>Tetracyclines have an anti-anabolic effect and accentuate uraemia.</li>
<li>NSAIDs cause more fluid retention.</li>
</ul>
<table><thead><tr><th style="text-align: left;">Antimicrobials needing dose reduction &lt;br&gt; in renal failure</th><th style="text-align: left;"></th></tr></thead><tbody><tr><td style="text-align: left;">Even in mild failure</td><td style="text-align: left;">Only in severe failure</td></tr><tr><td style="text-align: left;">Aminoglycosides</td><td style="text-align: left;">Cotrimoxazole</td></tr><tr><td style="text-align: left;">Cephalexin</td><td style="text-align: left;">Carbenicillin</td></tr><tr><td style="text-align: left;">Ethambutol</td><td style="text-align: left;">Cefotaxime</td></tr><tr><td style="text-align: left;">Vancomycin</td><td style="text-align: left;">Norfloxacin</td></tr><tr><td style="text-align: left;">Amphotericin B</td><td style="text-align: left;">Ciprofloxacin</td></tr><tr><td style="text-align: left;">Acyclovir</td><td style="text-align: left;">Metronidazole</td></tr></tbody></table>
<ul>
<li>Potentially nephrotoxic drugs, e.g. aminoglycosides, tetracyclines (except doxycycline), sulfonamides (crystalluria), vancomycin, nitrofurantoin, cyclosporine, amphotericin B should be avoided.
Thiazide diuretics tend to reduce g.f.r. They are ineffective in renal failure and can worsen uraemia; furosemide should be used instead. Potassium sparing diuretics are contraindicated because they can cause hyperkalemia <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>→</mo></mrow><annotation encoding="application/x-tex">\rightarrow</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.3669em;"></span><span class="mrel">→</span></span></span></span></span> cardiac depression. Repeated doses of pethidine are likely to cause muscle twitching and seizures due to accumulation of its excitatory metabolite norpethidine.</li>
</ul>
<p>Urinary antiseptics like nalidixic acid, nitrofurantoin and methenamine mandelate fail to achieve high concentration in urine and are likely to produce systemic toxicity.</p>
<p>Congestive heart failure It can alter drug kinetics by-
(i) Decreasing drug absorption from g.i.t. due to mucosal edema and splanchnic vasoconstriction. A significant reduction in procainamide and hydrochlorothiazide absorption has been documented.
(ii) Altering volume of distribution which can increase for some drugs due to expansion of extracellular fluid volume or decrease for others as a result of decreased tissue perfusion. For example, loading doses of drugs like lidocaine and procainamide should be lowered.
(iii) Retarding drug elimination as a result of decreased perfusion and congestion of liver, reduced glomerular filtration rate and increased tubular reabsorption; dosing rate of drugs may need reduction, as for lidocaine, procainamide, theophylline.
(iv) The decompensated heart is more sensitive to digitalis action.
Thyroid disease The hypothyroid patients are more sensitive to digoxin, morphine and CNS depressants. Hyperthyroid patients are relatively resistant to inotropic action of digoxin, but more prone to its arrhythmogenic action. The clearance of digoxin is roughly proportional to thyroid function, but this only partially accounts for the observed changes in sensitivity.
Other examples of modification of drug response by pathological states are:</p>
<ul>
<li>
<p>Antipyretics lower body temperature only when it is raised (fever).</p>
</li>
<li>
<p>Thiazides induce more marked diuresis in edematous patients.</p>
</li>
<li>
<p>Myocardial infarction patients are more prone to adrenaline and digitalis induced cardiac arrhythmias.</p>
</li>
<li>
<p>Myasthenic patients are very sensitive to curare. In them weakness is aggravated by quinine.</p>
</li>
<li>
<p>Schizophrenics tolerate large doses of phenothiazines.</p>
</li>
<li>
<p>Head injury patients are prone to go into respiratory failure with normal doses of morphine.</p>
</li>
<li>
<p>Atropine, tricyclic antidepressants, furosemide can cause urinary retention in individuals with prostatic hypertrophy.</p>
</li>
<li>
<p>Hypnotics given to a patient in severe pain may cause mental confusion and delirium.</p>
</li>
<li>
<p>Cotrimoxazole produces a higher incidence of adverse reactions in AIDS patients.</p>
</li>
</ul>
<ol start="10">
<li>Other drugs Drugs can modify the response to each other by pharmacokinetic or pharmacodynamic interaction between them. Many ways in which drugs can interact have already been considered (see Ch. 2, 3, 4), and a comprehensive account of clinically important drug interactions is presented in Ch. 71.</li>
<li>Cumulation Any drug will cumulate in the body if rate of administration is more than the rate of elimination. However, slowly eliminated drugs are particularly liable to cause cumulative toxicity, e.g. prolonged use of chloroquine causes retinal damage.</li>
</ol>
<ul>
<li>Full loading dose of digoxin should not be given if patient has received it within the past week.</li>
<li>A course of emetine should not be repeated within 6 weeks.</li>
</ul>
<ol start="12">
<li>Tolerance It refers to the requirement of higher dose of a drug to produce a given response. Tolerance is a widely occurring adaptive biological phenomenon. Loss of therapeutic efficacy after prolonged/intensive use of a drug (e.g. of sulfonylureas in type 2 diabetes, or of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi>β</mi><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\beta_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.05278em;">β</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.0528em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> agonists in bronchial asthma), is generally called 'refractoriness'. Drug tolerance may be:
Natural The species/individual is inherently less sensitive to the drug, e.g. rabbits are tolerant to atropine; black races are tolerant to mydriatics. Certain individuals in any population are hyporesponders to certain drugs, e.g. some subjects can consume large quantity of alcohol without getting inebriated; or some hypertensives do not respond to <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>β</mi></mrow><annotation encoding="application/x-tex">\beta</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mord mathnormal" style="margin-right: 0.05278em;">β</span></span></span></span></span> adrenergic blockers.
Acquired Acquired tolerance occurs by repeated use of a drug in an individual who was initially responsive. Body is capable of developing tolerance to most drugs, but the phenomenon is very easily recognized in the case of CNS depressants. An uninterrupted presence of the
drug in the body favours development of tolerance. However, significant tolerance does not develop to atropine, digoxin, cocaine, sodium nitroprusside, etc. Tolerance need not develop equally to all actions of a drug, consequently therapeutic index of a drug may increase or decrease with prolonged use, e.g.:</li>
</ol>
<ul>
<li>Tolerance develops to the sedative action of chlorpromazine but not to its antipsychotic action.</li>
<li>Tolerance occurs to the sedative action of phenobarbitone but not as much to its antiepileptic action.</li>
<li>Tolerance occurs to analgesic and euphoric action of morphine, but not as much to its constipating and miotic actions.
Cross tolerance It is the development of tolerance to pharmacologically related drugs, e.g. alcoholics are relatively tolerant to barbiturates and general anaesthetics. Closer the two drugs are, more complete is the cross tolerance between them, e.g.-</li>
</ul>
<p>There is partial cross tolerance between morphine and barbiturates but complete cross tolerance between morphine and pethidine.
Mechanisms of tolerance The mechanisms responsible for development of tolerance are incompletely understood. However, tolerance may be:
(i) Pharmacokinetic/drug disposition tolerancethe effective concentration of the drug at the site of action is decreased, mostly due to enhancement of drug elimination on chronic use, e.g. barbiturates and carbamazepine induce their own metabolism, while renal excretion of amphetamine is accelerated after regular intake.
(ii) Pharmacodynamic/cellular tolerance-drug action is lessened; cells of the target organ become less responsive, e.g. morphine, barbiturates, nitrates. This may be due to desensitization/down regulation of receptors (see p. 62 ), or weakening of response effectuation.
Tachyphylaxis (Tachy-fast, phylaxis-protection) It refers to rapid development of tolerance when doses of a drug repeated in quick succession result in marked reduction in response. This is usually seen with indirectly acting drugs,</p>
<p>such as ephedrine, tyramine, nicotine. These drugs act by releasing catecholamines in the body, synthesis of which is unable to match the rate of release: stores get depleted. Other mechanisms like slow dissociation of the drug from its receptor, desensitization/internalization or down regulation of receptor, etc. (see p. 62) and/or compensatory homeostatic adaptation.
Drug resistance It refers to tolerance of microorganisms to inhibitory action of antimicrobials, e.g. Staphylococci to penicillin. This phenomenon is described in Ch. 50).</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="rational-use-of-medicines">RATIONAL USE OF MEDICINES<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#rational-use-of-medicines" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>It is widely assumed that use of drugs by qualified doctors of modern medicine would be rational. However, in reality, irrationality abounds in almost every aspect of drug use. Medically inappropriate, ineffective and economically inefficient use of drugs occurs all over the world, more so in the developing countries.</p>
<p>As per the WHO - 'rational use of medicines requires that the patients receive medication appropriate to their clinical needs, in doses that meet their own individual requirements for an adequate period of time, and at the lowest cost to them and to their community'.</p>
<p>Rational use of medicines addresses every step in the supply-use chain of drugs, i.e. selection, procurement, storage, prescribing, dispensing, monitoring and feedback. However, only rational prescribing and related aspects are dealt here.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="rational-prescribing">Rational prescribing<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#rational-prescribing" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Rational prescribing is not just the choice of a correct drug for a disease, or mere matching of drugs with diseases, but also the appropriateness of the whole therapeutic set up along with follow up of the outcome. The criteria to evaluate rational prescribing are:</p>
<ul>
<li>Appropriate indication: the reason to prescribe the medicine is based on sound medical considerations.</li>
<li>Appropriate drug in efficacy, tolerability, safety, and suitability for the patient.</li>
<li>Appropriate dose, route and duration according to specific features of the patient.</li>
<li>Appropriate patient: no contraindications exist and the drug is acceptable to the patient; likelihood of adverse effect is minimal and less than the expected benefit.</li>
<li>Correct dispensing with appropriate information/instruction to the patient.</li>
<li>Adequate monitoring of patient's adherence to medication, as well as of anticipated beneficial and untoward effects of the medication.
There is no doubt that knowledge of the prescriber about drugs and disease is the most important determinant of his/her prescribing pattern, but it has been demonstrated time and again that simply improving knowledge has failed to promote rational drug use. A variety of other factors influence prescribing as summarized in the box.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="factors-influencing-prescribing">Factors influencing prescribing<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#factors-influencing-prescribing" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Knowledge of the prescriber.</li>
<li>Role models: one tends to follow prescribing practices of one's teachers or senior/popular physicians.</li>
<li>Patient load: heavy load tends to foster routinized symptom based prescribing.</li>
<li>Attitude to afford prompt symptomatic relief at all cost.</li>
<li>Imprecise diagnosis: medication is given to cover all possible causes of the illness.</li>
<li>Drug promotion and unrealistic claims by manufacturers.</li>
<li>Unethical inducements (gifts, dinner parties, conference delegation, etc.).</li>
<li>Patient's demands: many patients are not satisfied unless medication is prescribed; misconceptions, unrealistic expectations, 'pill for every ill' belief.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="irrationalities-in-prescribing">Irrationalities in prescribing<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#irrationalities-in-prescribing" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>It is helpful to know the commonly encountered irrationalities in prescribing so that a conscious effort is made to avoid them.</p>
<ul>
<li>
<p>Use of drug when none is needed; e.g. antibiotics for viral fevers and nonspecific diarrhoeas.</p>
</li>
<li>
<p>Compulsive coprescription of vitamins/tonics.</p>
</li>
<li>
<p>Use of drugs not related to the diagnosis, e.g. ampicillin/ciprofloxacin for any fever, proton pump inhibitors for any abdominal symptom.</p>
</li>
<li>
<p>Selection of wrong drug, e.g. tetracycline/ ciprofloxacin for pharyngitis, <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>β</mi></mrow><annotation encoding="application/x-tex">\beta</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mord mathnormal" style="margin-right: 0.05278em;">β</span></span></span></span></span> blocker as antihypertensive for asthmatic patient.</p>
</li>
<li>
<p>Prescribing ineffective/doubtful efficacy drugs, e.g. antioxidants, cough mixtures, memory enhancers, oral serratiopeptidase for injuries/swellings, etc.</p>
</li>
<li>
<p>Incorrect route of administration: injection when the drug can be given orally.</p>
</li>
<li>
<p>Incorrect dose: either underdosing or overdosing; more prevalent in drug prescribing for children.</p>
</li>
<li>
<p>Incorrect duration of treatment, e.g. prolonged postsurgical use of antibiotics or stoppage of antibiotics as soon as relief is obtained, such as in tuberculosis.</p>
</li>
<li>
<p>Unnecessary use of drug combinations, e.g. ciprofloxacin + tinidazole for any case of diarrhoea, ampicillin + cloxacillin for staphylococcal infection, routine use of ibuprofen + paracetamol as analgesic.</p>
</li>
<li>
<p>Unnecessary use of expensive medicines when cheaper drugs are equally effective; craze for latest drugs, e.g. routine use of newer antibiotics.</p>
</li>
<li>
<p>Unsafe use of drugs, e.g. corticosteroids for fever, anabolic steroids in children, use of a single antitubercular drug.</p>
</li>
<li>
<p>Polypharmacy without regard to drug interactions: each prescription on an average has 3-4 drugs, some may have as many as <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>10</mn><mo>−</mo><mn>12</mn></mrow><annotation encoding="application/x-tex">10-12</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">10</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">12</span></span></span></span></span> drugs, of which many are combinations.
Irrational prescribing has a number of adverse consequences for the patient as well as the community. The important ones are:</p>
</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="impact-of-irrational-prescribing">Impact of irrational prescribing<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#impact-of-irrational-prescribing" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Delay/inability in affording relief/cure of disease.</li>
<li>More adverse drug effects.</li>
<li>Prolongation of hospitalization; loss of man days.</li>
<li>Increased morbidity and mortality.</li>
<li>Emergence of microbial resistance.</li>
<li>Financial loss to the patient/community.</li>
<li>Loss of patient's confidence in the doctor.</li>
<li>Lowering of health standards of patients/ community.</li>
<li>Perpetuation of public health problem.</li>
</ul>
<p>Rational prescribing is a stepwise process of scientifically analyzing the therapeutic set up
based on relevant inputs about the patient as well as the drug, and then taking appropriate decisions. It does not end with handing over the prescription to the patient, but extends to subsequent monitoring, periodic evaluations and modifications as and when needed, till the therapeutic goals are achieved. The important steps are summarized in the box.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="process-of-rational-prescribing">Process of rational prescribing<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#process-of-rational-prescribing" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Establish a diagnosis (at least provisional).</li>
<li>Define therapeutic problem(s), e.g. pain, infection, etc.</li>
<li>Define therapeutic goals to be achieved, e.g. symptom relief, cure, prevention of complications, etc.</li>
<li>Select the class of drug capable of achieving each goal.</li>
<li>Identify the drug (from the class selected) based on:
Efficacy
Safety
Suitability
Cost</li>
<li>Decide the route, dose, duration of treatment, considering patient's condition.</li>
<li>Provide proper information and instructions about the medication.</li>
<li>Monitor adherence to the medication (compliance).</li>
<li>Monitor the extent to which therapeutic goal is achieved, e.g. BP lowering, peptic ulcer healing, etc.</li>
<li>Modify therapy if needed.</li>
<li>Monitor any adverse drug events that occur, and modify therapy if needed.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="information-instructions-to-the-patient">Information/instructions to the patient<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#information-instructions-to-the-patient" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Rational prescribing also includes giving relevant and adequate information to the patient about the drug(s) and disease, as well as necessary instructions to be followed.
Effects of the drug Which symptom is expected to disappear and when (e.g. antidepressant will take weeks to act); whether disease will be cured or not (e.g. diabetes, parkinsonism can only be ameliorated, but not cured), what happens if the drug is not taken as advised (e.g. tuberculosis will worsen and may prove fatal).
Side effects There is considerable debate as to how much the patient should be told about the side effects. Detailed descriptions may have</p>
<p>a suggestive effect or may scare the patient and dissuade him from taking the drug, while not informing tantamounts to negligence. The side effect, when it occurs, may upset the uninformed patient. Communicating the common side effects without discouraging the patient is a skill to be developed.
Instructions How and when to take the drug (special dosage forms like inhalers, transdermal patches, etc. may need demonstration); how long to take the drug; when to come back to the doctor; instructions about diet and exercise if needed; what laboratory tests are needed, e.g. prothrombin time with coumarine anticoagulants, leucocyte count with anticancer drugs.
Precautions/warnings What precautions to take; what not to do, e.g. driving (with conventional antihistaminics) or drinking (with metronidazole), or standing still (after sublingual glyceryl trinitrate); risk of allergy or any serious reaction, etc.</p>
<p>In the end it should be ensured that the instructions have been properly understood by the patient. Rational prescribing, thus, is a comprehensive process.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="expiry-date-of-pharmaceuticals">EXPIRY DATE OF PHARMACEUTICALS<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#expiry-date-of-pharmaceuticals" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>It is a legal requirement that all pharmaceutical products must carry the date of manufacture and date of expiry on their label. The period between the two dates is called the 'life period' or 'shelf-life' of the medicine. Under specified storage conditions, the product is expected to remain stable (retain <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&gt;</mo><mn>95</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">&gt;95 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&gt;</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">95%</span></span></span></span></span> potency) during this period. In India, the schedule P (Rule 96) of Drugs and Cosmetics Act (1940) specifies the life period (mostly 1-5 years) of medicinal products and the conditions of storage. The expiry of other medicines has to be specified by the manufacturer, but cannot exceed 5 years, unless permitted by the licencing authority on the basis of satisfactory stability proof.</p>
<p>The shelf-life of a medicine is determined by real time stability studies or by extrapolation from accelerated degradation studies. The expiry date does not mean that the medicine has actually been found to lose potency or become toxic after it, but simply that quality of the medicine is not assured beyond the expiry date, and the manufacturer is not liable if any harm arises from the use of the product. Infact, studies have shown that majority of solid oral dosage forms (tablets/capsules, etc.) stored under ordinary conditions in unopened containers remained stable for 1-5 years (some even up to 25 years) after the expiry
date. Liquid formulations (oral and parenteral) are less stable. Suspensions clump by freezing. Injectable solutions may develop precipitates, become cloudy or discoloured by prolonged storage. Adrenaline injection (in ampoules) has been found to lose potency few months after the expiry date of 1 year (it gets oxidized).</p>
<p>There is hardly any report of toxicity of expired medicines. The degradation product of only one drug (tetracycline) has caused toxicity in man. Outdated tetracycline capsules produced renal tubular damage resembling Fanconi syndrome in the early 1960s. The capsules have now been reformulated to minimize degradation.</p>
<p>Loss of potency beyond the 'life period' of the formulation depends on the drug as well as the storage conditions. High humidity and temperature accelerate degradation of many drugs. Though, majority of medicines, especially solid oral dosage forms, remain safe and active years after the stated expiry date, their use cannot be legally allowed beyond this date.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="evidence-based-medicine">EVIDENCE-BASED MEDICINE<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#evidence-based-medicine" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Extensive scientific investigation of drugs in man and introduction of numerous new drugs over the past few decades is gradually transforming the practice of medicine from 'experience based' wherein clinical decisions are made based on the experience (or rather impression) of the physician to 'evidence-based' wherein the same are guided by scientifically credible evidence from well designed clinical studies.</p>
<p>Evidence-based medicine is the process of systematically finding, evaluating and using contemporary research findings as the basis of clinical decisions.</p>
<p>Results of well designed multicentric interventional trials are forming the basis of constantly evolving guidelines for disease management. Today's physician has to be skilled in the new techniques of searching and evaluating the literature on efficacy, safety and appropriateness of a particular therapeutic measure (drug). Therapeutic evaluation of a drug includes:</p>
<ul>
<li>Quantitation of benefit afforded by it.</li>
<li>The best way (dosage, duration, patient selection, etc.) to use it.</li>
<li>How it compares with other available drugs.</li>
<li>Surveillance of adverse effects produced by it.</li>
</ul>
<p>Clinical studies are basically of the following three types:
a. Clinical trials</p>
<p>b. Cohort studies
c. Case control studies.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="clinical-trial">Clinical trial<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#clinical-trial" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Clinical trial is a prospective ethically designed investigation in human subjects to objectively discover/verify/compare the results of two or more therapeutic measures (drugs).</p>
<p>Clinical trials are designed to answer one or more precisely framed questions about the value of treating equivalent groups of patients by two or more modalities (drugs, dosage regimens, other interventions). Depending on the objective of the study, clinical trial may be conducted in healthy volunteers or in volunteer patients. Healthy volunteers may be used to determine pharmacokinetic characteristics, tolerability, safety and for certain type of drugs (e.g. hypoglycaemic, hypnotic, diuretic) even efficacy. For majority of drugs (e.g. antiepileptic, antipsychotic, antiinflammatory, antitubercular, etc.) therapeutic efficacy can only be assessed in patients.
Ethical considerations All clinical trials must be conducted only after scrutiny and approval by an independent ethics committee as per the 'Good Clinical Practice' (GCP) guidelines. In India, the ICMR (2006) has brought out 'Ethical guidelines, for biomedical research on human participants'. A proper written Informed consent of the patient/trial subject must be obtained. The ethics committee has to ensure that the study does not breach the ethical principles of:
Autonomy: Freedom, dignity and confidentiality of the subject; the right to choose whether or not to participate in the trial or to continue with it.
Beneficence: Motive to do good to the subject and/or the society at large.
Non-maleficence: Not to do harm or put the participant at undue risk/disadvantage.
Justice: Observance of fairness, honesty and impartiality in obtaining, analysing and communicating the data.</p>
<p>Controlled trial The inclusion of a proper comparator (control) group in clinical trials is crucial. The control group, which should be as similar to the test group as possible, receives either a placebo (if ethically permissible) or the existing standard treatment (active control). Separate test and control groups may run simultaneously (parallel group design), or all the subjects may be treated by the two options one after the other (cross over design) so that the same subjects serve as their own controls. Individual variation in response is thus avoided and sample size may be reduced. In the cross over design, some patients are treated first by drug ' <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>A</mi></mrow><annotation encoding="application/x-tex">A</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal">A</span></span></span></span></span> ' followed by drug 'B', while in others the order is reversed. This nullifies the effect (if any) of order of treatment. However, there may still be 'carry over' effects. This design is applicable only to certain chronic diseases which remain stable over long periods.</p>
<p>When one drug is compared to another drug or to a placebo, the dosage regimen (dose, frequency, duration) of the drug is decided in advance. The trial results are applicable only to this chosen regimen. No conclusions can be drawn about a higher or a lower dose. To determine the most appropriate dose, separate dose-ranging studies (trials) have to be performed.</p>
<p>It is well known that both the participants and the investigators of the trial are susceptible to conscious as well as unconscious bias in favour of or against the test drug. The greatest challenge in the conduct of clinical trial is the elimination of bias. The credibility of the trial depends on the measures that are taken to minimize bias. The two basic strategies for minimizing bias are 'randomization' and concealment or 'blinding'.
Randomization The subjects are allocated to either group using a preselected random number table or computer programme so that any subject has equal chance of being assigned to the test or the control group. Discretion (and likely bias) of the investigator/subject in treatment allocation is thus avoided. If considered</p>
<p>necessary, stratified randomization according to age/sex/disease severity/other patient variable may be adopted.
Blinding (masking) This refers to concealment of the nature of treatment (test or control) from the subject (single blind) or both the subject as well as the investigator (double blind). For this purpose the two medications have to appear similar in looks, number, weight, taste, etc. and are to be supplied in unlabelled packets marked for each patient. In double blind, the key/code to treatment allocation is kept by a third 'data management' party who is not involved in treating or recording observations. The code is broken at the completion of the trial and the results are analysed according to prespecified statistical method. However, all clinical trials need not be blinded. Those in which the nature of treatment is not concealed are called 'open' trials.</p>
<p>Randomized controlled double blind trial (RCT) is the most credible method of obtaining evidence of efficacy, safety or comparative value of treatments.
Inclusion/exclusion criteria The characteristics of the subject/patient (age, sex, disease/symptom, severity and/or duration of illness, coexistent and past diseases, concurrent/preceeding drug therapy, etc.) who are to be recruited in the trial or excluded from it must be decided in advance. The trial results are applicable only to the population specified by these criteria.
End point The primary and secondary (if any) end points (cure, degree of improvement, symptom relief, surrogate marker, avoidance of complication, curtailment of hospitalization, survival, quality of life, etc.) of the trial must be specified in advance. The results are analysed in relation to the specified end points.</p>
<p>Higher efficacy may not always be the aim of a clinical trial. A trial may be designed to prove 'non-inferiority' (of the new drug) to the existing treatment, and possibly afford advantages in terms of tolerability, safety, convenience, cost or applicability to special patient subgroup(s).</p>
<p>Sample size: Both financial and ethical considerations demand that the number of subjects in the trial be the minimum needed for a valid result. The minimum number of subjects for obtaining a decisive conclusion (test better than control/control better than test/no difference between the two) must be calculated statistically beforehand. Because the trial is conducted on a sample of the whole patient population, there is always a chance that the sample was not representative of the population. Thus, the results cannot be absolutely conclusive.
Two types of errors are possible:
Type I ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>α</mi></mrow><annotation encoding="application/x-tex">\alpha</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.4306em;"></span><span class="mord mathnormal" style="margin-right: 0.0037em;">α</span></span></span></span></span> ) error: a difference is found between the two groups while none exists. Its possibility is called 'significance' of the result, e.g. if test drug is found to be better than control at a significance level of 0.05 , it means that there is <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">5 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">5%</span></span></span></span></span> chance that this is not real.
Type II ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>β</mi></mrow><annotation encoding="application/x-tex">\beta</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mord mathnormal" style="margin-right: 0.05278em;">β</span></span></span></span></span> ) error: no difference is found while it really exists. The probability of failing to detect an actual difference is expressed by the 'power' of the trial. A power of 0.9 means that there is <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>10</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">10 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">10%</span></span></span></span></span> chance of missing a real difference.</p>
<p>The sample size of the trial depends on the desired level of significance and power. The other input needed for calculation of sample size is the magnitude of difference between the two groups that is expected or is considered clinically significant, e.g. a <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>10</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">10 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">10%</span></span></span></span></span> reduction in pain intensity may not be considered clinically significant, while a <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>10</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">10 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">10%</span></span></span></span></span> reduction in mortality may be worthwhile. Larger sample size is required to detect smaller difference. Also, higher the significance and power level desired, greater is the number of subjects. The variability of response in terms of the primary end point also affects the sample size. Responses that show greater individual variation need larger number of subjects to achieve the desired significance and power levels.</p>
<p>Many large scale trials are subjected to interim analysis from time to time as the trial progresses by an independent committee which can order an early termination if a decisive result (positive or negative) is obtained; because it would be unethical to subject some of the remaining patients to a treatment (test or control) which has been found inferior.</p>
<p>Multicentric trial Many large trials are conducted at more than one centre by as many teams of investigators, sometimes spread over several countries. The advantages are:</p>
<ul>
<li>Larger number of patients can be recruited in a shorter period of time.</li>
<li>Results are applicable to a wider population base which may cover several countries/ ethnic groups.</li>
<li>Regulatory requirements of several countries may be satisfied.</li>
<li>Credibility of the trial is enhanced.</li>
</ul>
<p>The phase III trials are generally multicentric.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="sequential-trial">Sequential trial<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#sequential-trial" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>This design attempts to detect a significant result as soon as it is achieved, minimizing the number of subjects. The trial is conducted on matched pairs of subjects and is scored as ' <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>A</mi></mrow><annotation encoding="application/x-tex">A</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal">A</span></span></span></span></span> ' treatment better than ' <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>B</mi></mrow><annotation encoding="application/x-tex">B</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.05017em;">B</span></span></span></span></span> ' or ' <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>B</mi></mrow><annotation encoding="application/x-tex">B</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.05017em;">B</span></span></span></span></span> ' better than ' <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>A</mi></mrow><annotation encoding="application/x-tex">A</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal">A</span></span></span></span></span> ' or no difference. This is plotted continuously as the trial proceeds till the boundries of predetermined level of significant superiority/inferiority/no difference are touched. The trial is then terminated. This design is applicable only to certain types of drugs and diseases for which clinical end points are achieved quickly and paired comparisons are possible. Moreover, it may not always be practicable to recruit matching pairs of trial subjects.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="meta-analysis">Meta-analysis<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#meta-analysis" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>This is an exercise in which data from several similarly conducted randomized controlled clinical trials with the same drug (or class of drugs) examining the same clinical end point(s) is pooled to bring out the overall balance of evidence by enlarging the number of test and control subjects and increasing the significance and power of the conclusions. Because individual trials are often conducted on relatively smaller number of patients, some may fail to detect a significant difference, while others may find it. Discordant results are published which confuse the medical practitioner. There are many criticisms of meta-analysis, such as:
a. bias in the selection of trials for analysis (selection bias);
b. unintentional exclusion of negative results which are less likely to be published (publication bias);
c. nonuniformity of the trials in details of methodology and conduct.
Nevertheless, meta-analysis is a useful tool to arrive at conclusions that may influence medical practice. For example, meta-analysis of trials has strongly supported the use of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>β</mi></mrow><annotation encoding="application/x-tex">\beta</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mord mathnormal" style="margin-right: 0.05278em;">β</span></span></span></span></span>-adrenergic blockers in heart failure and use of statins to reduce risk of coronary artery disease.
To be reliable, the meta-analysis should observe the following:</p>
<ul>
<li>Comprehensive search of the literature to identify all eligible trials.</li>
<li>Use objective criteria in selecting the trials for inclusion.</li>
<li>Include only randomized trials of assured quality.</li>
<li>Employ proper statistical methods in pooling and treating the data from individual trials.
Meta-analysis are now frequently published on contemporary therapeutic issues.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="cohort-study">Cohort study<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#cohort-study" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>This is a type of observational study in which no intervention for the sake of the study is done. 'Cohort' is a group of individuals having some common features. In the context of drug research, the common feature is that all study subjects have taken a particular drug. Occurrence of events (beneficial or adverse) in users and nonusers of the drug is compared. Prescription event monitoring is a cohort study. The cohort study can be a prospective or a retrospective study. In the prospective design, all patients who receive the study drug are followed up for therapeutic outcomes or adverse effects. A matching group of patients who have not received the drug is identified and followed up to serve as control. Cohort studies are primarily used to discover uncommon adverse effects that may be missed during formal therapeutic trials which involve fewer patients and often exclude certain type of patients who may be susceptible to that adverse effect. Its value for defining therapeutic outcomes is less credible. The limitations of cohort studies are that controls included may not be appropriate, and relatively long period of follow up is needed.</p>
<p>In the retrospective cohort study, health records of a population are scrutinized for exposure to the study drug and the subsequent</p>
<table><thead><tr><th style="text-align: center;">Grades of strength of evidence</th><th style="text-align: center;"></th><th style="text-align: center;"></th></tr></thead><tbody><tr><td style="text-align: center;">Grade I</td><td style="text-align: center;">Systematic reviews/Meta-analysis</td><td style="text-align: center;">Most reliable, may form the basis of clinical &lt;br&gt; decisions</td></tr><tr><td style="text-align: center;">Grade II</td><td style="text-align: center;">Well powered randomized controlled trial/more &lt;br&gt; than one trials</td><td style="text-align: center;">Reliable, but may be supported or refuted by &lt;br&gt; similar studies</td></tr><tr><td style="text-align: center;">Grade III</td><td style="text-align: center;">Open label trials/pilot studies/observational &lt;br&gt; (cohort and case-control) studies (prospective &lt;br&gt; or retrospective)</td><td style="text-align: center;">Less reliable, need more rigorous testing, may &lt;br&gt; indicate further investigation</td></tr><tr><td style="text-align: center;">Grade IV</td><td style="text-align: center;">Case reports/anecdotal reports/clinical &lt;br&gt; experience</td><td style="text-align: center;">Least reliable; may serve as pointers to initiate &lt;br&gt; formal studies</td></tr></tbody></table>
<p>beneficial/adverse events. Its value is questionable because many events may have been missed in the records and several unknown factors may have contributed to the findings. However, it may serve as pointer, or to arouse suspicion.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="case-control-study">Case control study<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#case-control-study" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>This type of observational study is used mainly to reveal association of a suspected rare adverse event with the use of a particular drug. Cases of the suspected adverse event (e.g. agranulocytosis) are collected from hospital records or disease registries, etc. A matched control group similar in other respects but not having the adverse event is selected. Drug histories of both groups are traced backwards to compare exposure to the indicated drug (e.g. phenylbutazone) among patients with the adverse event to those without it. The suspicion is strengthened if high association is found. Though case control studies can be performed rather quickly because the number of patients analysed is small compared to the cohort design, they do not prove causality. Moreover, the causative drug and the adverse event have to be suspected first to plan the study, whereas cohort study can reveal unsuspected adverse events. Variable accuracy of retrospective records, non-randomly selected control group, chances of bias and a variety of unknown factors make the case control study a weak instrument for affording convincing evidence.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="grading-strength-of-evidence">Grading strength of evidence<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#grading-strength-of-evidence" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>The strength of evidence from the conclusions of various kinds of trials, studies and reports has been graded from strong to weak as presented in the box.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="new-drug-development">NEW DRUG DEVELOPMENT<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#new-drug-development" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>In this era of bewildering new drug introduction and rapid attrition of older drugs, the doctor needs to have an overall idea of the manner in which new drugs are developed and marketed. Drug development now is a highly complex, tedious, competitive, costly and commercially risky process. From the synthesis/identification of the molecule to marketing, a new drug takes at least 10 years and costs 500-1000 million US$. As such, invention and development of new drugs is now possible only in the set up of big pharmaceutical houses that alone have the resources, infrastructure and dedicated teams of scientists to carry out the multiple specialized stages of the process. Though the pharmaceutical industry is often regarded cunning, greedy, unscrupulous, deceptive and fleecing the people, there is no denying that it is responsible for most of the progress in therapeutics as well as pharmacological knowledge of today.</p>
<p>The major steps/stages in the development of a new drug are given in the box.</p>
<p>Stages in new drug development
Synthesis/isolation of the compound:
Preclinical studies: screening, evaluation, pharmacokinetic and short-term toxicity testing in animals:
Scrutiny and grant of permission for clinical trials:
Pharmaceutical formulation, standardization of chemical/ biological/immuno-assay of the compound:
Clinical studies: phase I, phase II, phase III trials; long-term animal toxicity testing:
Review and grant of marketing permission:
Postmarketing surveillance:
(1-2 years)
(2-4 years)
(3-6 months)
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo stretchy="false">(</mo><mn>0.5</mn><mo>−</mo><mn>1</mn></mrow><annotation encoding="application/x-tex">(0.5-1</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mopen">(</span><span class="mord">0.5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">1</span></span></span></span></span> year)
(3-10 years)
(0.5-2 years)
(phase IV studies)</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="approaches-to-drug-discovery-invention">Approaches to drug discovery/ invention<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#approaches-to-drug-discovery-invention" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Exploration of natural sources Plants are the oldest source of medicines. Clues about these have been obtained from traditional systems of medicine prevalent in various parts of the world; Opium (morphine), Ephedra (ephedrine), Cinchona (quinine), curare (tubocurarine), belladonna (atropine), Quinghaosu (artemisinin) are the outstanding examples. Though animal parts have been used as cures since early times, it was physiological experiments performed in the <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mn>19</mn><mtext>th&nbsp;</mtext></msup></mrow><annotation encoding="application/x-tex">19^{\text {th }}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8491em;"></span><span class="mord">1</span><span class="mord"><span class="mord">9</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8491em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord text mtight"><span class="mord mtight">th&nbsp;</span></span></span></span></span></span></span></span></span></span></span></span></span></span> and early <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mn>20</mn><mtext>th&nbsp;</mtext></msup></mrow><annotation encoding="application/x-tex">20^{\text {th }}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8491em;"></span><span class="mord">2</span><span class="mord"><span class="mord">0</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8491em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord text mtight"><span class="mord mtight">th&nbsp;</span></span></span></span></span></span></span></span></span></span></span></span></span></span> century that led to introduction of some animal products into medicine, e.g. adrenaline, thyroxine, insulin, liver extract, antisera, etc. Few minerals (iron/calcium salts, etc.) are the other natural medicinal substances. The discovery of penicillin (1941) opened the flood-gates of a vast source-microorganisms-of a new kind of drugs (antibiotics). The use of microbes for production of vaccines is older than their use to produce antibiotics.</p>
<p>Though few drugs are now produced from plants, animals or microbes, these sources of medicines are by no means exhausted. However, they mostly serve as lead compounds.
Random or targeted chemical synthesis Synthetic chemistry made its debut in the <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mn>19</mn><mtext>th&nbsp;</mtext></msup></mrow><annotation encoding="application/x-tex">19^{\text {th }}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8491em;"></span><span class="mord">1</span><span class="mord"><span class="mord">9</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8491em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord text mtight"><span class="mord mtight">th&nbsp;</span></span></span></span></span></span></span></span></span></span></span></span></span></span> century and is now the largest source of medicines. Randomly synthesized compounds can be tested for a variety of pharmacological activities. Though some useful drugs (barbiturates, chlorpromazine) have been produced serendipitously by this approach, it has very low probability of hitting at the right activity in the right compound; rarely employed now.
Lead optimization A more practical approach is to synthesize chemical congeners of natural products/synthetic compounds with known pharmacological activity in the hope of producing
more selective/superior drugs. Many families of clinically useful drugs have been fathered by a 'lead compound'. Often only 'me too' drugs are produced, but sometimes breakthroughs are achieved, e.g. thiazide diuretics from acetazolamide, tricyclic antidepressants from phenothiazines.</p>
<p>Study of several congeners of the lead compound can delineate molecular features responsible for a particular property. Application of this structure-activity relationship information has proven useful on many occasions, e.g. selective <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi>β</mi><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\beta_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.05278em;">β</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.0528em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> agonists (salbutamol) and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>β</mi></mrow><annotation encoding="application/x-tex">\beta</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mord mathnormal" style="margin-right: 0.05278em;">β</span></span></span></span></span> blockers (propranolol, etc.) have been produced by modifying the structure of isoprenaline, <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">H</mi><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{H}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">H</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> blockers by modifying the side chain of histamine, ethinyl-estradiol by introducing a substitution that resists metabolic degradation, mesoprostol (more stable) by esterifying <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">P</mi><mi mathvariant="normal">G</mi><mi mathvariant="normal">E</mi></mrow><mn>1</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{PGE}_{1}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">PGE</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span>.</p>
<p>More commonly now, as described later in the rational approach, identification of the target biomolecule is the starting point for new drug invention. A lead compound capable of interacting with the target is searched by applying diverse approaches described above and below. The affinity and selectivity of the lead compound for the target is determined. It is then chemically modified to optimise these parameters as well as pharmacokinetic, pharmaceutical, toxicological and other characteristics. More suitable candidate drug(s) may thus emerge for further development.
Single enantiomers Many drugs are chiral compounds. Because pharmacological activity depends on three dimensional interaction of drug molecules with their target biomolecules, the enantiomers ( R and S forms or <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>d</mi></mrow><annotation encoding="application/x-tex">d</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6944em;"></span><span class="mord mathnormal">d</span></span></span></span></span> and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>l</mi></mrow><annotation encoding="application/x-tex">l</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6944em;"></span><span class="mord mathnormal" style="margin-right: 0.01968em;">l</span></span></span></span></span> isomers) of chiral drugs differ in biological activity, metabolic degradation, etc. Often only one of the enantiomers is active. Single enantiomer drug could be superior to its racemate, because the additional enantiomer may not only be a 'silent passenger' but contribute to side effects, toxicity (dextro-dopa is more toxic than levo-dopa), load on metabolism or even antagonize the active enantiomer. Regulatory authorities in many countries, led by US-FDA, have mandated separate investigation of the enantiomers in case the new drug is a chiral molecule. Approval is withheld unless the pure enantiomers are shown to be no better than the racemate. Several drugs, originally introduced as racemates, have now been made available as single enantiomer preparations as well (see box).
Rational approach This depends on sound physiological, biochemical, pathological knowledge and identification of specific target for drug action. Truly new classes of drugs generally follow the identification of a novel target for drug action, such as <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">H</mi><mo lspace="0em" rspace="0em">+</mo></msup><msup><mi mathvariant="normal">K</mi><mo lspace="0em" rspace="0em">+</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{H}^{+} \mathrm{K}^{+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7713em;"></span><span class="mord"><span class="mord mathrm">H</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.7713em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span><span class="mord"><span class="mord mathrm">K</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.7713em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span>ATPase for gastric acid suppression or glycoprotein IIa/IIIb receptor for platelet function inhibition. The drug is aimed at mitigating the derangement caused by the disease, e.g. levodopa was tried in parkinsonism based on the finding that the condition resulted from deficiency of dopamine in the striatum. The purine, pyrimidine, folate antimetabolites were introduced in cancer chemotherapy after elucidation of key role of these metabolites in cell proliferation. Because virus directed reverse transcriptase is unique to retroviruses, its inhibitors have been developed as anti-HIV drugs. This approach is very attractive but requires a lot of basic research.</p>
<table><thead><tr><th style="text-align: center;">Drugs marketed as single enantiomers</th><th style="text-align: center;"></th></tr></thead><tbody><tr><td style="text-align: center;">Enantiomer</td><td style="text-align: center;">Advantage claimed</td></tr><tr><td style="text-align: center;">(S) atenolol</td><td style="text-align: center;">half dose, better tolerated</td></tr><tr><td style="text-align: center;">(S) metoprolol</td><td style="text-align: center;">half dose</td></tr><tr><td style="text-align: center;">(S) amlodipine</td><td style="text-align: center;">half dose, less peripheral edema</td></tr><tr><td style="text-align: center;">(S) omeprazole (esomeprazole)</td><td style="text-align: center;">better oral bioavailability</td></tr><tr><td style="text-align: center;">(S) pantoprazole</td><td style="text-align: center;">more potent</td></tr><tr><td style="text-align: center;">(R) salbutamol</td><td style="text-align: center;">more active, (S) may antagonize (R)</td></tr><tr><td style="text-align: center;">(S) citalopram (escitalopram)</td><td style="text-align: center;">lower dose, less side effects</td></tr><tr><td style="text-align: center;">(S) naproxen</td><td style="text-align: center;">less burden on kidney (but inversion occurs in vivo)</td></tr><tr><td style="text-align: center;">cisatracurium</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>4</mn><mo>×</mo></mrow><annotation encoding="application/x-tex">4 \times</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">4</span><span class="mord">×</span></span></span></span></span> more potent, less histamine release</td></tr><tr><td style="text-align: center;">levofloxacin</td><td style="text-align: center;">more active, slower elimination</td></tr><tr><td style="text-align: center;">levocetirizine (R)</td><td style="text-align: center;">half dose, only (R) form active</td></tr><tr><td style="text-align: center;">desloratadine</td><td style="text-align: center;">half dose</td></tr></tbody></table>
<p>Molecular modelling Advances in protein chemistry and computer aided elucidation of three-dimensional structure of key receptors, enzymes, etc. has permitted designing of targeted compounds. Suitable computer programmes are being used to optimise the three-dimensional structure of the candidate drug to fit the identified target site(s) and/or have optimum pharmacokinetics. The designing of selective COX-2 inhibitors was prompted by the comparative configuration of COX-1 and COX-2 isoenzyme molecules. Study of drug binding to mutated receptors and elucidation of configuration of drugreceptor complexes is now guiding production of improved drugs. Attempts are being made to produce individualized drugs according to pharmacogenomic suitability.
Combinatorial chemistry Chemical groups are combined in a random manner to yield innumerable compounds and subjected to high-throughput screening on cells, genetically engineered microbes, receptors, enzymes, etc. in robotically controlled automated assay systems. Computerized analysis is used to identify the so called 'hits.' These compounds are then subjected to conventional tests. This new approach has vast potentials, but failure rates are high.
Biotechnology Several drugs are now being produced by recombinant DNA technology, e.g. human growth hormone, human insulin, interferon, etc. Some monoclonal and chimeral antibodies have been introduced as drugs.</p>
<p>New molecules, especially antibiotics, regulatory peptides, growth factors, cytokines, etc. produced by biotechnological methods can be evaluated as putative drugs. Other experimental approaches in new drug development are antisense oligonucleotides and gene therapy.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="preclinical-studies">Preclinical studies<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#preclinical-studies" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>After synthesizing/identifying a prospective compound, it is tested on animals to expose the whole
pharmacological profile. Experiments are generally performed on a rodent (mouse, rat, guinea pig, hamster, rabbit) and then on a larger animal (cat, dog, monkey). As the evaluation progresses unfavourable compounds get rejected at each step, so that only a few out of thousands reach the stage when administration to man is considered. The following types of tests are performed.</p>
<ol>
<li>Screening tests These are simple and rapidly performed tests to indicate presence or absence of a particular pharmacodynamic activity that is sought for, e.g. analgesic or hypoglycaemic activity.</li>
<li>Tests on isolated organs, bacterial cultures, etc. These also are preliminary tests to detect specific activity, such as antihistaminic, antisecretory, vasodilator, antibacterial, etc.</li>
<li>Tests on animal models of human disease Such as kindled seizures in rats, spontaneously (genetically) hypertensive rats, experimental tuberculosis in mouse, alloxan induced diabetes in rat or dog, etc.</li>
<li>Confirmatory tests and analogous activities Compounds found active are taken up for detailed study by more elaborate tests which confirm and characterize the activity. Other related activities, e.g. antipyretic and antiinflammatory activity in an analgesic are tested.</li>
<li>Systemic pharmacology Irrespective of the primary action of the drug, its effects on major organ systems such as nervous, cardiovascular, respiratory, renal, g.i.t are worked out. Mechanism of action, including additional mechanisms, e.g. <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>α</mi></mrow><annotation encoding="application/x-tex">\alpha</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.4306em;"></span><span class="mord mathnormal" style="margin-right: 0.0037em;">α</span></span></span></span></span> adrenergic blockade, calcium channel blockade, nitro-vasodilatation, etc. in a <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>β</mi></mrow><annotation encoding="application/x-tex">\beta</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mord mathnormal" style="margin-right: 0.05278em;">β</span></span></span></span></span> adrenergic blocker antihypertensive, are elucidated.</li>
<li>Quantitative tests The dose-response relationship, maximal effect and comparative potency/efficacy with existing drugs is ascertained.</li>
<li>Pharmacokinetics The absorption, volume of distribution, metabolism, excretion, pattern of tissue distribution and plasma half-life of the drug are quantified.</li>
<li>Toxicity tests The aim is to determine safety of the compound in at least 2 animal species, one rodent and one nonrodent, e.g. mouse/rat and dog by oral and parenteral routes.
Acute toxicity: Single escalating doses are given to small groups of animals that are observed for overt effects and mortality for 1-3 days. The dose which kills <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>50</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">50 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">50%</span></span></span></span></span> animals <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo fence="true">(</mo><msub><mrow><mi mathvariant="normal">L</mi><mi mathvariant="normal">D</mi></mrow><mn>50</mn></msub><mo fence="true">)</mo></mrow><annotation encoding="application/x-tex">\left(\mathrm{LD}_{50}\right)</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="minner"><span class="mopen delimcenter" style="top: 0em;">(</span><span class="mord"><span class="mord"><span class="mord mathrm">LD</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">50</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mclose delimcenter" style="top: 0em;">)</span></span></span></span></span></span> is calculated. Organ toxicity is examined by histopathology on all animals.
Subacute toxicity: Repeated doses are given for 2-12 weeks depending on the duration of intended treatment in man. Doses are selected on the basis of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">E</mi><mi mathvariant="normal">D</mi></mrow><mn>50</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{ED}_{50}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">ED</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">50</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">L</mi><mi mathvariant="normal">D</mi></mrow><mn>50</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{LD}_{50}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">LD</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">50</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span>. Animals are examined for overt effects, food intake, body weight, haematology, etc. and organ toxicity.
Chronic toxicity: The drug is given for 6-12 months and effects are studied as in subacute toxicity. This is generally undertaken concurrently with early clinical trials.
Reproduction and teratogenicity: Effects on spermatogenesis, ovulation, fertility and developing foetus are studied.</li>
</ol>
<p>Mutagenicity: Ability of the drug to induce genetic damage is assessed in bacteria (Ames test), mammalian cell cultures and in intact rodents.
Carcinogenicity: Drug is given for long-term, even the whole life of the animal and they are watched for development of tumours.</p>
<p>Standardised procedures under 'Good Laboratory Practices' (GLP) have been laid down for the conduct of animal experiments, especially toxicity testing.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="clinical-trials">Clinical trials<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#clinical-trials" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>When a compound deserving trial in man is identified by animal studies, the regulatory authorities are approached who on satisfaction issue an 'investigational new drug' (IND) licence. The drug is formulated into a suitable dosage form and clinical trials are conducted in a logical phased manner. To minimize any risk, initially few subjects receive the drug under close supervision. Later, larger numbers are treated with only relevant monitoring. Standards for the design, ethics, conduct, monitoring, auditing, recording and analyzing data and reporting of clinical trials have been laid down in the form of 'Good Clinical Practice' (GCP) guidelines by an International Conference on Harmonization (ICH). National agencies in most countries, including ICMR in India, have also framed ethical guidelines for clinical trials. Adherence to these provides assurance that the data and reported results are credible and accurate, and that the rights, integrity and confidentiality of trial subjects are protected as enunciated in the Helsinki Declaration of the World Medical Association. The requirements and regulations for the conduct of clinical trials on a new drug in India have been laid down in the schedule Y of the Drugs and Cosmetics Rules.</p>
<p>The clinical studies are conventionally divided into 4 phases.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="phase-i-human-pharmacology-and-safety">Phase I: Human pharmacology and safety<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#phase-i-human-pharmacology-and-safety" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>The first human administration of the drug is carried out by qualified clinical pharmacologists/trained physicians in a setting where all vital functions are monitored and emergency/ resuscitative facilities are available. Subjects (mostly healthy volunteers, sometimes patients) are exposed to the drug one by one
(total 20-80 subjects), starting with the lowest estimated dose (generally <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mi mathvariant="normal">/</mi><mn>100</mn></mrow><annotation encoding="application/x-tex">1 / 100</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">1/100</span></span></span></span></span> to <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mi mathvariant="normal">/</mi><mn>10</mn></mrow><annotation encoding="application/x-tex">1 / 10</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">1/10</span></span></span></span></span> of the highest dose producing no toxicity in animals) and increasing stepwise to achieve the effective dose. An attempt is made to determine the dose range that may be used in further studies. The emphasis is on safety, tolerability, and to detect any potentially dangerous effects on vital functions, such as precipitous fall/rise in blood pressure or heart rate, arrhythmias, bronchospasm, seizures, kidney/liver damage, etc. Unpleasant side effects are noted and an attempt is made to observe the pharmacodynamic effects in man. The human pharmacokinetic parameters of the drug are measured for the first time. No blinding is done: the study is open label.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="phase-0-microdosing-study">Phase 0: Microdosing study<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#phase-0-microdosing-study" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>This is a new strategy being developed to reduce the cost and time of the drug development process. The rate of rejection of candidate drugs at various stages of clinical development has progressively increased recently, discouraging pharmaceutical companies to venture into the risky business of new drug invention. This has alarmed the FDA (USA) and the European Medicines Agency to encourage novel cost-cutting approaches in drug development. One such tool is the microdosing human study undertaken before phase-1 trial, and is also called phase ' 0 ' study.</p>
<p>Many candidate drugs fail during clinical trials due to sub-optimal human pharmacokinetics. Very low doses, generally about <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mi mathvariant="normal">/</mi><mn>100</mn></mrow><annotation encoding="application/x-tex">1 / 100</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">1/100</span></span></span></span></span> th of the estimated human dose, or a maximum of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>100</mn><mi>μ</mi><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">100 \mu \mathrm{~g}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">100</span><span class="mord mathnormal">μ</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm" style="margin-right: 0.01389em;">g</span></span></span></span></span></span> total dose of candidate drug, are administered to healthy volunteers and pharmacokinetics is worked out using highly sophisticated instrumentation, such as Accelerator mass spectrometry (AMS) with radiolabelled drug, or LC-Tandem mass spectrometry (LC-MS-MS) to measure ultra low drug levels. These subpharmacological doses are not expected to produce any therapeutic or toxic effects, but yield human pharmacokinetic information. These studies may obviate the need for animal pharmacokinetic studies and can be undertaken before extensive animal toxicity tests. Thus, elaborate animal studies and costly phase 1 human trials could be avoided for candidate drugs which would have later failed due to unsuitable human pharmacokinetics. Moreover, the pharmacokinetic 0 phase data could be useful in more precise selection of doses for phase 1 study.</p>
<p>The major objection against phase ' 0 ' study is that the microdose pharmacokinetics may be quite different from that at pharmacological doses, since body may handle such divergent doses in different ways. The phase 0 studies have not yet been technically fully developed or adequately evaluated. They are neither established nor mandatory. However, they are promising, and most regulatory authorities are willing to allow and consider them.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="phase-ii-therapeutic-exploration-and-dose-ranging">Phase II: Therapeutic exploration and dose ranging<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#phase-ii-therapeutic-exploration-and-dose-ranging" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>This is conducted by physicians who are trained as clinical investigators, and involve 100-500 patients selected according to specific inclusion and exclusion criteria. The primary aim is establishment of therapeutic efficacy, dose range and ceiling effect in a controlled setting. Tolerability and pharmacokinetics are studied as extension of phase I. The study is mostly controlled and randomized, and may be blinded or open label. It is generally carried out at <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>2</mn><mo>−</mo><mn>4</mn></mrow><annotation encoding="application/x-tex">2-4</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">2</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">4</span></span></span></span></span> centres. The candidate drug may get dropped at this stage if the desired level of clinical efficacy is not obtained.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="phase-iii-therapeutic-confirmation-comparison">Phase III: Therapeutic confirmation/ comparison<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#phase-iii-therapeutic-confirmation-comparison" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Generally these are randomized double blind comparative trials conducted on a larger patient population (500-3000) by several physicians (usually specialists in treating the target disease) at many centres. The aim is to establish the value of the drug in relation to existing therapy. Safety and tolerability are assessed on a wider scale, while pharmacokinetic studies may be conducted on some of the participants to enlarge the population base of pharmacokinetic data. Indications are finalized and guidelines for therapeutic use are formulated. A 'new drug application' (NDA) is submitted to the licencing authority (like FDA), who if convinced give marketing permission. Restricted
marketing permission for use only in hospitals with specific monitoring facilities, or only by specially trained physicians may be granted in case of toxic drugs which are found useful in serious or otherwise incurable diseases.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="phase-iv-postmarketing-surveillance-data-gathering-studies">Phase IV: Postmarketing surveillance/data gathering studies<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#phase-iv-postmarketing-surveillance-data-gathering-studies" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>After the drug has been marketed for general use, practicing physicians are identified through whom data are collected on a structured proforma about the efficacy, acceptability and adverse effects of the drug in the real field situation (similar to prescription event monitoring). Patients treated in the normal course form the study population: numbers therefore are much larger. Uncommon/idiosyncratic adverse effects, or those that occur only after long-term use and unsuspected drug interactions are detected at this stage. Patterns of drug utilization and additional indications may emerge from the surveillance data.</p>
<p>Further therapeutic trials involving special groups like children, elderly, pregnant/lactating women, patients with renal/hepatic disease, etc. (which are generally excluded during clinical trials) may be undertaken at this stage. Modified release dosage forms, additional routes of administration, fixed dose drug combinations, etc. may be explored.</p>
<p>As such, most drugs continue their development even after marketing.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="problem-directed-study">PROBLEM DIRECTED STUDY<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#problem-directed-study" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>5.1 A 65 -year-old male hepatic cirrhosis patient was admitted to the hospital for treatment of gross ascites. He was administered inj. furosemide 40 mg i.m. three times a day to excrete the ascitic fluid. He responded with brisk diuresis, but on the 3rd day he was found to be talking irrelevant, was weak and partly disoriented. He had a fainting episode on getting up from the bed. His serum <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">K</mi><mo lspace="0em" rspace="0em">+</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{K}^{+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7713em;"></span><span class="mord"><span class="mord mathrm">K</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.7713em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span>was <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>2.8</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">E</mi><mi mathvariant="normal">q</mi></mrow><mi mathvariant="normal">/</mi><mi mathvariant="normal">L</mi></mrow><annotation encoding="application/x-tex">2.8 \mathrm{mEq} / \mathrm{L}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">2.8</span><span class="mord"><span class="mord mathrm">mEq</span></span><span class="mord">/</span><span class="mord mathrm">L</span></span></span></span></span> (low) and blood pH was 7.6 (raised).
(a) What is the likely cause of his condition on the 3rd day?
(b) What should be the principles of management of this complication?
(see Appendix-1 for solution)</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="chapter-6-adverse-drug-effects">Chapter 6 Adverse Drug Effects<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#chapter-6-adverse-drug-effects" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Adverse effect is 'any undesirable or unintended consequence of drug administration'. It is a broad term, includes all kinds of noxious effect-trivial, serious or even fatal.</p>
<p>For the purposes of detecting and quantifying only those adverse effects of a drug which are of some import and occur in ordinary therapeutic setting, the term adverse drug reaction (ADR) has been defined as 'any noxious change which is suspected to be due to a drug, occurs at doses normally used in man, requires treatment or decrease in dose or indicates caution in the future use of the same drug'. This definition excludes trivial or expected side effects and poisonings or overdose.
Another term 'adverse drug event' (ADE) has been used to mean 'any untoward medical occurrence that may present during treatment with a medicine, but which does not necessarily have a causal relationship with the treatment'. The idea is to record all adverse events first, and look for causality only while analyzing pooled data.</p>
<p>All drugs are capable of producing adverse effects, and whenever a drug is given a risk is taken. The magnitude of risk has to be considered along with the magnitude of expected therapeutic benefit in deciding whether to use or not to use a particular drug in a given patient, e.g. even risk of bone marrow depression may be justified in treating cancer, while mild drowsiness caused by an antihistaminic in treating common cold may be unacceptable.</p>
<p>Adverse effects may develop promptly or only after prolonged medication or even after stoppage of the drug. Adverse effects
are not rare; an incidence of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>10</mn><mo>−</mo><mn>25</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">10-25 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">10</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">25%</span></span></span></span></span> has been documented in different clinical settings. They are more common with multiple drug therapy and in the elderly. Adverse effects have been classified in many ways. One may divide them into:</p>
<p>Predictable (Type A or Augmented) reactions (mechanism based adverse reactions) These are based on the pharmacological properties of the drug, which means that they are augmented, but qualitatively normal response to the drug; include side effects, toxic effects and consequences of drug withdrawal. They are more common, dose related and mostly preventable and reversible.</p>
<p>Unpredictable (Type B or Bizarre) reactions These are based on peculiarities of the patient and not on drug's known actions; include allergy and idiosyncrasy. They are less common, often non-dose related, generally more serious and require withdrawal of the drug. Some of these reactions can be predicted and prevented if their genetic basis is known and suitable test to characterize the individual's phenotype is performed.</p>
<p>Severity of adverse drug reactions has been graded as:
Minor: No therapy, antidote or prolongation of hospitalization is required.
Moderate: Requires change in drug therapy, specific treatment or prolongs hospital stay by at least one day.</p>
<p>Severe: Potentially life-threatening, causes permanent damage or requires intensive medical treatment.
Lethal: Directly or indirectly contributes to death of the patient.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="pharmacovigilance">Pharmacovigilance<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#pharmacovigilance" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Pharmacovigilance has been defined by the WHO (2002) as the 'science and activities relating to the detection, assessment, understanding and prevention of adverse effects or any other drug related problems.' The information generated by pharmacovigilance is useful in educating doctors about ADRs and in the official regulation of drug use. Its main purpose is to reduce the risk of drug-related harm to the patient. It has an important role in the rational use of medicines, as it provides the basis for assessing safety of medicines.</p>
<p>The activities involved in pharmacovigilance are:
a. Postmarketing surveillance and other methods of ADR monitoring such as voluntary reporting by doctors (e.g. yellow card system of UK), prescription event monitoring, computerized medical record linkage and other cohort/case control studies as well as anecdotal case reports by doctors.</p>
<p>Voluntary reporting depends on the initiative and willingness of the health professionals. It is minimal in India, while even in the developed countries only <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>∼</mo><mn>10</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">\sim 10 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.3669em;"></span><span class="mrel">∼</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">10%</span></span></span></span></span> ADRs are reported voluntarily. Immediately occurring reactions and those that are dramatic are mostly reported. Though even rare reactions can be detected by this method, it does not provide incidence of the reaction.
b. Dissemination of ADR data through 'drug alerts', 'medical letters', advisories sent to doctors by pharmaceuticals and regulatory agencies (such as FDA in USA, committee on safety of medicines in UK).
c. Changes in the labelling of medicines indicating restrictions in use or statuary warnings, precautions, or even withdrawal of
the drug, by the regulatory decision making authority.
Pharmacovigilance centres have been set up in most countries. The Uppsala Monitoring Centre (Sweden) is the international collaborating centre. In India, the Central Drugs Standard Control Organization (CDSCO) is coordinating the pharmacovigilance programme, under which peripheral, regional and zonal monitoring centres have been set up along with a National Pharmacovigilance advisory committee. The pharmacovigilance centres collect, communicate and disseminate ADR data by linking with hospitals as well as practitioners and are also expected to provide expertise for assessing causality and severity of ADRs by using standard algorithms and rating scales like the 'Naranjo algorithm' (causallty assessment) and modified Hartwig scale (severity grading).</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="causality-assessment">Causality assessment<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#causality-assessment" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>When a patient undergoing drug therapy experiences an adverse event, it may be due to the drug, or the disease or some other causes. Most of the time, a clear-cut 'yes/no' cause and effect relationship between a drug and the adverse event cannot be pronounced. Causality is assessed on the basis of:</p>
<ul>
<li>Temporal relationship: How the time-sequence of the event is related to drug administration.</li>
<li>Previous knowledge: Whether the drug is known to produce the event in earlier recipients with a certain degree of consistency.</li>
<li>Dechallenge: Whether the event subsided on stopping the drug.</li>
<li>Rechallenge: Whether the event reappeared when the drug was administered again after a gap during which the event had subsided. Many times rechallenge is unethical/dangerous, and is not done.</li>
</ul>
<p>Assessed on the basis of the above criteria, causality has been graded as:</p>
<ol>
<li>Definite: Causality is proven.</li>
<li>Probable: Though not proven, drug is the likely cause of the event.</li>
<li>Possible: Drug as well as other causes could be responsible for the event.</li>
<li>Doubtful: Drug unlikely to be the cause, but cannot be ruled out.</li>
</ol>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="prevention-of-adverse-effects-to-drugs">Prevention of adverse effects to drugs<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#prevention-of-adverse-effects-to-drugs" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Adverse drug effects can be minimized but not altogether eliminated by observing the following practices:</p>
<ol>
<li>
<p>Avoid all inappropriate use of drugs in the context of patient's clinical condition.</p>
</li>
<li>
<p>Use appropriate dose, route and frequency of drug administration based on patient's specific variables.</p>
</li>
<li>
<p>Elicit and take into consideration previous history of drug reactions.</p>
</li>
<li>
<p>Elicit history of allergic diseases and exercise caution (drug allergy is more common in patients with allergic diseases).</p>
</li>
<li>
<p>Rule out possibility of drug interactions when more than one drug is prescribed.</p>
</li>
<li>
<p>Adopt correct drug administration technique (e.g. intravenous injection of vancomycin must be slow).</p>
</li>
<li>
<p>Carry out appropriate laboratory monitoring (e.g. prothrombin time with warfarin, serum drug levels with lithium).</p>
</li>
</ol>
<p>Adverse drug effects may be categorized into:</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="1-side-effects">1. Side effects<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#1-side-effects" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>These are unwanted but often unavoidable pharmacodynamic effects that occur at therapeutic doses. Generally, they are not serious but may occasionally be hazardous, e.g. postural hypotension caused by prazosin as a side effect may result in fall and fracture neck femur in an elderly patient. Side effects can be predicted from the pharmacological profile of a drug and are known to occur in a given percentage of drug recipients. Reduction in dose, usually ameliorates the symptoms.</p>
<p>A side effect may be based on the same action as the therapeutic effect, e.g. atropine is used in preanaesthetic medication for its antisecretory action. The same action produces dryness of mouth as a side effect. Glyceryl trinitrate relieves angina pectoris by dilating peripheral vasculature which is also responsible for postural hypotension and throbbing headache.</p>
<p>The side effect may also be based on a different facet of action, e.g. promethazine produces sedation which is unrelated to its antiallergic action; estrogens cause nausea which is unrelated to their antiovulatory action.</p>
<p>An effect may be therapeutic in one context but side effect in another context, e.g. codeine used for cough produces constipation as a side effect, but the latter is its therapeutic effect in traveller's diarrhoea; depression of A-V conduction is the desired effect of digoxin in atrial fibrillation, but the same may be undesirable when it is used for CHF.</p>
<p>Many drugs have been developed from observation of side effects, e.g. early sulfonamides used as antibacterial were found to produce hypoglycaemia and acidosis as side effects which directed research resulting in the development of hypoglycaemic sulfonylureas and the carbonic anhydrase inhibitor-acetazolamide.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="2-secondary-effects">2. Secondary effects<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#2-secondary-effects" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>These are indirect consequences of a primary action of the drug, e.g. suppression of bacterial flora by tetracyclines paves the way for superinfections; corticosteroids weaken host defence mechanisms so that latent tuberculosis gets activated.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="3-toxic-effects">3. Toxic effects<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#3-toxic-effects" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>These are the result of excessive pharmacological action of the drug due to overdosage or prolonged use. Overdosage may be absolute (accidental, homicidal, suicidal) or relative (i.e. usual dose of gentamicin in presence of renal failure). The manifestations are predictable and dose related. They result from functional alteration (high dose of atropine causing delirium) or drug induced tissue damage (hepatic necrosis from paracetamol overdosage). The CNS, CVS, kidney, liver, lung, skin and blood forming organs are most commonly involved in drug toxicity.</p>
<p>Toxicity may result from extension of the therapeutic effect itself, e.g. coma by barbiturates, complete A-V block by digoxin, bleeding due to heparin.</p>
<p>Another action of the drug can also be responsible for toxicity, e.g.-</p>
<ul>
<li>Morphine (analgesic) causes respiratory failure in overdosage.</li>
<li>Imipramine (antidepressant) overdose causes cardiac arrhythmia.</li>
<li>Streptomycin (antitubercular) causes vestibular damage on prolonged use.
Poisoning In a broad sense, poisoning implies harmful effects of a chemical on a biological system. It may result from large doses of drugs because 'it is the dose which distinguishes a</li>
</ul>
<p>drug from a poison'. Poison is a 'substance which endangers life by severely affecting one or more vital functions'. Poisons derived from biologic sources are also referred to as 'toxins'. Not only drugs, but other household, environmental and industrial chemicals, insecticides, etc. are frequently involved in poisonings. Specific antidotes such as receptor antagonists, chelating agents or specific antibodies are available only for few poisons. General supportive and symptomatic treatment, as the need arises, is all that can be done for others, and this is also important for poisons which have a selective antagonist.
The general detoxification and supportive measures are:</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="1-resuscitation-and-maintenance-of-vital-functions">1. Resuscitation and maintenance of vital functions<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#1-resuscitation-and-maintenance-of-vital-functions" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>a. Ensure patent airway, adequate ventilation, give artificial respiration/ <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>100</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">100 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">100%</span></span></span></span></span> oxygen inhalation as needed. This is important because severe poisoning often makes the patient comatose; protective airway reflexes and respiratory drive are lost.
b. Maintain blood pressure and heart beat by fluid and crystalloid infusion, pressor agents, cardiac stimulants, pacing, defibrillation, etc, as needed. Hypotension, often prolonged, is common in severe poisonings.
c. Prevent and manage seizures (with i.v. lorazepam).
d. Maintain body temperature.
e. Maintain blood sugar level by dextrose infusion, especially in patients with altered sensorium.
2. Termination of exposure (decontamination) Decontamination procedures should be started concurrently with the above supportive measures. It is done by removing the patient to fresh air (for inhaled poisons), removing contaminated clothing and washing the skin and eyes (for poisons entering from the surface), induction of emesis with syrup ipecac or gastric lavage (for ingested poisons). Emesis
should not be attempted in comatose or haemodynamically unstable patient, as well as for kerosene poisoning due to risk of aspiration into lungs. These procedures are also contraindicated in corrosive and CNS stimulant poisoning. Emesis/gastric lavage is not recommended if the patient presents <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&gt;</mo><mn>2</mn></mrow><annotation encoding="application/x-tex">&gt;2</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&gt;</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">2</span></span></span></span></span> hours after ingesting the poison; if the poison/its dose ingested are known to be non-life-threatening, or if the patient has vomited after consuming the poison. Thus, induction of vomiting or gastric lavage is useful only in very few cases of poisoning.
3. Prevention of absorption of ingested poisons A suspension of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>20</mn><mo>−</mo><mn>40</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">20-40 \mathrm{~g}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">20</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">40</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm" style="margin-right: 0.01389em;">g</span></span></span></span></span></span> (or <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mrow><mi mathvariant="normal">l</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">\mathrm{lg} / \mathrm{kg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">lg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span></span></span></span></span> body weight) of activated charcoal, which has large surface area and can adsorb many chemicals, should be administered in 200 ml of water. However, strong acids and alkalies, metallic salts, iodine, cyanide, caustics, alcohol, hydrocarbons and other organic solvents are not adsorbed by charcoal. Charcoal should not be administered if there is paralytic ileus or intestinal obstruction or when the patient reports <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&gt;</mo><mn>2</mn></mrow><annotation encoding="application/x-tex">&gt;2</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&gt;</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">2</span></span></span></span></span> hours after ingesting the poison.
4. Hastening elimination of the poison by inducing diuresis (furosemide, mannitol) or altering urinary pH (alkalinization for acidic drugs, e.g. barbiturates, aspirin). However, excretion of many poisons, especially those which are eliminated mainly by hepatic metabolism, is not enhanced by forced diuresis and risk of fluid overload/electrolyte imbalance outweighs the benefit. This procedure is generally not employed now. Haemodialysis is more efficacious in hastening elimination of many drugs, including phenobarbitone, carbamazepine, valproate, lithium, salicylate, theophylline, etc.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="4-intolerance">4. Intolerance<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#4-intolerance" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>It is the appearance of characteristic toxic effects of a drug in an individual at therapeutic doses. It is the converse of tolerance and indicates a low threshold of the individual to the action of a drug. Such subjects are individuals who fall on the extreme left side of the Gaussian</p>
<p>frequency distribution curve for sensitivity to the drug. Examples are:</p>
<ul>
<li>A single dose of triflupromazine induces muscular dystonias in some individuals, specially children.</li>
<li>Only few doses of carbamazepine may cause ataxia in some people.</li>
<li>One tablet of chloroquine may cause vomiting and abdominal pain in an occasional patient.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="5-idiosyncrasy">5. Idiosyncrasy<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#5-idiosyncrasy" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Idiosyncrasy refers to genetically determined abnormal reactivity to a chemical. The drug interacts with some unique feature of the individual, not found in majority of subjects, and produces the uncharacteristic reaction. As such, the type of reaction is restricted to individuals with a particular genotype (see p. 76). In addition, certain bizarre drug effects due to peculiarities of an individual (for which no definite genotype has been described) are included among idiosyncratic reactions, e.g.:</p>
<ul>
<li>Barbiturates cause excitement and mental confusion in some individuals.</li>
<li>Quinine/quinidine cause cramps, diarrhoea, purpura, asthma, angioedema of face and hypotension in some patients.</li>
<li>Chloramphenicol produces nondose-related serious aplastic anaemia in rare individuals.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="6-drug-allergy-hypersensitivity">6. Drug allergy (hypersensitivity)<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#6-drug-allergy-hypersensitivity" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>It is an immunologically mediated reaction producing stereotype symptoms which are unrelated to the pharmacodynamic profile of the drug. The symptoms may appear even with much smaller doses and have a different time course of onset and duration. This is also called drug hypersensitivity; but does not refer to increased response which is called supersensitivity. The target organs primarily affected in drug allergy are skin, airways, blood vessels, blood cells and gastrointestinal tract.</p>
<p>Allergic reactions occur only in a small proportion of the population exposed to the drug and cannot be produced in other individuals at any dose. Prior sensitization is needed
and a latent period of at least <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mo>−</mo><mn>2</mn></mrow><annotation encoding="application/x-tex">1-2</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">1</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">2</span></span></span></span></span> weeks is required after the first exposure. However, the sensitizing exposure may go unnoticed or may be environmental. The drug or its metabolite acts as an antigen (AG), or more commonly a hapten (incomplete antigen: drugs have small molecules which become antigenic only after binding with an endogenous protein) and induce production of antibody ( AB )/sensitized lymphocytes. Presence of AB to a drug is not necessarily followed by allergy to it. Chemically related drugs often show cross sensitivity. A particular drug can produce different types of allergic reactions in different individuals, while widely different drugs can produce similar reaction. The course of drug allergy is variable; an individual previously sensitive to a drug may subsequently tolerate it without a reaction and vice versa.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="cardinal-features-of-drug-allergy">Cardinal features of drug allergy<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#cardinal-features-of-drug-allergy" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Manifestations unrelated to the pharmacodynamic actions of the drug.</li>
<li>Manifestations similar to food/protein allergy, allergic diseases.</li>
<li>Severity of reaction poorly correlated with dose of the drug; even small dose may trigger severe reaction.</li>
<li>Occur only in few recipients, cannot be produced in other individuals.</li>
<li>Prior sensitization (known/unknown) is needed.</li>
<li>Positive dechallenge (on withdrawal of drug) and rechallenge (even with small dose).</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="mechanism-and-types-of-allergic-reactions">Mechanism and types of allergic reactions<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#mechanism-and-types-of-allergic-reactions" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="a-humoral">A. Humoral<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#a-humoral" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Type-I (anaphylactic) reactions Reaginic antibodies (IgE) are produced which get fixed to the mast cells and basophils. On exposure to the drug, AG: AB reaction takes place on the mast cell surface (see Fig. 11.2) releasing mediators like histamine, 5-HT, leukotrienes (especially LT-C4 and D4), prostaglandins, PAF, etc. resulting in urticaria, itching, angioedema, bronchospasm, rhinitis or anaphylactic shock. Anaphylaxis is usually heralded by paresthesia, flushing, swelling of lips, generalized itching,</p>
<p>wheezing, palpitation followed by syncope. The manifestations occur quickly (within minutes to few hours) after challenge and are called immediate hypersensitivity. Antihistaminic drugs are beneficial in some of these reactions.
Type-II (cytolytic) reactions Drug + component of a specific tissue cell act as AG. The resulting antibodies ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">IgG</mi><mo>⁡</mo><mo separator="true">,</mo><mi mathvariant="normal">IgM</mi><mo>⁡</mo></mrow><annotation encoding="application/x-tex">\operatorname{IgG}, \operatorname{IgM}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8778em; vertical-align: -0.1944em;"></span><span class="mop"><span class="mord mathrm">IgG</span></span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mop"><span class="mord mathrm">IgM</span></span></span></span></span></span> ) bind to the target cells; on reexposure AG: AB reaction takes place on the surface of these cells, complement is activated and cytolysis occurs resulting in one or more of thrombocytopenia, agranulocytosis, aplastic anaemia, haemolysis, organ damage (liver, kidney, muscle), systemic lupus erythematosus.
Type-III (retarded, Arthus) reactions These are mediated by circulating antibodies (predominantly IgG, mopping AB ). AG: AB complexes bind complement and precipitate on vascular endothelium and basement membrane in tissues, release chemotactic mediators and lytic enzymes giving rise to a destructive inflammatory response. Manifestations are rashes, serum sickness (fever, arthralgia, lymphadenopathy), polyarteritis nodosa, Stevens-Johnson syndrome (erythema multiforme, arthritis, nephritis, myocarditis, mental symptoms). The reaction develops in 3-4 days after exposure, and usually subsides in 1-2 weeks.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="b-cell-mediated">B. Cell mediated<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#b-cell-mediated" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Type-IV (delayed hypersensitivity) reactions These are mediated through production of sensitized T-lymphocytes carrying receptors for the AG. On contact with the AG these T cells produce lymphokines which attract granulocytes and generate an inflammatory response, causing contact dermatitis, certain types of rashes, fever, photosensitization. The reaction generally takes <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>2</mn><mo>−</mo><mn>3</mn></mrow><annotation encoding="application/x-tex">2-3</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">2</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">3</span></span></span></span></span> days to develop.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="treatment-of-drug-allergy">Treatment of drug allergy<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#treatment-of-drug-allergy" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>The offending drug must be immediately stopped. Most mild reactions (like skin rashes) subside by themselves and donot require specific treatment. Antihistamines <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo fence="true">(</mo><msub><mi mathvariant="normal">H</mi><mn>1</mn></msub><mo fence="true">)</mo></mrow><annotation encoding="application/x-tex">\left(\mathrm{H}_{1}\right)</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="minner"><span class="mopen delimcenter" style="top: 0em;">(</span><span class="mord"><span class="mord mathrm">H</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mclose delimcenter" style="top: 0em;">)</span></span></span></span></span></span> are beneficial in some
type I reactions (itching, urticaria, rhinitis, swelling of lips, etc.) and some skin rashes (see p. 182). In case of anaphylactic shock or angioedema of larynx the resuscitation council of UK has recommended the following measures:</p>
<ul>
<li>Put the patient in reclining position, administer oxygen at high flow rate and perform cardiopulmonary resuscitation if required.</li>
<li>Inject adrenaline 0.5 mg ( 0.5 ml of 1 in 1000 solution for adult, 0.3 ml for child <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>6</mn><mo>−</mo><mn>12</mn></mrow><annotation encoding="application/x-tex">6-12</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">6</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">12</span></span></span></span></span> years and 0.15 ml for child upto 6 years) i.m.; repeat every <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mo>−</mo><mn>10</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">m</mi><mi mathvariant="normal">i</mi><mi mathvariant="normal">n</mi></mrow></mrow><annotation encoding="application/x-tex">5-10 \mathrm{~min}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6679em;"></span><span class="mord">10</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm">min</span></span></span></span></span></span> in case patient does not improve or improvement is transient. This is the only life saving measure. Adrenaline should not be injected i.v. (can itself be fatal) unless shock is immediately life threatening. If adrenaline is to be injected i.v., it should be diluted to <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mo>:</mo><mn>10</mn><mo separator="true">,</mo><mn>000</mn></mrow><annotation encoding="application/x-tex">1: 10,000</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">1</span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">:</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">10</span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord">000</span></span></span></span></span> or <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mo>:</mo><mn>100</mn><mo separator="true">,</mo><mn>000</mn></mrow><annotation encoding="application/x-tex">1: 100,000</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">1</span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">:</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">100</span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord">000</span></span></span></span></span> and infused slowly with constant monitoring.</li>
<li>Administer a <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">H</mi><mn>1</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{H}_{1}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">H</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> antihistaminic (pheniramine <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>20</mn><mo>−</mo><mn>40</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">20-40 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">20</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">40</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span> or chlorpheniramine <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>10</mn><mo>−</mo><mn>20</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">10-20 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">10</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">20</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span> ) i.m./slow i.v. It may have adjuvant value.</li>
<li>Intravenous glucocorticoid (hydrocortisone sod. succinate 200 mg ) should be added in severe/recurrent cases. It acts slowly, but is specially valuable for prolonged reactions and in asthmatics. It may be followed by oral prednisolone for 3 days.
Adrenaline followed by a short course of glucocorticoids is indicated for bronchospasm attending drug hypersensitivity. Glucocorticoids are the only drug effective in type II, type III and type IV reactions.</li>
</ul>
<table><thead><tr><th style="text-align: left;">Drugs frequently causing allergic reactions</th><th style="text-align: left;"></th></tr></thead><tbody><tr><td style="text-align: left;">Penicillins</td><td style="text-align: left;">Aspirin</td></tr><tr><td style="text-align: left;">Cephalosporins</td><td style="text-align: left;">Indomethacin</td></tr><tr><td style="text-align: left;">Sulfonamides</td><td style="text-align: left;">Carbamazepine</td></tr><tr><td style="text-align: left;">Tetracyclines</td><td style="text-align: left;">Allopurinol</td></tr><tr><td style="text-align: left;">Quinolones</td><td style="text-align: left;">ACE inhibitors</td></tr><tr><td style="text-align: left;">Metronidazole</td><td style="text-align: left;">Methyldopa</td></tr><tr><td style="text-align: left;">Abacavir</td><td style="text-align: left;">Hydralazine</td></tr><tr><td style="text-align: left;">Antitubercular drugs</td><td style="text-align: left;">Local anaesthetics</td></tr><tr><td style="text-align: left;">Phenothiazines</td><td style="text-align: left;"></td></tr></tbody></table>
<p>Skin tests (intradermal, patch) or intranasal tests may forewarn in case of Type I hypersensitivity, but not in case of other types. However, these tests are not entirely reliable-false positive and false negative results are not rare.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="7-photosensitivity">7. Photosensitivity<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#7-photosensitivity" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>It is a cutaneous reaction resulting from drug induced sensitization of the skin to UV radiation. The reactions are of two types:
(a) Phototoxic Drug or its metabolite accumulates in the skin, absorbs light and undergoes a photochemical reaction followed by a photobiological reaction resulting in local tissue damage (sunburn-like), i.e. erythema, edema, vesicular eruption, blistering which have fast onset and shorter duration after exposure ends. This is followed by hyperpigmentation and desquamation. The lesions may be more severe with larger doses of the drug. The shorter wave lengths ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>290</mn><mo>−</mo><mn>320</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">n</mi><mi mathvariant="normal">m</mi></mrow></mrow><annotation encoding="application/x-tex">290-320 \mathrm{~nm}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">290</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">320</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm">nm</span></span></span></span></span></span>, UV-B) are responsible. Drugs involved in acute phototoxic reactions are tetracyclines (especially demeclocycline) and tar products. Drugs causing chronic and low grade sensitization are nalidixic acid, fluoroquinolones, dapsone, sulfonamides, phenothiazines, thiazides, amiodarone. This type of reaction is more common than photoallergic reaction.
(b) Photoallergic Drug or its metabolite induces a cell mediated immune response which on exposure to light of longer wave lengths ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>320</mn><mo>−</mo><mn>400</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">n</mi><mi mathvariant="normal">m</mi></mrow></mrow><annotation encoding="application/x-tex">320-400 \mathrm{~nm}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">320</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">400</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm">nm</span></span></span></span></span></span>, UV-A) produces a papular or eczematous contact dermatitis like picture that may persist long after exposure. Occasionally, antibodies may also mediate photoallergy and the reaction takes the form of immediate flare, itching and wheal on exposure to sun. Even small doses may trigger the reaction and lesions may extend beyond the exposed area. Drugs involved are sulfonamides, sulfonylureas, griseofulvin, chloroquine, chlorpromazine, carbamazepine.</p>
<p>Photosensitivity reactions can be prevented or minimized by avoidance of exposure to sun and effective use of topical sun screens (SPF 15-60; see Ch. 66). Local treatment of acute
sun burn and blistering consists of soothing lotions (e.g. calamine lotion), wet dressings and mild topical steroids. Strong topical steroids are needed for photoallergy; severe cases may require systemic steroid therapy.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="8-drug-dependence-and-drug-addiction">8. Drug dependence and drug addiction<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#8-drug-dependence-and-drug-addiction" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Drugs capable of altering mood and feelings are liable to repetitive use to derive euphoria, recreation, withdrawal from reality, social adjustment, etc. Some subjects who take the drug repeatedly for personal gratification, progress in indulgence with the drug and start according higher priority to taking the drug than to other basic needs, often in the face of known risks to health. Many of these drugs also induce adaptive physiological changes which result in escalation of the dose needed to produce the same effect. Thus, 'tolerance' develops and physiological equilibrium is disturbed when the drug is not present. Confusing terminology, viz'dependence', 'physical dependence', 'psychological dependence', 'addiction', 'habituation', 'drug abuse' has been used over the past to describe the above phenomena. The terms as understood and applied currently are briefly explained below.
Drug dependence It is an altered physiological state produced by repeated administration of a drug which necessitates the continued presence of the drug to maintain physiological equilibrium. Discontinuation of the drug results in a characteristic withdrawal (abstinence) syndrome. This has been earlier termed 'physical dependence', but is now simply called 'dependence'. Since the essence of the process is adaptation of the nervous system to function normally in the presence of the drug, it has been also called 'neuroadaptation'.</p>
<p>Drugs producing dependence are-opioids, barbiturates and other depressants including alcohol and benzodiazepines. Stimulant drugs, e.g. amphetamines, cocaine produce minimal or no dependence.
Drug addiction A person is said to have developed 'drug addiction' when he/she</p>
<p>believes that optimal state of well being is achieved only through the actions of the drug. The subject feels emotionally distressed if the drug is not taken. It often starts as liking for the drug effects and progresses to compulsive drug use in some individuals who lose control and cannot stop taking the drug, even if they known it to be harmful. This was earlier termed 'psychological dependence'. However, to avoid confusion, the widely understood term 'drug addiction' is used now.</p>
<p>Drug addiction is a pattern of compulsive drug use characterized by overwhelming involvement with the use of a drug. Procuring the drug and using it takes precedence over other activities. Even after withdrawal most addicts tend to relapse. Dependence, though a strong impetus for continued drug use, is not an essential feature of addiction. Amphetamines, cocaine, cannabis, LSD are drugs which produce addiction but little/no dependence. Moreover, drugs like nalorphine produce dependence without imparting addiction in the sense that there is little drug seeking behaviour.
Reinforcement It is the ability of the drug to produce effects that the user enjoys and which make him/her wish to take it again or to induce drug seeking behaviour. Certain drugs (opioids, cocaine) are strong reinforcers, while others (benzodiazepines) are weak reinforcers. Faster the drug acts, more reinforcing it is. Thus, inhaled drugs and those injected i.v. are highly reinforcing-produce an intense 'high' in dependent individuals.
Drug habituation This term has been used to denote less intensive involvement with the drug, so that its withdrawal produces only mild discomfort. Dependence is absent. Consumption of tea, coffee, tobacco, social drinking are regarded habituating but not addicting. Thus, the difference between addiction and habituation is only quantitative. It is difficult to delineate when 'desire' turns into 'craving'. As such, it is better to avoid using the term 'habituation' as a distinct phenomenon.
Drug abuse This is another frequently used term which refers to use of a drug by self
medication in a manner and amount that deviates from the approved medical and social patterns in a given culture at a given time. The term conveys social disapproval of the manner and purpose of drug use. For regulatory agencies, drug abuse refers to any use of an ilicit drug. The two major patterns of drug abuse are:
a. Continuous use: The drug is taken regularly, the subject wishes to continuously remain under the influence of the drug, e.g. opioids, alcohol, sedatives.
b. Occasional use: The drug is taken off-and-on to obtain pleasure or high, recreation (as in rave parties) or enhancement of sexual experience, e.g. cocaine, amphetamines, psychedelics, binge drinking (a pattern of excessive alcohol drinking), cannabis, solvents (inhalation), etc.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="9-drug-withdrawal-reactions">9. Drug withdrawal reactions<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#9-drug-withdrawal-reactions" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Apart from drugs that are usually recognised as producing dependence, sudden interruption of therapy with certain other drugs also results in adverse consequences, mostly in the form of worsening of the clinical condition for which the drug was being used, e.g.:</p>
<ul>
<li>Acute adrenal insufficiency may be precipitated by abrupt cessation of corticosteroid therapy.</li>
<li>Severe hypertension, restlessness and sympathetic overactivity may occur shortly after discontinuing clonidine.</li>
<li>Worsening of angina pectoris, precipitation of myocardial infarction may result from stoppage of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>β</mi></mrow><annotation encoding="application/x-tex">\beta</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mord mathnormal" style="margin-right: 0.05278em;">β</span></span></span></span></span> blockers.</li>
<li>Frequency of seizures may increase on sudden withdrawal of an antiepileptic.
These manifestations are also due to adaptive changes, and can be minimized by gradual withdrawal.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="10-teratogenicity">10. Teratogenicity<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#10-teratogenicity" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>It refers to the capacity of a drug to cause foetal abnormalities when administered to the pregnant mother. The placenta does not constitute a strict barrier, and any drug can cross it to a greater or lesser extent. The embryo is one of the most</p>
<table><thead><tr><th style="text-align: center;"></th><th style="text-align: center;">Human teratogenic drugs</th></tr></thead><tbody><tr><td style="text-align: center;">Drug</td><td style="text-align: center;">Abnormality</td></tr><tr><td style="text-align: center;">Thalidomide</td><td style="text-align: center;">phocomelia, multiple defects of internal organs</td></tr><tr><td style="text-align: center;">Anticancer drugs (methotrexate)</td><td style="text-align: center;">cleft palate, hydrocephalus, multiple defects, foetal death</td></tr><tr><td style="text-align: center;">Androgens</td><td style="text-align: center;">virilization; limb, esophageal, cardiac defects</td></tr><tr><td style="text-align: center;">Progestins</td><td style="text-align: center;">virilization of female foetus</td></tr><tr><td style="text-align: center;">Stilboestrol</td><td style="text-align: center;">vaginal carcinoma in teenage female offspring</td></tr><tr><td style="text-align: center;">Tetracyclines</td><td style="text-align: center;">discoloured and deformed teeth, retarded bone growth</td></tr><tr><td style="text-align: center;">Warfarin</td><td style="text-align: center;">depressed nose; eye and hand defects, growth retardation</td></tr><tr><td style="text-align: center;">Phenytoin</td><td style="text-align: center;">hypoplastic phalanges, cleft lip/palate, microcephaly</td></tr><tr><td style="text-align: center;">Phenobarbitone</td><td style="text-align: center;">various malformations</td></tr><tr><td style="text-align: center;">Carbamazepine</td><td style="text-align: center;">neural tube defects, assorted abnormalities</td></tr><tr><td style="text-align: center;">Valproate sod.</td><td style="text-align: center;">spina bifida and other neural tube defects, heart and limb abnormalities</td></tr><tr><td style="text-align: center;">Alcohol</td><td style="text-align: center;">low IQ baby, growth retardation, foetal alcohol syndrome</td></tr><tr><td style="text-align: center;">ACE inhibitors</td><td style="text-align: center;">hypoplasia of organs, growth retardation, foetal loss</td></tr><tr><td style="text-align: center;">Lithium</td><td style="text-align: center;">foetal goiter, cardiac and other abnormalities</td></tr><tr><td style="text-align: center;">Antithyroid drugs</td><td style="text-align: center;">foetal goiter and hypothyroidism</td></tr><tr><td style="text-align: center;">Indomethacin/aspirin</td><td style="text-align: center;">premature closure of ductus arteriosus</td></tr><tr><td style="text-align: center;">Isotretinoin</td><td style="text-align: center;">craniofacial, heart and CNS defects, hydrocephalus</td></tr></tbody></table>
<p>dynamic biological systems and in contrast to adults, drug effects are often irreversible. The thalidomide disaster (1958-61) resulting in thousands of babies born with phocomelia (seal like limbs) and other defects focused attention onto this type of adverse effect.</p>
<p>In 1959 and subsequent couple of years, the incidence of a rare birth defect phocomelia (hands and feet arising almost directly from shoulders and pelvis, similar to flippers of a seal) shot up sharply in Europe. Other birth defects also increased considerably. Soon it was noticed that all mothers with malformed babies had taken a new sedative-anti-morning sickness drug thalidomide (which was marketed in 1957) during early pregnancy. Epidemiological studies confirmed that intake of thalidomide in the first trimester of pregnancy was responsible for the birth defects, and the drug was immediately banned worldwide. It has now been marketed again for restricted use as adjuvant in cancer chemotherapy.
Drugs can affect the foetus at 3 stages-
(i) Fertilization and implantation-conception to 17 days-failure of pregnancy which often goes unnoticed.
(ii) Organogenesis-18 to 55 days of gestationmost vulnerable period, deformities are produced.
(iii) Growth and development- 56 days onwards - developmental and functional abnormalities can occur, e.g. ACE inhibitors can cause hypoplasia of organs, especially of lungs and kidneys; NSAIDs may induce premature closure of ductus arteriosus; androgens and progestins cause masculanization of female foetus, antithyroid drugs and lithium cause foetal goiter.
The type of malformation depends on the drug as well as the stage at which exposure to the teratogen occurred. Foetal exposure depends on the blood level and duration for which the drug remains in maternal circulation. The teratogenic potential of a drug is to be considered against the background of congenital abnormalities occurring spontaneously, which is <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>∼</mo><mn>2</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">\sim 2 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.3669em;"></span><span class="mrel">∼</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">2%</span></span></span></span></span> of all pregnancies. Majority of implicated drugs are low grade teratogens, i.e. increase the incidence of malformations only slightly, which may be very difficult to detect, confirm or refute. Nevertheless, some drugs have been clearly associated with causing foetal abnormalities in human beings.</p>
<p>These are listed in the box on p.100. However, only few mothers out of all those who receive these drugs during the vulnerable period will get a deformed baby, but the exact risk posed by a drug is difficult to estimate.</p>
<p>The US-FDA has graded the documentation of risk for causing birth defects into five categories viz. A, B, C, D and X, indicating a range from A (safe) to X (contraindicated). Because evidence on teratogenic potential of drugs keeps accumulating, the FDA grading has become out-dated in many cases, and its utility is being questioned. The FDA is likely to change this grading system soon.</p>
<p>It is, therefore, wise to avoid all drugs during pregnancy, unless compelling reasons exist for their use, regardless of the assigned pregnancy category, or presumed safety (also see Appendix-2).</p>
<p>Frequency of spontaneous as well as drug induced malformations, especially neural tube defects, may be reduced by folate therapy during pregnancy.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="11-mutagenicity-and-carcinogenicity">11. Mutagenicity and Carcinogenicity<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#11-mutagenicity-and-carcinogenicity" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>It refers to capacity of a drug to cause genetic defects and cancer respectively. Usually oxidation of the drug results in the production of reactive intermediates which affect genes and may cause structural changes in the chromosomes. Covalent
interaction with DNA can modify it to induce mutations, which may manifest as heritable defects in the next generation. If the modified DNA sequences code for factors that regulate cell proliferation/growth, i.e. are protooncogenes, or for proteins that inhibit transcription of protooncogenes, a tumour (cancer) may be produced. Even without interacting directly with DNA, certain chemicals can promote malignant change in genetically damaged cells, resulting in carcinogenesis. Chemical carcinogenesis generally takes several (10-40) years to develop. Drugs implicated in these adverse effects are-anticancer drugs, radioisotopes, estrogens, tobacco. Generally, drugs which show mutagenic or carcinogenic potential are not approved for marketing/are withdrawn, unless they are useful in life-threatening conditions.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="12-drug-induced-diseases">12. Drug induced diseases<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#12-drug-induced-diseases" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>These are also called iatrogenic (physician induced) diseases, and are functional disturbances (disease) caused by drugs which persist even after the offending drug has been withdrawn and largely eliminated, e.g.:</p>
<p>Peptic ulcer by NSAIDs and corticosteroids.
Parkinsonism by phenothiazines and other antipsychotics.
Hepatitis by isoniazid.
DLE by hydralazine.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="problem-directed-study">PROBLEM DIRECTED STUDY<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#problem-directed-study" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>6.1 A 40-year-man weighing 60 kg suffering from chronic cough with expectoration and fever was diagnosed to have cavitary pulmonary tuberculosis. He was put on the standard 1st line antitubercular regimen consisting of isoniazid (H) + rifampin (R) + pyrazinamide (Z) + ethambutol (E). His condition improved, but in the 4th week he developed jaundice with enlarged tender liver and rise in serum bilirubin as well as serum transaminase levels. He was suspected to have developed antitubercular drug induced hepatitis.
(a) Should his antitubercular treatment be stopped or continued?
(b) How would you proceed to confirm and identify the causative drug, and then select the alternative regimen?
(see Appendix-1 for solution)</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="drugs-acting-on-autonomic-nervous-system">DRUGS ACTING ON AUTONOMIC NERVOUS SYSTEM<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#drugs-acting-on-autonomic-nervous-system" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="autonomic-nervous-system-general-considerations">Autonomic Nervous System: General Considerations<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#autonomic-nervous-system-general-considerations" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="organization-and-function">ORGANIZATION AND FUNCTION<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#organization-and-function" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>The autonomic nervous system (ANS) functions largely below the level of consciousness and controls visceral functions. The major differences between the somatic and autonomic nervous systems are given in Table II.1.</p>
<p>Like the somatic nervous system, the ANS consists of afferents, centre and efferents.</p>
<p>Autonomic afferents Most visceral nerves are mixed nerves and carry nonmyelinated visceral afferent fibres as well. The cell bodies of these afferent fibres are located in the dorsal root ganglion of spinal nerves and in the sensory ganglia (e.g. nodose ganglion of vagus) of cranial nerves. They mediate visceral pain as well as cardiovascular, respiratory and other visceral reflexes.</p>
<p>Central autonomic connections There are no exclusively autonomic areas in the CNS; considerable intermixing and integration of somatic and autonomic innervation occurs. The highest seat regulating autonomic functions is in the hypothalamus-posterior and lateral nuclei are primarily sympathetic while anterior and medial nuclei are primarily parasympathetic. Many autonomic centres (pupillary, vagal, respiratory, etc.) are located in the mid-brain and the medulla in relation to the cranial nerves. The lateral column in the thoracic spinal cord contains cells which give rise to the sympathetic outflow.</p>
<p>Autonomic efferents The motor limb of the ANS is anatomically divided into sympathetic and parasympathetic. Many organs receive both</p>
<p>Table II.1: Differences between somatic and autonomic nervous system</p>
<table><thead><tr><th style="text-align: left;"></th><th style="text-align: left;">Somatic</th><th style="text-align: left;">Autonomic</th></tr></thead><tbody><tr><td style="text-align: left;">1. Organ supplied</td><td style="text-align: left;">Skeletal muscles</td><td style="text-align: left;">All other organs</td></tr><tr><td style="text-align: left;">2. Distal most synapse</td><td style="text-align: left;">Within CNS</td><td style="text-align: left;">Outside CNS (in ganglia)</td></tr><tr><td style="text-align: left;">3. Nerve fibres</td><td style="text-align: left;">Myelinated</td><td style="text-align: left;">Pregang.-myelinated &lt;br&gt; Postgang.-non-myelinated</td></tr><tr><td style="text-align: left;">4. Peripheral plexus formation</td><td style="text-align: left;">Absent</td><td style="text-align: left;">Present</td></tr><tr><td style="text-align: left;">5. Primary efferent transmitter</td><td style="text-align: left;">Acetylcholine</td><td style="text-align: left;">Acetylcholine, Noradrenaline</td></tr><tr><td style="text-align: left;">6. Effect of nerve section on organ supplied</td><td style="text-align: left;">Paralysis and atrophy</td><td style="text-align: left;">Activity maintained, no atrophy</td></tr></tbody></table>
<p>sympathetic and parasympathetic innervation and the two subdivisions are functionally antagonistic in majority of these. The level of activity of innervated organ at a given moment is the algebraic sum of sympathetic and parasympathetic tone. However, refractory period of atrial fibres is decreased by sympathetic as well as parasympathetic influences. Most blood vessels, spleen, sweat glands and hair follicles receive only sympathetic, while ciliary muscle, bronchial smooth muscle, gastric and pancreatic glands receive only parasympathetic innervation. Thus, the two divisions of ANS are not merely check-and-balance physiological antagonists of each other.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="enteric-nervous-system">Enteric nervous system<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#enteric-nervous-system" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>The enteric nervous system (ENS) located in the gut wall consists of a submucosal (Meissner's)
and a myenteric (Auerbach's) plexus along with its afferent and efferent neurons whose fibres travel anterograde, retrograde as well as in a circular manner. It receives inputs from both sympathetic and parasympathetic divisions of ANS, but in addition functions independently to integrate bowel movements as well as regulate secretion and absorption (see Fig. 48.2). As such, it has also been labelled as a distinct 'enteric nervous system'.</p>
<p>The general layout of ANS is depicted in Fig. II. 1 and the important differences between its two subdivisions are given in Table II.2.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="neurohumoral-transmission">NEUROHUMORAL TRANSMISSION<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#neurohumoral-transmission" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Neurohumoral transmission implies that nerves transmit their message across synapses and neuroeffector junctions by the release of humoral (chemical) messengers.
<img src="assets/images/image-20251214-b4e20cb8.jpeg" alt="img-40.jpeg"></p>
<p>Fig. II.1: The general outlay of efferent autonomic nervous system. The transmitter released and the primary postjunctional receptor subtype is shown at each synapse/neuroeffector junction
ACh-Acetylcholine, NA-Noradrenaline, N-Nicotinic, M-Muscarinic, <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>α</mi><mo>−</mo><mi>α</mi></mrow><annotation encoding="application/x-tex">\alpha-\alpha</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord mathnormal" style="margin-right: 0.0037em;">α</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.4306em;"></span><span class="mord mathnormal" style="margin-right: 0.0037em;">α</span></span></span></span></span> adrenergic, <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>β</mi><mo>−</mo><mi>β</mi></mrow><annotation encoding="application/x-tex">\beta-\beta</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mord mathnormal" style="margin-right: 0.05278em;">β</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mord mathnormal" style="margin-right: 0.05278em;">β</span></span></span></span></span> adrenergic</p>
<p>Table II.2: Differences between sympathetic and parasympathetic divisions of the autonomic nervous system</p>
<table><thead><tr><th style="text-align: center;"></th><th style="text-align: center;">Sympathetic</th><th style="text-align: center;">Parasympathetic</th></tr></thead><tbody><tr><td style="text-align: center;">1. Origin</td><td style="text-align: center;">Dorso-lumbar ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">T</mi><mn>1</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{T}_{1}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">T</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> to <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">L</mi><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{L}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">L</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> or <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">L</mi><mn>3</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{L}_{3}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">L</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">3</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> )</td><td style="text-align: center;">Cranio-sacral (III, VII, IX, X; <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">S</mi><mn>2</mn></msub><mo>−</mo><msub><mi mathvariant="normal">S</mi><mn>3</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{S}_{2}-\mathrm{S}_{3}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">S</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">S</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">3</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> )</td></tr><tr><td style="text-align: center;">2. Distribution</td><td style="text-align: center;">Wide</td><td style="text-align: center;">Limited to head, neck and trunk</td></tr><tr><td style="text-align: center;">3. Ganglia</td><td style="text-align: center;">Away from the organs supplied</td><td style="text-align: center;">On or close to the organ supplied</td></tr><tr><td style="text-align: center;">4. Postgang. fibre</td><td style="text-align: center;">Long</td><td style="text-align: center;">Short</td></tr><tr><td style="text-align: center;">5. Pre: post ganglionic fibre ratio</td><td style="text-align: center;">1: 20 to 1: 100</td><td style="text-align: center;">1: 1 to 1: 2 (except in enteric plexuses)</td></tr><tr><td style="text-align: center;">6. Neuroeffector transmitter</td><td style="text-align: center;">Major: NA &lt;br&gt; Minor: ATP, NPY, DA, ACh</td><td style="text-align: center;">Major: ACh &lt;br&gt; Minor: VIP, NO</td></tr><tr><td style="text-align: center;">7. Stability of transmitter</td><td style="text-align: center;">NA stable, diffuses for wider actions</td><td style="text-align: center;">ACh—rapidly destroyed locally</td></tr><tr><td style="text-align: center;">8. Important function</td><td style="text-align: center;">Tackling stress and emergency</td><td style="text-align: center;">Assimilation of food, conservation of energy</td></tr></tbody></table>
<p>NA-Noradrenaline, ACh—Acetylcholine, ATP—Adenosine triphosphate, NPY—Neuropeptide Y, DA—Dopamine, VIP—Vasoactive intestinal peptide, NO—Nitric oxide</p>
<p>Junctional transmission was thought to be electrical (it does occur in some lower animals and probably in certain areas of mammalian brain) but observations at the turn of last century prompted Elliott (1905) to suggest that sympathetic nerves functioned by the release of an adrenaline-like substance, and Dixon (1907) to propose that vagus released a muscarine like chemical. Otto Loewi (1921) provided direct proof of humoral transmission by perfusing two frog hearts in series. Stimulation of vagus nerve of the first heart caused arrest of both. Thus, a chemical must have been released by vagal stimulation in the first heart which passed in the perfusate and arrested the second heart. This vagusstoff was found in 1926 to be acetylcholine, which earlier Dale (1914) had characterised as 'parasympathomimetic'. The sympathetic transmitter was eventually shown to be noradrenaline in 1946 by Von Euler. Many humoral transmitters (dopamine, 5-HT, GABA, glutamic acid, purines, peptides, etc.) are now known.</p>
<p>To be considered as a postjunctionally acting neurohumoral transmitter a substance must fulfill the following criteria:
(i) It should be present in the presynaptic neurone (usually along with enzymes synthesizing it).
(ii) It should be released in the medium following nerve stimulation.
(iii) Its application should produce responses identical to those produced by nerve stimulation.
(iv) Its effects should be antagonized or potentiated by other substances which similarly alter effects of nerve stimulation.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="steps-in-neurohumoral-transmission">Steps in neurohumoral transmission<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#steps-in-neurohumoral-transmission" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>I. Impulse conduction The resting transmembrane potential ( 70 mV negative inside) is established by high <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">K</mi><mo lspace="0em" rspace="0em">+</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{K}^{+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7713em;"></span><span class="mord"><span class="mord mathrm">K</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.7713em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span>permeability of axonal membrane and high axoplasmic concentration of this ion coupled with low <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">N</mi><mi mathvariant="normal">a</mi></mrow><mo lspace="0em" rspace="0em">+</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{Na}^{+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8446em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Na</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8446em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span>permeability and its active extrusion from the neurone. Stimulation or arrival of an electrical impulse causes a sudden increase in <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">N</mi><mi mathvariant="normal">a</mi></mrow><mo lspace="0em" rspace="0em">+</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{Na}^{+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8446em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Na</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8446em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span>conductance <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>→</mo></mrow><annotation encoding="application/x-tex">\rightarrow</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.3669em;"></span><span class="mrel">→</span></span></span></span></span> depolarization and overshoot (reverse polarization: inside becoming 20 mV positive); <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">K</mi><mo lspace="0em" rspace="0em">+</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{K}^{+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7713em;"></span><span class="mord"><span class="mord mathrm">K</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.7713em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span> ions then move out in the direction of their concentration gradient and repolarization is achieved. The ionic distribution is normalized during the refractory period by the activation of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">N</mi><mi mathvariant="normal">a</mi></mrow><mo lspace="0em" rspace="0em">+</mo></msup><msup><mi mathvariant="normal">K</mi><mo lspace="0em" rspace="0em">+</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{Na}^{+} \mathrm{K}^{+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8446em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Na</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8446em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span><span class="mord"><span class="mord mathrm">K</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.7713em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span>pump. The action potential (AP) thus generated sets up local circuit currents which activate ionic channels at the next excitable part of the membrane (next node of Ranvier in myelinated fibre) and the AP is propagated without decrement.</p>
<p>Tetrodotoxin (from puffer fish) and saxitoxin (from certain shell-fish) selectively abolish</p>
<p>increase in <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">N</mi><mi mathvariant="normal">a</mi></mrow><mo lspace="0em" rspace="0em">+</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{Na}^{+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8446em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Na</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8446em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span>conductance in nerve fibres and thus block impulse conduction.
II. Transmitter release The transmitter (excitatory or inhibitory) is stored in prejunctional nerve endings within 'synaptic vesicles' (Fig. II.2). Nerve impulse promotes fusion of vesicular and axonal membranes through <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">C</mi><mi mathvariant="normal">a</mi></mrow><mrow><mn>2</mn><mo>+</mo></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{Ca}^{2+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8873em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Ca</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8873em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span> entry which fluidizes membranes. All contents of the vesicle (transmitter, enzymes and other proteins) are extruded by exocytosis (also see Fig. 2.6) in the junctional cleft.</p>
<p>While majority of the neurotransmitters are preformed, kept stored in synaptic vesicles and released on activation by exocytosis as outlined above, some mediators like NO, prostaglandins, endocannabinoids are synthesized on demand and reach their target by diffusion or by active transport.</p>
<p>The release process can be modulated by the transmitter itself and by other agents through activation of specific receptors located on the prejunctional membrane, e.g. noradrenaline (NA) release is inhibited by NA ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi>α</mi><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\alpha_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5806em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.0037em;">α</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.0037em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> receptor), dopamine, adenosine, prostaglandins and enkephalins
while isoprenaline ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi>β</mi><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\beta_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.05278em;">β</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.0528em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> receptor) and angiotensin ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">A</mi><mi mathvariant="normal">T</mi></mrow><mn>1</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{AT}_{1}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">AT</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> receptor) increase NA release. Similarly, <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi>α</mi><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\alpha_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5806em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.0037em;">α</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.0037em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> and muscarinic agonists inhibit acetylcholine <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo stretchy="false">(</mo><mrow><mi mathvariant="normal">A</mi><mi mathvariant="normal">C</mi><mi mathvariant="normal">h</mi></mrow><mo stretchy="false">)</mo></mrow><annotation encoding="application/x-tex">(\mathrm{ACh})</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mopen">(</span><span class="mord"><span class="mord mathrm">ACh</span></span><span class="mclose">)</span></span></span></span></span> release at autonomic neuroeffector sites (but not in ganglia and skeletal muscles).
III. Transmitter action on postjunctional membrane The released transmitter combines with specific receptors on the postjunctional membrane and depending on its nature induces an excitatory postsynaptic potential (EPSP) or an inhibitory postsynaptic potential (IPSP).
EPSP Increase in permeability to cations <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>→</mo><msup><mrow><mi mathvariant="normal">N</mi><mi mathvariant="normal">a</mi></mrow><mo lspace="0em" rspace="0em">+</mo></msup></mrow><annotation encoding="application/x-tex">\rightarrow \mathrm{Na}^{+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.3669em;"></span><span class="mrel">→</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.8446em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Na</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8446em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span>or <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">C</mi><mi mathvariant="normal">a</mi></mrow><mrow><mn>2</mn><mo>+</mo></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{Ca}^{2+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8873em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Ca</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8873em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span> influx (through fast or slow channels) causes depolarization followed by <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">K</mi><mo lspace="0em" rspace="0em">+</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{K}^{+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7713em;"></span><span class="mord"><span class="mord mathrm">K</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.7713em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span> efflux. These ionic movements are passive as the flow is down the concentration gradients.
IPSP Increase in permeability to anions, so that <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">C</mi><mi mathvariant="normal">l</mi></mrow><mo lspace="0em" rspace="0em">−</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{Cl}^{-}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8557em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Cl</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8557em;"><span style="top: -3.1473em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">−</span></span></span></span></span></span></span></span></span></span></span></span></span>ions move in (axonal <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">C</mi><mi mathvariant="normal">l</mi></mrow><mo lspace="0em" rspace="0em">−</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{Cl}^{-}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8557em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Cl</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8557em;"><span style="top: -3.1473em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">−</span></span></span></span></span></span></span></span></span></span></span></span></span>concentration is lower than its extracellular concentration) and tend to hyperpolarize the membrane <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>→</mo></mrow><annotation encoding="application/x-tex">\rightarrow</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.3669em;"></span><span class="mrel">→</span></span></span></span></span> an IPSP is generated. Stabilization of the membrane or hyperpolarization can also result
<img src="data:image/jpeg;base64,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